<SEC-DOCUMENT>0001493152-21-018675.txt : 20210805
<SEC-HEADER>0001493152-21-018675.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805080117
ACCESSION NUMBER:		0001493152-21-018675
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		63
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Lipocine Inc.
		CENTRAL INDEX KEY:			0001535955
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				990370688
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36357
		FILM NUMBER:		211146397

	BUSINESS ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108
		BUSINESS PHONE:		801 994 7383

	MAIL ADDRESS:	
		STREET 1:		675 ARAPEEN DRIVE, SUITE 202
		CITY:			SALT LAKE CITY
		STATE:			X1
		ZIP:			84108

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MARATHON BAR CORP
		DATE OF NAME CHANGE:	20111130
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>form10-q.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:LPCN="http://lipocine.com/20210630">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_035_LPCN_lipocine.com_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210101_20210630 -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DEntityCentralIndexKey_0001535955 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_051_edei%2D%2DCurrentFiscalYearEndDate_%2D%2DLS0xMi0zMQ== -->
<!-- Field: Set; Name: xdx; ID: xdx_058_edei%2D%2DDocumentFiscalPeriodFocus_Q2 -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_form10%2Dq.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_069_Pure_4_xbrli%2D%2Dpure -->
<body>
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCentralIndexKey">0001535955</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalPeriodFocus">Q2</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2021-06-30" id="xdx2ixbrl0050" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationReserveCurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0087" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2021-06-30" id="xdx2ixbrl0092" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2020-12-31" id="xdx2ixbrl0099" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2021-06-30" id="xdx2ixbrl0104" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:CommitmentsAndContingencies" contextRef="AsOf2020-12-31" id="xdx2ixbrl0105" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2021-06-30" id="xdx2ixbrl0110" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:PreferredStockValue" contextRef="AsOf2020-12-31" id="xdx2ixbrl0111" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0159" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0216" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0218" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-04-012021-06-30" id="xdx2ixbrl0230" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0231" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0283" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0291" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0292" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0293" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0294" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0298" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0299" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0300" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0302" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0305" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0306" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0308" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0309" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0313" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0315" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0316" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30" id="xdx2ixbrl0317" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0322" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0324" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0325" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0330" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0331" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0333" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0334" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0358" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0359" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0361" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0362" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0387" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0388" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0389" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0390" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0394" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0395" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0396" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0398" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0401" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0402" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0404" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0405" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0409" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0411" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0412" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0413" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0418" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0420" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0421" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0427" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0429" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0430" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0435" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0436" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0438" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0439" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0442" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0443" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0445" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0446" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0471" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0472" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0473" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0474" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0478" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0479" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0480" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0482" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0485" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0486" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0488" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0489" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0492" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0493" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0495" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0496" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0512" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0523" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0531" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0532" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0533" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0534" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0538" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0539" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" id="xdx2ixbrl0540" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0542" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0545" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0546" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0548" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0549" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0552" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0553" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0555" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0556" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0562" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0564" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0565" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0571" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0573" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0574" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" id="xdx2ixbrl0579" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0580" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0582" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0583" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember" id="xdx2ixbrl0587" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" id="xdx2ixbrl0589" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" id="xdx2ixbrl0590" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0626" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0657" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0680" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl0690" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl0728" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-06-30_custom_UnvestedRestrictedStockUnitsMember" id="xdx2ixbrl0791" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember" id="xdx2ixbrl0805" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2021-06-30" id="xdx2ixbrl0812" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember" id="xdx2ixbrl0820" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember" id="xdx2ixbrl0822" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0828" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2020-12-31" id="xdx2ixbrl0829" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0875" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0877" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0881" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0885" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0889" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0893" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0901" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0903" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0904" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0916" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0918" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0922" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0926" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" id="xdx2ixbrl0934" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member" id="xdx2ixbrl0936" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member" id="xdx2ixbrl0937" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" contextRef="AsOf2021-06-30" id="xdx2ixbrl0995" unitRef="USD" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-01to2021-06-30" id="xdx2ixbrl1122" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-06-30" id="xdx2ixbrl1123" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_StockIncentivePlan2014Member" id="xdx2ixbrl1148" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">P10Y</ix:nonNumeric>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" id="xdx2ixbrl1168" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" id="xdx2ixbrl1170" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1219" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" id="xdx2ixbrl1220" unitRef="Pure" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1255" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1257" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1263" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1265" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1267" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1269" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1271" unitRef="Shares" xs:nil="true"></ix:nonFraction>
  <ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" id="xdx2ixbrl1273" unitRef="USDPShares" xs:nil="true"></ix:nonFraction>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="lpcn-20210630.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-01-01to2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-08-04">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-08-04</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-03-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_TreasuryStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_UnvestedRestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_UnvestedRestrictedStockUnitsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LPCN:CorporateBondsNotesAndCommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommercialPaperMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember14581359">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-05</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-05-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:AbbottProductsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:AbbottProductsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-262021-01-28_custom_January2021OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:January2021OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-26</xbrli:startDate>
        <xbrli:endDate>2021-01-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-262020-02-27_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-26</xbrli:startDate>
        <xbrli:endDate>2020-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-02-26</xbrli:startDate>
        <xbrli:endDate>2020-02-27</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-02-27</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassBUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassBUnitsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:PreFundedWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-18">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-18</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-11-17</xbrli:startDate>
        <xbrli:endDate>2019-11-18</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-03-052017-03-06_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LPCN:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-03-05</xbrli:startDate>
        <xbrli:endDate>2017-03-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_AtMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AtMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_CommonStockMember_custom_AtMarketOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_AccreditedInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-11-122015-11-13">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-11-12</xbrli:startDate>
        <xbrli:endDate>2015-11-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-04-30_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2014-04-30_custom_EquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:EquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2014-04-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_StockIncentivePlan2014Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_November2019OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_custom_February2020OfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2020-12-31_us-gaap_WarrantMember14584484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2020-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-01-012021-06-30_us-gaap_WarrantMember14584484">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-01-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2021-06-30_us-gaap_WarrantMember14584515">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2021-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2021-04-012021-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-04-01</xbrli:startDate>
        <xbrli:endDate>2021-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_us-gaap_WarrantMember14584609">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-04-012020-06-30_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LPCN:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-04-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2020-01-012020-06-30_custom_CommonStockWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LPCN:CommonStockWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2020-01-01</xbrli:startDate>
        <xbrli:endDate>2020-06-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-02_custom_GlobalAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-04-01</xbrli:startDate>
        <xbrli:endDate>2019-04-02</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2022-07-12</xbrli:startDate>
        <xbrli:endDate>2022-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-07-12</xbrli:startDate>
        <xbrli:endDate>2023-07-13</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-11-14">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-11-14</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:LicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-22</xbrli:startDate>
        <xbrli:endDate>2013-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2013-07-222013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2013-07-22</xbrli:startDate>
        <xbrli:endDate>2013-07-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001535955</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:ServiceAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2013-07-23</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Pure">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; font-size: 1pt; border-bottom: Black 1.5pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>WASHINGTON,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_90F_edei--DocumentType_c20210101__20210630_zzKU33bLvto3"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentType">10-Q</ix:nonNumeric></span></b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 25%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_908_edei--DocumentQuarterlyReport_c20210101__20210630_zFhNWJEc5C9k"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:DocumentQuarterlyReport">&#9746;</ix:nonNumeric></span>&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
Quarterly Period ended <span id="xdx_904_edei--DocumentPeriodEndDate_c20210101__20210630_zevIDuzLVxvh"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">June 30, <span id="xdx_90F_edei--DocumentFiscalYearFocus_c20210101__20210630_zXbvwr5gAhS"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric></span></ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span>&#160;</p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="font: 12pt Times New Roman, Times, Serif; width: 0.25in"><span id="xdx_905_edei--DocumentTransitionReport_c20210101__20210630_z25Kr3ADfl37"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:DocumentTransitionReport">&#9744;</ix:nonNumeric></span>&#160;</td>
    <td style="font: 12pt Times New Roman, Times, Serif"><span style="font-size: 10pt"><b>Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>For
the transition period from to .</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Commission
File Number: <span id="xdx_907_edei--EntityFileNumber_c20210101__20210630_zC4lGNw9B5Zi"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityFileNumber">001-36357</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 40%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityRegistrantName_c20210101__20210630_ztgG36xGl6Mj"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityRegistrantName">LIPOCINE
INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Exact
name of registrant as specified in its charter)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 40%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_902_edei--EntityIncorporationStateCountryCode_c20210101__20210630_ztFfZnOze7L3"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="width: 2%">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 49%"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityTaxIdentificationNumber_c20210101__20210630_zpt1SNjk7Khf"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityTaxIdentificationNumber">99-0370688</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(State
    or Other Jurisdiction of</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Incorporation
    or Organization)</b></span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>(IRS
    Employer</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Identification
    No.)</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20210101__20210630_zUWU32oTggfi"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine1">675
    Arapeen Drive</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressAddressLine2_c20210101__20210630_zoGxEA2ULR1l"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressAddressLine2">Suite 202</ix:nonNumeric></span>,</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityAddressCityOrTown_c20210101__20210630_zQTSDdxlfGSi"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressCityOrTown">Salt
    Lake City</ix:nonNumeric></span>, <span id="xdx_908_edei--EntityAddressStateOrProvince_c20210101__20210630_zlIH4Py2pRGl"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Utah</ix:nonNumeric></span></b></span></p></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_907_edei--EntityAddressPostalZipCode_c20210101__20210630_zDBaVEV5gSp9"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityAddressPostalZipCode">84108</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Address
    of Principal Executive Offices)</b></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Zip
    Code)</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--CityAreaCode_c20210101__20210630_zGyD9QGgiIfh"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:CityAreaCode">801</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20210101__20210630_zypM91x96yTg"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:LocalPhoneNumber">994-7383</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(Registrant&#8217;s
telephone number, including area code)</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<!-- Field: Rule-Page --><div style="margin-left: auto; margin-right: auto; width: 40%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left">&#160;</p>



<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font: 10pt Times New Roman, Times, Serif">Title
    of each class</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 24%"><span style="font: 10pt Times New Roman, Times, Serif">Trading
    Symbol(s)</span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 36%"><span style="font: 10pt Times New Roman, Times, Serif">Name
    of each exchange on which registered</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_903_edei--Security12bTitle_c20210101__20210630_zUrE24uWv7Of"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:Security12bTitle">Common
    Stock, par value $0.0001 per share</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--TradingSymbol_c20210101__20210630_zeIGUwuVyKS7"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:TradingSymbol">LPCN</ix:nonNumeric></span></span></td>
    <td>&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">The
    <span id="xdx_903_edei--SecurityExchangeName_c20210101__20210630_zOgoRMzBDcE6"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">NASDAQ</ix:nonNumeric></span> Stock Market LLC</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports) and (2) has
been subject to such filing requirements for the past 90 days. <span id="xdx_90D_edei--EntityCurrentReportingStatus_c20210101__20210630_zCnmW7USmoJh"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityCurrentReportingStatus">Yes</ix:nonNumeric></span>: &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files). <span id="xdx_901_edei--EntityInteractiveDataCurrent_c20210101__20210630_zUm3oMxOFz0i"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" name="dei:EntityInteractiveDataCurrent">Yes</ix:nonNumeric></span> &#9746; No &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221;
&#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act (Check one):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 30%"><span style="font: 10pt Times New Roman, Times, Serif">Large
    accelerated filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 70%"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Accelerated
    filer</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9744;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--EntityFilerCategory_c20210101__20210630_zLv76icuSVXk"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory">Non-accelerated filer</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#9746;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Smaller
    reporting company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--EntitySmallBusiness_c20210101__20210630_zjB9R1fjt957"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleantrue" name="dei:EntitySmallBusiness">&#9746;</ix:nonNumeric></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
    growth company</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--EntityEmergingGrowthCompany_c20210101__20210630_zTctcBLKHRf1"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span><span style="font: 10pt Times New Roman, Times, Serif"></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to <span style="text-decoration: underline">Section 13(a) of the Exchange Act</span>. &#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; <span id="xdx_904_edei--EntityShellCompany_c20210101__20210630_zbqxJYYHS5g3"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt:booleanfalse" name="dei:EntityShellCompany">No</ix:nonNumeric></span>
&#9746;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Outstanding
Shares</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">As
of August 4, 2021, the registrant had <span id="xdx_908_edei--EntityCommonStockSharesOutstanding_c20210804_pdd" title="Entity Common Stock, Shares Outstanding"><ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" contextRef="AsOf2021-08-04" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span> shares of common stock outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt; border-bottom: Black 4pt solid">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>TABLE
OF CONTENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right; width: 0.5in"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 5.05pt 0 0; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">Page</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#ag_001">PART I&#8212;FINANCIAL INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ag_002">Financial Statements</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#ag_004">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">20</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_001">Quantitative and Qualitative Disclosures About Market Risks</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">36</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_002">Controls and Procedures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b><a href="#SS_003">PART II&#8212;OTHER INFORMATION</a></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_004">Legal Proceedings</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">37</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    1A.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_005">Risk Factors</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">38</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    2.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_006">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    3.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_007">Defaults Upon Senior Securities</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    4.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_008">Mine Safety Disclosures</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    5.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_009">Other Information</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">41</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">Item
    6.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><a href="#SS_010">Exhibits</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">42</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="ag_001"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>PART
I&#8212;FINANCIAL INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ag_002"></span>ITEM
1. FINANCIAL STATEMENTS</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Balance Sheets</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_111_zyJpKPIPBQ74" summary="xdx: Statement - Condensed Consolidated Balance Sheets (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20210630_zapqKQaq7sag" style="font-weight: bold; text-align: center">2021</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_490_20201231_zfoWEHpNYrzd" style="font-weight: bold; text-align: center">2020</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">June 30,</td><td style="font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td>
    <td colspan="2" style="font-weight: bold; text-align: center">December 31,</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AssetsAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AssetsCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--CashAndCashEquivalentsAtCarryingValue_i02I_pp0p0_maACzzjK_zx0N8gILYv19" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left; padding-left: 10pt">Cash and cash equivalents</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,967,713</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">19,217,382</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--RestrictedCashAndCashEquivalents_i02I_pp0p0_maACzzjK_zfOZX9ERxi7g" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Restricted cash</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0050">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:RestrictedCashAndCashEquivalents" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000,000</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--AvailableForSaleSecuritiesDebtSecuritiesCurrent_i02I_pp0p0_maACzzjK_zk9VJG0Ah0a1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Marketable investment securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--InterestReceivableCurrent_i02I_pp0p0_maACzzjK_zsagBYFrWMr3" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,568</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestReceivableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">391</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_i02I_pp0p0_maACzzjK_z18lzRcsBHv4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Prepaid and other current assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">283,180</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">661,258</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--AssetsCurrent_i02TI_pp0p0_mtACzzjK_maAzLiY_zx2REgNYKEkf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 20pt">Total current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,155,520</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AssetsCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,329,023</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--OtherAssetsNoncurrent_i01I_pp0p0_maAzLiY_zSdhdjVNFDDf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,753</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherAssetsNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">23,753</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--Assets_i01TI_pp0p0_mtAzLiY_z8fi86wQi8of" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total assets</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,179,273</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:Assets" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,352,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LiabilitiesAndStockholdersEquityAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: center">Liabilities and Stockholders&#8217; Equity</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LiabilitiesCurrentAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Current liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--AccountsPayableCurrent_i02I_pp0p0_maLCzwgd_zsvdQmmfRW7d" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">906,476</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccountsPayableCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,597,220</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--AccruedLiabilitiesCurrent_i02I_pp0p0_maLCzwgd_zENUfXNDp16h" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,444,188</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccruedLiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,653,178</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--DebtCurrent_i02I_pp0p0_maLCzwgd_zBs5MVUZKqs7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Debt - current portion</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,957,627</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,333,333</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--LitigationReserveCurrent_i02I_pp0p0_maLCzwgd_zkrxqD73zsJ4" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Litigation settlement liability - current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LitigationReserveCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0087">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LiabilitiesCurrent_i02TI_pp0p0_mtLCzwgd_maLz8Yi_zswwKrmEazwg" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 20pt">Total current liabilities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,808,291</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesCurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,583,731</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LongTermDebtNoncurrent_i01I_pp0p0_maLz8Yi_znRZJX2Cn4Q1" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Debt - non-current portion</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0092">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtNoncurrent" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,257,075</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--WarrantsAndRightsOutstanding_i01I_pp0p0_maLz8Yi_zNCxZNvdICT7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,429</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--LitigationReserveNoncurrent_i01I_pp0p0_maLz8Yi_zKnLtOiJo834" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt">Litigation settlement liability - non-current portion</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LitigationReserveNoncurrent" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,500,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0099">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--Liabilities_i01TI_pp0p0_mtLz8Yi_maLASEzESY_zhiBPLukEMkj" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total liabilities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,433,720</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:Liabilities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,010,857</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--CommitmentsAndContingencies_i01I_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Commitments and contingencies (notes 5, 7, 8 and 10)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0104">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0105">&#160;</span></td><td style="text-align: right"><span style="display: none; font-family: Times New Roman, Times, Serif">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--StockholdersEquityAbstract_i01B" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Stockholders&#8217; equity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--PreferredStockValue_i02I_pp0p0_maSEzJNc_zokJveuKk8r9" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Preferred stock, par value <span id="xdx_90D_eus-gaap--PreferredStockParOrStatedValuePerShare_c20210630_pdd" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_c20201231_pdd" title="Preferred stock, par value">$<ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_905_eus-gaap--PreferredStockSharesAuthorized_c20210630_pdd" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_c20201231_pdd" title="Preferred stock, shares authorized"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_905_eus-gaap--PreferredStockSharesIssued_iI_dc_c20210630_zQkw0ZN8jll" title="Preferred stock, shares issued"><span id="xdx_90F_eus-gaap--PreferredStockSharesIssued_iI_dc_c20201231_zSg2enpnbcc9" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20210630_zJ2YeGM8qumf" title="Preferred stock, shares outstanding"><span id="xdx_90A_eus-gaap--PreferredStockSharesOutstanding_iI_dc_c20201231_zmsxGV2uJUd9" title="Preferred stock, shares outstanding"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:PreferredStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> issued and outstanding</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0110">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0111">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--CommonStockValue_i02I_pp0p0_maSEzJNc_ziMv2pdaw9w6" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Common stock, par value <span id="xdx_902_eus-gaap--CommonStockParOrStatedValuePerShare_c20210630_pdd" title="Common stock, par value"><span id="xdx_90F_eus-gaap--CommonStockParOrStatedValuePerShare_c20201231_pdd" title="Common stock, par value">$<ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares"><ix:nonFraction name="us-gaap:CommonStockParOrStatedValuePerShare" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.0001</ix:nonFraction></ix:nonFraction></span></span> per share, <span id="xdx_908_eus-gaap--CommonStockSharesAuthorized_c20210630_pdd" title="Common stock, shares authorized"><span id="xdx_90B_eus-gaap--CommonStockSharesAuthorized_c20201231_pdd" title="Common stock, shares authorized"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:CommonStockSharesAuthorized" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">100,000,000</ix:nonFraction></ix:nonFraction></span></span> shares authorized; <span id="xdx_907_eus-gaap--CommonStockSharesIssued_c20210630_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,296,360</ix:nonFraction></span> and <span id="xdx_900_eus-gaap--CommonStockSharesIssued_c20201231_pdd" title="Common stock, shares issued"><ix:nonFraction name="us-gaap:CommonStockSharesIssued" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,041,967</ix:nonFraction></span> issued and <span id="xdx_90F_eus-gaap--CommonStockSharesOutstanding_c20210630_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span> and <span id="xdx_903_eus-gaap--CommonStockSharesOutstanding_c20201231_pdd" title="Common stock, shares outstanding"><ix:nonFraction name="us-gaap:CommonStockSharesOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,036,257</ix:nonFraction></span> outstanding</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,830</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CommonStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,005</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--AdditionalPaidInCapital_i02I_pp0p0_maSEzJNc_zbA0Adgquj7j" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Additional paid-in capital</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">217,986,752</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AdditionalPaidInCapital" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">187,407,634</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--TreasuryStockValue_i02NI_pp0p0_di_msSEzJNc_zw1x3hZNC7t2" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-left: 10pt">Treasury stock at cost, <span id="xdx_904_eus-gaap--TreasuryStockShares_c20210630_pdd" title="Treasury stock, shares"><span id="xdx_901_eus-gaap--TreasuryStockShares_c20201231_pdd" title="Treasury stock, shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares"><ix:nonFraction name="us-gaap:TreasuryStockShares" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></ix:nonFraction></span></span> shares</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,712</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:TreasuryStockValue" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">40,712</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--AccumulatedOtherComprehensiveIncomeLossNetOfTax_i02I_pp0p0_maSEzJNc_zi7h09YzoLh4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left; padding-left: 10pt">Accumulated other comprehensive loss</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0159">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_408_eus-gaap--RetainedEarningsAccumulatedDeficit_i02I_pp0p0_maSEzJNc_zgCt38xzx3me" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt">Accumulated deficit</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">182,209,131</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">172,032,008</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--StockholdersEquity_i02TI_pp0p0_mtSEzJNc_maLASEzESY_zhrKszv4cCf9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt">Total stockholders&#8217; equity</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,745,553</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">15,341,919</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--LiabilitiesAndStockholdersEquity_i01TI_pp0p0_mtLASEzESY_zlO1iQszmFO5" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt">Total liabilities and stockholders&#8217; equity</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">47,179,273</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">25,352,776</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Operations and Comprehensive Loss</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_307_113_zlaCvp9dE8m1" summary="xdx: Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_497_20210401__20210630_zJO1wlJTOM9b" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_498_20200401__20200630_zR3r0X5RJsIk" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49E_20210101__20210630_zJ7IbKjcrq06" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49B_20200101__20200630_zlGG9As7O9ta" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--OperatingExpensesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Operating expenses:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_i01_pp0p0_maOEzXox_zAxiAxygLey" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,464,687</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,268,984</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,045,228</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,780,739</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--GeneralAndAdministrativeExpense_i01_pp0p0_maOEzXox_ziuRR1cyEI31" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,525,592</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,953,535</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,059,544</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:GeneralAndAdministrativeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,038,795</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingExpenses_i01T_pp0p0_mtOEzXox_msOILzUd9_z0wCJ1lBoH8c" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total operating expenses</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">2,990,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,222,519</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,104,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OperatingExpenses" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">8,819,534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--OperatingIncomeLoss_iT_pp0p0_mtOILzUd9_maILFCOz3gp_z0ERLNDrDaoj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Operating loss</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,990,279</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,222,519</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,104,772</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OperatingIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,819,534</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NonoperatingIncomeExpenseAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Other income (expense):</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--InvestmentIncomeInterest_i01_pp0p0_maONIEzbJG_zsxRY1OrwEeb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Interest and investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">17,344</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">7,177</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">27,993</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InvestmentIncomeInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">67,115</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--InterestExpense_i01N_pp0p0_di_msONIEzbJG_zK5lBmAvTVb1" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">57,428</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">87,847</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">126,401</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:InterestExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">221,192</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40C_eus-gaap--UnrealizedGainLossOnDerivatives_i01_pp0p0_maONIEzbJG_zuDfY1vwBFF6" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Unrealized gain (loss) on warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">221,322</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,066,445</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,257</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:UnrealizedGainLossOnDerivatives" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,166,474</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40A_eus-gaap--LitigationSettlementExpense_i01N_pp0p0_di_msONIEzbJG_zcAZxuTYexLe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Litigation settlement</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0216">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0218">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--OtherNonoperatingIncomeExpense_i01T_pp0p0_mtONIEzbJG_maILFCOz3gp_zH5qpP10UK4k" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Total other expense, net</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,818,762</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">2,147,115</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">4,072,151</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">3,320,551</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_iT_pp0p0_mtILFCOz3gp_maNILzwHj_zmVewgCNBLc1" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Loss before income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,176,923</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,085</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--IncomeTaxExpenseBenefit_iN_pp0p0_di_msNILzwHj_zskrevG8UWA" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Income tax expense</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0230">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0231">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:IncomeTaxExpenseBenefit" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetIncomeLoss_iT_pp0p0_mtNILzwHj_zSLb3M95vHk" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--EarningsPerShareBasic_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Basic loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_i_pdd" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Weighted average common shares outstanding, basic</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,769,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,556,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,558,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--EarningsPerShareDiluted_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">Weighted average common shares outstanding, diluted</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,769,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,556,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,558,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--ComprehensiveIncomeNetOfTaxAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Comprehensive loss:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--NetIncomeLoss_i01_pp0p0_maCINOTzFuW_zRyWnLEc5HF5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Net loss</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40D_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_i01_pp0p0_maCINOTzFuW_zEsImTwrXONb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Net unrealized gain (loss) on available-for-sale securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">22,273</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">104</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">66</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--ComprehensiveIncomeNetOfTax_i01T_pp0p0_mtCINOTzFuW_zuK2j3KxU0f7" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left">Comprehensive loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,786,768</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,738</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,309</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,351</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Changes in Stockholders&#8217; Equity</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">For
the Three and Six Months Ended June 30, 2021 and 2020</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_30F_114_zPYsPcGXRfUf" summary="xdx: Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BE_us-gaap--StatementEquityComponentsAxis_us-gaap--CommonStockMember_zc5xCLzQcDVf" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B1_us-gaap--StatementEquityComponentsAxis_us-gaap--TreasuryStockMember_zaqpZODTMG13" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BB_us-gaap--StatementEquityComponentsAxis_us-gaap--AdditionalPaidInCapitalMember_zKcXG7L6mFa3" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Paid-In
    Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--AccumulatedOtherComprehensiveIncomeMember_ziULSJMfzsj6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Comprehensive
    Loss</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4BA_us-gaap--StatementEquityComponentsAxis_us-gaap--RetainedEarningsMember_znnNOcJbHEpe" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" id="xdx_4B8_zNSXZpZr0JKh" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Stockholders&#8217;
    Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Additional</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Other</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Paid-In
    Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Comprehensive<br />

    Loss</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Stockholders&#8217;<br />

    Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_434_c20200401__20200630_eus-gaap--StockholdersEquity_iS_zhAPalAPlL8b" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 26%"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at March 31, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z26yCDakcYf9" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">47,854,499</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,786</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98D_eus-gaap--SharesOutstanding_iS_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zPepLmVO9g77" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">163,426,502</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0283">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">156,837,840</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right">&#160;&#160;<span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,552,736</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--NetIncomeLoss_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0291">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0292">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0293">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0294">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Unrealized
    net gain on marketable investment securities</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0298">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0299">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0300">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0302">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0305">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0306">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,058</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0308">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0309">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,058</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40B_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Vesting
    of restricted stock units</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zenEFpXdGa6a" title="Vesting of restricted stock units, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0313">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0315">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0316">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0317">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercises_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock issued for warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_ecustom--StockIssuedDuringPeriodSharesWarrantsExercises_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4XIlKOHf4Pf" title="Common stock issued for warrant exercises, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodSharesWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,497,807</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,350</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0322">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,852,308</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0324">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0325">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,853,658</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_401_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Settlement
    of warrant liability on warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0330">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0331">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,591,362</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0333">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0334">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,591,362</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--CommonStockSoldThroughEquityOffering_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">Common stock sold through equity offering</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">Option exercises</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--StockIssuedDuringPeriodValueNewIssues_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif">Common stock sold through ATM offering</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;</td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left">&#160;</td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_i_pp0p0" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Costs
    associated with ATM offering</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0358">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0359">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,108</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0361">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0362">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,108</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_437_c20200401__20200630_eus-gaap--StockholdersEquity_iE_zlZGzWwuqDp4" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at June 30, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_ztGNsmYL8jHd" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,377,306</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,138</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_ztYbKtVF75Lh" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,327,120</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,207,474</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,084,968</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Additional</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Other</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Paid-In<br />
Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Comprehensive<br />
Loss</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated<br />
Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Stockholders&#8217;<br />
Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_432_c20200101__20200630_eus-gaap--StockholdersEquity_iS_zGXzQHnr47qi" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 26%"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at December 31, 2019</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zusXpW7t53m9" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">37,649,465</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,766</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iS_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zToAeNTYMCbg" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,391,969</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">38</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">151,067,189</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,287,796</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40D_eus-gaap--NetIncomeLoss_zN2yWudzPE4e" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0387">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0388">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0389">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0390">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_400_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zAsrk8Z65u09" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Unrealized
    net gain on marketable investment securities</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0394">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0395">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0396">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0398">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">66</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zpMOLMRPk9x6" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0401">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0402">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,971</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0404">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0405">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,971</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_405_eus-gaap--StockIssuedDuringPeriodValueRestrictedStockAwardGross_zie6ojQugJW7" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Vesting
    of restricted stock units</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--StockIssuedDuringPeriodSharesRestrictedStockAwardGross_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Vesting of restricted stock units, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">25,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0409">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">2</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0411">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0412">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0413">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_ecustom--CommonStockSoldThroughEquityOffering_zfCkfqi1oxia" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock sold through equity offering</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--CommonStockSoldThroughEquityOfferingShares_iP3custom--CommonStockSoldThroughEquityOffering_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zjic8mEXyyZ8" title="Common stock sold through equity offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOfferingShares" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,084,034</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,008</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0418">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,652,132</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0420">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0421">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,653,140</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_ecustom--StockIssuedDuringPeriodValueWarrantsExercises_z2tW5nbw6UJf" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock issued for warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_ecustom--StockIssuedDuringPeriodSharesWarrantsExercises_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Common stock issued for warrant exercises, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodSharesWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">13,618,807</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,362</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0427">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,912,796</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0429">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0430">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,914,158</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_zFvOehZWpBUe" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Settlement
    of warrant liability on warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0435">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0436">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,591,362</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0438">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0439">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,591,362</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_zwIENPiYMWcl" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Costs
    associated with ATM offering</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0442">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0443">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,108</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0445">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0446">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">8,108</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_439_c20200101__20200630_eus-gaap--StockholdersEquity_iE_zMdd6uYgfNS7" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at June 30, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4eaXsOHBFu3" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">61,377,306</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,138</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_982_eus-gaap--SharesOutstanding_iE_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zmDuH1Bnox0c" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">176,327,120</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">104</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">163,207,474</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">13,084,968</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Additional</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Other</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Paid-In
    Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Comprehensive
    Gain (Loss)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Stockholders&#8217;<br />

    Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_43A_c20210401__20210630_eus-gaap--StockholdersEquity_iS_zMShvUNfaFc9" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 26%"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at March 31, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zHTnB0CjClsg" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iS_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zAtr6v4ClK46" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,845,280</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">22,459</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">175,400,090</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-03-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">42,390,849</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_404_eus-gaap--NetIncomeLoss_zgzOuXdxzkXe" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0471">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0472">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0473">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0474">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_zMz9tJ5JvsVb" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Unrealized
    net gain on marketable investment securities</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0478">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0479">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0480">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,273</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0482">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">22,273</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40E_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_zc5mOYeYXEEd" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0485">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0486">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,747</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0488">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0489">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,747</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_zxscNlcuTF9a" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Costs
    associated with ATM offering</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0492">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0493">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,275</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0495">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0496">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">5,275</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_430_c20210401__20210630_eus-gaap--StockholdersEquity_iE_zxbVBAGKYHt6" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at June 30, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98F_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zh3mmrcM2cug" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iE_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zzHlrMuE1Ig6" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,986,752</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,209,131</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,745,553</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 8pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Common
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Treasury
    Stock</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Additional</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Other</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Total</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; white-space: nowrap; text-align: center"><p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Number
                                            of</span></p>
                                                                                <p style="font: 8pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><span style="font: 8pt Times New Roman, Times, Serif">Shares</span></p></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Amount</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Paid-In
    Capital</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Comprehensive
    Gain (Loss)</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Accumulated
    Deficit</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 8pt Times New Roman, Times, Serif; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">Stockholders&#8217;<br />

    Equity</span></td><td style="font: bold 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_435_c20210101__20210630_eus-gaap--StockholdersEquity_iS_ztSXubc5c9yd" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; width: 26%"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at December 31, 2020</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_981_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zClmoMdSWVo7" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,036,257</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 6%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,005</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98A_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zJcJYlu0Qynj" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 5%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,407,634</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0512">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">172,032,008</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 7%; text-align: right">&#160;&#160;<span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,341,919</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_439_c20210101__20210630_eus-gaap--StockholdersEquity_iS_z0Ag5iUZnYa1" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">Balances</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98C_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zJTY9j6NViw2" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">70,036,257</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">7,005</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zQHBc80iO5g1" title="Balance, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">187,407,634</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0523">-</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">172,032,008</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right">&#160;&#160;<span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" unitRef="USD">15,341,919</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
<tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40F_eus-gaap--NetIncomeLoss_z1vFAgl8cOLk" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Net
    loss</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0531">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0532">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0533">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0534">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_z7IDmryje6i8" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Unrealized
    net loss on marketable investment securities</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0538">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0539">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0540">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0542">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_z6Z9sJeSqQm5" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Stock-based
    compensation</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0545">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0546">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,313</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0548">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0549">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,313</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_408_eus-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_zCKZft0k53Fe" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Option
    exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iP3us-gaap--StockIssuedDuringPeriodValueStockOptionsExercised_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_znwsUsXfrayh" title="Option exercises, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,584</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0552">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0553">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,693</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0555">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0556">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">6,693</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_409_ecustom--CommonStockSoldThroughEquityOffering_zuO12drPn5Eg" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock sold through equity offering</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_988_ecustom--CommonStockSoldThroughEquityOfferingShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Common stock sold through equity offering, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOfferingShares" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,428,571</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1,643</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0562">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,838,814</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0564">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0565">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:CommonStockSoldThroughEquityOffering" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">26,840,457</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_403_ecustom--StockIssuedDuringPeriodValueWarrantsExercises_zrRysAVRGFHa" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock issued for warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_985_ecustom--StockIssuedDuringPeriodSharesWarrantsExercises_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_pdd" title="Common stock issued for warrant exercises, shares" style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodSharesWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">1</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0571">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">4,999</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0573">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0574">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:StockIssuedDuringPeriodValueWarrantsExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">5,000</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_407_ecustom--AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_zxL0UmIa2O3g" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Settlement
    of warrant liability on warrant exercises</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0579">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0580">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,365</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0582">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0583">&#160;</span></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">18,365</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_40C_eus-gaap--StockIssuedDuringPeriodValueNewIssues_zJrPfeJZ5w94" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">Common
    stock sold through ATM offering</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_iP3us-gaap--StockIssuedDuringPeriodValueNewIssues_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_z4rMw4EW8Ak2" title="Common stock sold through ATM offering, shares" style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,811,238</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">181</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0587">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,415,934</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0589">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif"><span style="-sec-ix-hidden: xdx2ixbrl0590">&#160;</span></span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">-</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">3,416,115</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_439_c20210101__20210630_eus-gaap--StockholdersEquity_iE_zl5w4OyqHSmb" style="font: 8pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">Balances
    at June 30, 2021</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_98B_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zqLUcx6KoYX8" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_983_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zr7ePZe1wlTg" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,986,752</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,209,131</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,745,553</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr id="xdx_433_c20210101__20210630_eus-gaap--StockholdersEquity_iE_zmINrwLByKn7" style="font: 8pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">Balances</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_984_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zhCoqvd3AWLh" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_CommonStockMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">8,830</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td id="xdx_986_eus-gaap--SharesOutstanding_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--TreasuryStockMember_zjO7MYPpbSpf" title="Balance, shares" style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:SharesOutstanding" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">5,710</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">40,712</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">217,986,752</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">186</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif">(<ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">182,209,131</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">)</span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 8pt Times New Roman, Times, Serif; text-align: right"><span style="font: 8pt Times New Roman, Times, Serif"><ix:nonFraction name="us-gaap:StockholdersEquity" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">35,745,553</ix:nonFraction></span></td><td style="font: 8pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 8pt Times New Roman, Times, Serif">&#160;</span></td></tr>
</table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIPOCINE
INC. AND SUBSIDIARIES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">Condensed
Consolidated Statements of Cash Flows</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0; margin-bottom: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_301_112_zYGJpTfZnwe5" summary="xdx: Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="display: none; vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210101__20210630_zjAQKUGl9cZ1" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49D_20200101__20200630_zZWlt8v9O6Lc" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--NetCashProvidedByUsedInOperatingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--NetIncomeLoss_i01_pp0p0_maNCPBUz8He_zu0RXuunhXgj" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; width: 64%; text-align: left">Net loss</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Adjustments to reconcile net loss to cash used in operating activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_i02_pp0p0_maNCPBUz8He_zbxa76QTRPCe" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Depreciation expense</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0626">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DepreciationAndAmortization" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,598</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensation_i02_pp0p0_maNCPBUz8He_zniYn4Uvht5" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Stock-based compensation expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">294,313</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensation" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">786,971</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--AccretionExpense_i02_pp0p0_maNCPBUz8He_zmV01D85XoDd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Non-cash interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--FairValueAdjustmentOfWarrants_i02_pp0p0_maNCPBUz8He_z9vAphGSmGp4" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Non-cash loss (gain) on change in fair value of warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">26,257</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,166,474</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--AccretionAmortizationOfDiscountsAndPremiumsInvestments_i02N_pp0p0_di_msNCPBUz8He_zXpKlqDUhTHc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Amortization of premium (discount) on marketable investment securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">203,958</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">9,755</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--IncreaseDecreaseInOperatingCapitalAbstract_i01B" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Changes in operating assets and liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--IncreaseDecreaseInAccruedInterestReceivableNet_i02N_pp0p0_di_msNCPBUz8He_zFYjrmkehIm2" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accrued interest income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">232,177</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,603</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_i02N_pp0p0_di_msNCPBUz8He_zNV49wpFRmyb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Prepaid and other current assets</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">378,078</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">398,579</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--IncreaseDecreaseInAccountsPayable_i02_pp0p0_maNCPBUz8He_zETJqHiQGHm9" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 20pt; text-align: left">Accounts payable</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">690,744</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccountsPayable" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">275,415</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_403_eus-gaap--IncreaseDecreaseInAccruedLiabilities_i02_pp0p0_maNCPBUz8He_zhb2HtByLXQ4" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 20pt; text-align: left">Accrued expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">208,990</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncreaseDecreaseInAccruedLiabilities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">543,955</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--LitigationSettlementExpense_i02_pp0p0_maNCPBUz8He_z0VxdNbKlKmi" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 20pt; text-align: left">Litigation settlement liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LitigationSettlementExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,000,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0657">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_409_eus-gaap--NetCashProvidedByUsedInOperatingActivities_i01T_pp0p0_mtNCPBUz8He_maCCERCztHv_zksG0WwNjQWi" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; padding-bottom: 1.5pt; text-align: left">Cash used in operating activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,425,056</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">7,455,510</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--NetCashProvidedByUsedInInvestingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash flows from investing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--PaymentsToAcquireAvailableForSaleSecuritiesDebt_i01N_pp0p0_di_msNCPBUzyrf_zgXSCjI9eQMf" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Purchases of marketable investment securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,876,211</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,466,811</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_406_eus-gaap--ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_i01_pp0p0_maNCPBUzyrf_z79uee4ECt2h" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Maturities of marketable investment securities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">450,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,350,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--NetCashProvidedByUsedInInvestingActivities_i01T_pp0p0_mtNCPBUzyrf_maCCERCztHv_z8FzyeFKpLub" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Cash used in investing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">35,426,211</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">116,811</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--NetCashProvidedByUsedInFinancingActivitiesAbstract_iB" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash flows from financing activities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--RepaymentsOfDebt_i01N_pp0p0_di_msNCPBUzmp2_zDbnEIQgtRE8" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Debt repayments</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,666,667</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:RepaymentsOfDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,111,111</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_40B_eus-gaap--ProceedsFromIssuanceOfDebt_i01_pp0p0_maNCPBUzmp2_zZio6N9a8geb" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Proceeds from debt</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0680">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">233,537</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ProceedsFromIssuanceOfCommonStock_i01_pp0p0_maNCPBUzmp2_zboIE6i9Eevg" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from common stock offering</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,840,457</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,653,140</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_ecustom--NetProceedsFromCostsAssociatedWithAtm_i01_pp0p0_maNCPBUzmp2_zRcbK9Tu2o61" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net proceeds from (costs associated with) ATM</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LPCN:NetProceedsFromCostsAssociatedWithAtm" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">3,416,115</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="LPCN:NetProceedsFromCostsAssociatedWithAtm" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">8,108</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromStockOptionsExercised_i01_pp0p0_maNCPBUzmp2_ztW0YMdFoybk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Proceeds from stock option exercises</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,693</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0690">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--ProceedsFromWarrantExercises_i01_pp0p0_maNCPBUzmp2_zjkF54CLLRrj" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">Net proceeds from exercise of warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">6,914,158</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--NetCashProvidedByUsedInFinancingActivities_i01T_pp0p0_mtNCPBUzmp2_maCCERCztHv_zznGlyfHBZo9" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; padding-left: 30pt; text-align: left">Cash provided by financing activities</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">28,601,598</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">11,681,616</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_405_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_iT_pp0p0_mtCCERCztHv_zo0OA49YuVhg" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 30pt; text-align: left">Net increase (decrease) in cash, cash equivalents, and restricted cash</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">13,249,669</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">4,109,295</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40F_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iS_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">Cash, cash equivalents, and restricted cash at beginning of period</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">24,217,382</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2019-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">14,728,523</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Cash, cash equivalents, and restricted cash at end of period</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,967,713</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" contextRef="AsOf2020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,837,818</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_403_eus-gaap--SupplementalCashFlowInformationAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Supplemental disclosure of cash flow information:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_eus-gaap--InterestPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Interest paid</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">92,515</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="us-gaap:InterestPaidNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">156,979</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--IncomeTaxesPaidNet_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Income taxes paid</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:IncomeTaxesPaidNet" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">200</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40A_eus-gaap--CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_iB" style="vertical-align: bottom; background-color: White">
    <td style="font-style: italic; text-align: left">Supplemental disclosure of non-cash investing and financing activity:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_ecustom--SettlementOfWarrantLiabilityOnWarrantExercises_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Settlement of warrant liability on warrant exercises</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="LPCN:SettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,365</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><ix:nonFraction name="LPCN:SettlementOfWarrantLiabilityOnWarrantExercises" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,591,362</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_406_eus-gaap--OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Net unrealized loss on available-for-sale securities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">186</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">66</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_407_ecustom--AccruedFinalPaymentChargeOnDebt_i01_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Accrued final payment charge on debt</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LPCN:AccruedFinalPaymentChargeOnDebt" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">33,886</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="LPCN:AccruedFinalPaymentChargeOnDebt" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">63,765</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--DebtInstrumentIncreaseAccruedInterest_i01_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Other accrued interest</td><td>&#160;</td>
    <td style="text-align: left"><span style="-sec-ix-hidden: xdx2ixbrl0728">&#160;</span></td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseAccruedInterest" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">448</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">See
accompanying notes to unaudited condensed consolidated financial statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>LIPOCINE
INC.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Notes
to Condensed Consolidated Financial Statements</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Unaudited)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zf26RVR5mCV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(1)
<span id="xdx_82A_z7Dnyaq5GlJ3">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (&#8220;Lipocine&#8221;
or the &#8220;Company&#8221;) in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).
The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries,
collectively referred to as the Company. In management&#8217;s opinion, the interim financial data presented includes all adjustments
(consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated.
Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules
and regulations of the SEC. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the
results that may be expected for any future period or for the year ending December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial
statements and the notes thereto for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating
to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally
accepted accounting principles. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing capital resources, together with interest thereon, will be sufficient to meet its projected operating
requirements through at least June 30, 2022 which includes an on-going clinical study for LPCN 1144, future clinical studies for LPCN
1148 and LPCN 1154, compliance with regulatory requirements and on-going litigation and settlement activities. The Company has based
this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it
currently expects if additional activities are performed by the Company including pre-commercial and commercial activities for TLANDO
and new clinical studies for LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1154. While the Company believes it has sufficient liquidity and
capital resources to fund our projected operating requirements through at least June 30, 2022, the Company will need to raise additional
capital at some point through the equity or debt markets or through out-licensing activities, before or after June 30, 2022, to support
its operations. If the Company is unsuccessful in raising additional capital, its ability to continue as a going concern will become
a risk. Further, the Company&#8217;s operating plan may change, and the Company may need additional funds to meet operational needs and
capital requirements for product development, regulatory compliance and clinical trial activities sooner than planned. In addition, the
Company&#8217;s capital resources may be consumed more rapidly if it pursues additional clinical studies for LPCN 1144, TLANDO XR, LPCN
1148 and LPCN 1154. Conversely, the Company&#8217;s capital resources could last longer if it reduces expenses, reduces the number of
activities currently contemplated under our operating plan or if it terminates, modifies the design or suspends on-going clinical studies..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:EarningsPerShareTextBlock"><p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_z3hFYjXuOHlc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(2)
<span id="xdx_82C_zPvpJhRmKqgc">Earnings (Loss) per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares
outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options,
warrants and, unvested restricted stock units to the extent such shares are dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 7; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zFklzRIFvkA6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three and six months
ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zEGLUH0xIVKg" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; width: 44%; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210401__20210630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200401__20200630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20210630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20200630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20210630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200401__20200630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,769,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20210630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,556,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20200630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,558,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Basic loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20210401__20210630_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareBasic_c20210101__20210630_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20200101__20200630_pdd" title="Basic loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareBasic" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Diluted loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210401__20210630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,809,041</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200401__20200630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">6,369,634</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20210630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">10,177,123</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20200630_pp0p0" title="Net loss" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" sign="-" unitRef="USD">12,140,285</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20210630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">88,290,650</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200401__20200630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">49,769,253</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20210630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">85,556,110</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20200630_pdd" title="Weighted avg. common shares outstanding" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">45,558,442</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareDiluted_c20210401__20210630_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.08</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareDiluted_c20200401__20200630_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.13</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EarningsPerShareDiluted_c20210101__20210630_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.12</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20200101__20200630_pdd" title="Diluted loss per share attributable to common stock" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:EarningsPerShareDiluted" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" sign="-" unitRef="USDPShares">0.27</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_znx1cR5mx2M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgUzANzH4zb7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
computation of diluted loss per share for the six months ended June 30, 2021 and 2020 does not include the following stock options and
warrants to purchase shares or unvested restricted stock units in the computation of diluted loss per share because these instruments
were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zF1rtWgD3N2" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,915,790</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="width: 14%; text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,012,041</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unvested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_zJp5UKSV93Ec" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_pdd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-06-30_custom_UnvestedRestrictedStockUnitsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">605,682</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount" style="text-align: right"><ix:nonFraction name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,423,210</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AB_zdJO1gF3Lrk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 8; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"><p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zwBgd4irrirh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3) <span id="xdx_821_zecIPDIXMdJb">Marketable Investment Securities</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#8217; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock"><p id="xdx_899_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zCqDFj7M3vK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zKMnjojBKDl5" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Corporate bonds, notes and commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" title="Amortized Cost" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,245</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" title="Gross unrealized holding gains" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zst3WqwmDm4i" title="Gross unrealized holding losses" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zLlkTmW4Idgj" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630_pp0p0" title="Amortized Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630_pp0p0" title="Gross unrealized holding gains" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0812">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630_zAi4Bj0aoh87" title="Gross unrealized holding losses" style="border-bottom: Black 2.5pt double; text-align: right">(<ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">186</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20210630_pp0p0" title="Aggregate fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" title="Amortized Cost" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" title="Gross unrealized holding gains" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zmxd8v90C1W1" title="Gross unrealized holding losses" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" title="Aggregate fair value" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pp0p0" title="Amortized Cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pp0p0" title="Gross unrealized holding gains" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231_zPbrHA3pBLta" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0829">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231_pp0p0" title="Aggregate fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_zqFSCfC6I3vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 13.5pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Maturities
of debt securities classified as available-for-sale securities at June 30, 2021 are as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock"><p id="xdx_891_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zn0nVmjl1fa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zzdYpf7yemTk" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 60%; text-align: left">Due within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20210630_znVIirmXF7Ei" title="Due within one year" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,245</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c20210630_pp0p0" title="Due within one year" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20210630_zJ8B4Bhi0one" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,245</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20210630_zasMMEuy9VW3" title="Total maturities of debt securities classified as available-for-sale securities, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_z6kib6qku1J5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">There
were no sales of marketable investment securities during the three and six months ended June 30, 2021 and 2020 and therefore <span id="xdx_90C_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210401__20210630_zKwGbR2fgt42" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_903_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200401__20200630_zea6w7zv2wJe" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_90D_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210101__20210630_zR71wdpBYe01" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_904_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200101__20200630_zeA2Qoe8eJ7f" title="Available-for-sale securities, gross realized gain (loss)"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="From2021-04-012021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="From2020-04-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet" contextRef="From2020-01-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span> realized
gains or losses. Additionally, during the three months ended June 30, 2021 and 2020, <span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20210401__20210630_zcWrB1QUvwsg" title="Proceeds from sale and maturity of marketable securities"><span id="xdx_90F_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20200401__20200630_zqhI4aSg1l18" title="Proceeds from sale and maturity of marketable securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-04-012021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2020-04-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></span></span> marketable investment securities matured, and
$<span id="xdx_908_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20210630_zVjTQYyspbqf" title="Proceeds from sale and maturity of marketable securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">450,000</ix:nonFraction></span> and $<span id="xdx_901_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20200630_zrZHqaVHSr6l" title="Proceeds from sale and maturity of marketable securities"><ix:nonFraction name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.3</ix:nonFraction></span> million of marketable investment securities matured during the six months ended June 30, 2021 and 2020, respectively.
The Company determined there were <span title="Other-than-temporary impairments"><span id="xdx_902_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210401__20210630_zMd8HawUJRF6" title="Other-than-temporary impairments"><span id="xdx_90B_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200401__20200630_zYGkwhjna2uj" title="Other-than-temporary impairments"><span id="xdx_905_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20210630_zsvSuCfsMDZ3" title="Other-than-temporary impairments"><span id="xdx_90A_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20200630_z7xRAGNQKJMi" title="Other-than-temporary impairments"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2021-04-012021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2020-04-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2021-01-01to2021-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" contextRef="From2020-01-012020-06-30" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span></span></span></span></span> other-than-temporary impairments for the three and six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueDisclosuresTextBlock"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zlVS9aypAdT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(4)
<span id="xdx_825_zZsThDQdpmO5">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 Inputs: Quoted prices for identical instruments in active markets. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 9; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock"><p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zsBKdAnZU4a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zrUBVqzHxtQc" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,179,073</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,179,073</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Commercial Paper</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" title="Assets, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,987,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,987,623</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Corporate bonds and notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgtLYI7LEiDl" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,684,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeJC3drlne3i" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbtmpRH0yD3a" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">21,684,436</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvXAm5ktI2gf" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">45,851,132</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,179,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8jtsVdOssfj" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzUYEB4ZuPl2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRwp7qyph7Mb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdMb09hfXwQ" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,429</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630_zDJW2QD4mtOb" title="Liabilities, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">46,976,561</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z394n7Gf8Kc" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">10,179,073</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK2SoRNz2Wd1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">35,672,059</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgZ8Bucc3v9j" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,429</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="width: 12%; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember14581359" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,849,577</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AssetsFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" title="Assets, fair value" style="border-bottom: Black 2.5pt double; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJHVG9AW6Uu9" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9hoR9TLBpVf" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE6Z3F33HOb8" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Liabilities, fair value" id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_z7MtH1P16mO3" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">20,019,628</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Liabilities, fair value" id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">18,399,585</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Liabilities, fair value" id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">449,992</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td title="Liabilities, fair value" id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvrtQbFL3ta6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LiabilitiesFairValueDisclosure" contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A3_zJkTJfUhi1a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
equivalents: Cash equivalents primarily consist of highly-rated money market funds and treasury bills with original maturities to the
Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market
funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices
or broker or dealer quotations for similar assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Warrant
liability: <span style="background-color: white">The warrant liability (which relates to warrants to purchase shares of common stock)
is marked-to-market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements
of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#8217; equity. The fair value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant
assumptions used in preparing the option pricing model for valuing the warrant liability as of June 30, 2021, include (i) volatility
of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zDStewBsJte1" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72.62</ix:nonFraction></span>%, (ii) risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zQGmDgUTEB0c" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.46</ix:nonFraction></span>%, (iii) strike price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zs1ivdHxrAna" title="Strike price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span>, (iv) fair value of common stock of $<span id="xdx_904_eus-gaap--SharePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zmZI7KROlM3b" title="Fair value of common stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></span>, and (v) expected
life of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zYXJ1wS2EgAl" title="Expected term"><ix:nonNumeric contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.38</ix:nonNumeric></span> years. The significant assumptions used in preparing the option pricing model for valuing the warrant liability as of December
31, 2020, include (i) volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zWNkpRoEqCni" title="Expected volatility"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.46</ix:nonFraction></span>%, (ii) risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zAlbqTWtL06" title="Risk-free interest rate"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.27</ix:nonFraction></span>%, (iii) strike price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRl268Gaae8a" title="Strike price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></span>, (iv) fair value of common
stock of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKq3vYmuYFbk" title="Fair value of common stock"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction></span>, and (v) expected life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zNAsZ0exovC3" title="Expected term"><ix:nonNumeric contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.9</ix:nonNumeric></span> years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 10; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2, or Level 3 for the three and six
months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:DebtDisclosureTextBlock"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z7UbT5BzuIja" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(5)
<span id="xdx_82F_zs2chRFIdIbg">Loan and Security Agreements and Other Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Silicon
Valley Bank Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon
Valley Bank (&#8220;SVB&#8221;) pursuant to which SVB agreed to lend the Company $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zPenQJXHCw5k" title="Aggregate amount"><ix:nonFraction name="us-gaap:DebtInstrumentFaceAmount" contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" name="us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (<span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pdd" title="Interest rate"><ix:nonFraction name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" contextRef="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">4.25</ix:nonFraction>%</span> as of June
30, 2021), which interest is payable monthly</ix:nonNumeric></span>. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zEBKDqGbjSFb" title="Debt instrument, maturity date"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:datemonthdayyearen" name="us-gaap:DebtInstrumentMaturityDate">June 1, 2022</ix:nonNumeric></span>. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z1cyT8gzoNel" title="Debt instrument, balloon payment to be paid"><ix:nonFraction name="us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" contextRef="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">650,000</ix:nonFraction></span> (the &#8220;Final Payment Charge&#8221;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, increase in amount"><ix:nonFraction name="us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet" contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">624,000</ix:nonFraction></span> has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#8217;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, as TLANDO was not approved
by the United States Food and Drug Administration (&#8220;FDA&#8221;) prior to May 31, 2018, the Company maintained $<span id="xdx_904_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20180531__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAjDgTLyP5Vh" title="Cash collateral for borrowed securities"><ix:nonFraction name="us-gaap:CashCollateralForBorrowedSecurities" contextRef="AsOf2018-05-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">5.0</ix:nonFraction></span> million of cash
collateral at SVB as required under the Loan and Security Agreement until such time as TLANDO is approved by the FDA. However on February
16, 2021, the Company amended the Loan and Security Agreement with SVB to, among other things, remove the financial trigger and financial
trigger release event provisions requiring the Company to maintain a minimum cash collateral value and collateral pledge thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4zL5llX0Vn5" title="Debt instrument, restrictive covenants"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" name="us-gaap:DebtInstrumentRestrictiveCovenants">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus <span id="xdx_907_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_dp_uPure_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zlbxsicGzdQg" title="Debt instrument, basis spread on interest rate for debt default"><ix:nonFraction name="LPCN:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">5.0</ix:nonFraction></span>% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</ix:nonNumeric></span> These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit
facility, the Company&#8217;s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater
than $<span id="xdx_906_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, minimum amount considered for insolvency"><ix:nonFraction name="LPCN:DebtInstrumentMinimumAmountConsideredForInsolvency" contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">100,000</ix:nonFraction></span> individually or in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Future
maturities of principal payments on the Loan and Security Agreement at June 30, 2021 (excluding accrued final payment fee) are as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"><p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1SZVfVzWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z6RFgppwRNJ1" style="display: none">Schedule of Maturities of Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zPqWdHIQ0u18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">(in thousands)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzdw8_zsgvcvVvWvpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,666</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzdw8_zRO4famUECu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">1,667</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_iI_pn3n3_maLTDzdw8_zvcuXlIsdiNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzdw8_ztFsB8fyqitf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Long-term
    Debt</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LongTermDebt" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">3,333</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AA_z5Wo6sNsbdtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>


<ix:exclude><!-- Field: Page; Sequence: 11; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
June 15, 2020 and through December 31, 2020, the Company deferred Federal Insurance Contributions Act (&#8220;FICA&#8221;) taxes under
the CARES Act Section 2302. Payment of these tax deferrals are delayed to December 31, 2021 and December 31, 2022. As of June 30, 2021
the tax deferrals totaled $<span id="xdx_90A_ecustom--DeferredFederalInsuranceContributionsActTaxPayments_c20210630_pp0p0" title="Deferred FICA payroll tax payments"><ix:nonFraction name="LPCN:DeferredFederalInsuranceContributionsActTaxPayments" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">36,000</ix:nonFraction></span> and are included in accrued liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:IncomeTaxDisclosureTextBlock"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zlvLaioHuR1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(6)
<span id="xdx_82B_zZhI94j6oQQ3">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
tax provision for interim periods is determined using an estimate of the Company&#8217;s effective tax rate for the full year adjusted
for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the
annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2021 and December 31, 2020, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals
of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock"><p id="xdx_805_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zqmQ5D9Bnmb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(7)
<span id="xdx_827_zuTlCzkpXzw1">Contractual Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(a)
Abbott Products, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual <span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zM6Zpn38Nkl7" title="Percentage of net sales"><ix:nonFraction name="LPCN:CollaborativeArrangementRoyaltiesPercentageOfNetSales" contextRef="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1</ix:nonFraction>%</span> royalty on net sales. Such
royalties are limited to $<span><span id="xdx_900_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zt2tDNeHn1Qa" title="Royalties, commitment amount"><ix:nonFraction name="us-gaap:RoyaltyGuaranteesCommitmentsAmount" contextRef="AsOf2021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span></span> million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by <span id="xdx_90B_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zRFZ6Ul7fsA1" title="Percentage of royalties reduction based upon product launch"><ix:nonFraction name="LPCN:PercentageOfRoyaltiesReductionBasedUponProductLaunch" contextRef="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">50</ix:nonFraction></span>%.
The Company did not incur any royalties expense during the three and six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(b)
Contract Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors and primarily clinical researchers who serve
as advisors to the Company. The Company incurred expenses of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20210401__20210630_pp0p0" title="Contract research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">786,000</ix:nonFraction></span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200401__20200630_zqTu8K6GJzsf" title="Contract research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.2</ix:nonFraction></span> million, respectively, for the three months ended June
30, 2021 and 2020 and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20210630_ztlvwdg0UN7a" title="Contract research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.7</ix:nonFraction></span> million and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20200630_zJOsrakd2PM7" title="Contract research and development expenses"><ix:nonFraction name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.9</ix:nonFraction></span> million, respectively, for the six months ended June 30, 2021 and 2020 under these agreements
and has recorded these expenses in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeOperatingLeasesTextBlock"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zBvhC5AE1iv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(8)
<span id="xdx_822_zdxNOJ0zY7xg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021 and on March 3, 2021, the Company extended the lease through February 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zUfUMlUBOOp4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Future
minimum lease payments under non-cancelable operating leases as of June 30, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zrEM2MWZVo35" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210630_zFppP7jvIsE3" style="text-align: center; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzsoZ_zB8frL0bvIue" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,191</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzsoZ_zUbrtUbBqKTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">55,064</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzsoZ_zERVpyKDdUBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">220,255</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A7_zVuTwIz5Upsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s rent expense was $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20210401__20210630_pp0p0" title="Rent expense"><span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20200401__20200630_pp0p0" title="Rent expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">83,000</ix:nonFraction></ix:nonFraction></span></span> for each of the three months ended June 30, 2021 and 2020 and was $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Rent expense"><span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Rent expense"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD"><ix:nonFraction name="us-gaap:OperatingLeaseExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">165,000</ix:nonFraction></ix:nonFraction></span></span> for each of the six
months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 12; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyyQKbNBuRx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(9)
<span id="xdx_822_zljeLAwMdnX9">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(a)
Issuance of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $<span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1ZifzEzVQJg" title="Proceeds from issuance of common stock, gross"><ix:nonFraction name="LPCN:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">28.7</ix:nonFraction></span> million, before deducting underwriter fees and other offering expenses of $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy8udAiuqHaj" title="Agent fees and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.9</ix:nonFraction></span> million. In the January 2021 Offering,
the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z87TsmWqcuH3" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">16,428,571</ix:nonFraction></span> shares of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February
2020 Offering were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_z1hytR5Y1gTi" title="Proceeds from issuance of common stock, gross"><ix:nonFraction name="LPCN:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction></span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0" title="Agent fees and other offering expenses"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">347,000</ix:nonFraction></span>. In the
February 2020 Offering, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zLOX5oSbAU8d" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,084,034</ix:nonFraction></span> Class A Units at an offering price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDAIk3tknmX5" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.595</ix:nonFraction></span> per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDcmCkfOm5Z1" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.53</ix:nonFraction></span>
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;November 2019 Offering&#8221;). The gross proceeds from the November 2019 Offering
were approximately $<span id="xdx_90F_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmTg3Iz6obsj"><ix:nonFraction name="LPCN:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.0</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, before deducting placement agent fees
and other offering expenses of $<span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0p0"><ix:nonFraction name="us-gaap:PaymentsOfStockIssuanceCosts" contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">404,000</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">.
In the November 2019 Offering, the Company sold (i) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z8vFPGNUcZYh"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,450,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Class A Units, with each Class A Unit consisting
of one share of its common stock and a common warrant to purchase one share of its common stock, and (ii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,550,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Class B Units, with each Class B Unit consisting
of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its common stock, at
a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgyBCUDgVwV2"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per Class A Unit and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmJObtiULXq3"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.4999</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per Class B Unit. The pre-funded warrants, which
were exercised for common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed
certain beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zwdg8vL3Rfm4"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember" decimals="INF" unitRef="USDPShares">.0001</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment. Additionally,
the common stock warrants were immediately exercisable at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118_zUlwhOJdNCCb"><ix:nonFraction name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" contextRef="AsOf2019-11-18" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment, and expire
on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common stock warrants can be exercised at any
time that the pre-funded warrant holder or the common stock warrant holder would beneficially own, after such exercise, more than 4.99%
(or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after giving effect to such exercise. On the
date of the November 2019 Offering, the Company allocated approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zbDObIxKhwBk"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">768,000</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgjKERfJbjGg"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodValueNewIssues" contextRef="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.8</ix:nonFraction>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to common stock/additional paid-in capital
and warrant liability, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $50.0 million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#8217;s sales agent. Cantor may sell the Company&#8217;s common stock by any method permitted by law deemed
to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor <span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember_zzzbtHM5gGMk" title="Percentage of gross proceeds on sale of shares"><ix:nonFraction name="LPCN:PercentageOfGrossProceedOnSaleOfShares" contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">3.0</ix:nonFraction></span>% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
shares of the Company&#8217;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#8220;Form S-3&#8221;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 13; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, we had sold an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zFLwBGDdEs4e" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-06-30_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">15,023,073</ix:nonFraction></span> shares at a weighted-average sales price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zF5HJzr6DXX2" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-06-30_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">2.19</ix:nonFraction></span> per share under the Sales
Agreement for aggregate gross proceeds of $<span id="xdx_907_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z6ipZYcjzE86" title="Proceeds from issuance of common stock, gross"><ix:nonFraction name="LPCN:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2021-01-012021-06-30_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">32.9</ix:nonFraction></span> million and net proceeds of $31.7 million, after deducting sales agent commission and
discounts and our other offering costs. During the three months ended June 30, 2021, the Company did not sell any shares of our common
stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072). During the six months ended June 30, 2021, the
Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zie1VQsNJ05e" title="Stock issued during period, shares, new issues"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember_custom_AtMarketOfferingMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,811,238</ix:nonFraction></span> shares of our common stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072) at
a weighted-average sales price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_zrguVuJpBMZ6" title="Shares issued, price per share"><ix:nonFraction name="us-gaap:SharesIssuedPricePerShare" contextRef="AsOf2021-06-30_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.95</ix:nonFraction></span> per share, resulting in net proceeds of approximately $3.4 million under the Sales Agreement
which is net of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock"><ix:nonFraction name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="From2021-01-012021-06-30_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">112,000</ix:nonFraction></span> in expenses. During the three and six months ended June 30, 2020, the Company did not sell any shares of our
common stock pursuant to the prior Registration Statement on Form S-3 (File No. 333-220942). As of June 30, 2021, the Company had $<span id="xdx_904_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_z2fhijm6gRxh" title="Proceeds from issuance of common stock, gross"><ix:nonFraction name="LPCN:ProceedsFromIssuanceOfCommonStockGross" contextRef="From2021-01-012021-06-30_custom_AccreditedInvestorsMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">41.2</ix:nonFraction></span>
million available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(b)
Rights Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
November 13, 2015, the Company and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $<span id="xdx_90E_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_z76l5ygPZ052" title="Class of warrant or right, redemption price of warrants or rights"><ix:nonFraction name="LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" contextRef="From2015-11-122015-11-13" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">63.96</ix:nonFraction></span> per one-thousandth share (the &#8220;Purchase Price&#8221;). The Rights will generally become
exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or
associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined
by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring
Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of
which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except
in certain situations, a person or group of affiliated or associated persons becomes an &#8220;Acquiring Person&#8221; upon acquiring
beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#8217;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#8217;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company will be entitled to redeem the Rights at $<span id="xdx_900_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20210630_zQ3O4iENhhM9" title="Class of warrant or right, redemption price of warrants or rights"><ix:nonFraction name="LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.001</ix:nonFraction></span> per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#8217;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021, unless the
rights are earlier redeemed or exchanged by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(c)
Share-Based Payments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#8217;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#8217;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#8217;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#8217;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 14; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#8217;s common stock price, (ii) the periods of time over
which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected
dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which
is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of
operations amounted to approximately $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630_zW18lo2IIVz9" title="Allocated share-based compensation expense"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">147</ix:nonFraction></span>,000 and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630_zw7mXSh8Vg9b"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">465</ix:nonFraction></span>,000, respectively, for the three months ended June 30, 2021 and 2020, and amounted
to $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630_z1f570IcXqD2"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">294</ix:nonFraction></span>,000 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_zQroveiqLwOh"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="-3" scale="3" unitRef="USD">787</ix:nonFraction></span>,000, respectively, for the six months ended June 30, 2021 and 2020, and is allocated as follows:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLmIf86cXnic" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zTBJ1F1cgMLg" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 48.95pt; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zF8Nnry2PyU9" title="Allocated Share-based Compensation Expense" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">69,483</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWDpZeOg2EEc" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">199,777</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRKTDCTA07E6" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">136,369</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgm0rPZL3m16" style="width: 10%; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">334,441</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTbIMjkqgqc" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">77,264</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zABAm4CjHjAi" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">265,281</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgqhrLRgq0si" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">157,944</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zonanIsgmPa7" style="border-bottom: Black 1.5pt solid; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember" format="ixt:numdotdecimal" decimals="0" unitRef="USD">452,530</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Allocated
    Share-based Compensation Expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_zdJtDHK6Qsx6" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-04-012021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">146,747</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_zc5IX2x1QfK5" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">465,058</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_zD87BeQzAEr1" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">294,313</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_zt6tr7toSVtl" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="0" unitRef="USD">786,971</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



</ix:nonNumeric><p id="xdx_8A3_zeZv2xiL6zX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company issued <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIOZRETbdzzl" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">66,000</ix:nonFraction></span> stock options and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGY7HOxfEbw3" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">376,000</ix:nonFraction></span> stock options, respectively, during the three and six months ended June 30, 2021 and
issued <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNpwvwMdPyrj" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">113,000</ix:nonFraction></span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zpxgyen6yLai" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">739,000</ix:nonFraction></span> stock options during the three and six months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Key
assumptions used in the determination of the fair value of stock options granted are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#8220;SAB&#8221;) No. 107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risk-Free
Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Volatility</i>: The volatility factor is based solely on the Company&#8217;s trading history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
options granted during the six months ended June 30, 2021 and 2020, the Company calculated the fair value of each option grant on the
respective dates of grant using the following weighted average assumptions:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwmpvSuawot1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zgecfC0mfGQd" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210630_zmDJMKFGsSW8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20200630_zW7zEcE5d5k9" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zlLije1vKWVg" title="Expected term"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.70</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630_zxoJsHRWHrkj" title="Expected term"><ix:nonNumeric contextRef="From2020-01-012020-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">5.81</ix:nonNumeric></span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zcJlPuXYgIZh" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.52</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">1.33</ix:nonFraction></td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zvXnDLRRuXS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">95.52</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">99.52</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A2_zgtdnN0Mb3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">FASB
ASC 718, <i>Stock Compensation,</i> requires the Company to recognize compensation expense for the portion of options that are expected
to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If
the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required
in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20210630_z3LIhw34OZU4" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized"><ix:nonFraction name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.1</ix:nonFraction></span> million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan. That cost is expected to be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630_zqNbaQGCgRJd" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">2.21</ix:nonNumeric></span> years
and will be adjusted for subsequent changes in estimated forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 15; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(d)
Stock Option Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#8220;2014 Plan&#8221;) subject to shareholder approval
which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation
rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2014-04-30_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,000,000</ix:nonFraction></span> shares were authorized for issuance
under the 2014 Plan. Additionally, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20140430__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2014-04-30_custom_EquityIncentivePlanMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">271,906</ix:nonFraction></span> remaining authorized shares under the 2011 Equity Incentive Plan (&#8220;2011 Plan&#8221;)
were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan
was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted
under the 2014 Plan from <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,271,906</ix:nonFraction></span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,471,906</ix:nonFraction></span>. Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further
amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under
the 2014 Plan from <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">2,471,906</ix:nonFraction></span> to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,221,906</ix:nonFraction></span>. Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended
and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014
Plan from <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">3,221,906</ix:nonFraction></span> to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,721,906</ix:nonFraction></span>. The board of directors, on an option-by-option basis, determines the number of shares, exercise price,
term, and vesting period for options granted. Options granted generally have a <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zKndHewrps2l" title="Contractual life::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1148">ten</span></span>-year contractual life. The Company issues shares of
common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares
held in treasury. An aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zvJRZema1pe7" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" contextRef="AsOf2021-06-30_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,721,906</ix:nonFraction></span> shares are authorized for issuance under the 2014 Plan, with <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="AsOf2021-06-30_custom_StockIncentivePlan2014Member" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,584,874</ix:nonFraction></span> shares remaining available
for grant as of June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY50Qz52B1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zponXz4ot0Ui" style="display: none">Schedule of Stock Option Activity</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding stock options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zLwTwd2zLfh7" title="Number of shares, Balance at beginning of the period (in shares)" style="width: 17%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,564,458</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4uEsg0iVKM9" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)" style="width: 25%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.36</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zx2A1aNSMa4c" title="Number of shares, Options granted (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">376,000</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIuzppetXTx5" title="Weighted average exercise price, Options granted (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.44</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqElCoELOdTa" title="Number of shares, Options exercised (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">4,584</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zEKKE1j0p4Fi" title="Weighted average exercise price, Options exercised (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.46</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKOPcUjH6b71" title="Number of shares, Options forfeited (in shares)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" title="Weighted average exercise price, Options forfeited (in dollars per share)" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFy5JTxVWtj" title="Number of shares, Options cancelled (in shares)" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">20,084</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zkiISkgOEuv3" title="Weighted average exercise price, Options cancelled (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">6.45</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zw9KMa1wqCPj" title="Number of shares, Balance at end of the period (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,915,790</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zRy9gaViWFUb" title="Weighted average exercise price, Balance at end of the period (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.16</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGBFslhK1UUa" title="Number of shares, Options exercisable (in shares)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,528,729</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl7VB44qqrA7" title="Weighted average exercise price, Options exercisable (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.24</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AD_zO02laWGFiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock"><p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zbN5aK9liofg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z9gHRxkwNHWh" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number exerciseable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 10%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zYu9Fjg4nOYe" title="Number of options outstanding, shares" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">3,915,790</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zNNMiMxLBh05" title="Options outstanding, Weighted average remaining contractual life (Years)"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">6.39</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_z1nqIaCWFF4k" title="Options outstanding, Weighted average exercise price (in dollars per share)" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">3.16</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0" title="Options outstanding, Aggregate intrinsic value" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">636,639</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20210630_z83YayXslyP7" title="Number of options exercisable" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">2,528,729</ix:nonFraction></td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_z0V2SHtTusWa" title="Options exercisable, Weighted average remaining contractual life (Years)"><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">4.84</ix:nonNumeric></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_zkC9ca7vZgGc" title="Options exercisable, Weighted average exercise price"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">4.24</ix:nonFraction></span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630_pp0p0" title="Options exercisable, Aggregate intrinsic value"><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">311,190</ix:nonFraction></span></td><td style="text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8AF_zLFHVuLecOIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. There were <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zwbS4AjMonLl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:numwordsen" decimals="0" unitRef="Shares">zero
</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zjv5INWO2DWl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">4,584</ix:nonFraction></span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, stock options exercised during the three and six months ended June 30, 2021, and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNY6RxuqMC0f" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zBGMUeeHZWr1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember" format="ixt-sec:numwordsen" decimals="0" unitRef="Shares"><ix:nonFraction name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484" format="ixt-sec:numwordsen" decimals="0" unitRef="Shares">no</ix:nonFraction></ix:nonFraction></span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">stock options exercised during the three and
six months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>


<ix:exclude><!-- Field: Page; Sequence: 16; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(e)
Common Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for its common stock warrants under ASC 480, <i>Distinguishing Liabilities from Equity</i>, which requires any
financial instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#8217;s
equity shares, or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring
assets, to be classified as a liability. In accordance with ASC 480, the Company&#8217;s outstanding warrants from the November 2019
Offering are classified as a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair
value recognized as gain (loss) on change in fair value of warrant liability in the Company&#8217;s consolidated statements of
operations. The warrants issued in the November 2019 Offering allow the warrant holder, if certain change in control events occur,
the option to receive an amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option
pricing model with certain defined assumptions upon a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company had <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d" title="Warrants outstanding"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="AsOf2021-06-30_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">1,094,030</ix:nonFraction></span> common stock warrants outstanding from the November 2019 Offering to purchase an equal number
of shares of common stock. The fair value of these warrants on June 30, 2021 and on December 31, 2020 was determined using the Black-Scholes
option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="LPCN:ScheduleOfFairValueOfWarrantsTableTextBlock"><p id="xdx_891_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zyFENORiDsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zp3NCmSqWXbk" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Expected life in years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z09NG5MkR0Eg" title="Expected life in years"><ix:nonNumeric contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.38</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYqGocmKiMe" title="Expected life in years"><ix:nonNumeric contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">3.88</ix:nonNumeric></span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf5RGxpsBjDk" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">0.46</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVDPwmuU1Je" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="Pure">0.27</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNZLkp6Is9a" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOwQqz8wAW9j" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcOGy88fz0c" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">72.62</ix:nonFraction></td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFK1yzVh9NMg" style="text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">88.46</ix:nonFraction></td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwaZkYUGnL6c" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.40</ix:nonFraction></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6vyfjDH9hj5" style="text-align: right"><ix:nonFraction name="us-gaap:SharePrice" contextRef="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">1.36</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8A9_zWbRIeQjF1Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and six months ended June 30, 2021, the Company recorded a non-cash gain of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zs6NnteTNPil" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-04-012021-06-30_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">221,000</ix:nonFraction></span> and $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHYhVOSzjJK9" title="Fair value adjustment of warrants"><span><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">26,000</ix:nonFraction></span></span>, respectively, from the change
in fair value of the November 2019 Offering warrants. During the three and six months ended June 30, 2020, the Company recorded a non-cash
loss of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWkKNHYUXju9" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-04-012020-06-30_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.1</ix:nonFraction></span> million and $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zDVtFQDKo2Re" title="Fair value adjustment of warrants"><ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2020-01-012020-06-30_custom_November2019OfferingMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">3.2</ix:nonFraction></span> million from the change in fair value of the November 2019 Offering warrants. The following table is a
reconciliation of the warrant liability measured at fair value using level 3 inputs:</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="LPCN:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock"><p id="xdx_89F_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zBrfZqVXUHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zbtPMe30hS83" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zAASvD6PZTY4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zRhOtC0TMVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2020-12-31" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,170,051</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Settlement of liability on warrant exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(<ix:nonFraction name="LPCN:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">18,365</ix:nonFraction></td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Change in fair value of common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(<ix:nonFraction name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="From2021-01-01to2021-06-30" format="ixt:numdotdecimal" decimals="0" sign="-" unitRef="USD">26,257</ix:nonFraction></td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:WarrantsAndRightsOutstanding" contextRef="AsOf2021-06-30" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,125,429</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

</ix:nonNumeric><p id="xdx_8A4_z0FpmroS8r9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
in the February 2020 Offering, the Company issued <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0d" title="Issued"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="From2021-01-012021-06-30_custom_February2020OfferingMember" format="ixt:numdotdecimal" decimals="0" unitRef="Shares">5,042,017</ix:nonFraction></span> common stock warrants, however, because these warrants do not provide the
warrant holder the option to put the warrant back to the Company, the warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<ix:nonNumeric contextRef="From2021-01-01to2021-06-30" continuedAt="ConU001249-01" escape="true" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"><p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SONOWOAWAE-MPE_znLjgJKxw7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span id="xdx_8B8_zWLYDtd7Grbl" style="display: none">Schedule
of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">Outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmDTWqWwmmah" title="Number of shares, Balance at beginning of the period" style="width: 20%; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2020-12-31_us-gaap_WarrantMember14584484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,944,366</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEGxKHoNM9i" title="Weighted average Exercise Price, Beginning of the period" style="width: 25%; text-align: right"><ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2020-12-31_us-gaap_WarrantMember14584484" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5j3hk4Nhjj3" title="Issued" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XX0Wv7TZab" title="Exercised" style="text-align: right">(<ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sIBrNn3Gu2" title="Exercised" style="text-align: right"><ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.50</ix:nonFraction></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9lDr6uZ8Y3" title="Expired" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezwjN9XJ1Hl" title="Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPh0HtUZNjKe" title="Cancelled" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" title="Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lJBS67disk" title="Forfeited" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: center">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSfdtI9MEUEh" title="Number of shares, Balance at ending of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTPT1VA2txc" title="Weighted average Exercise Price, Ending of the period" style="border-bottom: Black 2.5pt double; text-align: right"><ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


</ix:nonNumeric><p id="xdx_8AB_z9WE8xG13hB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and six months ended June 30, 2021, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_dc_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXVW4WwLGkw9"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-04-012021-06-30_us-gaap_WarrantMember" format="ixt-sec:numwordsen" decimals="INF" unitRef="Shares">zero</ix:nonFraction></span> and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvSbpYrAhALa" title="Common warrants to purchase share of our common stock"><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">10,000</ix:nonFraction></span> common stock warrants to purchase one share of our common stock were exercised,
respectively, resulting in proceeds of <span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pp0p0_dc_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxq1tOOwQ8"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-04-012020-06-30_us-gaap_WarrantMember" format="ixt-sec:numwordsen" decimals="0" scale="0" unitRef="USD">zero</ix:nonFraction></span> and $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwxgUEBQx87" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember14584609" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">5,000</ix:nonFraction></span>. Additionally, during the three and six months ended June 30, 2020, <span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPq1vIEGwFbl" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-04-012020-06-30_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,497,807</ix:nonFraction></span>
and <span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zgcno4EZRawf" title="Proceeds from exercise of warrants"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">13,618,807</ix:nonFraction></span> common stock warrants to purchase one share of our common stock were exercised, respectively, resulting in proceeds of
approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200401__20200630_zRsMVpzsux24"><span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20200630_z7nwWLCkWVSh"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-04-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD"><ix:nonFraction name="us-gaap:ProceedsFromWarrantExercises" contextRef="From2020-01-012020-06-30" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">6.9</ix:nonFraction></ix:nonFraction></span></span> million in each of the three and six-month periods ending June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 17; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C00_gL3SONOWOAWAE-MPE_zF7xBcdU6fC9"><ix:continuation continuedAt="ConU001249-02" id="ConU001249-01">The
following table summarizes information about common stock warrants outstanding at June 30, 2021:</ix:continuation></span></span></p>

<div id="xdx_C03_gL3SONOWOAWAE-MPE_zTx5vU2ZE725"><ix:continuation continuedAt="ConU001249-03" id="ConU001249-02"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zeLvIOq7pmD3" summary="xdx: Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Warrants outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Number exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average remaining contractual life (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average exercise price</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Aggregate intrinsic value</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 26%"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 22%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUsDS15dVYd" title="Number of warrants exercisable, shares" style="text-align: right"><span><ix:nonFraction name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515" format="ixt:numdotdecimal" decimals="INF" unitRef="Shares">1,934,366</ix:nonFraction></span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>&#160;</span></td><td style="text-align: right"><span><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQExU5rxjy3g" title="Weighted average remaining contractual life"><ix:nonNumeric contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484" format="ixt-sec:duryear" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">3.50</ix:nonNumeric></span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zntgohBvSxsk" title="Weighted average exercise price, per share" style="text-align: right"><span><span title="Weighted average Exercise Price, Ending of the period"><ix:nonFraction name="LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515" format="ixt:numdotdecimal" decimals="INF" unitRef="USDPShares">0.51</ix:nonFraction></span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlX259qtjsIg" title="Aggregate intrinsic value" style="text-align: right"><span><ix:nonFraction name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">1,715,719</ix:nonFraction></span></td><td style="text-align: left"><span>&#160;</span></td></tr>
  </table>

</ix:continuation></div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C09_gL3SONOWOAWAE-MPE_z7UxHFC1QoY4"><ix:continuation id="ConU001249-03">&#160;</ix:continuation></span></span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ2XWsTWguH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(10)
<span id="xdx_82A_z1vdK7tZE0Y4">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#8217;s JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement for expired
U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus has answered
the complaint and asserted counterclaims of non-infringement, inequitable conduct and invalidity. The Company answered Clarus&#8217;s
counterclaims on April 29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February
11, 2020 and a Summary Judgement Hearing on January 15, 2021. In May 2021, the Court granted Clarus&#8217; motion for Summary Judgment,
finding the asserted claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy
the written description requirement of 35 U.S.C. &#167; 112. Clarus still had remaining counterclaims before the Court. On July 13, 2021,
Clarus and the Company entered into a global settlement agreement (&#8220;Global Agreement&#8217;) which resolved all outstanding claims
of this litigation as well as the on-going United States Patent and Trademark Office (&#8220;USPTO&#8221;) Interference No. 106,128 between
the parties. Under the terms of the Global Agreement, the Company agreed to pay Clarus $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_znAXOqCrqB0d" title="Litigation settlement"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">4.0</ix:nonFraction></span> million payable as follows: $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_z22uHYa8BcH" title="Litigation settlement"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">2.5</ix:nonFraction></span> million
immediately, $<span id="xdx_902_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zsmNIE49vZs7" title="Litigation settlement"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">1.0</ix:nonFraction></span> million on July 13, 2022 and $<span id="xdx_907_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_pp0p0" title="Litigation settlement"><ix:nonFraction name="us-gaap:LitigationSettlementAmountAwardedToOtherParty" contextRef="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">500,000</ix:nonFraction></span> on July 13, 2023. No future royalties are owing from either party. On July 15,
2021, the Court dismissed with prejudice the Company&#8217;s claims and Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to
the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading
and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this nature. The retention amount
payable by the Company under our policy is $<span id="xdx_900_eus-gaap--RetentionPayable_iI_pn4n6_c20191114_zjL5vveK3R6h" title="Retention payable"><ix:nonFraction name="us-gaap:RetentionPayable" contextRef="AsOf2019-11-14" format="ixt:numdotdecimal" decimals="-4" scale="6" unitRef="USD">1.25</ix:nonFraction></span> million. The Company filed a motion to dismiss the class action lawsuit on July 24,
2020. In response, the plaintiffs filed their response to the motion to dismiss the class action lawsuit on September 22, 2020 and the
Company filed its reply to its motion to dismiss on October 22, 2020. The Company intends to vigorously defend itself against these allegations
and has not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate
be made of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (&#8220;the Lipocine &#8216;779 Application&#8221;)
with the USPTO. On October 16 and November 3, 2020, Lipocine filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (&#8220;the Clarus &#8216;178 Application&#8221;). Pursuant to the Company&#8217;s request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and the Company was initially declared Senior Party. A conference
call with the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing
certain motions and setting the schedule for the preliminary motions phase. On July 13, 2021, Clarus and the Company entered into the
Global Agreement to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#8217;s request
for adverse judgment in interference No. 106,128 in accordance with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<ix:exclude><!-- Field: Page; Sequence: 18; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page --></ix:exclude>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Guarantees
and Indemnifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnification provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z3CfOZnXV6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(11)
<span id="xdx_824_zJW5cwyEu5ee">Agreement with Spriaso, LLC</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned
by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and
transferred to Spriaso all of the Company&#8217;s rights, title and interest in its intellectual property to develop products for the
cough and cold field. In addition, Spriaso received all rights and obligations under the Company&#8217;s product development agreement
with a third-party. In exchange, the Company will receive a royalty of <span id="xdx_902_ecustom--PercentageOfRoyalty_pid_dp_uPure_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zPJSXkktasVe" title="Percentage of royalty"><ix:nonFraction name="LPCN:PercentageOfRoyalty" contextRef="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="INF" scale="-2" unitRef="Pure">20</ix:nonFraction></span> percent of the net proceeds received by Spriaso, up to a maximum
of $<span id="xdx_903_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zvEAUNWU2s6h" title="Proceeds from affiliates"><ix:nonFraction name="us-gaap:ProceedsFromContributionsFromAffiliates" contextRef="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="-5" scale="6" unitRef="USD">10.0</ix:nonFraction></span> million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. <span id="xdx_901_ecustom--AgreementDescription_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember" title="Agreement description"><ix:nonNumeric contextRef="From2013-07-222013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember" name="LPCN:AgreementDescription">Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain
employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an
amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain
employees to Spriaso at a rate of $<span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zmxMROTlQsc8" title="Employee related liabilities"><ix:nonFraction name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" contextRef="AsOf2013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember" format="ixt:numdotdecimal" decimals="0" scale="0" unitRef="USD">230</ix:nonFraction></span>/hour for a period of six months.</ix:nonNumeric></span> The agreement was further amended on July 23, 2015, on January
23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017, on January 23, 2018, on July 23, 2018 and again on January 23, 2019
to extend the term of the agreement for an additional six months. The agreement was further amended on July 23, 2019 and again on July
23, 2020 to extend the term of the agreement for an additional twelve months. The agreement may be extended upon written agreement of
Spriaso and the Company. The Company did not receive any reimbursements during the three and six months ended June 30, 2021 and 2020,
respectively. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for
a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB
ASC Topic 810-10, <i>Consolidations</i>, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</ix:nonNumeric><ix:nonNumeric contextRef="From2021-01-01to2021-06-30" escape="true" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"><p id="xdx_80C_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zdKyzGwsOKc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(12)
<span id="xdx_827_zWAE3dhkISEb">Recent Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements Issued Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: #212529">In
2016, the FASB issued </span><span style="font: 10pt Times New Roman, Times, Serif">Accounting Standards Update (&#8220;ASU&#8221;)
<span style="color: #212529">2016-13, <i>Measurement of Credit Losses on Financial Instruments </i>(&#8220;ASU 2016-13&#8221;). This
standard replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on
instruments within its scope, including trade receivables, and requires entities to measure all expected credit losses for financial
assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The original
effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">However,
in October 2019, the FASB issued ASU 2019-10, <i>Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates</i>, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies<i>.</i> A company&#8217;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.</span></p>

</ix:nonNumeric><p id="xdx_812_zvp2Jpt5mxh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<table cellpadding="0" cellspacing="0" border="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
<tr style="vertical-align: top">
  <td style="width: 0.65in"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="ag_004"></span>ITEM 2. </b></span></td>
  <td style="text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL
CONDITION AND RESULTS OF OPERATIONS</b></span></td></tr>
</table>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>The
following discussion of our financial condition and results of operations should be read in conjunction with our unaudited condensed
consolidated financial statements and the related notes thereto and other financial information included elsewhere in this report. For
additional context with which to understand our financial condition and results of operations, see the management&#8217;s discussion
and analysis included in our Form 10-K, filed with the SEC on March 11, 2021, our first quarter Form 10-Q filed with the SEC on May 6,
2021, as well as the financial statements and related notes contained therein.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>As
used in the discussion below, &#8220;we,&#8221; &#8220;our,&#8221; and &#8220;us&#8221; refers to Lipocine.</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Forward-Looking
Statements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">This
section and other parts of this report contain forward-looking statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that involve risks and uncertainties. Forward-looking
statements provide current expectations of future events based on certain assumptions and include any statement that does not directly
relate to any historical or current fact. Forward-looking statements may refer to such matters as products, product benefits, pre-clinical
and clinical development timelines, clinical and regulatory expectations and plans, expected responses to regulatory actions, anticipated
financial performance, future revenues or earnings, business prospects, projected ventures, new products and services, anticipated market
performance, expected research and development and other expenses, future expectations for liquidity and capital resources needs and
similar matters. Such words as &#8220;may&#8221;, &#8220;will&#8221;, &#8220;expect&#8221;, &#8220;continue&#8221;, &#8220;estimate&#8221;,
&#8220;project&#8221;, and &#8220;intend&#8221; and similar terms and expressions are intended to identify forward looking statements.
Forward-looking statements are not guarantees of future performance and our actual results may differ significantly from the results
discussed in the forward-looking statements. Factors that might cause such differences include, but are not limited to, those discussed
in Part II, Item 1A (Risk Factors) of this Form 10-Q, or in Part II, Item 1A (Risk Factors) of our Form 10-Q for the quarter ended March
31, 2021 filed with the SEC on May 6, 2021 or in Part I, Item 1A (Risk Factors) of our Form 10-K filed with the SEC on March 11, 2021.
Except as required by applicable law, we assume no obligation to revise or update any forward-looking statements for any reason.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Overview
of Our Business</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">We
are a clinical-stage biopharmaceutical company focused on applying our oral drug delivery technology for the development of pharmaceutical
products focusing on metabolic and endocrine disorders. Our proprietary delivery technologies are designed to improve patient compliance
and safety through orally available treatment options. Our primary development programs are based on oral delivery solutions for poorly
bioavailable drugs. We have a portfolio of proprietary product candidates designed to produce favorable PK characteristics and facilitate
lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions
that limit bioavailability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
most advanced product candidate, TLANDO&#174;, is an oral TRT comprised of TU. On December 8, 2020, we received tentative approval from
the FDA regarding our NDA filed in February 2020 for TLANDO as a TRT in adult males for conditions associated with a deficiency of endogenous
testosterone, also known as hypogonadism. In granting tentative approval, the FDA concluded that TLANDO has met all required quality,
safety and efficacy standards necessary for approval. However, TLANDO has not received final approval and is not eligible for final approval
to market in the U.S. until the expiration of the exclusivity period previously granted to Clarus Therapeutics, Inc. with respect to
<span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March 27, 2022. We remain committed to taking appropriate
actions with the goal of receiving final approval to permit the launch of TLANDO. The FDA has also required us to conduct certain post-marketing
studies to (i) assess patient understanding of key risks relating to TLANDO and (ii) evaluate development of adrenal insufficiency with
chronic TLANDO therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Additional
pipeline candidates include LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU for the treatment of
non-cirrhotic NASH which is currently in Phase 2 testing, TLANDO&#174; XR, a next generation oral TRT product comprised of
testosterone tridecanoate (&#8220;TT&#8221;) with the potential for once daily dosing which has completed Phase 2 testing, LPCN
1148, an oral prodrug of bioidentical testosterone for the management of symptoms associated with cirrhosis, LPCN 1154, an
oral neuro-steroid targeted for the treatment of postpartum depression (&#8220;PPD&#8221;)<span style="background-color: white">,</span>
and LPCN 1107, potentially the first oral HPC product indicated for the prevention of recurrent PTB, which has completed a dose
finding Phase 2 clinical study and has been granted orphan drug designation by the FDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">LPCN
1144 is currently being tested in the <i>LiFT</i> (&#8220;Liver Fat intervention with oral Testosterone&#8221;) proof-of-concept (&#8220;POC&#8221;)
Phase 2 clinical study, a paired-biopsy study in confirmed non-cirrhotic NASH subjects. Study enrollment has been completed and positive
top-line primary endpoint results after 12 weeks of treatment were released in January 2021. Treatments with LPCN 1144 resulted in robust
liver fat reduction, assessed by MRI-PDFF technique, and showed improvement of liver injury markers with no observed tolerability issues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
date, we have funded our operations primarily through the sale of equity securities, debt and convertible debt and through up-front payments,
research funding and royalty and milestone payments from our license and collaboration arrangements. We have not generated any revenues
from product sales and we do not expect to generate revenue from product sales unless and until we obtain regulatory approval of TLANDO
or other products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have incurred losses in most years since our inception. As of June 30, 2021, we had an accumulated deficit of $182.2 million. Income
and losses fluctuate year to year, primarily depending on the nature and timing of research and development occurring on our product
candidates. Our net loss was $10.2 million for the six months ended June 30, 2021, compared to $12.1 million for the six months ended
June 30, 2020. Substantially all of our operating losses resulted from expenses incurred in connection with our product candidate development
programs, our research activities and general and administrative costs, including on-going litigation, associated with our operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to continue to incur significant expenses and operating losses for the foreseeable future as we:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -18.35pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">conduct
    any other post-approval clinical studies required in support of TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">perform
    pre-commercialization and commercialization activities in support of TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">conduct
    further development of our other product candidates, including LPCN 1144, LPCN 1148, LPCN 1154 and LPCN 1107;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">continue
    our research efforts;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">research
    new products or new uses for our existing products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">maintain,
    expand and protect our intellectual property portfolio; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">provide
    general and administrative support for our operations, including on-going litigation.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">To
fund future long-term operations, including the potential commercialization of TLANDO or other products, we will need to raise additional
capital. The amount and timing of future funding requirements will depend on many factors, including capital market conditions, regulatory
requirements and outcomes related to TLANDO, regulatory requirements related to our other product development programs, the timing and
results of our ongoing development efforts, the potential expansion of our current development programs, potential new development programs,
our ability to license our products to third parties, the pursuit of various potential commercial activities and strategies associated
with our development programs and related general and administrative support. We anticipate that we will seek to fund our operations
through public or private equity or debt financings or other sources, such as potential license, partnering and collaboration agreements.
We cannot be certain that anticipated additional financing will be available to us on favorable terms, in amounts sufficient to fund
our operations or at all. Although we have previously been successful in obtaining financing through public and private equity securities
offerings and our license and collaboration agreements, there can be no assurance that we will be able to do so in the future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
Product Candidates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Our
current portfolio includes our most advanced product candidate, TLANDO, an oral TRT product candidate, which received tentative approval
from the FDA on December 8, 2020. Additionally, we are in the process of establishing our pipeline of other clinical candidates including
an oral androgen therapy for the treatment of non-cirrhotic NASH, LPCN 1144, a next-generation potential once daily oral TRT, TLANDO
XR, an androgen therapy for the management of cirrhosis, LPCN 1148, an oral neuro-steroid targeted for the treatment of PPD<span style="background-color: white">,
</span>LPCN 1154, an oral therapy for the prevention of PTB, LPCN 1107, and we continue to explore other product candidates targeting
indications with a significant unmet need.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">These
products are based on our proprietary Lip&#8217;ral drug delivery technology platform. Lip&#8217;ral technology is a patented technology
based on lipidic compositions which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble
drugs. The drug loaded dispersed phase presents the solubilized drug efficiently at the absorption site (gastrointestinal tract membrane)
thus improving the absorption process and making the drug less dependent on physiological variables such as dilution, gastro-intestinal
pH and food effects for absorption. Lip&#8217;ral based formulation enables improved solubilization and higher drug-loading capacity,
which can lead to improved bioavailability, reduced dose, faster and more consistent absorption, reduced variability, reduced sensitivity
to food effects, improved patient compliance, and targeted lymphatic delivery where appropriate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Our
Development Pipeline</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 15pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>TLANDO:
An Oral Product Candidate for Testosterone Replacement Therapy</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Our
most advanced product, TLANDO, is an oral formulation of the chemical, TU, which is an eleven carbon side chain attached to T. TU is
an ester prodrug of T. An ester is chemically formed by bonding an acid and an alcohol. Upon the cleavage, or breaking, of the ester
bond, T is formed. TU has been approved for use outside the United States for many years for delivery via intra-muscular injection and
in oral dosage form and more recently TU has received regulatory approval in the United States for delivery via intra-muscular injection
and in oral dosage form. We are using our proprietary technology to facilitate steady gastrointestinal solubilization and absorption
of TU. Proof of concept was initially established in 2006, and subsequently TLANDO was licensed in 2009 to Solvay Pharmaceuticals, Inc.
which was then acquired by Abbott. Following a portfolio review associated with the spin-off of AbbVie by Abbott in 2011, the rights
to TLANDO were reacquired by us. All obligations under the prior license agreement have been completed except that Lipocine will owe
Abbott a perpetual 1% royalty on net sales. Such royalties are limited to $1 million in the first two calendar years following product
launch, after which period there is not a cap on royalties and no maximum aggregate amount. If generic versions of any such product are
introduced, then royalties are reduced by 50%.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>NDA
PDUFA Outcome</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
December 8, 2020 we received tentative approval from the FDA regarding our NDA filed in February 2020 for TLANDO as a TRT in adult males
for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative approval, the
FDA concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval. However, TLANDO has not
received final approval and is not eligible for final approval to market in the U.S. until the expiration of the exclusivity period previously
granted to Clarus with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March 27, 2022. We remain
committed to taking appropriate actions with the goal of receiving final approval to permit the launch of TLANDO.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 4pt; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Under
the Pediatric Research Equity Act (&#8220;PREA&#8221;), if TLANDO receives full approval, we will need to address the PREA requirement
to assess the safety and effectiveness of TLANDO in pediatric patients. The FDA has also required us to conduct certain post-marketing
studies including: (i) conduct an appropriately designed label comprehension and knowledge study that assesses patient understanding
of key risk messages in the Medication Guide for TLANDO and (ii) conduct an appropriately designed one-year trial to evaluate development
of adrenal insufficiency with chronic TLANDO therapy. The timetables for these post-marketing requirements will be established at the
time of full approval of TLANDO. We are actively pursuing and currently evaluating commercial alternatives with TLANDO, should it receive
FDA approval, including out-licensing TLANDO to a third-party, launching TLANDO on our own, or launching TLANDO on our own with the assistance
from a &#8220;risk share&#8221; partner.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Competition Update</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 27, 2019, Clarus&#8217; product JATENZO&#174;, an oral TU product, was approved by the FDA and also received three years of data
exclusivity. On February 10, 2020, Clarus announced that JATENZO&#174; has been launched and is commercially available. Based on the FDA&#8217;s
tentative approval of TLANDO, we will not be able to begin marketing TLANDO until receiving final approval no earlier than March 27,
2022, the expiration of the exclusivity period granted to Clarus with respect to JATENZO&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
our competitors may introduce other T-replacement therapies. For example, on January 5, 2021 Marius submitted a NDA to the FDA seeking
approval of KYZATREX&#174;, its novel oral TU soft gelatin capsule for the treatment of primary and secondary hypogonadism in adult men.
According to Marius, it has been assigned a PDUFA date of October 31, 2021 for KYZATREX&#174;.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are also aware of other pharmaceutical companies that have T-replacement therapies or testosterone therapies in development that may
be approved for marketing in the United States or outside of the United States.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Based
on publicly available information, we believe that several other T-replacement therapies that would be competitive with TLANDO are in
varying stages of development, some of which may be approved, marketed and/or commercialized prior to TLANDO. These therapies include
T-gels, oral-T, an aromatase inhibitor, a new class of drugs called Selective Androgen Receptor Modulators and hydroalcoholic gel formulations
of DHT.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>LPCN
1144: An Oral Prodrug of Bioidentical Testosterone Product Candidate for the Treatment of NASH</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">We
are currently evaluating LPCN 1144, an oral prodrug of bioidentical testosterone comprised of TU, for the treatment of non-cirrhotic
NASH. NASH is a more advanced state of NAFLD and can progress to a cirrhotic liver and eventually hepatocellular carcinoma/ liver cancer.
Twenty to thirty percent of the U.S. population is estimated to suffer from NAFLD and fifteen to twenty percent of this group progress
to NASH, which is a substantially large population that lacks effective therapy. Currently, there are no FDA approved treatments for
NASH, a silent killer that affects approximately 30 million Americans. Approximately 50% of NASH patients are in adult males. NAFLD/NASH
is becoming more common due to its strong correlation with obesity and metabolic syndrome, including components of metabolic syndrome
such as diabetes, cardiovascular disease and high blood pressure. In men, especially with comorbidities associated with NAFLD/NASH, testosterone
deficiency has been associated with an increased accumulation of visceral adipose tissue and insulin resistance, which could be factors
contributing to NAFLD/NASH. There is currently no approved therapy for the treatment of NASH although there are several drug candidates
currently under development with many having clinical failures to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>History
of Liver Disease</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">The
liver is the largest internal organ in the human body and its proper function is indispensable for many critical metabolic functions,
including the regulation of lipid and sugar metabolism, the production of important proteins, including those involved in blood clotting,
and purification of blood. There are over 100 described diseases of the liver, and because of its many functions, these can be highly
debilitating and life-threatening unless effectively treated. Liver diseases can result from injury to the liver caused by a variety
of insults, including HCV, HBV, obesity, chronic excessive alcohol use or autoimmune diseases. Regardless of the underlying cause of
the disease, there are important similarities in the disease progression including increased inflammatory activity and excessive liver
cell apoptosis, which if unresolved leads to fibrosis. Fibrosis, if allowed to progress, will lead to cirrhosis, or excessive scarring
of the liver, and eventually reduced liver function. Some patients with liver cirrhosis have a partially functioning liver and may appear
asymptomatic for long periods of time, which is referred to as decompensated liver disease. Decompensated liver disease is when the liver
is unable to perform its normal functions. Many people with active liver disease remain undiagnosed largely because liver disease patients
are often asymptomatic for many years.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Markers
of Liver Cell Death</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">ALT
is an enzyme that is produced in liver cells and is naturally found in the blood of healthy individuals. In liver disease, liver cells
are damaged and as a consequence, ALT is released into the blood, increasing ALT levels above the normal range. Physicians routinely
test blood levels of ALT to monitor the health of a patient&#8217;s liver. ALT level is a clinically important biochemical marker of
the severity of liver inflammation and ongoing liver disease. Elevated levels of ALT represent general markers of liver cell death and
inflammation without regard to any specific mechanism. AST is a second enzyme found in the blood that is produced in the liver and routinely
measured by physicians along with ALT. As with ALT, AST is often elevated in liver disease and, like ALT, is considered an overall marker
of liver inflammation.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Relationship
between Hypogonadism and NAFLD</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Preclinical
and clinical studies in the NAFLD/NASH literature have shown the prevalence of testosterone deficiency across the NAFLD/NASH histological
spectrum wherein low testosterone was independently associated with NAFLD/NASH with an inverse relationship between testosterone and
NAFLD/NASH symptom severity. A recent NIDDK report suggests that 75% of biopsy confirmed NASH subjects have less than 372 ng/dL of total
testosterone and that the degree of fibrosis severity is inversely related to free testosterone levels; thus, providing a good rationale
for testing LPCN 1144 in adult NASH patients regardless of their hypogonadal status. We have received clearance from the FDA to clinically
investigate LPCN 1144 in an expanded target population of adult male NASH patients. Specifically, the FDA waived the limitation of only
testing LPCN 1144 in NASH subjects with total testosterone levels below 300 ng/dL (threshold for hypogonadism).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>Current
Status</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have initiated the <i>LiFT</i> Phase 2 clinical study in confirmed non-cirrhotic NASH subjects. The <i>LiFT</i> clinical study is a prospective,
multi-center, randomized, double-blind, placebo-controlled multiple-arm study in biopsy-confirmed hypogonadal or eugonadal male NASH
subjects with grade F1/F3 fibrosis and a NAFLD Activity Score &#8805; 4 with a 36-week treatment period. The <i>LiFT</i> clinical study
enrolled 56 biopsy confirmed NASH male subjects. Subjects were randomized 1:1:1 to one of three arms (Treatment A is a twice daily oral
dose of 142 mg testosterone equivalent, Treatment B is a twice daily oral dose of 142 mg testosterone equivalent formulated with 217
mg of d-alpha tocopherol equivalent, and the third arm is twice daily matching placebo). We currently expect 36-week biopsy data in August
2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
primary endpoint of the <i>LiFT</i> clinical study is change in hepatic fat fraction via MRI-PDFF and exploratory liver fat/marker end
points post 12 weeks of treatment. Additionally, key secondary endpoints post 36 weeks of treatment include assessment of histological
change for NASH resolution and/or fibrosis improvement as well as liver fat data. Other important endpoints include the following: change
in liver injury markers, anthropomorphic measurements, lipids, insulin resistance and inflammatory/fibrosis markers; as well as patient
reported outcomes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
subjects will have access to LPCN 1144 through an open label extension study. The extension study will enable the collection of additional
data on LPCN 1144 for up to a total of 72 weeks of therapy.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Treatments
with LPCN 1144 post 12 weeks of treatment resulted in robust liver fat reduction, assessed by MRI-PDFF, and showed improvement of liver
injury markers with no observed tolerability issues. Inclusion of d-alpha tocopherol formulated with the testosterone prodrug resulted
in additional liver benefits, notably improved key liver markers without compromising tolerability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Key
results are presented in the following tables:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Table
1. Mean absolute liver fat using MRI-PDFF in all subjects (n=56)* at Week 12.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change from baseline (CBL)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placebo-adjusted CBL</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Treatment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">p-value</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">p value</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left">A (n = 18)</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">-7.7</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">&lt;0.0001</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">-6.1</td><td style="width: 2%">&#160;</td>
    <td style="width: 18%; text-align: center">0.0001</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">B (n = 19)</td><td>&#160;</td>
    <td style="text-align: center">-9.2</td><td>&#160;</td>
    <td style="text-align: center">&lt;0.0001</td><td>&#160;</td>
    <td style="text-align: center">-7.5</td><td>&#160;</td>
    <td style="text-align: center">&lt;0.0001</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Placebo (n = 19)</td><td>&#160;</td>
    <td style="text-align: center">-1.7</td><td>&#160;</td>
    <td style="text-align: center">NS</td><td>&#160;</td>
    <td style="text-align: center">n/a</td><td>&#160;</td>
    <td style="text-align: center">n/a</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
Missing data was obtained using Multiple Imputation</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">NS:
Not significant (p &gt; 0.05)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Table
2. Mean relative liver fat using MRI-PDFF at Week 12 in subjects (n=52) with liver fat &#8805; 5% at baseline.*</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font-size: 11pt">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Change from baseline (CBL)</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="3" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placebo-adjusted CBL</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Treatment</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">p value</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">%</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">p value</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 20%; font-weight: bold; text-align: left; padding-bottom: 1.5pt">A (n = 17)</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 18%; text-align: center; padding-bottom: 1.5pt">-40.0</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 18%; text-align: center; padding-bottom: 1.5pt">&lt;0.0001</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 18%; text-align: center; padding-bottom: 1.5pt">-30.0</td><td style="width: 2%; padding-bottom: 1.5pt">&#160;</td>
    <td style="width: 18%; text-align: center; padding-bottom: 1.5pt">0.0002</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">B (n = 17)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">-46.9</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&lt;0.0001</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">-37.0</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">&lt;0.0001</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Placebo (n = 18)</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">-9.9</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">NS</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">n/a</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="text-align: center; padding-bottom: 1.5pt">n/a</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
Based on available data.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Table
3. Responders with &gt; 30% Relative Reduction in Liver Fat at Week 12, Intent to Treat Dataset (n=56)*.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Treatment</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Responder</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>(% of subjects)</b></span></p></td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>p value</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>vs Placebo</b></span></p></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 32%; font-weight: bold; text-align: left">A (n = 18)</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center">66.7</td><td style="width: 2%">&#160;</td>
    <td style="width: 32%; text-align: center">0.0058</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">B (n = 19)</td><td>&#160;</td>
    <td style="text-align: center">63.2</td><td>&#160;</td>
    <td style="text-align: center">0.0026</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Placebo (n = 19)</td><td>&#160;</td>
    <td style="text-align: center">15.8</td><td>&#160;</td>
    <td style="text-align: center">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
Subjects with missing data are considered non-responders</span></p>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Table
4. Average changes in key serum liver injury markers ALT and AST at Week 12 (n=52)*.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">ALT (U/L)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="14" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">AST (U/L)</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; font-size: 11pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Absolute</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placebo-Adjusted Absolute</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Absolute</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Placebo-Adjusted Absolute</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; font-weight: bold">Treatment</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CBL</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>p value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>vs BL</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CBL</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>p value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>vs Placebo</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CBL</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>p value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>vs BL</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">CBL</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>p value</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>vs Placebo</b></p></td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 28%; font-weight: bold; text-align: left">A (n = 16)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-9.4</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">0.0054</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-11.1</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">0.0164</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-4.9</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">0.0402</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">-7.7</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 5%; text-align: right">0.0216</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">B (n = 19)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-22.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;0.0001</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-24.1</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;0.0001</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-10.4</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&lt;0.0001</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-13.2</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">0.0001</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Placebo (n = 17)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">NS</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2.8</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">NS</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">n/a</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
All available data</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">During
the 12 weeks of treatment, the observed rate and severity of Treatment Emergent Adverse Events (&#8220;TEAEs&#8221;) in both the LPCN
1144 treatment arms were comparable to the placebo arm. Three subjects in the placebo group and one subject in the combined treatment
arms discontinued study drug due to TEAEs. We currently expect 36-week biopsy data in August 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Previous
to the <i>LiFT</i> clinical study, we completed a 16-week POC liver imaging clinical study to assess liver fat changes in hypogonadal
men at risk of developing NASH using MRI-PDFF technique. Treatment results from the POC liver imaging study demonstrated that 48% of
the treated NAFLD subjects, defined as baseline liver fat of at least 5%, had NAFLD resolution, defined as liver fat &lt;5% post treatment.
Additionally, 100% of the subjects experiencing NAFLD resolution had at least a 35% relative liver fat reduction from baseline with a
relative mean liver fat reduction of 55% in this group.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>TLANDO
XR: A Next-Generation Long-Acting Oral Product Candidate for TRT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">TLANDO
XR is a next-generation, novel ester prodrug of testosterone comprised of TT which uses the Lip&#8217;ral technology to enhance solubility
and improve systemic absorption. We completed a Phase 2b dose finding study in hypogonadal men in the third quarter of 2016. The primary
objectives of the Phase 2b clinical study were to determine the starting Phase 3 dose of TLANDO XR along with safety and tolerability
of TLANDO XR and its metabolites following oral administration of single and multiple doses in hypogonadal men. The Phase 2b clinical
trial was a randomized, open label, two-period, multi-dose PK study that enrolled hypogonadal males into five treatment groups. Each
of the 12 subjects in a group received treatment for 14 days. Results of the Phase 2b study suggest that the primary objectives were
met, including identifying the dose expected to be tested in a Phase 3 study. Good dose-response relationship was observed over the tested
dose range in the Phase 2b study. Additionally, the target Phase 3 dose met primary and secondary end points. Overall, TLANDO XR was
well tolerated with no drug-related severe or serious adverse events reported in the Phase 2b study.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally
in October 2014, we completed a Phase 2a proof -of-concept (&#8220;POC&#8221;) study in hypogonadal men. The Phase 2a open-label, dose-escalating
single and multiple dose study enrolled 12 males. Results from the Phase 2a clinical study demonstrated the feasibility of a once daily
dosing with TLANDO XR in hypogonadal men and a good dose response. Additionally, the study confirmed that steady state is achieved by
day 14 with consistent inter-day performance observed on day 14, 21 and 28. No subjects exceeded Cmax of 1500 ng/dL at any time during
the 28-day dosing period on multi-dose exposure. Overall, TLANDO XR was well tolerated with no serious AE&#8217;s reported.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">We
have also completed a preclinical toxicology study with TLANDO XR in dogs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 32pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">In
February 2018 we had a meeting with the FDA to discuss these pre-clinical results and to discuss the Phase 3 clinical study and path
forward for TLANDO XR. Based on the results of the FDA meeting and additional pre-clinical trials conducted after the FDA meeting, we
have proposed a Phase 3 protocol for TLANDO XR and have solicited FDA feedback. Based on initial FDA feedback, we expect the Phase 3
clinical trial design to follow the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use
(&#8220;ICH&#8221;) guidelines and will include a three-month efficacy treatment period and a one-year safety component for up to 100
subjects. We continue to refine the Phase 3 protocol and plan to request FDA approval of the protocol once it is finalized. Additionally,
the FDA previously requested that a food effect study needs to be completed, and that ambulatory blood pressure monitoring (&#8220;ABPM&#8221;)
be included as part of the Phase 3 clinical study. We anticipate the next steps in developing TLANDO XR will be to scale up the formulation
and conduct a food effect study with TLANDO XR. We are also exploring the possibility of licensing TLANDO XR to a third party, although
no licensing agreement has been entered into by us.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>LPCN
1148: An Oral Prodrug of Bioidentical Testosterone Product Candidate for the Management of Cirrhosis</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">Cirrhosis
is end-stage NAFLD for which there is no FDA approved drug treatment. Liver cirrhosis is estimated to affect in excess of 600,000 Americans,
with men affected at twice the rate of women, and results in approximately 45,000 deaths every year. Due to a lack of available organs,
only a third of waitlisted patients are getting liver transplants, and patients that do receive a transplant are increasingly being described
as frail. Low testosterone affects up to 90% of cirrhotic men, and is a predictor of mortality and increased adverse events including
ascites, hepatic encephalopathy, and clinically significant portal hypertension. We are targeting LPCN 1148 for the management of symptoms
associated with liver cirrhosis. We believe LPCN 1148 targets unmet needs for cirrhosis subjects including improvement in the quality
of life of patients while on the liver transplant waiting list, prevention or reduction in the occurrence of decompensation events and
improvement in post liver transplant survival, including outcomes and costs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
are currently planning to conduct a Phase 2 POC study (NCT04874350) in male cirrhotic subjects to evaluate the therapeutic potential
of LPCN 1148 for the management of cirrhotic subjects. The planned Phase 2 POC study is a prospective, multi-center, randomized,
placebo-controlled study in approximately 48 to 60 male cirrhotic patients that are on the liver transplant list. Subjects will be
randomized 1:1 to one of two arms. The treatment arm is an oral dose of a testosterone ester and the second arm is matching placebo.
The primary endpoint is change in skeletal muscle index at week 24 with key secondary endpoints including change in liver frailty
index and number of waitlist events, including all-cause mortality. Total treatment is expected to be 52
weeks. We currently expect the first subject will be dosed in the fourth quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>LPCN
1154: An Oral Neuro-Steroid Candidate for the Treatment of Postpartum Depression</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">PPD
is a major depressive disorder that is under diagnosed in the U.S., impacts approximately 1 in 7 women after giving birth. PPD
can lead to devastating consequences for a woman, her newborn and her family. Currently, there is no oral therapy approved for the treatment
of PPD. The active moiety in LPCN 1154 is an endogenous positive allosteric modulator of &#947;-aminobutyric acid (&#8220;GABA<sub>A</sub>&#8221;)
receptor. LPCN 1154 is expected to be an &#8220;at home&#8221; treatment with easier treatment access than the current standard of care
invasive option that requires hospitalization with significant limitations. Moreover, LPCN 1154 is expected to provide the required level
of privacy for a mother, avoiding bonding/breast feeding interruptions due to the required hospitalizations for the current option.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
June 14, 2021, we announced that the FDA has cleared the Company&#8217;s Investigational New Drug Application (&#8220;IND&#8221;) to
initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154 for the treatment of PPD in adults. We recently initiated
a pharmacokinetic (&#8220;PK&#8221;) study to assess dose proportionality with LPCN 11154 with top-line results expected in the third
quarter of 2021. Following the PK study, we plan to conduct a proof-of-concept study to evaluate the safety, tolerability, and efficacy
of LPCN 1154 in adult female subjects diagnosed with PPD. We expect the first subject dosed will occur in the fourth quarter of 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>LPCN
1107: An Oral Product Candidate for the Prevention of Preterm Birth</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">We
believe LPCN 1107 has the potential to become the first oral HPC product indicated for the reduction of risk of PTB (delivery less than
37 weeks) in women with singleton pregnancy who have a history of singleton spontaneous PTB. Prevention of PTB is a significant unmet
need as approximately 11.7% of all U.S. pregnancies result in PTB, a leading cause of neonatal mortality and morbidity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">We
have completed a multi-dose PK dose selection study in pregnant women. The objective of the multi-dose PK selection study was to assess
HPC blood levels in order to identify the appropriate LPCN 1107 Phase 3 dose. The multi-dose PK dose selection study was an open-label,
four-period, four-treatment, randomized, single and multiple dose, PK study in pregnant women of three dose levels of LPCN 1107 and the
IM HPC (Makena&#174;). The study enrolled 12 healthy pregnant women (average age of 27 years) with a gestational age of approximately
16 to 19 weeks. Subjects received three dose levels of LPCN 1107 (400 mg BID, 600 mg BID, or 800 mg BID) in a randomized, crossover manner
during the first three treatment periods and then received five weekly injections of HPC during the fourth treatment period. During each
of the LPCN 1107 treatment periods, subjects received a single dose of LPCN 1107 on Day 1 followed by twice daily administration from
Day 2 to Day 8. Following completion of the three LPCN 1107 treatment periods and a washout period, all subjects received five weekly
injections of HPC. Results from this study demonstrated that average steady state HPC levels (Cavg0-24) were comparable or higher for
all three LPCN 1107 doses than for injectable HPC. Additionally, HPC levels as a function of daily dose were linear for the three LPCN
1107 doses. Also, unlike the injectable HPC, steady state exposure was achieved for all three LPCN 1107 doses within seven days. We have
also completed a proof-of-concept Phase 1b clinical study of LPCN 1107 in healthy pregnant women in January 2015 and a POC Phase 1a clinical
study of LPCN 1107 in healthy non-pregnant women in May 2014. These studies were designed to determine the PK and bioavailability of
LPCN 1107 relative to an IM HPC, as well as safety and tolerability.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">A
traditional PK/PD based Phase 2 clinical study in the intended patient population is not expected to be required prior to entering into
Phase 3. Therefore, based on the results of our multi-dose PK study we had an End-of-Phase 2 meeting and subsequent guidance meetings
with the FDA to define a pivotal Phase 2b/3 development plan for LPCN 1107. However, these discussions will need to be updated based
on recent developments with Covis&#8217; Makena&#174;. We plan to resume our interactions with the FDA to discuss our pivotal Phase 2b/3
clinical trial design and better understand next steps to advance LPCN 1107. Additionally, a pivotal Phase 2b/3 study will not occur
until the results from a planned food-effect study with LPCN 1107 are reviewed by the FDA, though manufacturing scale-up work for LPCN
1107 has been completed.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">We
do not anticipate the initiation of a pivotal Phase 2b/3 study with LPCN 1107 to occur until the required food effect study is complete.
We currently intend to proceed with plans to conduct the required food effect clinical study. We are exploring the possibility of licensing
LPCN 1107 to a third party, although no licensing agreement has been entered into by the Company. No assurance can be given that any
license agreement will be completed, or, if an agreement is completed, that such an agreement would be on acceptable terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA has granted orphan drug designation to LPCN 1107 based on a major contribution to patient care. Orphan designation qualifies Lipocine
for various development incentives, including tax credits for qualified clinical testing, and a waiver of the prescription drug user
fee when we file our NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Recent
Competition Update</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
October 5, 2020, the FDA&#8217;s CDER proposed that Makena be withdrawn from the market because the PROLONG trial failed to verify the
clinical benefit of Makena and concluded that the available evidence does not show Makena is effective for its approved use.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">CDER
issued AMAG, the NDA holder at the time, a Notice of Opportunity for Hearing (&#8220;NOOH&#8221;) to withdraw approval of Makena, for
which AMAG Pharmaceuticals responded by requesting a hearing and providing detail on the company&#8217;s position, recognizing clinicians&#8217;
decade-long use of Makena&#8217;s treatment and the public health implications of withdrawing approval. The FDA Commissioner has not
determined whether it will hold a public hearing, and if one is granted, the process is expected to take months. During this time, Makena
and the approved generics of Makena will remain on the market until the FDA makes a final decision about these products.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; color: #333333"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Currently,
Makena and the approved generics of Makena are the only products approved for the prevention of recurrent preterm birth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">The
FDA also indicated that it intends to hold a meeting with experts in obstetrics, neonatal care, and clinical trial design to discuss
how to facilitate development of effective and safe therapies to treat preterm birth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Financial
Operations Overview</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Revenue</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">To
date, we have not generated any revenues from product sales and do not expect to do so until one of our product candidates receives approval
from the FDA. Revenues to date have been generated substantially from license fees, royalty and milestone payments and research support
from our licensees. Since our inception through June 30, 2021, we have generated $28.1 million in revenue under our various license and
collaboration arrangements and from government grants. We may never generate revenues from TLANDO or any of our other clinical or preclinical
development programs or licensed products as we may never succeed in obtaining regulatory approval or commercializing any of these product
candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Research
and Development Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Research
and development expenses consist primarily of salaries, benefits, stock-based compensation and related personnel costs, fees paid to
external service providers such as contract research organizations and contract manufacturing organizations, contractual obligations
for clinical development, clinical sites, manufacturing and scale-up for late-stage clinical trials, formulation of clinical drug supplies,
and expenses associated with regulatory submissions. Research and development expenses also include an allocation of indirect costs,
such as those for facilities, office expense, travel, and depreciation of equipment based on the ratio of direct labor hours for research
and development personnel to total direct labor hours for all personnel. We expense research and development expenses as incurred. Since
our inception, we have spent approximately $123.9 million in research and development expenses through June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
December 8, 2020 we received tentative approval from the FDA regarding our NDA filed in February 2020 for TLANDO as a TRT in adult males
for conditions associated with a deficiency of endogenous testosterone, also known as hypogonadism. In granting tentative approval, the
FDA concluded that TLANDO has met all required quality, safety and efficacy standards necessary for approval. However, TLANDO has not
received final approval and is not eligible for final approval to market in the U.S. until the expiration of the exclusivity period previously
granted to Clarus with respect to <span style="text-transform: uppercase">Jatenzo</span>&#174;, which expires on March 27, 2022. As a
result, we are uncertain as to whether we will incur additional research and developments costs for TLANDO. Any further expenditures,
if needed, are subject to numerous uncertainties regarding timing and cost to completion.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
expect to continue to incur significant costs as we develop our other product candidates, including the ongoing <i>LiFT</i> Phase 2 clinical
study with LPCN 1144.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
general, the cost of clinical trials may vary significantly over the life of a project as a result of uncertainties in clinical development,
including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the number of sites included in the trials;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;<span style="font: 10pt Times New Roman, Times, Serif"> </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the length of time required to enroll suitable subjects;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the duration of subject follow-ups;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the length of time required to collect, analyze and
    report trial results;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#9679;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost, timing and outcome of regulatory review;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">potential changes by the FDA in clinical trial and
    NDA filing requirements for testosterone replacement therapies.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
have also incurred significant manufacturing costs to prepare launch supplies for TLANDO and additional expenditures will be required
to prepare for a commercial launch of TLANDO, should it be approved, if it is not out-licensed. However, future expenditures are subject
to numerous uncertainties regarding timing and cost to completion, including, among others:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.3in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the timing and outcome of regulatory filings and FDA
    reviews and actions for TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">our dependence on third-party manufacturers for the
    production of satisfactory finished product for registration and launch should regulatory approval be obtained;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the potential for future license or co-promote arrangements
    for TLANDO, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our future plans
    and capital requirements; and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the effect on our product development activities of
    actions taken by the FDA or other regulatory authorities.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -18.35pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">A
change of outcome for any of these variables with respect to the development of TLANDO and our other product development candidates could
mean a substantial change in the costs and timing associated with these efforts, will require us to raise additional capital, and may
require us to reduce operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Given
the stage of clinical development and the significant risks and uncertainties inherent in the clinical development, manufacturing and
regulatory approval process, we are unable to estimate with any certainty the time or cost to complete the development of LPCN 1144,
TLANDO XR, LPCN 1148, LPCN 1154, LPCN 1107 and other product candidates. Clinical development timelines, the probability of success and
development costs can differ materially from expectations and results from our clinical trials may not be favorable. If we are successful
in progressing LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, LPCN 1107 or other product candidates into later stage development, we will
require additional capital. The amount and timing of our future research and development expenses for these product candidates will depend
on the preclinical and clinical success of both our current development activities and potential development of new product candidates,
as well as ongoing assessments of the commercial potential of such activities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Summary
of Research and Development Expense</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
are conducting on-going clinical and regulatory activities with most of our product candidates. Additionally, we incur costs for our
other research programs. The following table summarizes our research and development expenses:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Three
    Months Ended June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Six
    Months Ended June 30,</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2021</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">2020</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">External service provider
    costs:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; width: 44%"><span style="font: 10pt Times New Roman, Times, Serif">TLANDO</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">22,528</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">122,544</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">109,251</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">207,477</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">LPCN 1144</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">554,042</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,330,886</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,317,272</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,060,439</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">TLANDO
    XR</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,490</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">71,898</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt"><span style="font: 10pt Times New Roman, Times, Serif">LPCN 1154</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">94,642</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">102,073</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">LPCN
    1107</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">54,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,360</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">55,381</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,360</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total external service provider
    costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">725,593</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,456,280</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,583,977</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,342,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Internal personnel costs</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">514,705</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">682,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,084,972</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,174,705</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
    research and development costs</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">224,389</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">130,370</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">376,279</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">263,860</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-left: 10pt; text-align: left; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Total
    research and development</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">1,464,687</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">2,268,984</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">3,045,228</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">$</span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font: 10pt Times New Roman, Times, Serif">4,780,739</span></td><td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
expect research and development expenses to increase in the future as we complete on-going clinical studies, including the <i>LiFT</i>
Phase 2 clinical study with LPCN 1144, as we conduct future clinical studies with LPCN 1148, LPCN 1154 and LPCN 1107, and as we manufacture
commercial supplies of TLANDO pre-approval if it is not out-licensed. However, if we are unable to raise additional capital, we may need
to reduce research and development expenses in order to extend our ability to continue as a going concern.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>General
and Administrative Expenses</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">General
and administrative expenses consist primarily of salaries and related benefits, including stock-based compensation related to our executive,
finance, business development, marketing, sales and support functions. Other general and administrative expenses include rent and utilities,
travel expenses, professional fees for auditing, tax and legal services, litigation settlement and market research and market analytics.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">General
and administrative expenses also include expenses for the cost of preparing, filling and prosecuting patent applications and maintaining,
enforcing and defending intellectual property-related claims, including the patent interference and patent infringement lawsuits against
Clarus.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
expect that general and administrative expenses will decrease in the future as we expect to incur decreased legal fees due to the global
settlement agreement (&#8220;Global Agreement&#8221;) with Clarus. We expect that such decreases will be offset by other increases as
we mature as a public company, including legal and consulting fees, accounting and audit fees, director fees, increased directors&#8217;
and officers&#8217; insurance premiums, fees for investor relations services and enhanced business and accounting systems, litigation
costs, professional fees and other costs. If TLANDO is approved by the FDA and it is not out-licensed, we expect we will incur significant
additional expenses relating to the commercialization of TLANDO, including, among other things, expenses relating to building out sales
and marketing teams, manufacturing expenses, expenses relating to licensing TLANDO to third parties, and other expenses. However, if
we are unable to raise additional capital, we may need to further reduce general and administrative expenses in order to extend our ability
to continue as a going concern. If we are unable to raise additional capital, we may be unable to effectively commercialize TLANDO if
not out-licensed after receiving FDA approval.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Other
Expense (Income), Net</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Other
expense (income), net consists primarily of interest income earned on our cash, cash equivalents and marketable investment securities
and interest expense incurred on our outstanding Loan and Security Agreement, losses (gains) on our warrant liability and litigation
settlement accruals.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Results
of Operations</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison
of the Three Months Ended June 30, 2021 and 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes our results of operations for the three months ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">1,464,687</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">2,268,984</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(804,297</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,525,592</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,953,535</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(427,943</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest and investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(17,344</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(7,177</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">10,167</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">57,428</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">87,847</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(30,419</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss (gain) on warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(221,322</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">2,066,445</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(2,287,767</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Litigation settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in research and development expenses during the three months ended June 30, 2021 was primarily due to a $777,000 decrease in
contract research organization expense and outside consulting costs related to the LPCN 1144 <i>LiFT</i> Phase 2 clinical study in NASH
subjects, a $100,000 decrease in costs associated with TLANDO and a $168,000 decrease in personnel expense which was mainly due to a
decrease in stock compensation and bonus expense. The decreases were offset by a $95,000 increase in costs related to LPCN 1154 and a
$53,000 increase in costs for LPCN 1107, as well as net increases in other R&amp;D expenses of $94,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in general and administrative expenses during the three months ended June 30, 2021 was primarily due to a $273,000 decrease
in personnel costs, which was mainly due to a decrease in stock compensation and bonus expense, and a $239,000 decrease in legal costs
in 2021 as compared to 2020 relating to a decrease the following legal activities: lawsuit filed against Clarus Therapeutics Inc. for
patent infringement in April 2019 and the on-going class action lawsuit defense. These decreases were offset by a $49,000 increase in
corporate insurance expenses and a $35,000 increase in other general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
and Investment Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
increase in interest and investment income during the three months ended June 30, 2021 was due to higher cash and marketable investment
securities balances in 2021 compared to 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in interest expense during the three months ended June 30, 2021 was due to a decrease in interest expense on our Loan and Security
Agreement with SVB, as a result of lower principal balances and lower interest rates in 2021 compared to 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Loss
(Gain) on Warrant Liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded a gain of $221,000 and a loss of $2.1 million, respectively, on warrant liability during the three months ended June 30, 2021
and 2020 related to the change in the fair value of outstanding common stock warrants issued in the November 2019 Offering. The gain
in 2021 was attributable to a decrease in the value of warrants outstanding as of June 30, 2021 as compared to March 31, 2021 due to
a decrease in our stock price. The loss in 2020 was mainly due to an increase in the value of warrants outstanding as of June 30, 2020
as compared to March 31, 2020 due to an increase in our stock price. There were zero and 10,006,000 common stock warrants from the
November 2019 Offering exercised during the three months ended June 30, 2021 and 2020, respectively. The warrants are classified as a
liability due to a provision contained within the warrant agreement which allows the warrant holder the option to elect to receive an
amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option pricing model with certain
defined assumptions upon a change of control. The warrant liability will continue to fluctuate in the future based on inputs to the Black-Scholes
model including our current stock price, the remaining life of the warrants, the volatility of our stock price, the risk-free interest
rate and the number of common stock warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Litigation
Settlement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded an expense of $4.0 million and zero, respectively, on litigation settlement during the three months ended June 30, 2021 and
2020 related to the Global Agreement with Clarus to resolve all outstanding claims in the on-going intellectual property litigation between
the two companies as well as the on-going interference proceeding between the two companies. Under the terms of the settlement, we agreed
to pay Clarus $4.0 million payable as follows: $2.5 million immediately, $1.0 million on July 13, 2022 and $500,000 on July 13, 2023.
No future royalties are owing from either party. Under the terms of the Global Agreement, Lipocine and Clarus have agreed to dismiss
the Lipocine Inc. v Clarus Therapeutics, Inc., No 19-cv-622 (WCB) litigation in the U.S. District Court for the District
of Delaware. Also, both parties have reached an agreement on the interference proceedings captioned Clarus Therapeutics, Inc. v. Lipocine
Inc., Interference No. 106,128 in the U.S. Patent and Trademark Office.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Comparison
of the Six Months Ended June 30, 2021 and 2020</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes our results of operations for the six months ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six months ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Variance</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 46%; text-align: left">Research and development expenses</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">3,045,228</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">4,780,739</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 14%; text-align: right">(1,735,511</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">General and administrative expenses</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,059,544</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,038,795</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(979,251</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Interest and investment income</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(27,993</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(67,115</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(39,122</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Interest expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">126,401</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">221,192</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(94,791</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Loss (gain) on warrant liability</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(26,257</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">3,166,474</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(3,192,731</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Litigation settlement</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#8212;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">4,000,000</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Income tax expense</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">200</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">-</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Research
and Development Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in research and development expenses during the six months ended June 30, 2021 was primarily due to a $1.7 million decrease
in contract research organization expense and outside consulting costs related to the LPCN 1144 <i>LiFT</i> Phase 2 clinical study in
NASH subjects, a $98,000 decrease in costs associated with TLANDO and a $90,000 net decrease in personnel expense which was mainly due
to a decrease in stock compensation expense offset by increases in salaries partially due to headcount increases. These decreases were
offset by a $102,000 increase in costs related to LPCN 1154 and a $53,000 increase in costs for LPCN 1107, as well as increases in other
R&amp;D expenses of $41,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>General
and Administrative Expenses</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in general and administrative expenses during the six months ended June 30, 2021 was primarily due to a $847,000 decrease in
legal costs in 2021 as compared to 2020 relating to a decrease the following legal activities: lawsuit filed against Clarus Therapeutics
Inc. for patent infringement in April 2019 and the on-going class action lawsuit defense, and a decrease of $288,000 in personnel costs
mainly due a reduction in stock compensation expense. These decreases were offset by a $99,000 increase in corporate insurance expenses
and a $57,000 increase in other general and administrative expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
and Investment Income</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in interest and investment income during the six months ended June 30, 2021 was due to lower interest rates in 2021 compared
to 2020, despite higher cash and marketable investment securities balances.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Interest
Expense</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
decrease in interest expense during the six months ended June 30, 2021 was due to a decrease in interest expense on our Loan and Security
Agreement with SVB, mainly as a result of lower principal balances 2021 compared to 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Loss
(Gain) on Warrant Liability</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
recorded a gain of $26,000 and a loss of $3.2 million, respectively, on warrant liability during the six months ended June
30, 2021 and 2020 related to the change in the fair value of outstanding common stock warrants issued in the November 2019 Offering.
The gain in 2021 was attributable to a decrease in the value of warrants outstanding as of June 30, 2021 as compared to December 31,
2020 due to a small decrease in the number of warrants outstanding, a decrease in our volatility and the shorter term remaining on
the outstanding warrants and the loss in 2020 was mainly due to an increase in the value of warrants outstanding as of June 30, 2020
as compared to December 31, 2019 due to an increase in our stock price. There were 10,000 and 10,127,000 common stock warrants from
the November 2019 Offering exercised during the six months ended June 30, 2021 and 2020, respectively. The warrants are classified
as a liability due to a provision contained within the warrant agreement which allows the warrant holder the option to elect to
receive an amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option pricing model
with certain defined assumptions upon a change of control. The warrant liability will continue to fluctuate in the future based on
inputs to the Black-Scholes model including our current stock price, the remaining life of the warrants, the volatility of our stock
price, the risk-free interest rate and the number of common stock warrants outstanding.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Litigation
Settlement</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"> We
recorded an expense of $4.0 million and zero, respectively, on litigation settlement during the six months ended June 30, 2021 and 2020
related to the Global Agreement with Clarus to resolve all outstanding claims in the on-going intellectual property litigation between
the two companies as well as the on-going interference proceeding between the two companies. Under the terms of the settlement, we agreed
to pay Clarus $4.0 million payable as follows: $2.5 million immediately, $1.0 million on July 13, 2022 and $500,000 on July 13, 2023.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Liquidity
and Capital Resources</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Since
our inception, our operations have been primarily financed through sales of our equity securities, debt and payments received under our
license and collaboration arrangements. We have devoted our resources to funding research and development programs, including discovery
research, preclinical and clinical development activities. We have incurred operating losses in most years since our inception and we
expect to continue to incur operating losses into the foreseeable future as we evaluate our options related to TLANDO should it receive
final approval and it&#8217;s not out-licensed and as we advance clinical development of LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154,
LPCN 1107 and any other product candidate, including continued research efforts.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, we had $46.6 million of unrestricted cash, cash equivalents and marketable investment securities compared to $19.7
million at December 31, 2020. Additionally, as of December 31, 2020 we had $5.0 million of restricted cash, which was required to be
maintained as cash collateral under the SVB Loan and Security Agreement until TLANDO is approved by the FDA. However on February 16,
2021, we amended the Loan and Security Agreement with SVB (as defined below) to, among other things, remove the cash collateral requirement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 28, 2021, we completed a public offering of securities registered under an effective registration statement filed pursuant to
the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $28.7 million, before deducting underwriter fees and other offering expenses of $1.9 million. In the January 2021 Offering,
we sold 16,428,571 shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">On
April 21, 2020, we entered into a loan (the &#8220;Loan&#8221;) from SVB in the aggregate amount of $234,000, pursuant to the Paycheck
Protection Program (the &#8220;PPP&#8221;) under Division A, Title I of the CARES Act, which was enacted March 27, 2020. The Loan, which
was in the form of a note dated April 21, 2020, originally matured on April 21, 2022 and bears interest at a rate of 1.0% per annum,
payable monthly commencing on November 21, 2020. Under the terms of the PPP, certain amounts of the Loan may be forgiven if they are
used for qualifying expenses as described in the CARES Act. On November 2, 2020, we were notified by the Small Business Administration
that our PPP Loan had been forgiven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
February 27, 2020, we completed a registered direct offering of securities registered under an effective registration statement filed
pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February 2020
Offering were approximately $6.0 million, before deducting placement agent fees and other offering expenses of $347,000. In the February
2020 Offering, the Company sold 10,084,034 Class A Units, with each Class A Unit consisting of one share of common stock and a one-half
of one common warrant to purchase one share of common stock, at a price of $0.595 per Class A Unit. The common stock warrants were immediately
exercisable at an exercise price of $0.53 per share, subject to adjustment, and expire on February 27, 2025. By their terms, however,
the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own, after such exercise,
more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after giving effect to such
exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
November 18, 2019, we completed the November 2019 Offering. The gross proceeds from the November 2019 Offering were approximately $6.0
million, before deducting placement agent fees and other offering expenses of $404,000. In the November 2019 Offering, the Company sold
(i) 10,450,000 Class A Units, with each Class A Unit consisting of one share of common stock and a common warrant to purchase one share
of common stock, and (ii) 1,550,000 Class B Units, with each Class B Unit consisting of one pre-funded warrant to purchase one share
of common stock and one common warrant to purchase one share of common stock, at a price of $0.50 per Class A Unit and $0.4999 per Class
B Unit. The pre-funded warrants, which were exercised for common stock in December 2019, were issued in lieu of common stock in order
to ensure the purchaser did not exceed certain beneficial ownership limitations. The pre-funded warrants were immediately exercisable
at an exercise price of $.0001 per share, subject to adjustment. Additionally, the common stock warrants were immediately exercisable
at an exercise price of $0.50 per share, subject to adjustment, and expire on November 17, 2024. By their terms, however, neither the
pre-funded warrants nor the common stock warrants can be exercised at any time that the pre-funded warrant holder or the common stock
warrant holder would beneficially own, after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares
of common stock then outstanding after giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 5, 2018, we entered into the Loan and Security Agreement with SVB pursuant to which SVB agreed to lend us $10.0 million. The
principal borrowed under the Loan and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in money rates
section of The Wall Street Journal or any successor publication representing the rate of interest per annum then in effect, plus one
percent per annum, which interest is payable monthly. Additionally on April 1, 2020, we entered into a Deferral Agreement with SVB. Under
the Deferral Agreement, principal repayments were deferred by six months and we were only required to make monthly interest payments
during the deferral period. The Loan matures on June 1, 2022. Previously, we were only required to make monthly interest payments until
December 31, 2018, following which we also made equal monthly payments of principal and interest until the signing of the Deferral Agreement.
We will also be required to pay an additional final payment at maturity equal to $650,000 (the &#8220;Final Payment Charge&#8221;). At
our option, we may prepay all amounts owed under the Loan and Security Agreement (including all accrued and unpaid interest and the Final
Payment Charge). In connection with the Loan and Security Agreement, we granted to SVB a security interest in substantially all of our
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, as TLANDO was not approved
by the FDA by May 31, 2018, we were required to maintain $5.0 million of cash collateral at SVB until such time as TLANDO is approved
by the FDA. However on February 16, 2021, we amended the Loan and Security Agreement with SVB to, among other things, remove the financial
trigger and financial trigger release event provisions requiring us to maintain a minimum cash collateral value and collateral pledge
thereof. While any amounts are outstanding under the Loan and Security Agreement, we are subject to a number of affirmative and negative
covenants, including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB,
as collateral agent, with the right to exercise remedies against us and the collateral securing the credit facility, including foreclosure
against the property securing the credit facilities, including our cash. These events of default include, among other things, any failure
by us to pay principal or interest due under the credit facility, a breach of certain covenants under the credit facility, the Company&#8217;s
insolvency, a material adverse change, and one or more judgments against us in an amount greater than $100,000 individually or in the
aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.45pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 6, 2017, we entered into the Sales Agreement with Cantor pursuant to which we may issue and sell, from time to time, shares of
our common stock having an aggregate offering price of up to the amount we have registered on an effective registration statement pursuant
to which the offering is being made. We currently have registered up to $50.0 million for sale under the Sales Agreement, pursuant to
our Registration Statement on Form S-3 (File No. 333-250072), through Cantor as our sales agent. Cantor may sell our common stock by
any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act,
including sales made directly on or through the NASDAQ Capital Market or any other existing trade market for our common stock, in negotiated
transactions at market prices prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted
by law. Cantor uses its commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and
regulations to sell these shares. We pay Cantor 3.0% of the aggregate gross proceeds from each sale of shares under the Sales Agreement.
We have also provided Cantor with customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.45pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.45pt"><span style="font: 10pt Times New Roman, Times, Serif">The
shares of our common stock sold under the Sales Agreement are sold and issued pursuant to our Registration Statement on Form S-3 (File
No. 333-250072) (the &#8220;Form S-3&#8221;), which was previously declared effective by the Securities and Exchange Commission, and
the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.45pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
are not obligated to make any sales of our common stock under the 2020 Sales Agreement. The offering of our common stock pursuant to
the 2020 Sales Agreement will terminate upon the termination of the 2020 Sales Agreement as permitted therein. We and Cantor may each
terminate the 2020 Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the three months ended June 30, 2021, we did not sell any shares of our common stock our current Registration Statement on Form S-3 (File
No. 333-250072). As of June 30, 2021, we had $41.2 million available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">We
believe that our existing capital resources, together with interest thereon, will be sufficient to meet our projected operating requirements
through at least June 30, 2022 which includes an on-going clinical study for LPCN 1144, future clinical studies for LPCN 1148 and LPCN
1154, compliance with regulatory requirements, satisfaction of our obligations under the settlement agreement with Clarus, and on-going
litigation activities. We have based this estimate on assumptions that may prove to be wrong, and we could utilize our available capital
resources sooner than we currently expect if additional activities are performed by us including pre-commercial and commercial activities
for TLANDO if not out-licensed and new clinical studies for LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154 and LPCN 1107. While we believe
we have sufficient liquidity and capital resources to fund our projected operating requirements through at least June 30, 2022, we will
need to raise additional capital at some point through the equity or debt markets or through out-licensing activities, either before
or after June 30, 2022, to support our operations, including, if FDA approval is received, potential commercialization activities for
TLANDO. If we are unsuccessful in raising additional capital, our ability to continue as a going concern will be limited. Further, our
operating plan may change, and we may need additional funds to meet operational needs and capital requirements for product development,
regulatory compliance and clinical trial activities sooner than planned. In addition, our capital resources may be consumed more rapidly
if we pursue additional clinical studies for LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154 and LPCN 1107. Conversely, our capital resources
could last longer if we reduce expenses, reduce the number of activities currently contemplated under our operating plan or if we terminate,
modify or suspend on-going clinical studies. We can raise capital pursuant to the Sales Agreement when not restricted due to terms of
previous financings but may choose not to issue common stock if our market price is too low to justify such sales in our discretion.
There are numerous risks and uncertainties associated with the development and, subject to approval by the FDA, commercialization of
our product candidates. There are numerous risks and uncertainties impacting our ability to enter into collaborations with third parties
to participate in the development and potential commercialization of our product candidates. We are unable to precisely estimate the
amounts of increased capital outlays and operating expenditures associated with our anticipated or unanticipated clinical studies and
ongoing development and pre-commercialization efforts. All of these factors affect our need for additional capital resources. To fund
future operations, we will need to ultimately raise additional capital and our requirements will depend on many factors, including the
following:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">further clinical development requirements or other
    requirements of the FDA related to approval of TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost and timing of pre-commercialization and commercialization
    activities in support of TLANDO;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the scope, rate of progress, results and cost of our
    clinical studies, preclinical testing and other related activities for all of our product candidates, including LPCN 1144, TLANDO
    XR, LPCN 1148, LPCN 1154 and LPCN 1107;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost of manufacturing clinical supplies, and establishing
    commercial supplies, of our product candidates and any products that we may develop;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost and timing of establishing sales, marketing
    and distribution capabilities, if any;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the terms and timing of any collaborative, licensing,
    settlement and other arrangements that we may establish;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the number and characteristics of product candidates
    that we pursue;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost, timing and outcomes of regulatory approvals;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the timing, receipt and amount of sales, profit sharing
    or royalties, if any, from our potential products;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the cost of preparing, filing, prosecuting, defending
    and enforcing any patent claims and other intellectual property rights;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the extent to which we acquire or invest in businesses,
    products or technologies, although we currently have no commitments or agreements relating to any of these types of transactions;
    and</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">&#9679;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">the extent to which we grow significantly in the number
    of employees or the scope of our operations.</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -0.25in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Funding
may not be available to us on favorable terms, or at all. Also, market conditions may prevent us from accessing the debt and equity capital
markets, including sales of our common stock through the Sales Agreement. If we are unable to obtain adequate financing when needed,
we may have to delay, reduce the scope of or suspend one or more of our clinical studies, research and development programs or, if any
of our product candidates receive approval from the FDA, commercialization efforts. We may seek to raise any necessary additional capital
through a combination of public or private equity offerings, including the Sales Agreement, debt financings, collaborations, strategic
alliances, licensing arrangements and other marketing and distribution arrangements. These arrangements may not be available to us or
available on terms favorable to us. To the extent that we raise additional capital through marketing and distribution arrangements, other
collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish valuable rights to our product
candidates, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us.
If we do raise additional capital through public or private equity offerings, the ownership interest of our existing stockholders will
be diluted, and the terms of these securities may include liquidation or other preferences, warrants or other terms that adversely affect
our stockholders&#8217; rights or further complicate raising additional capital in the future. If we raise additional capital through
debt financing, we may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional
debt, making capital expenditures or declaring dividends. If we are unable, for any reason, to raise needed capital, we will have to
reduce costs, delay research and development programs, liquidate assets, dispose of rights, commercialize products or product candidates
earlier than planned or on less favorable terms than desired or reduce or cease operations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 34; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Sources
and Uses of Cash</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table provides a summary of our cash flows for the six months ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto">
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Cash used in operating activities</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(6,425,056</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 14%; text-align: right">(7,455,510</td><td style="width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Cash used in investing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(35,426,211</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(116,811</td><td style="text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Cash provided by financing activities</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">28,601,598</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">11,681,616</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Net
Cash From Operating Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 and 2020, net cash used in operating activities was $6.4 million and $7.5 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in operating activities during the six months June 30, 2021 and 2020 was primarily attributable to cash outlays to support
ongoing operations, including research and development expenses and general and administrative expenses. During 2021 and 2020, we were
performing activities related to the LPCN 1144 <i>LiFT</i> Phase 2 paired biopsy clinical study as well as preparing for future trials
with LPCN 1154 in 2021. During 2020, we also were performing activities around the submission of the TLANDO NDA.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Net
Cash From Investing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 and 2020, net cash used in investing activities was $35.4 million and $117,000, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash used in investing activities during the six months ended June 30, 2021 and 2020, was primarily the result of purchasing marketable
investment securities, net, of $35.4 million and $117,000, respectively. There were no capital expenditures for the six months ended
June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Net
Cash From Financing Activities</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">During
the six months ended June 30, 2021 and 2020 net cash provided by financing activities was $28.6 million and $11.7 million, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities during the six months ended June 30, 2021 was attributable to the net proceeds from the sale of
16,428,571 shares of common stock pursuant to January 2021 Offering resulting in net proceeds of $26.8 million and $3.4 million in proceeds
from the sale of 1,811,238 shares of common stock pursuant to the Sales Agreement with Cantor, offset by $1.7 million in debt principal
repayments under the SVB Loan and Security Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Net
cash provided by financing activities during the six months ended June 30, 2020 was attributable to the net proceeds from the sale of
10,084,034 shares of common stock pursuant to February 2020 Offering resulting in net proceeds of $5.7 million, to $6.9 million in proceeds
from the exercise of warrants and to $234,000 in loan proceeds under the Payment Protection Program offset by $1.1 million in debt principal
repayments under the SVB Loan and Security Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Contractual
Commitments and Contingencies</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Long-Term
Debt Obligations and Interest on Debt</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
January 5, 2018, we entered into a Loan and Security Agreement with SVB pursuant to which SVB agreed to lend us $10.0 million. The principal
borrowed under the Loan and Security Agreement bears interest at a rate equal to the Prime Rate plus one percent per annum, which interest
is payable monthly. The loan matures on June 1, 2022 and we are required to make equal monthly payments of principal and interest for
the remaining term of the loan beginning on November 1, 2020 although there was a principal deferment period of six months beginning
on April 1, 2020 due to COVID-19. We will also be required to pay the Final Payment Charge at maturity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">On
April 21, 2020, we were granted a Loan from SVB in the aggregate amount of approximately $234,000, pursuant to the PPP under Division
A, Title I of the CARES Act, which was enacted March 27, 2020. The PPP Loan, which was in the form of a Note dated April 21, 2020, originally
matured on April 21, 2022 and bears interest at a rate of 1.0% per annum, payable monthly commencing on November 21, 2020. Under the
terms of the PPP, certain amounts of the PPP Loan may be forgiven if they are used for qualifying expenses as described in the CARES
Act. On November 2, 2020, we were notified by the Small Business Administration that our PPP Loan had been forgiven.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 35; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Purchase
Obligations</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
enter into contracts and issue purchase orders in the normal course of business with clinical research organizations for clinical trials
and clinical and commercial supply manufacturing and with vendors for preclinical research studies, research supplies and other services
and products for operating purposes. These contracts generally provide for termination on notice and are cancellable obligations.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Operating
Leases</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
August 2004, we entered into an agreement to lease our facility in Salt Lake City, Utah consisting of office and laboratory space which
serves as our corporate headquarters. On March 3, 2021, we modified and extended the lease through February 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>Critical
Accounting Policies and Significant Judgments and Estimates</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Our
management&#8217;s discussion and analysis of our financial condition and results of operations is based on our financial statements
which we have prepared in accordance with U.S. generally accepted accounting principles. In preparing our financial statements, we are
required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods.
Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent
from other sources. Actual results may differ from these estimates under different assumptions or conditions. There have been no significant
and material changes in our critical accounting policies during the six months ended June 30, 2021, as compared to those disclosed
in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations-Critical Accounting Policies and
Significant Judgments and Estimates&#8221; in our Form 10-K filed March 11, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>New
Accounting Standards</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Refer
to Note 12, in &#8220;Notes to Unaudited Condensed Consolidated Financial Statements&#8221; for a discussion of accounting standards
not yet adopted.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Off-Balance
Sheet Arrangements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_001"></span>ITEM 3.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">We
are exposed to various market risks, which include potential losses arising from adverse changes in market rates and prices, such as
interest rates. We do not enter into derivatives or other financial instruments for trading or speculative purposes.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Interest
Rate Risk</i></b><i>. </i>Our interest rate risk exposure results from our investment portfolio. Our primary objectives in managing our
investment portfolio are to preserve principal, maintain proper liquidity to meet operating needs and maximize yields. The securities
we hold in our investment portfolio are subject to interest rate risk. At any time, sharp changes in interest rates can affect the fair
value of the investment portfolio and its interest earnings. After a review of our marketable investment securities, we believe that
in the event of a hypothetical ten percent increase in interest rates, the resulting decrease in fair value of our marketable investment
securities would be insignificant to the consolidated financial statements. Currently, we do not hedge these interest rate exposures.
We have established policies and procedures to manage exposure to fluctuations in interest rates. We place our investments with high
quality issuers and limit the amount of credit exposure to any one issuer and do not use derivative financial instruments in our investment
portfolio. We invest in highly liquid, investment-grade securities and money market funds of various issues, types and maturities. These
securities are classified as available-for-sale and, consequently, are recorded on the balance sheet at fair value with unrealized gains
or losses reported as accumulated other comprehensive income as a separate component in stockholders&#8217; deficit unless a loss is
deemed other than temporary, in which case the loss is recognized in earnings.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Additionally
in January 2018, we entered into the Loan and Security Agreement with SVB for $10.0 million. A one percent increase in the prime rate
would result in a $17,000 increase in interest expense, while a one percent decrease in the prime rate would result in a $19,000 decrease
in interest expense.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 36; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_002"></span>ITEM 4.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>CONTROLS AND PROCEDURES</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Evaluation
of Disclosure Controls and Procedures</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">We
maintain &#8220;disclosure controls and procedures&#8221; within the meaning of Rule 13a-15(e) of the Securities Exchange Act of 1934,
as amended, or the Exchange Act. Our disclosure controls and procedures, or Disclosure Controls, are designed to ensure that information
required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is
recorded, processed, summarized and reported within the time periods specified in the U.S. Securities and Exchange Commission&#8217;s
rules and forms. Our Disclosure Controls include, without limitation, controls and procedures designed to ensure that such information
is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate
to allow timely decisions regarding required disclosure.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of
our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive
Officer and our Chief Financial Officer. Based on the controls evaluation, our Chief Executive Officer and Chief Financial Officer have
concluded that our Disclosure Controls were effective as of June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Changes
in Internal Control over Financial Reporting</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">There
have been no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) during the
most recent fiscal quarter covered by this report, that have materially affected, or are reasonably likely to materially affect, our
internal control over financial reporting.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span id="SS_003"></span><span style="font: 10pt Times New Roman, Times, Serif"><b>PART
II&#8212;OTHER INFORMATION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_004"></span>ITEM 1.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>LEGAL PROCEEDINGS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 2, 2019, we filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that Clarus&#8217;s
JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and
6,923,988. However on February 11, 2020, we voluntarily dismissed allegations of patent infringement for expired U.S. Patent Nos. 6,569,463
and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus has answered the complaint and asserted
counterclaims of non-infringement and invalidity. We answered Clarus&#8217;s counterclaims on April 29, 2019. The Court held a scheduling
conference on August 15, 2019, a claim construction hearing on February 11, 2020 and a summary judgment hearing on January 15, 2021.
In May 2021, the Court granted Clarus&#8217; motion for Summary Judgment, finding the asserted claims of Lipocine&#8217;s U.S. patents
9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C. &#167;
112. Clarus still had remaining claims before the Court. On July 13, 2021, Clarus and Lipocine entered into a global settlement agreement
(&#8220;Global Agreement&#8221;) which resolved all outstanding claims of this litigation as well as the on-going United States Patent
and Trademark Office (&#8220;USPTO&#8221;) Interference No. 106,128 between the parties. Under the terms of the Global Agreement, Lipocine
agreed to pay Clarus $4.0 million payable as follows: $2.5 million immediately, $1.0 million on July 13, 2022 and $500,000 on July 13,
2023. No future royalties are owing from either party. On July 15, 2021, the Court dismissed with prejudice Lipocine&#8217;s claims and
Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 14, 2019, we and certain of our officers were named as defendants in a purported shareholder class action lawsuit, <i>Solomon
Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint alleges
that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to the FDA
contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading and/or
lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. We have insurance that covers claims of this nature. The retention amount payable
by us under our policy is $1.25 million. We filed a motion to dismiss this class action lawsuit on July 24, 2020. In response, the plaintiffs
filed their response to the motion to dismiss the class action lawsuit on September 22, 2020 and we filed our reply to our motion to
dismiss on October 22, 2020. We intend to vigorously defend ourselves against these allegations and have not recorded a liability related
to this shareholder class action lawsuit as the outcome is not probable nor can an estimate be made of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 37; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
March 13, 2020, we filed U.S. patent application serial number 16/818,779 (&#8220;the Lipocine &#8216;779 Application&#8221;) with the
USPTO. On October 16 and November 3, 2020, we filed suggestions for interference with the USPTO requesting that a patent interference
be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics, Inc.
(&#8220;the Clarus &#8216;178 Application&#8221;). Pursuant to our request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;) at
the USPTO declared the interference on January 4, 2021 to ultimately determine, as between us and Clarus, who is entitled to the claimed
subject matter. The interference number is 106,128, and we were initially declared Senior Party. A conference call with the PTAB was
held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing certain motions and setting
the schedule for the preliminary motions phase. On July 13, 2021, we entered into the Global Agreement with Clarus to resolve interference
No. 106,128 among other items. On July 26, 2021, the PTAB granted our request for adverse judgment in interference No. 106,128 in accordance
with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_005"></span>ITEM 1A.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>RISK FACTORS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">In
addition to the other information set forth in this Report, consider the risk factors discussed in Part 1, &#8220;Item 1A. Risk Factors&#8221;
in the Company&#8217;s Annual Report filed on Form 10-K for the year ended December 31, 2020 filed with the SEC on March 11, 2021, risk
factors discussed in Item 1A of the Form 10-Q for the quarter ended March 31, 2021 filed with the SEC on May 6, 2021 and the risk factors
discussed in Item 1A of this Form 10-Q, which could materially affect our business, financial condition or future results. The risks
described in the aforementioned report are not the only risks facing the Company. Additional risks and uncertainties not currently known
to the Company or that it currently deems to be not material also may materially adversely affect the Company&#8217;s business, financial
condition and or operating results.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following are the risk factors that have materially changed from our risk factors included in our Form 10-K for the year ended December
31, 2020 filed with the SEC on March 11, 2021 and from our risk factors included in our Form 10-Q for the quarter ended March 31, 2021
filed with the SEC on May 6, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Relating to Our Business and Industry</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
research and development programs and processes are at an early stage of development, which makes it difficult to evaluate our business
and prospects, or predict if or when we will successfully commercialize our product candidates.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
operations to date have primarily been limited to conducting research and development activities under license and collaboration agreements.
Our current portfolio consists of our most advanced product candidate TLANDO as well as five additional earlier stage clinical candidates,
LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154 and LPCN 1107. We have never marketed or commercialized a drug product. Consequently, any
predictions about our future performance may not be as accurate as they could be if we were further along our commercialization path.
In addition, as a pre-commercial stage business, we may encounter unforeseen expenses, difficulties, complications, delays and other
unknown factors.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Our
clinical product candidates are at an early stage of development and will require significant further investment and regulatory approvals
prior to marketing and commercialization. As such, our product development processes for TLANDO, LPCN 1144, TLANDO XR, LPCN 1148, LPCN
1154 and LPCN 1107 are very risky and uncertain, and our product candidates may fail to advance beyond the current study. Even if we
obtain required financing, we cannot ensure successful product development or that we will obtain regulatory approval or successfully
commercialize any of our product candidates and generate product revenues.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
will need to grow our Company, and we may encounter difficulties in managing this growth, which could disrupt our operations.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, we had 13 employees. To manage our anticipated future growth, we must continue to implement and improve our managerial,
operational and financial systems, expand our facilities and continue to recruit and train additional qualified personnel. Also, our
management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial
amount of time to managing these growth activities. Due to our limited resources, we may not be able to effectively manage the expansion
of our operations or recruit and train additional qualified personnel. This may result in weaknesses in our infrastructure, give rise
to operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. The physical
expansion of our operations may lead to significant costs and may divert financial resources from other projects. If our management is
unable to effectively manage our future growth, our expenses may increase more than expected, our ability to generate revenue could be
reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize
our product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may have to dedicate resources to the defense and resolution of litigation.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Securities
legislation in the United States makes it relatively easy for stockholders to sue. This can lead to frivolous lawsuits which take substantial
time, money, resources and attention or force us to settle such claims rather than seek adequate judicial remedy or dismissal of such
claims. Historically, securities class action litigation has often been brought against a company following a decline in the market price
of its securities. Biotechnology and pharmaceutical companies, including the Company, have experienced significant stock price volatility
in recent years, increasing the risk of such litigation. As we defend the class action lawsuits or future patent infringement actions
should they be filed, or if we are required to defend additional actions brought by other shareholders, we may be required to pay substantial
litigation costs and managerial attention and financial resources may be diverted from business operations even if the outcome is in
our favor. In addition, while our insurance carrier may cover the costs of settling claims, the Company&#8217;s capital resources are
critical to its continued operations, and the payment of litigation settlements and associated legal fees diverts these capital resources
away from our operations, even if such amounts do not have a material impact on our financial statements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 38; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to
the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading
and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. We have insurance that covers claims of this nature.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.45in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Defendants
intend to vigorously defend themselves against these allegations, but doing so may result in substantial litigation costs and managerial
attention and financial resources may be diverted from business operations even if outcome is in favor of our current and former officers
and directors and the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">On
April 2, 2019, we filed a lawsuit against Clarus in the United States District Court in Delaware alleging that Clarus&#8217;s JATENZO&#174;
product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390; 6,569,463; and 6,923,988.
Clarus has answered the complaint and asserted counterclaims of non-infringement and invalidity. We answered Clarus&#8217;s counterclaims
on April 29, 2019. On February 11, 2020, we voluntarily dismissed allegations of patent infringement for expired U.S. Patent Nos. 6,569,463
and 6,923,988 in an effort to streamline the issues and associated costs for dispute. The Court held a scheduling conference on August
15, 2019, a claim construction hearing on February 11, 2020 and a summary judgment hearing on January 15, 2021. In May 2021, the Court
granted Clarus&#8217; motion for Summary Judgment, finding the asserted claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057;
9,480,690; and 9,757,390 invalid for failure to satisfy the written description requirement of 35 U.S.C. &#167; 112. Clarus still had
remaining claims before the Court. On July 13, 2021, we entered into a Global Agreement with Clarus which resolved all outstanding claims
of this litigation. Under the terms of the settlement, we agreed to pay Clarus $4.0 million payable as follows: $2.5 million immediately,
$1.0 million on July 13, 2022 and $500,000 on July 13, 2023. The payment of this and other settlement payments diverts capital resources
away from our operations, which may adversely affect our business.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Related to Ownership of Our Common Stock</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
value of our warrants outstanding from the November 2019 Offering is subject to potentially material increases and decreases based on
fluctuations in the price of our common stock.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">In
November 2019, we completed a public offering of common stock and warrants to purchase common stock (the &#8220;November 2019 Offering&#8221;).
Gross proceeds from the November 2019 Offering were approximately $6.0 million. In the November 2019 Offering, the Company sold (i) 10,450,000
Class A Units, with each Class A Unit consisting of one share of common stock and a common stock warrant to purchase one share of common
stock, and (ii) 1,550,000 Class B Units, with each Class B Unit consisting of one pre-funded warrant to purchase one share of a common
stock and one common stock warrant to purchase one share of common stock at a price of $0.50 per Class A Unit and $0.4999 per Class B
Unit. The pre-funded warrants were issued in lieu of common stock in order to ensure the purchaser did not exceed certain beneficial
ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $.0001 per share, subject to adjustment.
Additionally, the common stock warrants were immediately exercisable at an exercise price of $0.50 per share and expire on November 17,
2024.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">We
account for the common stock warrants as a derivative instrument, and changes in the fair value of the warrants are included under other
income (expense) in the Company&#8217;s statements of operations for each reporting period. At June 30, 2021, the aggregate fair value
of the warrant liability included in the Company&#8217;s consolidated balance sheet was $1.1 million. We use the Black-Scholes option
pricing model to determine the fair value of the warrants. As a result, the option-pricing model requires the input of several assumptions,
including the stock price volatility, share price and risk-free interest rate. Changes in these assumptions can materially affect the
fair value estimate. While the liability may only result from a change of control at that point in time, we ultimately may incur amounts
significantly different than the carrying value.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 39; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Our
management and directors will be able to exert influence over our affairs.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, our executive officers and directors beneficially owned approximately 4.9% of our common stock. These stockholders,
if they act together, may be able to influence our management and affairs and all matters requiring stockholder approval, including significant
corporate transactions. This concentration of ownership may have the effect of delaying or preventing a change in control and might affect
the market price of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>The
market price of our common stock has been volatile over the past year and may continue to be volatile.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">The
market price and trading volume of our common stock has been volatile over the past year and it may continue to be volatile. Over the
past year, our common stock has traded as low as $1.17 and as high as $2.28 per share. We cannot predict the price at which our common
stock will trade in the future and it may decline. The price at which our common stock trades may fluctuate significantly and may be
influenced by many factors, including our financial results; developments generally affecting our industry; general economic, industry
and market conditions; the depth and liquidity of the market for our common stock; investor perceptions of our business; reports by industry
analysts; announcements by other market participants, including, among others, investors, our competitors, and our customers; regulatory
action affecting our business; and the impact of other &#8220;Risk Factors&#8221; discussed herein and in our Annual Report. In addition,
changes in the trading price of our common stock may be inconsistent with our operating results and outlook. The volatility of the market
price of our common stock may adversely affect investors&#8217; ability to purchase or sell shares of our common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Relating to Our Intellectual Property</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights,
and we may be unable to protect our rights to our products and technology.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
we or our collaborators choose to go to court to stop a third party from using the inventions claimed in our owned or licensed patents,
that third party may ask a court to rule that the patents are invalid and should not be enforced against that third party. These lawsuits
are expensive and would consume time and other resources, including financial resources, even if we were successful in stopping the infringement
of these patents. In addition, there is a risk that a court will decide that these patents are not valid or not enforceable and that
we do not have the right to stop others from using the inventions.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">There
is also the risk that, even if the validity of these patents is not challenged or is upheld, the court will refuse to stop the third
party on the ground that such third-party&#8217;s activities do not infringe on our owned or licensed patents. In addition, the U.S.
Supreme Court has changed some standards relating to the granting of patents and assessing the validity of patents. As a consequence,
issued patents may be found to contain invalid claims according to the newly revised standards. Some of our owned or licensed patents
may be subject to challenge and subsequent invalidation or significant narrowing of claim scope in a reexamination or other proceeding
before the USPTO, or during litigation, under the revised criteria which make it more difficult to obtain or maintain patents.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">While
our in-licensed patents and applications are not currently used in our product candidates, should we develop other product candidates
that are covered by this intellectual property, we will rely on our licensor to file and prosecute patent applications and maintain patents
and otherwise protect the intellectual property we license from them. Our licensor has retained the first right, but not the obligation
to initiate an infringement proceeding against a third-party infringer of the intellectual property licensed to us, and enforcement of
our in-licensed patents or defense of any claims asserting the invalidity or unenforceability of these patents would also be subject
to the control or cooperation of our licensor. It is possible that our licensor&#8217;s defense activities may be less vigorous than
had we conducted the defense ourselves.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
also license our patent portfolio, including U.S. and foreign patents and patent applications that cover our TLANDO and our other product
candidates, to third parties for their respective products and product candidates. Under our agreements with our licensees, we have the
right, but not the obligation, to enforce our current and future licensed patents against infringers of our licensees. In certain cases,
our licensees may have primary enforcement rights and we have the obligation to cooperate. In the event of an enforcement action against
infringers of our licensees, our licensees might not have the interest or resources to successfully preserve the patents, the infringers
may countersue, and as a result our patents may be found invalid or unenforceable or of a narrower scope of coverage and leave us with
no patent protection for TLANDO and our other product candidates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
may be subject to a third-party pre-issuance submission of prior art to the PTO, or become involved in opposition, derivation, reexamination,
inter partes review, post-grant review or interference proceedings challenging our owned or licensed patent rights or the patent rights
of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our owned
or licensed patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment
to us, or result in our inability to manufacture or commercialize products without infringing third party patent rights. In addition,
if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from
collaborating with us to license, develop or commercialize current or future product candidates and impair our ability to raise needed
capital.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Page; Sequence: 40; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">If
we are required to defend patent infringement actions brought by other third parties, or if we sue to protect our own patent rights or
otherwise to protect our proprietary information and to prevent its disclosure, we may be required to pay substantial litigation costs
and managerial attention and financial resources may be diverted from business operations even if the outcome is in our favor.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>Risks
Relating to Our Financial Position and Capital Requirements</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have incurred significant operating losses in most years since our inception and anticipate that we will incur continued losses for the
foreseeable future.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">We
have focused a significant portion of our efforts on developing TLANDO and more recently on LPCN 1144. We have funded our operations
to date through sales of our equity securities, debt and payments received under our license and collaboration arrangements. We have
incurred losses in most years since our inception. As of June 30, 2021, we had an accumulated deficit of $182.2 million.
Substantially all of our operating losses resulted from costs incurred in connection with our research and development programs and
from general and administrative costs associated with our operations. These losses, combined with expected future losses, have had
and will continue to have an adverse effect on our stockholders&#8217; equity and working capital. We expect our research and
development expenses to significantly increase in connection with clinical trials associated with LPCN 1144, TLANDO XR, LPCN 1148,
LPCN 1154 and LPCN 1107, if initiated. In addition, if we eventually obtain final marketing approval for TLANDO and its not
out-licensed, we may incur significant sales, marketing and commercialization expenses. As a result, we expect to continue to incur
significant operating losses for the foreseeable future as we evaluate our options with TLANDO and further clinical development of
LPCN 1144, TLANDO XR, LPCN 1148, LPCN 1154, LPCN 1107 and our other programs and continued research efforts. Because of the numerous
risks and uncertainties associated with developing pharmaceutical products, we are unable to predict the extent of any future losses
or when we will become profitable, if at all.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>We
have limited shares available for issuance to raise capital to fund our operations and grant stock-based incentive awards to employees,
directors, and consultants. If we are unable to increase the number of shares of common stock available for issuance, our business will
be adversely affected.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Currently,
we have 100,000,000 authorized shares of common stock. As of June 30, 2021, we had 88,290,650 shares of common stock outstanding. After
taking into account the 3,915,790 shares reserved for issuance upon the exercise of outstanding options and 1,934,366 reserved for issuance
upon the exercise of outstanding warrants, as of June 30, 2021, we have a limited number of shares available for issuance. If we are
not able to increase the number of shares of common stock available for issuance, including, for example, through an amendment to our
certificate of incorporation or a reverse stock split, we will have limited shares available for issuance to raise capital to fund our
operations, make grants of stock-based incentive awards, or take such other actions requiring available capital stock needed to operate
our business. Further delays in securing, or the failure to secure, shareholder approval of such actions, if needed, may prevent
us from executing a capital raising transaction, which may have a material adverse effect on our business and financial condition.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_006"></span>ITEM 2.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">None. </span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_007"></span>ITEM 3.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>DEFAULTS UPON SENIOR SECURITIES</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_008"></span>ITEM 4.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>MINE SAFETY DISCLOSURES</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_009"></span>ITEM 5.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>OTHER INFORMATION</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">None.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 41; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <span style="font: 10pt Times New Roman, Times, Serif"><b><span id="SS_010"></span>ITEM 6.</b></span> <span style="font: 10pt Times New Roman, Times, Serif"><b>EXHIBITS</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.05pt; text-align: justify; text-indent: -55.1pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>INDEX
TO EXHIBI<i>TS</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="7" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Incorporation
                                            By Reference</b></span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: bottom; width: 8%"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 55%"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit
                                            Description</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: center"></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 8%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Form</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>
</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 8%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>SEC
                                            File No.</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>
</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 8%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>
</td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 1%"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; white-space: nowrap; width: 8%; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b>Filing
                                            Date</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"></p>
</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">31.1<sup>*</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex31-1.htm">Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</a></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">31.2<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><a href="ex31-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</span></a></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">32.1<sup>*</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex32-1.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Principal Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">32.2<sup>*</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><a href="ex32-2.htm"><span style="font: 10pt Times New Roman, Times, Serif">Certification of Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. 1350 (1)</span></a></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.INS<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">XBRL
    Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within
    the Inline XBRL document.</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.SCH<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Schema Document</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.CAL<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.DEF<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.LAB<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Labels Linkbase Document</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">101.PRE<sup>*</sup></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0; text-align: justify"></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0"><span style="font: 10pt Times New Roman, Times, Serif">Inline
    XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">104</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Cover
    Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because
    its XBRL tags are embedded within the Inline XBRL document.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><sup>*</sup></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Filed
    herewith</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; white-space: nowrap; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">(1)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">This
    certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and
    is not to be incorporated by reference into any filing of the Registrant under the Securities Act, or the Exchange Act (whether made
    before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 42; Value: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Lipocine
    Inc.</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Registrant)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Dated: August 5, 2021</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Mahesh V. Patel</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Mahesh
V. Patel, President and Chief</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Executive
Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
    Executive Officer)</span></p></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">Dated: August 5, 2021</span></td>
    <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Morgan R. Brown</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Morgan
    R. Brown, Executive Vice President</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">and
Chief Financial Officer</span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Principal
Financial and Accounting Officer)</span></p></td></tr>
</table>

<p style="margin: 0">&#160;</p>

<!-- Field: Page; Sequence: 43; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence -->&#160;</td></tr></table></div>
    <!-- Field: /Page -->


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;<span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!--   -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>2
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Mahesh V. Patel, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q
    of Lipocine Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain
    any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
    under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and
    other financial information included in this report, fairly present in all material respects the financial condition, results of
    operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and
    I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
    and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or
    caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
    to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
    the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting,
    or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
    the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
    accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s
    disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
    and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s
    internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
    fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
    the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and
    I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses
    in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
    ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management
    or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 5, 2021 </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; width: 50%"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
                                            Mahesh V. Patel</I></FONT></P></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh V. Patel, President
    and Chief Executive Officer</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal Executive
    Officer)</FONT></TD></TR>
  </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>3
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATIONS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Morgan R. Brown, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I have reviewed this quarterly report on Form 10-Q
    of Lipocine Inc.;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, this report does not contain
    any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances
    under which such statements were made, not misleading with respect to the period covered by this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based on my knowledge, the financial statements, and
    other financial information included in this report, fairly present in all material respects the financial condition, results of
    operations and cash flows of the registrant as of, and for, the periods presented in this report;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and
    I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e)
    and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant
    and have:</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such disclosure controls and procedures, or
    caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating
    to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during
    the period in which this report is being prepared;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">designed such internal control over financial reporting,
    or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding
    the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally
    accepted accounting principles;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">evaluated the effectiveness of the registrant&rsquo;s
    disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls
    and procedures, as of the end of the period covered by this report based on such evaluation; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">disclosed in this report any change in the registrant&rsquo;s
    internal control over financial reporting that occurred during the registrant&rsquo;s most recent fiscal quarter (the registrant&rsquo;s
    fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,
    the registrant&rsquo;s internal control over financial reporting; and</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The registrant&rsquo;s other certifying officer and
    I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&rsquo;s auditors
    and the audit committee of the registrant&rsquo;s board of directors (or persons performing the equivalent functions):</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">all significant deficiencies and material weaknesses
    in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&rsquo;s
    ability to record, process, summarize and report financial information; and</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">any fraud, whether or not material, that involves management
    or other employees who have a significant role in the registrant&rsquo;s internal control over financial reporting.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 5, 2021 </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Morgan R. Brown</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
    R. Brown, Executive Vice President and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>4
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report on Form 10-Q of Lipocine Inc. (the &ldquo;Corporation&rdquo;) for the quarter ended June 30, 2021
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, Mahesh V. Patel,
President and Chief Executive Officer of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b) and 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 5, 2021 </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Mahesh V. Patel</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mahesh
    V. Patel, President and Chief Executive Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></P></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>5
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBIT
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with the Quarterly Report on Form 10-Q of Lipocine Inc. (the &ldquo;Corporation&rdquo;) for the quarter ended June 30, 2021
as filed with the Securities and Exchange Commission on the date hereof (the &ldquo;Report&rdquo;), the undersigned, Morgan R. Brown,
Executive Vice President and Chief Financial Officer of the Corporation, hereby certifies, pursuant to Rule 13a-14(b) or Rule 15d-14(b)
and 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to his knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations
of the Corporation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    August 5, 2021 </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: justify; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Morgan R. Brown</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Morgan
    R. Brown, Executive Vice President and</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Financial and Accounting Officer)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>lpcn-20210630.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWauDObP9z5Z8CekhvWB2bXk6by0rSdU0diWA6r3mscoI -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:LPCN="http://lipocine.com/20210630" elementFormDefault="qualified" targetNamespace="http://lipocine.com/20210630">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://lipocine.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" id="StatementsOfOperationsAndComprehensiveLoss">
	  <link:definition>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" id="StatementsOfChangesInStockholdersEquity">
	  <link:definition>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/BasisOfPresentation" id="BasisOfPresentation">
	  <link:definition>00000007 - Disclosure - Basis of Presentation</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/EarningsLossPerShare" id="EarningsLossPerShare">
	  <link:definition>00000008 - Disclosure - Earnings (Loss) per Share</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" id="MarketableInvestmentSecurities">
	  <link:definition>00000009 - Disclosure - Marketable Investment Securities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/FairValue" id="FairValue">
	  <link:definition>00000010 - Disclosure - Fair Value</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" id="LoanAndSecurityAgreementsAndOtherLiabilities">
	  <link:definition>00000011 - Disclosure - Loan and Security Agreements and Other Liabilities</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000012 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ContractualAgreements" id="ContractualAgreements">
	  <link:definition>00000013 - Disclosure - Contractual Agreements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/Leases" id="Leases">
	  <link:definition>00000014 - Disclosure - Leases</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquity" id="StockholdersEquity">
	  <link:definition>00000015 - Disclosure - Stockholders&#8217; Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000016 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" id="AgreementWithSpriasoLlc">
	  <link:definition>00000017 - Disclosure - Agreement with Spriaso, LLC</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/RecentAccountingPronouncements" id="RecentAccountingPronouncements">
	  <link:definition>00000018 - Disclosure - Recent Accounting Pronouncements</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/EarningsLossPerShareTables" id="EarningsLossPerShareTables">
	  <link:definition>00000019 - Disclosure - Earnings (Loss) per Share (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" id="MarketableInvestmentSecuritiesTables">
	  <link:definition>00000020 - Disclosure - Marketable Investment Securities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/FairValueTables" id="FairValueTables">
	  <link:definition>00000021 - Disclosure - Fair Value (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" id="LoanAndSecurityAgreementsAndOtherLiabilitiesTables">
	  <link:definition>00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LeasesTables" id="LeasesTables">
	  <link:definition>00000023 - Disclosure - Leases (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquityTables" id="StockholdersEquityTables">
	  <link:definition>00000024 - Disclosure - Stockholders&#8217; Equity (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" id="ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails">
	  <link:definition>00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" id="ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails">
	  <link:definition>00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" id="ScheduleOfAvailable-for-saleSecuritiesDetails">
	  <link:definition>00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" id="ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails">
	  <link:definition>00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" id="MarketableInvestmentSecuritiesDetailsNarrative">
	  <link:definition>00000029 - Disclosure - Marketable Investment Securities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" id="ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails">
	  <link:definition>00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/FairValueDetailsNarrative" id="FairValueDetailsNarrative">
	  <link:definition>00000031 - Disclosure - Fair Value (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" id="ScheduleOfMaturitiesOfDebtDetails">
	  <link:definition>00000032 - Disclosure - Schedule of Maturities of Debt (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" id="LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" id="ContractualAgreementsDetailsNarrative">
	  <link:definition>00000034 - Disclosure - Contractual Agreements (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
	  <link:definition>00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/LeasesDetailsNarrative" id="LeasesDetailsNarrative">
	  <link:definition>00000036 - Disclosure - Leases (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" id="ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails">
	  <link:definition>00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" id="ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails">
	  <link:definition>00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" id="ScheduleOfStockOptionActivityDetails">
	  <link:definition>00000039 - Disclosure - Schedule of Stock Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" id="ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails">
	  <link:definition>00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" id="ScheduleOfFairValueOfWarrantsDetails">
	  <link:definition>00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" id="ScheduleOfReconciliationOfWarrantLiabilityDetails">
	  <link:definition>00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" id="ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails">
	  <link:definition>00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" id="StockholdersEquityDetailsNarrative">
	  <link:definition>00000044 - Disclosure - Stockholders&#8217; Equity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000045 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" id="AgreementWithSpriasoLlcDetailsNarrative">
	  <link:definition>00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="lpcn-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
    <element id="LPCN_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_CorporateBondsNotesAndCommercialPaperMember" name="CorporateBondsNotesAndCommercialPaperMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_LoanAndSecurityAgreementMember" name="LoanAndSecurityAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_SiliconValleyBankMember" name="SiliconValleyBankMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AbbottProductsIncMember" name="AbbottProductsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_January2021OfferingMember" name="January2021OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_February2020OfferingMember" name="February2020OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ClassAUnitMember" name="ClassAUnitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_November2019OfferingMember" name="November2019OfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ClassBUnitsMember" name="ClassBUnitsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AtMarketOfferingMember" name="AtMarketOfferingMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AccreditedInvestorsMember" name="AccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_StockIncentivePlan2014Member" name="StockIncentivePlan2014Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_EquityIncentivePlanMember" name="EquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_CommonStockWarrantMember" name="CommonStockWarrantMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_GlobalAgreementMember" name="GlobalAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ClarusTherapeuticsIncMember" name="ClarusTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_LicenseAgreementMember" name="LicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_SpriasoLLCMember" name="SpriasoLLCMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ServiceAgreementMember" name="ServiceAgreementMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_StockIssuedDuringPeriodValueWarrantsExercises" name="StockIssuedDuringPeriodValueWarrantsExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" name="StockIssuedDuringPeriodSharesWarrantsExercises" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" name="AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_CommonStockSoldThroughEquityOffering" name="CommonStockSoldThroughEquityOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_CommonStockSoldThroughEquityOfferingShares" name="CommonStockSoldThroughEquityOfferingShares" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" name="AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_NetProceedsFromCostsAssociatedWithAtm" name="NetProceedsFromCostsAssociatedWithAtm" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" name="SettlementOfWarrantLiabilityOnWarrantExercises" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AccruedFinalPaymentChargeOnDebt" name="AccruedFinalPaymentChargeOnDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock" name="ScheduleOfFairValueOfWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" name="ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" nillable="true" xbrli:periodType="duration" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" name="LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" name="DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" name="DebtInstrumentMinimumAmountConsideredForInsolvency" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_DeferredFederalInsuranceContributionsActTaxPayments" name="DeferredFederalInsuranceContributionsActTaxPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" name="CollaborativeArrangementRoyaltiesPercentageOfNetSales" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" name="PercentageOfRoyaltiesReductionBasedUponProductLaunch" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" name="AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" nillable="true" xbrli:periodType="instant" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ProceedsFromIssuanceOfCommonStockGross" name="ProceedsFromIssuanceOfCommonStockGross" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_PercentageOfGrossProceedOnSaleOfShares" name="PercentageOfGrossProceedOnSaleOfShares" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" name="ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" nillable="true" xbrli:periodType="duration" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_PercentageOfRoyalty" name="PercentageOfRoyalty" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_AgreementDescription" name="AgreementDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived" name="RoyaltiesOnPercentageOfNetSalesToBeReceived" nillable="true" xbrli:periodType="duration" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ClassUnitMember" name="ClassUnitMember" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_Plan2014Member" name="Plan2014Member" nillable="true" xbrli:periodType="duration" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" />
    <element id="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>7
<FILENAME>lpcn-20210630_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20210630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BasisOfPresentation" xlink:href="lpcn-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShare" xlink:href="lpcn-20210630.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValue" xlink:href="lpcn-20210630.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20210630.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/RecentAccountingPronouncements" xlink:href="lpcn-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShareTables" xlink:href="lpcn-20210630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueTables" xlink:href="lpcn-20210630.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueDetailsNarrative" xlink:href="lpcn-20210630.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20210630.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_NetProceedsFromCostsAssociatedWithAtm" xlink:label="loc_LPCNNetProceedsFromCostsAssociatedWithAtm" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_LPCNNetProceedsFromCostsAssociatedWithAtm" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BasisOfPresentation" xlink:title="00000007 - Disclosure - Basis of Presentation" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShare" xlink:title="00000008 - Disclosure - Earnings (Loss) per Share" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValue" xlink:title="00000010 - Disclosure - Fair Value" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:title="00000011 - Disclosure - Loan and Security Agreements and Other Liabilities" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000013 - Disclosure - Contractual Agreements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000017 - Disclosure - Agreement with Spriaso, LLC" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/RecentAccountingPronouncements" xlink:title="00000018 - Disclosure - Recent Accounting Pronouncements" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShareTables" xlink:title="00000019 - Disclosure - Earnings (Loss) per Share (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000020 - Disclosure - Marketable Investment Securities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueTables" xlink:title="00000021 - Disclosure - Fair Value (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:title="00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000023 - Disclosure - Leases (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000029 - Disclosure - Marketable Investment Securities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueDetailsNarrative" xlink:title="00000031 - Disclosure - Fair Value (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:label="loc_LPCNLongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLongTermDebt" xlink:to="loc_LPCNLongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:title="00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000034 - Disclosure - Contractual Agreements (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - Leases (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000044 - Disclosure - Stockholders&#8217; Equity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>8
<FILENAME>lpcn-20210630_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20210630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BasisOfPresentation" xlink:href="lpcn-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShare" xlink:href="lpcn-20210630.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValue" xlink:href="lpcn-20210630.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20210630.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/RecentAccountingPronouncements" xlink:href="lpcn-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShareTables" xlink:href="lpcn-20210630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueTables" xlink:href="lpcn-20210630.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueDetailsNarrative" xlink:href="lpcn-20210630.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20210630.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapTreasuryStockMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_70" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_70" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross_70" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross_70" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="loc_LPCNStockIssuedDuringPeriodValueWarrantsExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNStockIssuedDuringPeriodValueWarrantsExercises_70" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="loc_LPCNStockIssuedDuringPeriodSharesWarrantsExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNStockIssuedDuringPeriodSharesWarrantsExercises_70" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_LPCNAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_70" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOffering" xlink:label="loc_LPCNCommonStockSoldThroughEquityOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNCommonStockSoldThroughEquityOffering_70" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOfferingShares" xlink:label="loc_LPCNCommonStockSoldThroughEquityOfferingShares_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNCommonStockSoldThroughEquityOfferingShares_70" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_70" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_70" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_70" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_70" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:label="loc_LPCNAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_70" xlink:type="arc" order="17" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/BasisOfPresentation" xlink:title="00000007 - Disclosure - Basis of Presentation" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShare" xlink:title="00000008 - Disclosure - Earnings (Loss) per Share" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValue" xlink:title="00000010 - Disclosure - Fair Value" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:title="00000011 - Disclosure - Loan and Security Agreements and Other Liabilities" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000013 - Disclosure - Contractual Agreements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000017 - Disclosure - Agreement with Spriaso, LLC" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/RecentAccountingPronouncements" xlink:title="00000018 - Disclosure - Recent Accounting Pronouncements" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShareTables" xlink:title="00000019 - Disclosure - Earnings (Loss) per Share (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000020 - Disclosure - Marketable Investment Securities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueTables" xlink:title="00000021 - Disclosure - Fair Value (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:title="00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000023 - Disclosure - Leases (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_UnvestedRestrictedStockUnitsMember" xlink:label="loc_LPCNUnvestedRestrictedStockUnitsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNUnvestedRestrictedStockUnitsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapMarketableSecuritiesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CorporateBondsNotesAndCommercialPaperMember" xlink:label="loc_LPCNCorporateBondsNotesAndCommercialPaperMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LPCNCorporateBondsNotesAndCommercialPaperMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCommercialPaperMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities_50" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000029 - Disclosure - Marketable Investment Securities (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCommercialPaperMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure_370" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure_370" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure_370" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueDetailsNarrative" xlink:title="00000031 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Debt (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:title="00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LoanAndSecurityAgreementMember" xlink:label="loc_LPCNLoanAndSecurityAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_LPCNLoanAndSecurityAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SiliconValleyBankMember" xlink:label="loc_LPCNSiliconValleyBankMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_LPCNSiliconValleyBankMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet_60" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="loc_us-gaapCashCollateralForBorrowedSecurities_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCashCollateralForBorrowedSecurities_60" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="loc_us-gaapDebtInstrumentRestrictiveCovenants_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRestrictiveCovenants_60" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="loc_LPCNDebtInstrumentBasisSpreadOnInterestRateForDebtDefault_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDebtInstrumentBasisSpreadOnInterestRateForDebtDefault_60" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="loc_LPCNDebtInstrumentMinimumAmountConsideredForInsolvency_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDebtInstrumentMinimumAmountConsideredForInsolvency_60" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DeferredFederalInsuranceContributionsActTaxPayments" xlink:label="loc_LPCNDeferredFederalInsuranceContributionsActTaxPayments_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDeferredFederalInsuranceContributionsActTaxPayments_60" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000034 - Disclosure - Contractual Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AbbottProductsIncMember" xlink:label="loc_LPCNAbbottProductsIncMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNAbbottProductsIncMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="loc_LPCNCollaborativeArrangementRoyaltiesPercentageOfNetSales_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_LPCNCollaborativeArrangementRoyaltiesPercentageOfNetSales_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="loc_LPCNPercentageOfRoyaltiesReductionBasedUponProductLaunch_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_LPCNPercentageOfRoyaltiesReductionBasedUponProductLaunch_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_70" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - Leases (Details Narrative)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_130" xlink:type="arc" order="0" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_40" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_40" xlink:type="arc" order="13" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_November2019OfferingMember" xlink:label="loc_LPCNNovember2019OfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNNovember2019OfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_50" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice_50" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_40" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_40" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_40" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_40" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_40" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_40" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_40" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_40" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_40" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_40" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000044 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_January2021OfferingMember" xlink:label="loc_LPCNJanuary2021OfferingMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNJanuary2021OfferingMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_February2020OfferingMember" xlink:label="loc_LPCNFebruary2020OfferingMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNFebruary2020OfferingMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_November2019OfferingMember" xlink:label="loc_LPCNNovember2019OfferingMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNNovember2019OfferingMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AtMarketOfferingMember" xlink:label="loc_LPCNAtMarketOfferingMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNAtMarketOfferingMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AccreditedInvestorsMember" xlink:label="loc_LPCNAccreditedInvestorsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNAccreditedInvestorsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassAUnitMember" xlink:label="loc_LPCNClassAUnitMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNClassAUnitMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassBUnitsMember" xlink:label="loc_LPCNClassBUnitsMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNClassBUnitsMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PreFundedWarrantsMember" xlink:label="loc_LPCNPreFundedWarrantsMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNPreFundedWarrantsMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SalesAgreementMember" xlink:label="loc_LPCNSalesAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LPCNSalesAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_170" xlink:type="arc" order="171" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_460" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_460" xlink:type="arc" order="461" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockWarrantMember" xlink:label="loc_LPCNCommonStockWarrantMember_500" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LPCNCommonStockWarrantMember_500" xlink:type="arc" order="501" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_250" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_250" xlink:type="arc" order="251" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIncentivePlan2014Member" xlink:label="loc_LPCNStockIncentivePlan2014Member_300" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNStockIncentivePlan2014Member_300" xlink:type="arc" order="301" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_EquityIncentivePlanMember" xlink:label="loc_LPCNEquityIncentivePlanMember_310" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNEquityIncentivePlanMember_310" xlink:type="arc" order="311" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_320" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_320" xlink:type="arc" order="321" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_330" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_330" xlink:type="arc" order="331" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_LPCNProceedsFromIssuanceOfCommonStockGross_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNProceedsFromIssuanceOfCommonStockGross_530" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts_530" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_530" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare_530" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_530" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_530" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfGrossProceedOnSaleOfShares" xlink:label="loc_LPCNPercentageOfGrossProceedOnSaleOfShares_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNPercentageOfGrossProceedOnSaleOfShares_530" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_530" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_LPCNClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_530" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_530" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_530" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_530" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_530" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_530" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_530" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_530" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_530" xlink:type="arc" order="16" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_530" xlink:type="arc" order="17" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_530" xlink:type="arc" order="18" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_530" xlink:type="arc" order="19" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_530" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_530" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_530" xlink:type="arc" order="21" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_GlobalAgreementMember" xlink:label="loc_LPCNGlobalAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNGlobalAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClarusTherapeuticsIncMember" xlink:label="loc_LPCNClarusTherapeuticsIncMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNClarusTherapeuticsIncMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable" xlink:label="loc_us-gaapRetentionPayable_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRetentionPayable_60" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LicenseAgreementMember" xlink:label="loc_LPCNLicenseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNLicenseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ServiceAgreementMember" xlink:label="loc_LPCNServiceAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNServiceAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SpriasoLLCMember" xlink:label="loc_LPCNSpriasoLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNSpriasoLLCMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyalty" xlink:label="loc_LPCNPercentageOfRoyalty_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LPCNPercentageOfRoyalty_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaapProceedsFromContributionsFromAffiliates_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromAffiliates_40" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AgreementDescription" xlink:label="loc_LPCNAgreementDescription_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LPCNAgreementDescription_40" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent_40" xlink:type="arc" order="3" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>9
<FILENAME>lpcn-20210630_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="us-gaap_TreasuryStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockMember" xlink:to="us-gaap_TreasuryStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockMember_lbl" xml:lang="en-US">Treasury Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Retained Earnings [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_UnvestedRestrictedStockUnitsMember" xlink:label="LPCN_UnvestedRestrictedStockUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_UnvestedRestrictedStockUnitsMember" xlink:to="LPCN_UnvestedRestrictedStockUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_UnvestedRestrictedStockUnitsMember_lbl" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US">Financial Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CorporateBondsNotesAndCommercialPaperMember" xlink:label="LPCN_CorporateBondsNotesAndCommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CorporateBondsNotesAndCommercialPaperMember" xlink:to="LPCN_CorporateBondsNotesAndCommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_CorporateBondsNotesAndCommercialPaperMember_lbl" xml:lang="en-US">Corporate Bonds Notes And Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommercialPaperMember_lbl" xml:lang="en-US">Commercial Paper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US">Cash and Cash Equivalents [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US">Money Market Funds [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LoanAndSecurityAgreementMember" xlink:label="LPCN_LoanAndSecurityAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LoanAndSecurityAgreementMember" xlink:to="LPCN_LoanAndSecurityAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_LoanAndSecurityAgreementMember_lbl" xml:lang="en-US">Loan And Security Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="us-gaap_LineOfCreditFacilityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCreditFacilityAxis" xlink:to="us-gaap_LineOfCreditFacilityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCreditFacilityAxis_lbl" xml:lang="en-US">Lender Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SiliconValleyBankMember" xlink:label="LPCN_SiliconValleyBankMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SiliconValleyBankMember" xlink:to="LPCN_SiliconValleyBankMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_SiliconValleyBankMember_lbl" xml:lang="en-US">Silicon Valley Bank [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Series [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AbbottProductsIncMember" xlink:label="LPCN_AbbottProductsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AbbottProductsIncMember" xlink:to="LPCN_AbbottProductsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AbbottProductsIncMember_lbl" xml:lang="en-US">Abbott Products Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="us-gaap_CollaborativeArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementMember" xlink:to="us-gaap_CollaborativeArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementMember_lbl" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US">Sale of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_January2021OfferingMember" xlink:label="LPCN_January2021OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_January2021OfferingMember" xlink:to="LPCN_January2021OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_January2021OfferingMember_lbl" xml:lang="en-US">January2021 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_February2020OfferingMember" xlink:label="LPCN_February2020OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_February2020OfferingMember" xlink:to="LPCN_February2020OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_February2020OfferingMember_lbl" xml:lang="en-US">February2020 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xml:lang="en-US">Class of Stock [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassAUnitMember" xlink:label="LPCN_ClassAUnitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassAUnitMember" xlink:to="LPCN_ClassAUnitMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ClassAUnitMember_lbl" xml:lang="en-US">Class A Unit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_November2019OfferingMember" xlink:label="LPCN_November2019OfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_November2019OfferingMember" xlink:to="LPCN_November2019OfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_November2019OfferingMember_lbl" xml:lang="en-US">November 2019 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassBUnitsMember" xlink:label="LPCN_ClassBUnitsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassBUnitsMember" xlink:to="LPCN_ClassBUnitsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ClassBUnitsMember_lbl" xml:lang="en-US">Class B Units [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PreFundedWarrantsMember" xlink:label="LPCN_PreFundedWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PreFundedWarrantsMember" xlink:to="LPCN_PreFundedWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_PreFundedWarrantsMember_lbl" xml:lang="en-US">Pre Funded Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SalesAgreementMember" xlink:label="LPCN_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SalesAgreementMember" xlink:to="LPCN_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AtMarketOfferingMember" xlink:label="LPCN_AtMarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AtMarketOfferingMember" xlink:to="LPCN_AtMarketOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AtMarketOfferingMember_lbl" xml:lang="en-US">At Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AccreditedInvestorsMember" xlink:label="LPCN_AccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AccreditedInvestorsMember" xlink:to="LPCN_AccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AccreditedInvestorsMember_lbl" xml:lang="en-US">Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIncentivePlan2014Member" xlink:label="LPCN_StockIncentivePlan2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIncentivePlan2014Member" xlink:to="LPCN_StockIncentivePlan2014Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_StockIncentivePlan2014Member_lbl" xml:lang="en-US">Stock Incentive Plan2014 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_EquityIncentivePlanMember" xlink:label="LPCN_EquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_EquityIncentivePlanMember" xlink:to="LPCN_EquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_EquityIncentivePlanMember_lbl" xml:lang="en-US">Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockWarrantMember" xlink:label="LPCN_CommonStockWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CommonStockWarrantMember" xlink:to="LPCN_CommonStockWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_CommonStockWarrantMember_lbl" xml:lang="en-US">Common Stock Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_GlobalAgreementMember" xlink:label="LPCN_GlobalAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_GlobalAgreementMember" xlink:to="LPCN_GlobalAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_GlobalAgreementMember_lbl" xml:lang="en-US">Global Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClarusTherapeuticsIncMember" xlink:label="LPCN_ClarusTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClarusTherapeuticsIncMember" xlink:to="LPCN_ClarusTherapeuticsIncMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ClarusTherapeuticsIncMember_lbl" xml:lang="en-US">Clarus Therapeutics Inc [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioForecastMember_lbl" xml:lang="en-US">Forecast [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LicenseAgreementMember" xlink:label="LPCN_LicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LicenseAgreementMember" xlink:to="LPCN_LicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_LicenseAgreementMember_lbl" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SpriasoLLCMember" xlink:label="LPCN_SpriasoLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SpriasoLLCMember" xlink:to="LPCN_SpriasoLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_SpriasoLLCMember_lbl" xml:lang="en-US">Spriaso L L C [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ServiceAgreementMember" xlink:label="LPCN_ServiceAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ServiceAgreementMember" xlink:to="LPCN_ServiceAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ServiceAgreementMember_lbl" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xml:lang="en-US">Marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">Liabilities and Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="us-gaap_DebtCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtCurrent" xlink:to="us-gaap_DebtCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtCurrent_lbl" xml:lang="en-US">Debt - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="us-gaap_LitigationReserveCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveCurrent" xlink:to="us-gaap_LitigationReserveCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveCurrent_lbl" xml:lang="en-US">Litigation settlement liability - current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtNoncurrent_lbl" xml:lang="en-US">Debt - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstanding_lbl" xml:lang="en-US">Warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="us-gaap_LitigationReserveNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationReserveNoncurrent" xlink:to="us-gaap_LitigationReserveNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationReserveNoncurrent_lbl" xml:lang="en-US">Litigation settlement liability - non-current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and contingencies (notes 5, 7, 8 and 10)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="us-gaap_TreasuryStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_TreasuryStockValue_lbl" xml:lang="en-US">Treasury stock at cost, 5,710 shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="us-gaap_TreasuryStockShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockShares" xlink:to="us-gaap_TreasuryStockShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockShares_lbl" xml:lang="en-US">Treasury stock, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense):</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="us-gaap_InvestmentIncomeInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeInterest" xlink:to="us-gaap_InvestmentIncomeInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentIncomeInterest_lbl" xml:lang="en-US">Interest and investment income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrealizedGainLossOnDerivatives" xlink:to="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrealizedGainLossOnDerivatives_lbl" xml:lang="en-US">Unrealized gain (loss) on warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xml:lang="en-US">Litigation settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US">Total other expense, net</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_lbl" xml:lang="en-US">Loss before income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US">Income tax expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US">Basic loss per share attributable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US">Weighted average common shares outstanding, basic</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US">Diluted loss per share attributable to common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US">Weighted average common shares outstanding, diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTaxAbstract_lbl" xml:lang="en-US">Comprehensive loss:</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US">Net unrealized gain (loss) on available-for-sale securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US">Comprehensive loss</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balances</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_lbl" xml:lang="en-US">Unrealized net loss on marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xml:lang="en-US">Vesting of restricted stock units, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="LPCN_StockIssuedDuringPeriodValueWarrantsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="LPCN_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_StockIssuedDuringPeriodValueWarrantsExercises_lbl" xml:lang="en-US">Common stock issued for warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises_lbl" xml:lang="en-US">Common stock issued for warrant exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_lbl" xml:lang="en-US">Settlement of warrant liability on warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOffering" xlink:label="LPCN_CommonStockSoldThroughEquityOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CommonStockSoldThroughEquityOffering" xlink:to="LPCN_CommonStockSoldThroughEquityOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_CommonStockSoldThroughEquityOffering_lbl" xml:lang="en-US">Common stock sold through equity offering</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOfferingShares" xlink:label="LPCN_CommonStockSoldThroughEquityOfferingShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CommonStockSoldThroughEquityOfferingShares" xlink:to="LPCN_CommonStockSoldThroughEquityOfferingShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_CommonStockSoldThroughEquityOfferingShares_lbl" xml:lang="en-US">Common stock sold through equity offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Option exercises, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Common stock sold through ATM offering</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Common stock sold through ATM offering, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:to="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_lbl" xml:lang="en-US">Costs associated with ATM offering</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balances</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="us-gaap_AccretionExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionExpense" xlink:to="us-gaap_AccretionExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionExpense_lbl" xml:lang="en-US">Non-cash interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Non-cash loss (gain) on change in fair value of warrant liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US">Amortization of premium (discount) on marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xml:lang="en-US">Accrued interest income</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US">Prepaid and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementExpense_2_lbl" xml:lang="en-US">Litigation settlement liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_lbl" xml:lang="en-US">Purchases of marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_lbl" xml:lang="en-US">Maturities of marketable investment securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US">Debt repayments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfDebt" xlink:to="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfDebt_lbl" xml:lang="en-US">Proceeds from debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Net proceeds from common stock offering</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_NetProceedsFromCostsAssociatedWithAtm" xlink:label="LPCN_NetProceedsFromCostsAssociatedWithAtm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_NetProceedsFromCostsAssociatedWithAtm" xlink:to="LPCN_NetProceedsFromCostsAssociatedWithAtm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_NetProceedsFromCostsAssociatedWithAtm_lbl" xml:lang="en-US">Net proceeds from (costs associated with) ATM</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from stock option exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Net proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Interest paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxesPaidNet_lbl" xml:lang="en-US">Income taxes paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activity:</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_lbl" xml:lang="en-US">Settlement of warrant liability on warrant exercises</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_lbl" xml:lang="en-US">Net unrealized loss on available-for-sale securities</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AccruedFinalPaymentChargeOnDebt" xlink:label="LPCN_AccruedFinalPaymentChargeOnDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AccruedFinalPaymentChargeOnDebt" xlink:to="LPCN_AccruedFinalPaymentChargeOnDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AccruedFinalPaymentChargeOnDebt_lbl" xml:lang="en-US">Accrued final payment charge on debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:to="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseAccruedInterest_lbl" xml:lang="en-US">Other accrued interest</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_lbl" xml:lang="en-US">Basis of Presentation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US">Earnings (Loss) per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US">Marketable Investment Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US">Fair Value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Loan and Security Agreements and Other Liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="us-gaap_HealthCareOrganizationsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_HealthCareOrganizationsAbstract" xlink:to="us-gaap_HealthCareOrganizationsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_HealthCareOrganizationsAbstract_lbl" xml:lang="en-US">Health Care Organizations [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:label="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:to="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock_lbl" xml:lang="en-US">Contractual Agreements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="us-gaap_LesseeDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeDisclosureAbstract" xlink:to="us-gaap_LesseeDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeDisclosureAbstract_lbl" xml:lang="en-US">Lessee Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US">Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Stockholders&#8217; Equity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Agreement with Spriaso, LLC</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingChangesAndErrorCorrectionsAbstract_lbl" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_lbl" xml:lang="en-US">Schedule of Available-for-Sale Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value, Assets Measured on Recurring Basis</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_lbl" xml:lang="en-US">Schedule of Maturities of Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Schedule of Key Assumption of Fair Value of Stock Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_lbl" xml:lang="en-US">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:to="LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of Fair Value of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:to="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Reconciliation of Warrant Liability</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xml:lang="en-US">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2_lbl" xml:lang="en-US">Weighted avg. common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_2_lbl" xml:lang="en-US">Weighted avg. common shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:to="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityLineItems_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xml:lang="en-US">Marketable Securities [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xml:lang="en-US">Marketable Securities [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xml:lang="en-US">Amortized Cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US">Gross unrealized holding gains</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US">Gross unrealized holding losses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xml:lang="en-US">Aggregate fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US">Due within one year</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US">Total maturities of debt securities classified as available-for-sale securities, amortized cost</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US">Total maturities of debt securities classified as available-for-sale securities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet_lbl" xml:lang="en-US">Available-for-sale securities, gross realized gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US">Proceeds from sale and maturity of marketable securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_lbl" xml:lang="en-US">Other-than-temporary impairments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xml:lang="en-US">Assets, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xml:lang="en-US">Liabilities, fair value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable_lbl" xml:lang="en-US">Schedule of Fair Value, Off-balance Sheet Risks [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems_lbl" xml:lang="en-US">Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Risk-free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_lbl" xml:lang="en-US">Strike price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US">Fair value of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:label="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:to="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US">Long-term Debt</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="us-gaap_ScheduleOfShortTermDebtTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShortTermDebtTable" xlink:to="us-gaap_ScheduleOfShortTermDebtTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShortTermDebtTable_lbl" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="us-gaap_ShortTermDebtLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermDebtLineItems" xlink:to="us-gaap_ShortTermDebtLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShortTermDebtLineItems_lbl" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US">Aggregate amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:to="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate_lbl" xml:lang="en-US">Debt Instrument, Interest Rate, Basis for Effective Rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage_lbl" xml:lang="en-US">Interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentMaturityDate_lbl" xml:lang="en-US">Debt instrument, maturity date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_lbl" xml:lang="en-US">Debt instrument, balloon payment to be paid</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet_lbl" xml:lang="en-US">Debt instrument, increase in amount</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="us-gaap_CashCollateralForBorrowedSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCollateralForBorrowedSecurities" xlink:to="us-gaap_CashCollateralForBorrowedSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCollateralForBorrowedSecurities_lbl" xml:lang="en-US">Cash collateral for borrowed securities</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentRestrictiveCovenants" xlink:to="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentRestrictiveCovenants_lbl" xml:lang="en-US">Debt instrument, restrictive covenants</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:to="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_lbl" xml:lang="en-US">Debt instrument, basis spread on interest rate for debt default</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:to="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency_lbl" xml:lang="en-US">Debt instrument, minimum amount considered for insolvency</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DeferredFederalInsuranceContributionsActTaxPayments" xlink:label="LPCN_DeferredFederalInsuranceContributionsActTaxPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DeferredFederalInsuranceContributionsActTaxPayments" xlink:to="LPCN_DeferredFederalInsuranceContributionsActTaxPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_DeferredFederalInsuranceContributionsActTaxPayments_lbl" xml:lang="en-US">Deferred FICA payroll tax payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="dei_EntityListingsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityListingsLineItems" xlink:to="dei_EntityListingsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityListingsLineItems_lbl" xml:lang="en-US">Entity Listings [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:to="LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales_lbl" xml:lang="en-US">Percentage of net sales</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:to="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyGuaranteesCommitmentsAmount_lbl" xml:lang="en-US">Royalties, commitment amount</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:to="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch_lbl" xml:lang="en-US">Percentage of royalties reduction based upon product launch</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_lbl" xml:lang="en-US">Contract research and development expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US">Total minimum lease payments</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="us-gaap_OptionIndexedToIssuersEquityTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTable" xlink:to="us-gaap_OptionIndexedToIssuersEquityTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTable_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Balance at beginning of the period (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Balance at beginning of the period (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Number of shares, Options granted (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options granted (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Number of shares, Options exercised (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercised (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Number of shares, Options forfeited (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options forfeited (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xml:lang="en-US">Number of shares, Options cancelled (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options cancelled (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Balance at end of the period (in shares)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average exercise price, Balance at end of the period (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Number of shares, Options exercisable (in shares)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average exercise price, Options exercisable (in dollars per share)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Number of options outstanding, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Options outstanding, Weighted average remaining contractual life (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Options outstanding, Weighted average exercise price (in dollars per share)</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Options outstanding, Aggregate intrinsic value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Number of options exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Options exercisable, Weighted average remaining contractual life (Years)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options exercisable, Weighted average exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Options exercisable, Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable_lbl" xml:lang="en-US">Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockLineItems" xlink:to="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockLineItems_lbl" xml:lang="en-US">Subsidiary, Sale of Stock [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected life in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_2_lbl" xml:lang="en-US">Share Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_2_lbl" xml:lang="en-US">Balance at December 31, 2020</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:label="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:to="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_lbl" xml:lang="en-US">Settlement of liability on warrant exercise</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_2_lbl" xml:lang="en-US">Change in fair value of common stock warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_WarrantsAndRightsOutstanding_3_lbl" xml:lang="en-US">Balance at June 30, 2021</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_lbl" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_lbl" xml:lang="en-US">Number of shares, Balance at beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted average Exercise Price, Beginning of the period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Issued</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_lbl" xml:lang="en-US">Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_lbl" xml:lang="en-US">Expired</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_lbl" xml:lang="en-US">Cancelled</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2_lbl" xml:lang="en-US">Number of shares, Balance at ending of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted average Exercise Price, Ending of the period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3_lbl" xml:lang="en-US">Number of warrants exercisable, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xml:lang="en-US">Weighted average remaining contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Weighted average exercise price, per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xml:lang="en-US">Aggregate intrinsic value</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ProceedsFromIssuanceOfCommonStockGross" xlink:label="LPCN_ProceedsFromIssuanceOfCommonStockGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ProceedsFromIssuanceOfCommonStockGross" xlink:to="LPCN_ProceedsFromIssuanceOfCommonStockGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ProceedsFromIssuanceOfCommonStockGross_lbl" xml:lang="en-US">Proceeds from issuance of common stock, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US">Agent fees and other offering expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Stock issued during period, shares, new issues</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xml:lang="en-US">Shares issued, price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_2_lbl" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfGrossProceedOnSaleOfShares" xlink:label="LPCN_PercentageOfGrossProceedOnSaleOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfGrossProceedOnSaleOfShares" xlink:to="LPCN_PercentageOfGrossProceedOnSaleOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_PercentageOfGrossProceedOnSaleOfShares_lbl" xml:lang="en-US">Percentage of gross proceeds on sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_lbl" xml:lang="en-US">Class of warrant or right, redemption price of warrants or rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Allocated share-based compensation expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_2_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, grants in period, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Employee service share-based compensation, nonvested awards, compensation cost not yet recognized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, number of shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Contractual life</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3_lbl" xml:lang="en-US">Share-based compensation arrangement by share-based payment award, options, exercises in period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xml:lang="en-US">Warrants outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_3_lbl" xml:lang="en-US">Fair value adjustment of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Common warrants to purchase share of our common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromWarrantExercises_2_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:to="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LitigationSettlementAmountAwardedToOtherParty_lbl" xml:lang="en-US">Litigation settlement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable" xlink:label="us-gaap_RetentionPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetentionPayable" xlink:to="us-gaap_RetentionPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetentionPayable_lbl" xml:lang="en-US">Retention payable</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyalty" xlink:label="LPCN_PercentageOfRoyalty" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfRoyalty" xlink:to="LPCN_PercentageOfRoyalty_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_PercentageOfRoyalty_lbl" xml:lang="en-US">Percentage of royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributionsFromAffiliates" xlink:to="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributionsFromAffiliates_lbl" xml:lang="en-US">Proceeds from affiliates</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AgreementDescription" xlink:label="LPCN_AgreementDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AgreementDescription" xlink:to="LPCN_AgreementDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_AgreementDescription_lbl" xml:lang="en-US">Agreement description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent_lbl" xml:lang="en-US">Employee related liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIssuedDuringPeriodValueWarrantsExercises" xlink:to="LPCN_StockIssuedDuringPeriodValueWarrantsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_StockIssuedDuringPeriodValueWarrantsExercises_doc" xml:lang="en-US">Common stock issued for warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises_doc" xml:lang="en-US">Settlement of warrant liability on warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:to="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering_doc" xml:lang="en-US">Additional paid in capital, share-based payment arrangement, costs associated with ATM offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CommonStockSoldThroughEquityOffering" xlink:to="LPCN_CommonStockSoldThroughEquityOffering_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_CommonStockSoldThroughEquityOffering_doc" xml:lang="en-US">Common stock sold through equity offering.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:to="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_StockIssuedDuringPeriodSharesWarrantsExercises_doc" xml:lang="en-US">Common stock issued for warrant exercises, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CommonStockSoldThroughEquityOfferingShares" xlink:to="LPCN_CommonStockSoldThroughEquityOfferingShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_CommonStockSoldThroughEquityOfferingShares_doc" xml:lang="en-US">Common stock sold through equity offering, shares.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_NetProceedsFromCostsAssociatedWithAtm" xlink:to="LPCN_NetProceedsFromCostsAssociatedWithAtm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_NetProceedsFromCostsAssociatedWithAtm_doc" xml:lang="en-US">Net proceeds from (costs associated with) ATM.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_doc" xml:lang="en-US">Settlement of warrant liability on warrant exercises.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AccruedFinalPaymentChargeOnDebt" xlink:to="LPCN_AccruedFinalPaymentChargeOnDebt_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AccruedFinalPaymentChargeOnDebt_doc" xml:lang="en-US">Accrued final payment charge on debt.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_UnvestedRestrictedStockUnitsMember" xlink:to="LPCN_UnvestedRestrictedStockUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_UnvestedRestrictedStockUnitsMember_doc" xml:lang="en-US">Unvested Restricted Stock Units Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_CorporateBondsNotesAndCommercialPaperMember" xlink:to="LPCN_CorporateBondsNotesAndCommercialPaperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_CorporateBondsNotesAndCommercialPaperMember_doc" xml:lang="en-US">Corporate Bonds Notes And Commercial Paper Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LoanAndSecurityAgreementMember" xlink:to="LPCN_LoanAndSecurityAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_LoanAndSecurityAgreementMember_doc" xml:lang="en-US">Loan and Security Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SiliconValleyBankMember" xlink:to="LPCN_SiliconValleyBankMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_SiliconValleyBankMember_doc" xml:lang="en-US">Silicon Valley Bank</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:to="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_doc" xml:lang="en-US">Debt instrument, basis spread on interest rate for debt default.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:to="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency_doc" xml:lang="en-US">The amount of debt instrument minimum amount considered for insolvency.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_DeferredFederalInsuranceContributionsActTaxPayments" xlink:to="LPCN_DeferredFederalInsuranceContributionsActTaxPayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_DeferredFederalInsuranceContributionsActTaxPayments_doc" xml:lang="en-US">This information is pertaining to the amount of deferral of FICA tax payments totaled and are included in accrued liabilities.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived" xlink:label="LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived" xlink:to="LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_RoyaltiesOnPercentageOfNetSalesToBeReceived_doc" xml:lang="en-US">Royalties on percentage of net sales to be received.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AbbottProductsIncMember" xlink:to="LPCN_AbbottProductsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AbbottProductsIncMember_doc" xml:lang="en-US">Abbott Products Inc Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:to="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch_doc" xml:lang="en-US">Percentage of royalties reduction based upon product launch.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfRoyalty" xlink:to="LPCN_PercentageOfRoyalty_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_PercentageOfRoyalty_doc" xml:lang="en-US">Percentage of royalty.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LicenseAgreementMember" xlink:to="LPCN_LicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_LicenseAgreementMember_doc" xml:lang="en-US">License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SpriasoLLCMember" xlink:to="LPCN_SpriasoLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_SpriasoLLCMember_doc" xml:lang="en-US">Spriaso LLC[Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AgreementDescription" xlink:to="LPCN_AgreementDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AgreementDescription_doc" xml:lang="en-US">Agreement description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ServiceAgreementMember" xlink:to="LPCN_ServiceAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ServiceAgreementMember_doc" xml:lang="en-US">Service Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_GlobalAgreementMember" xlink:to="LPCN_GlobalAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_GlobalAgreementMember_doc" xml:lang="en-US">Global Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClarusTherapeuticsIncMember" xlink:to="LPCN_ClarusTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ClarusTherapeuticsIncMember_doc" xml:lang="en-US">Clarus Therapeutics, Inc [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ProceedsFromIssuanceOfCommonStockGross" xlink:to="LPCN_ProceedsFromIssuanceOfCommonStockGross_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ProceedsFromIssuanceOfCommonStockGross_doc" xml:lang="en-US">The cash inflow from the additional capital contribution to the entity.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_January2021OfferingMember" xlink:to="LPCN_January2021OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_January2021OfferingMember_doc" xml:lang="en-US">January 2021 Offering [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_February2020OfferingMember" xlink:to="LPCN_February2020OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_February2020OfferingMember_doc" xml:lang="en-US">Represents the information pertaining to February 2020 Offering.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassUnitMember" xlink:label="LPCN_ClassUnitMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassUnitMember" xlink:to="LPCN_ClassUnitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ClassUnitMember_doc" xml:lang="en-US">Represents the information pertaining to class A units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_November2019OfferingMember" xlink:to="LPCN_November2019OfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_November2019OfferingMember_doc" xml:lang="en-US">November 2019 Offering Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassBUnitsMember" xlink:to="LPCN_ClassBUnitsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ClassBUnitsMember_doc" xml:lang="en-US">Represents the information pertaining to class B units.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PreFundedWarrantsMember" xlink:to="LPCN_PreFundedWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_PreFundedWarrantsMember_doc" xml:lang="en-US">Represents the information pertaining to prefunded warrants.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_PercentageOfGrossProceedOnSaleOfShares" xlink:to="LPCN_PercentageOfGrossProceedOnSaleOfShares_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_PercentageOfGrossProceedOnSaleOfShares_doc" xml:lang="en-US">Percentage of gross proceeds on sale of shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SalesAgreementMember" xlink:to="LPCN_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_SalesAgreementMember_doc" xml:lang="en-US">Sales agreement [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AtMarketOfferingMember" xlink:to="LPCN_AtMarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AtMarketOfferingMember_doc" xml:lang="en-US">At Market Offering Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AccreditedInvestorsMember" xlink:to="LPCN_AccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AccreditedInvestorsMember_doc" xml:lang="en-US">Accredited Investors Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:to="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_doc" xml:lang="en-US">Class of Warrant or Right, Redemption Price of Warrants or Rights</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_StockIncentivePlan2014Member" xlink:to="LPCN_StockIncentivePlan2014Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_StockIncentivePlan2014Member_doc" xml:lang="en-US">Stock Incentive Plan 2014 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_EquityIncentivePlanMember" xlink:to="LPCN_EquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_EquityIncentivePlanMember_doc" xml:lang="en-US">Equity Incentive Plan Member.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_Plan2014Member" xlink:label="LPCN_Plan2014Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_Plan2014Member" xlink:to="LPCN_Plan2014Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_Plan2014Member_doc" xml:lang="en-US">Plan 2014 Member.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:to="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_doc" xml:lang="en-US">Adjustment for settlement of liability on warrant exercised.</link:label>
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentsAwardNonOptionEquityInstrumentCancelled_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payments Award Non Option Equity Instrument Cancelled</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average Exercise Price, period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_doc" xml:lang="en-US">Weighted average Exercise Price, issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ClassAUnitMember" xlink:to="LPCN_ClassAUnitMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ClassAUnitMember_doc" xml:lang="en-US">Class A Unit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:to="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_doc" xml:lang="en-US">Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:to="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_doc" xml:lang="en-US">Schedule of Reconciliation of Warrant Liability [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TreasuryStockValue" xlink:to="us-gaap_TreasuryStockValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TreasuryStockValue_2_lbl" xml:lang="en-US">Treasury Stock, Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_2_lbl" xml:lang="en-US">Interest Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2_lbl" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_2_lbl" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_2_lbl" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_2_lbl" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Interest Receivable, Net</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_2_lbl" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_2_lbl" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_lbl" xml:lang="en-US">Payments to Acquire Debt Securities, Available-for-sale</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_2_lbl" xml:lang="en-US">Repayments of Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_3_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:to="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_SettlementOfWarrantLiabilityOnWarrantExercises_3_lbl" xml:lang="en-US">Settlement of warrant liability on warrant exercises [Default Label]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_2_lbl" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_2_lbl" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2_lbl" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_2_lbl" xml:lang="en-US">Long-term Debt</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2_lbl" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:to="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>10
<FILENAME>lpcn-20210630_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://lipocine.com/role/Cover" xlink:href="lpcn-20210630.xsd#Cover" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheets" xlink:href="lpcn-20210630.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:href="lpcn-20210630.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:href="lpcn-20210630.xsd#StatementsOfOperationsAndComprehensiveLoss" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:href="lpcn-20210630.xsd#StatementsOfChangesInStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StatementsOfCashFlows" xlink:href="lpcn-20210630.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/BasisOfPresentation" xlink:href="lpcn-20210630.xsd#BasisOfPresentation" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShare" xlink:href="lpcn-20210630.xsd#EarningsLossPerShare" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecurities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValue" xlink:href="lpcn-20210630.xsd#FairValue" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilities" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/IncomeTaxes" xlink:href="lpcn-20210630.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreements" xlink:href="lpcn-20210630.xsd#ContractualAgreements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/Leases" xlink:href="lpcn-20210630.xsd#Leases" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquity" xlink:href="lpcn-20210630.xsd#StockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingencies" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlc" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/RecentAccountingPronouncements" xlink:href="lpcn-20210630.xsd#RecentAccountingPronouncements" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/EarningsLossPerShareTables" xlink:href="lpcn-20210630.xsd#EarningsLossPerShareTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueTables" xlink:href="lpcn-20210630.xsd#FairValueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesTables" xlink:href="lpcn-20210630.xsd#LeasesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityTables" xlink:href="lpcn-20210630.xsd#StockholdersEquityTables" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#MarketableInvestmentSecuritiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/FairValueDetailsNarrative" xlink:href="lpcn-20210630.xsd#FairValueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfMaturitiesOfDebtDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:href="lpcn-20210630.xsd#ContractualAgreementsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/LeasesDetailsNarrative" xlink:href="lpcn-20210630.xsd#LeasesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfStockOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfFairValueOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:href="lpcn-20210630.xsd#ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:href="lpcn-20210630.xsd#StockholdersEquityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="lpcn-20210630.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:href="lpcn-20210630.xsd#AgreementWithSpriasoLlcDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheets" xlink:title="00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="loc_us-gaapInterestReceivableCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapInterestReceivableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaapDebtCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDebtCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveCurrent" xlink:label="loc_us-gaapLitigationReserveCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLitigationReserveCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaapLongTermDebtNoncurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLongTermDebtNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationReserveNoncurrent" xlink:label="loc_us-gaapLitigationReserveNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLitigationReserveNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaapAdditionalPaidInCapital" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapital" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaapTreasuryStockValue" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapTreasuryStockValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaapTreasuryStockShares" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapTreasuryStockShares" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss" xlink:title="00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaapInvestmentIncomeInterest" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInvestmentIncomeInterest" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnDerivatives" xlink:label="loc_us-gaapUnrealizedGainLossOnDerivatives" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapUnrealizedGainLossOnDerivatives" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaapOtherNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapOtherNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaapIncomeTaxExpenseBenefit" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapIncomeTaxExpenseBenefit" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAbstract" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapNetIncomeLoss_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaapComprehensiveIncomeNetOfTax" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapComprehensiveIncomeNetOfTaxAbstract" xlink:to="loc_us-gaapComprehensiveIncomeNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfChangesInStockholdersEquity" xlink:title="00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders&apos; Equity (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaapTreasuryStockMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapTreasuryStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodValueWarrantsExercises" xlink:label="loc_LPCNStockIssuedDuringPeriodValueWarrantsExercises" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNStockIssuedDuringPeriodValueWarrantsExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIssuedDuringPeriodSharesWarrantsExercises" xlink:label="loc_LPCNStockIssuedDuringPeriodSharesWarrantsExercises" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNStockIssuedDuringPeriodSharesWarrantsExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_LPCNAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNAdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOffering" xlink:label="loc_LPCNCommonStockSoldThroughEquityOffering" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNCommonStockSoldThroughEquityOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockSoldThroughEquityOfferingShares" xlink:label="loc_LPCNCommonStockSoldThroughEquityOfferingShares" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNCommonStockSoldThroughEquityOfferingShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:label="loc_LPCNAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_LPCNAdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StatementsOfCashFlows" xlink:title="00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaapAccretionExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaapLitigationSettlementExpense" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapLitigationSettlementExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquireAvailableForSaleSecuritiesDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfAvailableForSaleSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfDebt" xlink:label="loc_us-gaapRepaymentsOfDebt" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfDebt" xlink:label="loc_us-gaapProceedsFromIssuanceOfDebt" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_NetProceedsFromCostsAssociatedWithAtm" xlink:label="loc_LPCNNetProceedsFromCostsAssociatedWithAtm" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_LPCNNetProceedsFromCostsAssociatedWithAtm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaapIncomeTaxesPaidNet" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapIncomeTaxesPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SettlementOfWarrantLiabilityOnWarrantExercises" xlink:label="loc_LPCNSettlementOfWarrantLiabilityOnWarrantExercises" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_LPCNSettlementOfWarrantLiabilityOnWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:label="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AccruedFinalPaymentChargeOnDebt" xlink:label="loc_LPCNAccruedFinalPaymentChargeOnDebt" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_LPCNAccruedFinalPaymentChargeOnDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseAccruedInterest" xlink:label="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentIncreaseAccruedInterest" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/BasisOfPresentation" xlink:title="00000007 - Disclosure - Basis of Presentation">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapBusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShare" xlink:title="00000008 - Disclosure - Earnings (Loss) per Share">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaapEarningsPerShareTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecurities" xlink:title="00000009 - Disclosure - Marketable Investment Securities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValue" xlink:title="00000010 - Disclosure - Fair Value">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaapFairValueDisclosuresTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueDisclosuresTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities" xlink:title="00000011 - Disclosure - Loan and Security Agreements and Other Liabilities">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/IncomeTaxes" xlink:title="00000012 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreements" xlink:title="00000013 - Disclosure - Contractual Agreements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaapHealthCareOrganizationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock" xlink:label="loc_us-gaapBusinessAndContractualArrangementsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationsAbstract" xlink:to="loc_us-gaapBusinessAndContractualArrangementsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/Leases" xlink:title="00000014 - Disclosure - Leases">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaapLesseeDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeasesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeasesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquity" xlink:title="00000015 - Disclosure - Stockholders&#8217; Equity">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingencies" xlink:title="00000016 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlc" xlink:title="00000017 - Disclosure - Agreement with Spriaso, LLC">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/RecentAccountingPronouncements" xlink:title="00000018 - Disclosure - Recent Accounting Pronouncements">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:label="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingChangesAndErrorCorrectionsAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/EarningsLossPerShareTables" xlink:title="00000019 - Disclosure - Earnings (Loss) per Share (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesTables" xlink:title="00000020 - Disclosure - Marketable Investment Securities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:label="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapDebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapInvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueTables" xlink:title="00000021 - Disclosure - Fair Value (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables" xlink:title="00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesTables" xlink:title="00000023 - Disclosure - Leases (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaapLesseeDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityTables" xlink:title="00000024 - Disclosure - Stockholders&#8217; Equity (Tables)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock" xlink:label="loc_LPCNScheduleOfFairValueOfWarrantsTableTextBlock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LPCNScheduleOfFairValueOfWarrantsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:label="loc_LPCNScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LPCNScheduleOfReconciliationOfWarrantLiabilityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails" xlink:title="00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaapEarningsPerShareBasic" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareBasic" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapNetIncomeLossAvailableToCommonStockholdersDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaapEarningsPerShareDiluted" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapEarningsPerShareDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails" xlink:title="00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaapEarningsPerShareAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEarningsPerShareAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapAwardTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_UnvestedRestrictedStockUnitsMember" xlink:label="loc_LPCNUnvestedRestrictedStockUnitsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNUnvestedRestrictedStockUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityEquityTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails" xlink:title="00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="loc_us-gaapMarketableSecuritiesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapMarketableSecuritiesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="loc_us-gaapMarketableSecuritiesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapMarketableSecuritiesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CorporateBondsNotesAndCommercialPaperMember" xlink:label="loc_LPCNCorporateBondsNotesAndCommercialPaperMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LPCNCorporateBondsNotesAndCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapMarketableSecuritiesLineItems" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails" xlink:title="00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative" xlink:title="00000029 - Disclosure - Marketable Investment Securities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:label="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapAvailableForSaleSecuritiesGrossRealizedGainLossNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:label="loc_us-gaapOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapInvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="loc_us-gaapOtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails" xlink:title="00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="loc_us-gaapCashAndCashEquivalentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapCashAndCashEquivalentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCashAndCashEquivalentsAxis" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaapMoneyMarketFundsMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapMoneyMarketFundsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaapCommercialPaperMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="loc_us-gaapCommercialPaperMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaapFairValueInputsLevel1Member" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel1Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaapFairValueInputsLevel2Member" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel2Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaapCorporateDebtSecuritiesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapCorporateDebtSecuritiesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaapAssetsFairValueDisclosure" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapAssetsFairValueDisclosure" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="loc_us-gaapLiabilitiesFairValueDisclosure" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="loc_us-gaapLiabilitiesFairValueDisclosure" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/FairValueDetailsNarrative" xlink:title="00000031 - Disclosure - Fair Value (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaapFairValueDisclosuresAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable" xlink:label="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueDisclosuresAbstract" xlink:to="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:label="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfFairValueOffBalanceSheetRisksTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueOffBalanceSheetRisksDisclosureInformationLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails" xlink:title="00000032 - Disclosure - Schedule of Maturities of Debt (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:label="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:label="loc_LPCNLongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_LPCNLongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaapLongTermDebt" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapLongTermDebt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative" xlink:title="00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaapScheduleOfShortTermDebtTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfShortTermDebtTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaapShortTermDebtLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapShortTermDebtLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LoanAndSecurityAgreementMember" xlink:label="loc_LPCNLoanAndSecurityAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_LPCNLoanAndSecurityAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityAxis" xlink:label="loc_us-gaapLineOfCreditFacilityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShortTermDebtTable" xlink:to="loc_us-gaapLineOfCreditFacilityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LineOfCreditFacilityLenderDomain" xlink:label="loc_us-gaapLineOfCreditFacilityLenderDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityAxis" xlink:to="loc_us-gaapLineOfCreditFacilityLenderDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SiliconValleyBankMember" xlink:label="loc_LPCNSiliconValleyBankMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLineOfCreditFacilityLenderDomain" xlink:to="loc_LPCNSiliconValleyBankMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaapDebtInstrumentFaceAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentFaceAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate" xlink:label="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateBasisForEffectiveRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="loc_us-gaapDebtInstrumentMaturityDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:label="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet" xlink:label="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentIncreaseDecreaseForPeriodNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCollateralForBorrowedSecurities" xlink:label="loc_us-gaapCashCollateralForBorrowedSecurities" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapCashCollateralForBorrowedSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentRestrictiveCovenants" xlink:label="loc_us-gaapDebtInstrumentRestrictiveCovenants" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_us-gaapDebtInstrumentRestrictiveCovenants" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:label="loc_LPCNDebtInstrumentBasisSpreadOnInterestRateForDebtDefault" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDebtInstrumentBasisSpreadOnInterestRateForDebtDefault" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency" xlink:label="loc_LPCNDebtInstrumentMinimumAmountConsideredForInsolvency" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDebtInstrumentMinimumAmountConsideredForInsolvency" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_DeferredFederalInsuranceContributionsActTaxPayments" xlink:label="loc_LPCNDeferredFederalInsuranceContributionsActTaxPayments" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShortTermDebtLineItems" xlink:to="loc_LPCNDeferredFederalInsuranceContributionsActTaxPayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ContractualAgreementsDetailsNarrative" xlink:title="00000034 - Disclosure - Contractual Agreements (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_HealthCareOrganizationsAbstract" xlink:label="loc_us-gaapHealthCareOrganizationsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapHealthCareOrganizationsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AbbottProductsIncMember" xlink:label="loc_LPCNAbbottProductsIncMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNAbbottProductsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaapCollaborativeArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_us-gaapCollaborativeArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:label="loc_LPCNCollaborativeArrangementRoyaltiesPercentageOfNetSales" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_LPCNCollaborativeArrangementRoyaltiesPercentageOfNetSales" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyGuaranteesCommitmentsAmount" xlink:label="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRoyaltyGuaranteesCommitmentsAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:label="loc_LPCNPercentageOfRoyaltiesReductionBasedUponProductLaunch" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_LPCNPercentageOfRoyaltiesReductionBasedUponProductLaunch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaapLesseeDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapLesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/LeasesDetailsNarrative" xlink:title="00000036 - Disclosure - Leases (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeDisclosureAbstract" xlink:label="loc_us-gaapLesseeDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="loc_us-gaapOperatingLeaseExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLesseeDisclosureAbstract" xlink:to="loc_us-gaapOperatingLeaseExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails" xlink:title="00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaapGeneralAndAdministrativeExpenseMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapGeneralAndAdministrativeExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails" xlink:title="00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfStockOptionActivityDetails" xlink:title="00000039 - Disclosure - Schedule of Stock Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTable" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityLineItems" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails" xlink:title="00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails" xlink:title="00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_November2019OfferingMember" xlink:label="loc_LPCNNovember2019OfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNNovember2019OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueByFairValueHierarchyLevelAxis" xlink:to="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaapFairValueInputsLevel3Member" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFairValueMeasurementsFairValueHierarchyDomain" xlink:to="loc_us-gaapFairValueInputsLevel3Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaapSharePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails" xlink:title="00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:label="loc_LPCNAdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_LPCNAdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaapWarrantsAndRightsOutstanding_2" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapWarrantsAndRightsOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails" xlink:title="00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice" xlink:label="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_LPCNShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/StockholdersEquityDetailsNarrative" xlink:title="00000044 - Disclosure - Stockholders&#8217; Equity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:label="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockLineItems" xlink:label="loc_us-gaapSubsidiarySaleOfStockLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaapSubsidiarySaleOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapSubsidiarySaleOfStockAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaapSaleOfStockNameOfTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockAxis" xlink:to="loc_us-gaapSaleOfStockNameOfTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_January2021OfferingMember" xlink:label="loc_LPCNJanuary2021OfferingMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNJanuary2021OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_February2020OfferingMember" xlink:label="loc_LPCNFebruary2020OfferingMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNFebruary2020OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_November2019OfferingMember" xlink:label="loc_LPCNNovember2019OfferingMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNNovember2019OfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AtMarketOfferingMember" xlink:label="loc_LPCNAtMarketOfferingMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNAtMarketOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AccreditedInvestorsMember" xlink:label="loc_LPCNAccreditedInvestorsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSaleOfStockNameOfTransactionDomain" xlink:to="loc_LPCNAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaapStatementClassOfStockAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementClassOfStockAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaapClassOfStockDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementClassOfStockAxis" xlink:to="loc_us-gaapClassOfStockDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassAUnitMember" xlink:label="loc_LPCNClassAUnitMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNClassAUnitMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassBUnitsMember" xlink:label="loc_LPCNClassBUnitsMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNClassBUnitsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PreFundedWarrantsMember" xlink:label="loc_LPCNPreFundedWarrantsMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_LPCNPreFundedWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfStockDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaapFinancialInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapFinancialInstrumentAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapFinancialInstrumentAxis" xlink:to="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SalesAgreementMember" xlink:label="loc_LPCNSalesAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="loc_LPCNSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_2" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_CommonStockWarrantMember" xlink:label="loc_LPCNCommonStockWarrantMember" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_LPCNCommonStockWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_StockIncentivePlan2014Member" xlink:label="loc_LPCNStockIncentivePlan2014Member" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNStockIncentivePlan2014Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_EquityIncentivePlanMember" xlink:label="loc_LPCNEquityIncentivePlanMember" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_LPCNEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable" xlink:to="loc_srtRangeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ProceedsFromIssuanceOfCommonStockGross" xlink:label="loc_LPCNProceedsFromIssuanceOfCommonStockGross" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNProceedsFromIssuanceOfCommonStockGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaapPaymentsOfStockIssuanceCosts" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapPaymentsOfStockIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaapSharesIssuedPricePerShare" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharesIssuedPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfGrossProceedOnSaleOfShares" xlink:label="loc_LPCNPercentageOfGrossProceedOnSaleOfShares" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNPercentageOfGrossProceedOnSaleOfShares" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:label="loc_LPCNClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_LPCNClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsidiarySaleOfStockLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000045 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityListingsLineItems" xlink:label="loc_deiEntityListingsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiEntityListingsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_GlobalAgreementMember" xlink:label="loc_LPCNGlobalAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNGlobalAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ClarusTherapeuticsIncMember" xlink:label="loc_LPCNClarusTherapeuticsIncMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNClarusTherapeuticsIncMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srtStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtStatementScenarioAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srtScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementScenarioAxis" xlink:to="loc_srtScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srtScenarioForecastMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtScenarioUnspecifiedDomain" xlink:to="loc_srtScenarioForecastMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementAmountAwardedToOtherParty" xlink:label="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapLitigationSettlementAmountAwardedToOtherParty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetentionPayable" xlink:label="loc_us-gaapRetentionPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityListingsLineItems" xlink:to="loc_us-gaapRetentionPayable" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative" xlink:title="00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_LicenseAgreementMember" xlink:label="loc_LPCNLicenseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_ServiceAgreementMember" xlink:label="loc_LPCNServiceAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_LPCNServiceAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_SpriasoLLCMember" xlink:label="loc_LPCNSpriasoLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_LPCNSpriasoLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_PercentageOfRoyalty" xlink:label="loc_LPCNPercentageOfRoyalty" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LPCNPercentageOfRoyalty" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromContributionsFromAffiliates" xlink:label="loc_us-gaapProceedsFromContributionsFromAffiliates" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapProceedsFromContributionsFromAffiliates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="lpcn-20210630.xsd#LPCN_AgreementDescription" xlink:label="loc_LPCNAgreementDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_LPCNAgreementDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>form10-q_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:LPCN="http://lipocine.com/20210630"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="lpcn-20210630.xsd" xlink:type="simple"/>
    <context id="From2021-01-01to2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-08-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2021-08-04</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="AsOf2020-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="AsOf2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LPCN:CorporateBondsNotesAndCommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember14581359">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-05</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-05-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">LPCN:LoanAndSecurityAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LineOfCreditFacilityAxis">LPCN:SiliconValleyBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:AbbottProductsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:AbbottProductsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-262021-01-28_custom_January2021OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:January2021OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-26</startDate>
            <endDate>2021-01-28</endDate>
        </period>
    </context>
    <context id="From2020-02-262020-02-27_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-26</startDate>
            <endDate>2020-02-27</endDate>
        </period>
    </context>
    <context id="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-02-26</startDate>
            <endDate>2020-02-27</endDate>
        </period>
    </context>
    <context id="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-27</instant>
        </period>
    </context>
    <context id="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-27</instant>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassAUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:ClassBUnitsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">LPCN:PreFundedWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="AsOf2019-11-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2019-11-18</instant>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-17</startDate>
            <endDate>2019-11-18</endDate>
        </period>
    </context>
    <context id="From2017-03-052017-03-06_custom_SalesAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">LPCN:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-05</startDate>
            <endDate>2017-03-06</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_AtMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_AtMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_CommonStockMember_custom_AtMarketOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AtMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_AccreditedInvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:AccreditedInvestorsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2015-11-122015-11-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <startDate>2015-11-12</startDate>
            <endDate>2015-11-13</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2014-04-30_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-30</instant>
        </period>
    </context>
    <context id="AsOf2014-04-30_custom_EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2014-04-30</instant>
        </period>
    </context>
    <context id="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_StockIncentivePlan2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">LPCN:StockIncentivePlan2014Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_November2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:November2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_custom_February2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">LPCN:February2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_WarrantMember14584484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-06-30_us-gaap_WarrantMember14584484">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="AsOf2021-06-30_us-gaap_WarrantMember14584515">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="From2021-04-012021-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_us-gaap_WarrantMember14584609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-04-012020-06-30_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LPCN:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2020-01-012020-06-30_custom_CommonStockWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">LPCN:CommonStockWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-02_custom_GlobalAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-02</endDate>
        </period>
    </context>
    <context id="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-02</endDate>
        </period>
    </context>
    <context id="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-07-12</startDate>
            <endDate>2022-07-13</endDate>
        </period>
    </context>
    <context id="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:GlobalAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:ClarusTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-07-12</startDate>
            <endDate>2023-07-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-11-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
        </entity>
        <period>
            <instant>2019-11-14</instant>
        </period>
    </context>
    <context id="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:LicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-22</startDate>
            <endDate>2013-07-23</endDate>
        </period>
    </context>
    <context id="From2013-07-222013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-22</startDate>
            <endDate>2013-07-23</endDate>
        </period>
    </context>
    <context id="AsOf2013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001535955</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">LPCN:ServiceAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">LPCN:SpriasoLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-07-23</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-06-30">0001535955</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-01-01to2021-06-30">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-06-30">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-06-30">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:RestrictedCashAndCashEquivalents
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0050"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationReserveCurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0087"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0092"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationReserveNoncurrent
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0099"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0104"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0105"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0110"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0111"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0159"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0216"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0218"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-04-012021-06-30"
      id="xdx2ixbrl0230"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0231"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0283"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0291"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0292"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0293"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0294"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0299"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0302"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0306"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0313"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0315"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0316"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30"
      id="xdx2ixbrl0317"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0322"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0324"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0325"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0330"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0331"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0333"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0334"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0358"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0359"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0361"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0362"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0387"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0388"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0390"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0394"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0395"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0396"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0398"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0401"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0402"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0404"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0405"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0409"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0411"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0412"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0413"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0418"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0420"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0421"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0427"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0429"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0430"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0435"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0436"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0438"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0439"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0443"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0445"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0446"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0471"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0472"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0473"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0474"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0478"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0479"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0480"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0482"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0486"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0488"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0489"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0492"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0493"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0495"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0496"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0512"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0523"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0531"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0532"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0533"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0534"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0538"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0539"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0540"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0542"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0545"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0546"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0548"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0549"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0552"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0553"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0555"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0556"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0562"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0564"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0565"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0571"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0573"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0574"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      id="xdx2ixbrl0579"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0580"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0582"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0583"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_TreasuryStockMember"
      id="xdx2ixbrl0587"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      id="xdx2ixbrl0589"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0590"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0626"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0657"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0680"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl0690"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl0728"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-06-30_custom_UnvestedRestrictedStockUnitsMember"
      id="xdx2ixbrl0791"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember"
      id="xdx2ixbrl0805"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0812"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember"
      id="xdx2ixbrl0820"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember"
      id="xdx2ixbrl0822"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0828"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2020-12-31"
      id="xdx2ixbrl0829"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0875"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0877"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0881"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0885"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0889"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0893"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0901"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0903"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0904"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0916"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0918"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0922"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0926"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"
      id="xdx2ixbrl0934"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel1Member"
      id="xdx2ixbrl0936"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel2Member"
      id="xdx2ixbrl0937"
      unitRef="USD"
      xsi:nil="true"/>
    <LPCN:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths
      contextRef="AsOf2021-06-30"
      id="xdx2ixbrl0995"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-01to2021-06-30"
      id="xdx2ixbrl1122"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-06-30"
      id="xdx2ixbrl1123"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="From2021-01-012021-06-30_custom_StockIncentivePlan2014Member"
      id="xdx2ixbrl1148">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      id="xdx2ixbrl1168"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      id="xdx2ixbrl1170"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1219"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      id="xdx2ixbrl1220"
      unitRef="Pure"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1255"
      unitRef="Shares"
      xsi:nil="true"/>
    <LPCN:ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1257"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1263"
      unitRef="Shares"
      xsi:nil="true"/>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1265"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1267"
      unitRef="Shares"
      xsi:nil="true"/>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1269"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1271"
      unitRef="Shares"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      id="xdx2ixbrl1273"
      unitRef="USDPShares"
      xsi:nil="true"/>
    <dei:DocumentType contextRef="From2021-01-01to2021-06-30">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2021-01-01to2021-06-30">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-06-30">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-06-30">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport contextRef="From2021-01-01to2021-06-30">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2021-01-01to2021-06-30">001-36357</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2021-01-01to2021-06-30">LIPOCINE INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-01-01to2021-06-30">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-01-01to2021-06-30">99-0370688</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-01-01to2021-06-30">675     Arapeen Drive</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2021-01-01to2021-06-30">Suite 202</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2021-01-01to2021-06-30">Salt     Lake City</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-01-01to2021-06-30">UT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-01-01to2021-06-30">84108</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-01-01to2021-06-30">801</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-01-01to2021-06-30">994-7383</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="From2021-01-01to2021-06-30">Common     Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-01-01to2021-06-30">LPCN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-01-01to2021-06-30">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-06-30">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2021-01-01to2021-06-30">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2021-01-01to2021-06-30">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2021-01-01to2021-06-30">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-08-04" decimals="INF" unitRef="Shares">88290650</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">10967713</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">19217382</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">5000000</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672059</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">232568</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">391</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">283180</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">661258</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">47155520</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25329023</us-gaap:AssetsCurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">23753</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">23753</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">47179273</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25352776</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">906476</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1597220</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1444188</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1653178</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">3957627</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">3333333</us-gaap:DebtCurrent>
    <us-gaap:LitigationReserveCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">2500000</us-gaap:LitigationReserveCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">8808291</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">6583731</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">2257075</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1125429</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1170051</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:LitigationReserveNoncurrent contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1500000</us-gaap:LitigationReserveNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">11433720</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">10010857</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2020-12-31"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">88296360</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">70041967</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">88290650</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">70036257</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">8830</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">7005</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">217986752</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">187407634</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockShares contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">5710</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares contextRef="AsOf2020-12-31" decimals="INF" unitRef="Shares">5710</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">40712</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">40712</us-gaap:TreasuryStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-186</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">-182209131</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-172032008</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35745553</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15341919</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">47179273</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">25352776</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1464687</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">2268984</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3045228</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4780739</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">1525592</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">1953535</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3059544</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4038795</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">2990279</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">4222519</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">6104772</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">8819534</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-2990279</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-4222519</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-6104772</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-8819534</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">17344</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">7177</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">27993</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">67115</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">57428</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">87847</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">126401</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">221192</us-gaap:InterestExpense>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">221322</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-2066445</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">26257</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:UnrealizedGainLossOnDerivatives
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-3166474</us-gaap:UnrealizedGainLossOnDerivatives>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">4000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-3818762</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-2147115</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-4072151</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-3320551</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10176923</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140085</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">49769253</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">85556110</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">45558442</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">49769253</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">85556110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">45558442</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">22273</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-104</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-186</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-66</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6786768</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369738</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177309</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140351</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">47854499</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">4786</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">163426502</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-156837840</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" decimals="0" unitRef="USD">6552736</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-104</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-104</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">465058</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">465058</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <LPCN:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13497807</LPCN:StockIssuedDuringPeriodSharesWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1350</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6852308</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">6853658</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5591362</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">5591362</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-8108</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-8108</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">61377306</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6138</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">176327120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-163207474</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">13084968</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">37649465</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">3766</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">157391969</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-38</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-151067189</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">6287796</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-66</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-66</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">786971</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">786971</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">25000</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-2</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <LPCN:CommonStockSoldThroughEquityOfferingShares
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10084034</LPCN:CommonStockSoldThroughEquityOfferingShares>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1008</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5652132</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5653140</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">13618807</LPCN:StockIssuedDuringPeriodSharesWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1362</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6912796</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">6914158</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">5591362</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5591362</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-8108</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-8108</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">61377306</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">6138</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">176327120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-104</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-163207474</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">13084968</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8830</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">217845280</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-22459</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-175400090</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">42390849</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">22273</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">22273</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">146747</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">146747</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">-5275</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-5275</LPCN:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8830</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">217986752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-182209131</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35745553</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">70036257</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7005</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">187407634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-172032008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15341919</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">70036257</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">7005</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">187407634</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-172032008</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">15341919</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-012021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-012021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-186</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-186</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">294313</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">294313</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">6693</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">6693</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <LPCN:CommonStockSoldThroughEquityOfferingShares
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">16428571</LPCN:CommonStockSoldThroughEquityOfferingShares>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1643</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">26838814</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:CommonStockSoldThroughEquityOffering
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">26840457</LPCN:CommonStockSoldThroughEquityOffering>
    <LPCN:StockIssuedDuringPeriodSharesWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">10000</LPCN:StockIssuedDuringPeriodSharesWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">1</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">4999</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:StockIssuedDuringPeriodValueWarrantsExercises
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">5000</LPCN:StockIssuedDuringPeriodValueWarrantsExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">18365</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">18365</LPCN:AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">1811238</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">181</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">3415934</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3416115</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8830</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">217986752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-182209131</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35745553</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">8830</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="INF"
      unitRef="Shares">5710</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_TreasuryStockMember"
      decimals="0"
      unitRef="USD">-40712</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">217986752</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="0"
      unitRef="USD">-186</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-06-30_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-182209131</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35745553</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1598</us-gaap:DepreciationAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">294313</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">786971</us-gaap:ShareBasedCompensation>
    <us-gaap:AccretionExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">33886</us-gaap:AccretionExpense>
    <us-gaap:AccretionExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">63765</us-gaap:AccretionExpense>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26257</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">3166474</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-203958</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">9755</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">232177</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-8603</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-378078</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-398579</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-690744</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-275415</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-208990</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">543955</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:LitigationSettlementExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">4000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-6425056</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-7455510</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">35876211</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4466811</us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">450000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4350000</us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-35426211</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-116811</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">1666667</us-gaap:RepaymentsOfDebt>
    <us-gaap:RepaymentsOfDebt
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">1111111</us-gaap:RepaymentsOfDebt>
    <us-gaap:ProceedsFromIssuanceOfDebt
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">233537</us-gaap:ProceedsFromIssuanceOfDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">26840457</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5653140</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <LPCN:NetProceedsFromCostsAssociatedWithAtm
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">3416115</LPCN:NetProceedsFromCostsAssociatedWithAtm>
    <LPCN:NetProceedsFromCostsAssociatedWithAtm
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-8108</LPCN:NetProceedsFromCostsAssociatedWithAtm>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">6693</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">6914158</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">28601598</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">11681616</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-13249669</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">4109295</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">24217382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" decimals="0" unitRef="USD">14728523</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">10967713</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-06-30" decimals="0" unitRef="USD">18837818</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">92515</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">156979</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">200</us-gaap:IncomeTaxesPaidNet>
    <LPCN:SettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">18365</LPCN:SettlementOfWarrantLiabilityOnWarrantExercises>
    <LPCN:SettlementOfWarrantLiabilityOnWarrantExercises
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">5591362</LPCN:SettlementOfWarrantLiabilityOnWarrantExercises>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-186</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-66</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <LPCN:AccruedFinalPaymentChargeOnDebt
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">33886</LPCN:AccruedFinalPaymentChargeOnDebt>
    <LPCN:AccruedFinalPaymentChargeOnDebt
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">63765</LPCN:AccruedFinalPaymentChargeOnDebt>
    <us-gaap:DebtInstrumentIncreaseAccruedInterest
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">448</us-gaap:DebtInstrumentIncreaseAccruedInterest>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zf26RVR5mCV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(1)
&lt;span id="xdx_82A_z7Dnyaq5GlJ3"&gt;Basis of Presentation&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (&#x201c;Lipocine&#x201d;
or the &#x201c;Company&#x201d;) in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#x201c;SEC&#x201d;).
The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries,
collectively referred to as the Company. In management&#x2019;s opinion, the interim financial data presented includes all adjustments
(consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated.
Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules
and regulations of the SEC. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the
results that may be expected for any future period or for the year ending December 31, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;These
unaudited condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial
statements and the notes thereto for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating
to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally
accepted accounting principles. Actual results could differ from these estimates.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company believes that its existing capital resources, together with interest thereon, will be sufficient to meet its projected operating
requirements through at least June 30, 2022 which includes an on-going clinical study for LPCN 1144, future clinical studies for LPCN
1148 and LPCN 1154, compliance with regulatory requirements and on-going litigation and settlement activities. The Company has based
this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it
currently expects if additional activities are performed by the Company including pre-commercial and commercial activities for TLANDO
and new clinical studies for LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1154. While the Company believes it has sufficient liquidity and
capital resources to fund our projected operating requirements through at least June 30, 2022, the Company will need to raise additional
capital at some point through the equity or debt markets or through out-licensing activities, before or after June 30, 2022, to support
its operations. If the Company is unsuccessful in raising additional capital, its ability to continue as a going concern will become
a risk. Further, the Company&#x2019;s operating plan may change, and the Company may need additional funds to meet operational needs and
capital requirements for product development, regulatory compliance and clinical trial activities sooner than planned. In addition, the
Company&#x2019;s capital resources may be consumed more rapidly if it pursues additional clinical studies for LPCN 1144, TLANDO XR, LPCN
1148 and LPCN 1154. Conversely, the Company&#x2019;s capital resources could last longer if it reduces expenses, reduces the number of
activities currently contemplated under our operating plan or if it terminates, modifies the design or suspends on-going clinical studies..&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <us-gaap:EarningsPerShareTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_z3hFYjXuOHlc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 24.5pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(2)
&lt;span id="xdx_82C_zPvpJhRmKqgc"&gt;Earnings (Loss) per Share&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares
outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options,
warrants and, unvested restricted stock units to the extent such shares are dilutive.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zFklzRIFvkA6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three and six months
ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_zEGLUH0xIVKg" style="display: none"&gt;Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic loss per share attributable to common stock:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; width: 44%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(6,809,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(6,369,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(10,177,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(12,140,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Weighted avg. common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;88,290,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;49,769,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;85,556,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;45,558,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Basic loss per share attributable to common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EarningsPerShareBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diluted loss per share attributable to common stock:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(6,809,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(6,369,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(10,177,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(12,140,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Weighted avg. common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;88,290,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;49,769,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;85,556,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;45,558,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Diluted loss per share attributable to common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EarningsPerShareDiluted_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EarningsPerShareDiluted_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EarningsPerShareDiluted_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_znx1cR5mx2M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgUzANzH4zb7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
computation of diluted loss per share for the six months ended June 30, 2021 and 2020 does not include the following stock options and
warrants to purchase shares or unvested restricted stock units in the computation of diluted loss per share because these instruments
were antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zF1rtWgD3N2" style="display: none"&gt;Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,915,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,012,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_zJp5UKSV93Ec" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;605,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,934,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,423,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zdJO1gF3Lrk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zFklzRIFvkA6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three and six months
ended June 30, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BB_zEGLUH0xIVKg" style="display: none"&gt;Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold"&gt;Three Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Six Months Ended June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Basic loss per share attributable to common stock:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; width: 44%; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(6,809,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(6,369,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(10,177,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss"&gt;(12,140,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Weighted avg. common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;88,290,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;49,769,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;85,556,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;45,558,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Basic loss per share attributable to common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--EarningsPerShareBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock"&gt;(0.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-weight: bold; text-align: left"&gt;Diluted loss per share attributable to common stock:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Numerator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"&gt;Net loss&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(6,809,041&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(6,369,634&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(10,177,123&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss"&gt;(12,140,285&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt"&gt;Denominator&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt"&gt;Weighted avg. common shares outstanding&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;88,290,650&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;49,769,253&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;85,556,110&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding"&gt;45,558,442&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;Diluted loss per share attributable to common stock&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--EarningsPerShareDiluted_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.08&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--EarningsPerShareDiluted_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.13&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--EarningsPerShareDiluted_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock"&gt;(0.27&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">49769253</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">85556110</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">45558442</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">-6809041</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">-6369634</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-10177123</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">-12140285</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="Shares">88290650</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="Shares">49769253</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Shares">85556110</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Shares">45558442</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-04-012021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-04-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.13</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.12</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="USDPShares">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgUzANzH4zb7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
computation of diluted loss per share for the six months ended June 30, 2021 and 2020 does not include the following stock options and
warrants to purchase shares or unvested restricted stock units in the computation of diluted loss per share because these instruments
were antidilutive:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zF1rtWgD3N2" style="display: none"&gt;Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 64%; text-align: left"&gt;Stock options&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,915,790&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,012,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Unvested restricted stock units&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_zJp5UKSV93Ec" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0791"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;605,682&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Warrants&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;1,934,366&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"&gt;3,423,210&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3915790</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3012041</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-06-30_custom_UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      unitRef="Shares">605682</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3423210</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zwBgd4irrirh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(3) &lt;span id="xdx_821_zecIPDIXMdJb"&gt;Marketable Investment Securities&lt;/span&gt; &lt;/b&gt;&lt;/span&gt;&lt;/p&gt;


&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#x2019; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_899_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zCqDFj7M3vK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BB_zKMnjojBKDl5" style="display: none"&gt;Schedule of Available-for-Sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;unrealized holding&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;gains&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;losses&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 44%; text-align: left"&gt;Corporate bonds, notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zst3WqwmDm4i" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"&gt;(186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zLlkTmW4Idgj" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;&#160;&lt;/span&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630_zAi4Bj0aoh87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"&gt;(186&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;gains&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;losses&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 44%; text-align: left"&gt;Commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zmxd8v90C1W1" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Aggregate fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231_zPbrHA3pBLta" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#160;&lt;/span&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_zqFSCfC6I3vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 13.5pt; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Maturities
of debt securities classified as available-for-sale securities at June 30, 2021 are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zn0nVmjl1fa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zzdYpf7yemTk" style="display: none"&gt;Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 60%; text-align: left"&gt;Due within one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20210630_znVIirmXF7Ei" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20210630_zJ8B4Bhi0one" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20210630_zasMMEuy9VW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_z6kib6qku1J5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;There
were no sales of marketable investment securities during the three and six months ended June 30, 2021 and 2020 and therefore &lt;span id="xdx_90C_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210401__20210630_zKwGbR2fgt42" title="Available-for-sale securities, gross realized gain (loss)"&gt;&lt;span id="xdx_903_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200401__20200630_zea6w7zv2wJe" title="Available-for-sale securities, gross realized gain (loss)"&gt;&lt;span id="xdx_90D_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210101__20210630_zR71wdpBYe01" title="Available-for-sale securities, gross realized gain (loss)"&gt;&lt;span id="xdx_904_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200101__20200630_zeA2Qoe8eJ7f" title="Available-for-sale securities, gross realized gain (loss)"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; realized
gains or losses. Additionally, during the three months ended June 30, 2021 and 2020, &lt;span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20210401__20210630_zcWrB1QUvwsg" title="Proceeds from sale and maturity of marketable securities"&gt;&lt;span id="xdx_90F_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20200401__20200630_zqhI4aSg1l18" title="Proceeds from sale and maturity of marketable securities"&gt;no&lt;/span&gt;&lt;/span&gt; marketable investment securities matured, and
$&lt;span id="xdx_908_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20210630_zVjTQYyspbqf" title="Proceeds from sale and maturity of marketable securities"&gt;450,000&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20200630_zrZHqaVHSr6l" title="Proceeds from sale and maturity of marketable securities"&gt;4.3&lt;/span&gt; million of marketable investment securities matured during the six months ended June 30, 2021 and 2020, respectively.
The Company determined there were &lt;span title="Other-than-temporary impairments"&gt;&lt;span id="xdx_902_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210401__20210630_zMd8HawUJRF6" title="Other-than-temporary impairments"&gt;&lt;span id="xdx_90B_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200401__20200630_zYGkwhjna2uj" title="Other-than-temporary impairments"&gt;&lt;span id="xdx_905_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20210630_zsvSuCfsMDZ3" title="Other-than-temporary impairments"&gt;&lt;span id="xdx_90A_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20200630_z7xRAGNQKJMi" title="Other-than-temporary impairments"&gt;no&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; other-than-temporary impairments for the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_899_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zCqDFj7M3vK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8BB_zKMnjojBKDl5" style="display: none"&gt;Schedule of Available-for-Sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;unrealized holding&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;gains&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;losses&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="text-align: center; margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 44%; text-align: left"&gt;Corporate bonds, notes and commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0805"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zst3WqwmDm4i" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"&gt;(186&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zLlkTmW4Idgj" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0812"&gt;&#160;&lt;/span&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630_zAi4Bj0aoh87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses"&gt;(186&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;gains&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Gross&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;unrealized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;holding&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;losses&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 44%; text-align: left"&gt;Commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0820"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zmxd8v90C1W1" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0822"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Aggregate fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0828"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231_zPbrHA3pBLta" style="border-bottom: Black 2.5pt double; text-align: right"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0829"&gt;&#160;&lt;/span&gt;-&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">35672245</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">186</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2021-06-30_custom_CorporateBondsNotesAndCommercialPaperMember"
      decimals="0"
      unitRef="USD">35672059</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672245</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">186</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672059</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember"
      decimals="0"
      unitRef="USD">449992</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember"
      decimals="0"
      unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">449992</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_891_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zn0nVmjl1fa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0.5in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B8_zzdYpf7yemTk" style="display: none"&gt;Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amortized&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Cost&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Aggregate&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;fair value&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; width: 60%; text-align: left"&gt;Due within one year&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20210630_znVIirmXF7Ei" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20210630_zJ8B4Bhi0one" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost"&gt;35,672,245&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20210630_zasMMEuy9VW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672245</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672059</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672245</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">35672059</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">450000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="From2020-01-012020-06-30"
      decimals="-5"
      unitRef="USD">4300000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zlVS9aypAdT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(4)
&lt;span id="xdx_825_zZsThDQdpmO5"&gt;Fair Value&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#x25cf;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    1 Inputs: Quoted prices for identical instruments in active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#x25cf;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"&gt;&#x25cf;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;    &lt;/span&gt;&lt;/td&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
    &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;All
of the Company&#x2019;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zsBKdAnZU4a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zrUBVqzHxtQc" style="display: none"&gt;Schedule of Fair Value, Assets Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair value measurements at reporting date using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents - money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Commercial Paper&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right" title="Assets, fair value"&gt;13,987,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;13,987,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Corporate bonds and notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgtLYI7LEiDl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;21,684,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeJC3drlne3i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbtmpRH0yD3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;21,684,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvXAm5ktI2gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0893"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;45,851,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8jtsVdOssfj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzUYEB4ZuPl2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRwp7qyph7Mb" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdMb09hfXwQ" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630_zDJW2QD4mtOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;46,976,561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z394n7Gf8Kc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,179,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK2SoRNz2Wd1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgZ8Bucc3v9j" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Fair value measurements at reporting date using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 1 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 2 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 3 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents - money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;18,849,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0934"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJHVG9AW6Uu9" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0936"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9hoR9TLBpVf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE6Z3F33HOb8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_z7MtH1P16mO3" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;20,019,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvrtQbFL3ta6" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zJkTJfUhi1a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Cash
equivalents: Cash equivalents primarily consist of highly-rated money market funds and treasury bills with original maturities to the
Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market
funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices
or broker or dealer quotations for similar assets.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Warrant
liability: &lt;span style="background-color: white"&gt;The warrant liability (which relates to warrants to purchase shares of common stock)
is marked-to-market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements
of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#x2019; equity. The fair value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant
assumptions used in preparing the option pricing model for valuing the warrant liability as of June 30, 2021, include (i) volatility
of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zDStewBsJte1" title="Expected volatility"&gt;72.62&lt;/span&gt;%, (ii) risk free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zQGmDgUTEB0c" title="Risk-free interest rate"&gt;0.46&lt;/span&gt;%, (iii) strike price of $&lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zs1ivdHxrAna" title="Strike price"&gt;0.50&lt;/span&gt;, (iv) fair value of common stock of $&lt;span id="xdx_904_eus-gaap--SharePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zmZI7KROlM3b" title="Fair value of common stock"&gt;1.40&lt;/span&gt;, and (v) expected
life of &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zYXJ1wS2EgAl" title="Expected term"&gt;3.38&lt;/span&gt; years. The significant assumptions used in preparing the option pricing model for valuing the warrant liability as of December
31, 2020, include (i) volatility of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zWNkpRoEqCni" title="Expected volatility"&gt;88.46&lt;/span&gt;%, (ii) risk free interest rate of &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zAlbqTWtL06" title="Risk-free interest rate"&gt;0.27&lt;/span&gt;%, (iii) strike price of $&lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRl268Gaae8a" title="Strike price"&gt;0.50&lt;/span&gt;, (iv) fair value of common
stock of $&lt;span id="xdx_900_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKq3vYmuYFbk" title="Fair value of common stock"&gt;1.36&lt;/span&gt;, and (v) expected life of &lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zNAsZ0exovC3" title="Expected term"&gt;3.9&lt;/span&gt; years.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2, or Level 3 for the three and six
months ended June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zsBKdAnZU4a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BA_zrUBVqzHxtQc" style="display: none"&gt;Schedule of Fair Value, Assets Measured on Recurring Basis&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Fair value measurements at reporting date using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 1 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 2 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Level 3 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents - money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0875"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0877"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Commercial Paper&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right" title="Assets, fair value"&gt;13,987,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0881"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;13,987,623&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0885"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Corporate bonds and notes&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgtLYI7LEiDl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;21,684,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeJC3drlne3i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0889"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbtmpRH0yD3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;21,684,436&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvXAm5ktI2gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0893"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;45,851,132&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;10,179,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0901"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8jtsVdOssfj" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzUYEB4ZuPl2" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0903"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRwp7qyph7Mb" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0904"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdMb09hfXwQ" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630_zDJW2QD4mtOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;46,976,561&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z394n7Gf8Kc" style="border-bottom: Black 2.5pt double; text-align: right"&gt;10,179,073&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK2SoRNz2Wd1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;35,672,059&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgZ8Bucc3v9j" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Fair value measurements at reporting date using&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 1 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 2 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold"&gt;Level 3 inputs&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Assets:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 36%; text-align: left"&gt;Cash equivalents - money market funds&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0916"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0918"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Commercial paper&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0922"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0926"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;18,849,577&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0934"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Warrant liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJHVG9AW6Uu9" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0936"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9hoR9TLBpVf" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0937"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE6Z3F33HOb8" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_z7MtH1P16mO3" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;20,019,628&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;18,399,585&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;449,992&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvrtQbFL3ta6" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value"&gt;1,170,051&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      unitRef="USD">10179073</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">10179073</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember"
      decimals="0"
      unitRef="USD">13987623</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">13987623</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember"
      decimals="0"
      unitRef="USD">21684436</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">21684436</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">45851132</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">10179073</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">35672059</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1125429</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1125429</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">46976561</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">10179073</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">35672059</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2021-06-30_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1125429</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember14581359"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_CommercialPaperMember_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">18849577</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">20019628</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel1Member"
      decimals="0"
      unitRef="USD">18399585</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel2Member"
      decimals="0"
      unitRef="USD">449992</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="AsOf2020-12-31_us-gaap_FairValueInputsLevel3Member"
      decimals="0"
      unitRef="USD">1170051</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.7262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember">P3Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.8846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.36</us-gaap:SharePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_us-gaap_WarrantMember">P3Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z7UbT5BzuIja" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(5)
&lt;span id="xdx_82F_zs2chRFIdIbg"&gt;Loan and Security Agreements and Other Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Silicon
Valley Bank Loan&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#x201c;Loan and Security Agreement&#x201d;) with Silicon
Valley Bank (&#x201c;SVB&#x201d;) pursuant to which SVB agreed to lend the Company $&lt;span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zPenQJXHCw5k" title="Aggregate amount"&gt;10.0&lt;/span&gt; million. &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember"&gt;The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (&lt;span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pdd" title="Interest rate"&gt;4.25%&lt;/span&gt; as of June
30, 2021), which interest is payable monthly&lt;/span&gt;. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zEBKDqGbjSFb" title="Debt instrument, maturity date"&gt;June 1, 2022&lt;/span&gt;. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $&lt;span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z1cyT8gzoNel" title="Debt instrument, balloon payment to be paid"&gt;650,000&lt;/span&gt; (the &#x201c;Final Payment Charge&#x201d;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $&lt;span id="xdx_903_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, increase in amount"&gt;624,000&lt;/span&gt; has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#x2019;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, as TLANDO was not approved
by the United States Food and Drug Administration (&#x201c;FDA&#x201d;) prior to May 31, 2018, the Company maintained $&lt;span id="xdx_904_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20180531__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAjDgTLyP5Vh" title="Cash collateral for borrowed securities"&gt;5.0&lt;/span&gt; million of cash
collateral at SVB as required under the Loan and Security Agreement until such time as TLANDO is approved by the FDA. However on February
16, 2021, the Company amended the Loan and Security Agreement with SVB to, among other things, remove the financial trigger and financial
trigger release event provisions requiring the Company to maintain a minimum cash collateral value and collateral pledge thereof.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_90A_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4zL5llX0Vn5" title="Debt instrument, restrictive covenants"&gt;While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus &lt;span id="xdx_907_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_dp_uPure_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zlbxsicGzdQg" title="Debt instrument, basis spread on interest rate for debt default"&gt;5.0&lt;/span&gt;% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.&lt;/span&gt; These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit
facility, the Company&#x2019;s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater
than $&lt;span id="xdx_906_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, minimum amount considered for insolvency"&gt;100,000&lt;/span&gt; individually or in the aggregate.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
maturities of principal payments on the Loan and Security Agreement at June 30, 2021 (excluding accrued final payment fee) are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1SZVfVzWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_z6RFgppwRNJ1" style="display: none"&gt;Schedule of Maturities of Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210630_zPqWdHIQ0u18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amount&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzdw8_zsgvcvVvWvpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzdw8_zRO4famUECu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_iI_pn3n3_maLTDzdw8_zvcuXlIsdiNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzdw8_ztFsB8fyqitf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Long-term
    Debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AA_z5Wo6sNsbdtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Other&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Effective
June 15, 2020 and through December 31, 2020, the Company deferred Federal Insurance Contributions Act (&#x201c;FICA&#x201d;) taxes under
the CARES Act Section 2302. Payment of these tax deferrals are delayed to December 31, 2021 and December 31, 2022. As of June 30, 2021
the tax deferrals totaled $&lt;span id="xdx_90A_ecustom--DeferredFederalInsuranceContributionsActTaxPayments_c20210630_pp0p0" title="Deferred FICA payroll tax payments"&gt;36,000&lt;/span&gt; and are included in accrued liabilities.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2018-01-05_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="-5"
      unitRef="USD">10000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (4.25% as of June
30, 2021), which interest is payable monthly</us-gaap:DebtInstrumentInterestRateBasisForEffectiveRate>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="INF"
      unitRef="Pure">0.0425</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">2022-06-01</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid
      contextRef="AsOf2021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">650000</us-gaap:DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid>
    <us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet
      contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">624000</us-gaap:DebtInstrumentIncreaseDecreaseForPeriodNet>
    <us-gaap:CashCollateralForBorrowedSecurities
      contextRef="AsOf2018-05-31_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="-5"
      unitRef="USD">5000000.0</us-gaap:CashCollateralForBorrowedSecurities>
    <us-gaap:DebtInstrumentRestrictiveCovenants contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</us-gaap:DebtInstrumentRestrictiveCovenants>
    <LPCN:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault
      contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="INF"
      unitRef="Pure">0.050</LPCN:DebtInstrumentBasisSpreadOnInterestRateForDebtDefault>
    <LPCN:DebtInstrumentMinimumAmountConsideredForInsolvency
      contextRef="From2021-01-012021-06-30_custom_LoanAndSecurityAgreementMember_custom_SiliconValleyBankMember"
      decimals="0"
      unitRef="USD">100000</LPCN:DebtInstrumentMinimumAmountConsideredForInsolvency>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1SZVfVzWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BE_z6RFgppwRNJ1" style="display: none"&gt;Schedule of Maturities of Debt&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20210630_zPqWdHIQ0u18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold"&gt;Years Ending December 31,&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Amount&lt;/p&gt;
                                                                  &lt;p style="margin-top: 0; margin-bottom: 0"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzdw8_zsgvcvVvWvpi" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 80%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;1,666&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzdw8_zRO4famUECu" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;2022&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_iI_pn3n3_maLTDzdw8_zvcuXlIsdiNb" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0995"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzdw8_ztFsB8fyqitf" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Long-term
    Debt&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;3,333&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1666000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">1667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebt contextRef="AsOf2021-06-30" decimals="-3" unitRef="USD">3333000</us-gaap:LongTermDebt>
    <LPCN:DeferredFederalInsuranceContributionsActTaxPayments contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">36000</LPCN:DeferredFederalInsuranceContributionsActTaxPayments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zlvLaioHuR1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(6)
&lt;span id="xdx_82B_zZhI94j6oQQ3"&gt;Income Taxes&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
tax provision for interim periods is determined using an estimate of the Company&#x2019;s effective tax rate for the full year adjusted
for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the
annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;At
June 30, 2021 and December 31, 2020, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals
of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_805_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zqmQ5D9Bnmb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(7)
&lt;span id="xdx_827_zuTlCzkpXzw1"&gt;Contractual Agreements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(a)
Abbott Products, Inc.&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual &lt;span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zM6Zpn38Nkl7" title="Percentage of net sales"&gt;1%&lt;/span&gt; royalty on net sales. Such
royalties are limited to $&lt;span&gt;&lt;span id="xdx_900_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zt2tDNeHn1Qa" title="Royalties, commitment amount"&gt;1.0&lt;/span&gt;&lt;/span&gt; million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by &lt;span id="xdx_90B_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zRFZ6Ul7fsA1" title="Percentage of royalties reduction based upon product launch"&gt;50&lt;/span&gt;%.
The Company did not incur any royalties expense during the three and six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(b)
Contract Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors and primarily clinical researchers who serve
as advisors to the Company. The Company incurred expenses of $&lt;span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20210401__20210630_pp0p0" title="Contract research and development expenses"&gt;786,000&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200401__20200630_zqTu8K6GJzsf" title="Contract research and development expenses"&gt;1.2&lt;/span&gt; million, respectively, for the three months ended June
30, 2021 and 2020 and $&lt;span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20210630_ztlvwdg0UN7a" title="Contract research and development expenses"&gt;1.7&lt;/span&gt; million and $&lt;span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20200630_zJOsrakd2PM7" title="Contract research and development expenses"&gt;2.9&lt;/span&gt; million, respectively, for the six months ended June 30, 2021 and 2020 under these agreements
and has recorded these expenses in research and development expenses.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock>
    <LPCN:CollaborativeArrangementRoyaltiesPercentageOfNetSales
      contextRef="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      unitRef="Pure">0.01</LPCN:CollaborativeArrangementRoyaltiesPercentageOfNetSales>
    <us-gaap:RoyaltyGuaranteesCommitmentsAmount
      contextRef="AsOf2021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:RoyaltyGuaranteesCommitmentsAmount>
    <LPCN:PercentageOfRoyaltiesReductionBasedUponProductLaunch
      contextRef="From2021-01-012021-06-30_custom_AbbottProductsIncMember_us-gaap_CollaborativeArrangementMember"
      decimals="INF"
      unitRef="Pure">0.50</LPCN:PercentageOfRoyaltiesReductionBasedUponProductLaunch>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">786000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2020-04-012020-06-30"
      decimals="-5"
      unitRef="USD">1200000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2021-01-01to2021-06-30"
      decimals="-5"
      unitRef="USD">1700000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="From2020-01-012020-06-30"
      decimals="-5"
      unitRef="USD">2900000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zBvhC5AE1iv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(8)
&lt;span id="xdx_822_zdxNOJ0zY7xg"&gt;Leases&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021 and on March 3, 2021, the Company extended the lease through February 28, 2022.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zUfUMlUBOOp4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
minimum lease payments under non-cancelable operating leases as of June 30, 2021 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zrEM2MWZVo35" style="display: none"&gt;Schedule of Future Minimum Rental Payments for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210630_zFppP7jvIsE3" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Operating&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Year ending December 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzsoZ_zB8frL0bvIue" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;165,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzsoZ_zUbrtUbBqKTf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzsoZ_zERVpyKDdUBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;220,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A7_zVuTwIz5Upsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company&#x2019;s rent expense was $&lt;span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20210401__20210630_pp0p0" title="Rent expense"&gt;&lt;span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20200401__20200630_pp0p0" title="Rent expense"&gt;83,000&lt;/span&gt;&lt;/span&gt; for each of the three months ended June 30, 2021 and 2020 and was $&lt;span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Rent expense"&gt;&lt;span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Rent expense"&gt;165,000&lt;/span&gt;&lt;/span&gt; for each of the six
months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zUfUMlUBOOp4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Future
minimum lease payments under non-cancelable operating leases as of June 30, 2021 are:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zrEM2MWZVo35" style="display: none"&gt;Schedule of Future Minimum Rental Payments for Operating Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.75in"&gt;
  &lt;tr style="display: none; vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49E_20210630_zFppP7jvIsE3" style="text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="text-align: center; font-weight: bold"&gt;Operating&lt;/td&gt;&lt;td style="font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;leases&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Year ending December 31:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzsoZ_zB8frL0bvIue" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; width: 80%; text-align: left"&gt;2021&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right"&gt;165,191&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzsoZ_zUbrtUbBqKTf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;55,064&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzsoZ_zERVpyKDdUBk" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;220,255&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">165191</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">55064</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">220255</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">83000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">83000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">165000</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeaseExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">165000</us-gaap:OperatingLeaseExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyyQKbNBuRx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(9)
&lt;span id="xdx_822_zljeLAwMdnX9"&gt;Stockholders&#x2019; Equity&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(a)
Issuance of Common Stock&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#x201c;January 2021 Offering&#x201d;). The gross proceeds from the January 2021 Offering were
approximately $&lt;span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1ZifzEzVQJg" title="Proceeds from issuance of common stock, gross"&gt;28.7&lt;/span&gt; million, before deducting underwriter fees and other offering expenses of $&lt;span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy8udAiuqHaj" title="Agent fees and other offering expenses"&gt;1.9&lt;/span&gt; million. In the January 2021 Offering,
the Company sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z87TsmWqcuH3" title="Stock issued during period, shares, new issues"&gt;16,428,571&lt;/span&gt; shares of its common stock.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#x201c;February 2020 Offering&#x201d;). The gross proceeds from the February
2020 Offering were approximately $&lt;span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_z1hytR5Y1gTi" title="Proceeds from issuance of common stock, gross"&gt;6.0&lt;/span&gt; million, before deducting placement agent fees and other offering expenses of $&lt;span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0" title="Agent fees and other offering expenses"&gt;347,000&lt;/span&gt;. In the
February 2020 Offering, the Company sold &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zLOX5oSbAU8d" title="Stock issued during period, shares, new issues"&gt;10,084,034&lt;/span&gt; Class A Units at an offering price of $&lt;span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDAIk3tknmX5" title="Shares issued, price per share"&gt;0.595&lt;/span&gt; per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $&lt;span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDcmCkfOm5Z1" title="Shares issued, price per share"&gt;0.53&lt;/span&gt;
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#x201c;November 2019 Offering&#x201d;). The gross proceeds from the November 2019 Offering
were approximately $&lt;span id="xdx_90F_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmTg3Iz6obsj"&gt;6.0
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million, before deducting placement agent fees
and other offering expenses of $&lt;span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0p0"&gt;404,000&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;.
In the November 2019 Offering, the Company sold (i) &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z8vFPGNUcZYh"&gt;10,450,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Class A Units, with each Class A Unit consisting
of one share of its common stock and a common warrant to purchase one share of its common stock, and (ii) &lt;span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d"&gt;1,550,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Class B Units, with each Class B Unit consisting
of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its common stock, at
a price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgyBCUDgVwV2"&gt;0.50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per Class A Unit and $&lt;span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmJObtiULXq3"&gt;0.4999
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per Class B Unit. The pre-funded warrants, which
were exercised for common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed
certain beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $&lt;span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zwdg8vL3Rfm4"&gt;.0001
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share, subject to adjustment. Additionally,
the common stock warrants were immediately exercisable at an exercise price of $&lt;span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118_zUlwhOJdNCCb"&gt;0.50
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;per share, subject to adjustment, and expire
on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common stock warrants can be exercised at any
time that the pre-funded warrant holder or the common stock warrant holder would beneficially own, after such exercise, more than 4.99%
(or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after giving effect to such exercise. On the
date of the November 2019 Offering, the Company allocated approximately $&lt;span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zbDObIxKhwBk"&gt;768,000
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and $&lt;span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgjKERfJbjGg"&gt;4.8
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;million to common stock/additional paid-in capital
and warrant liability, respectively.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $50.0 million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#x2019;s sales agent. Cantor may sell the Company&#x2019;s common stock by any method permitted by law deemed
to be an &#x201c;at the market offering&#x201d; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor &lt;span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember_zzzbtHM5gGMk" title="Percentage of gross proceeds on sale of shares"&gt;3.0&lt;/span&gt;% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
shares of the Company&#x2019;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#x201c;Form S-3&#x201d;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#x2019; prior notice.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, we had sold an aggregate of &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zFLwBGDdEs4e" title="Stock issued during period, shares, new issues"&gt;15,023,073&lt;/span&gt; shares at a weighted-average sales price of $&lt;span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zF5HJzr6DXX2" title="Shares issued, price per share"&gt;2.19&lt;/span&gt; per share under the Sales
Agreement for aggregate gross proceeds of $&lt;span id="xdx_907_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z6ipZYcjzE86" title="Proceeds from issuance of common stock, gross"&gt;32.9&lt;/span&gt; million and net proceeds of $31.7 million, after deducting sales agent commission and
discounts and our other offering costs. During the three months ended June 30, 2021, the Company did not sell any shares of our common
stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072). During the six months ended June 30, 2021, the
Company sold &lt;span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zie1VQsNJ05e" title="Stock issued during period, shares, new issues"&gt;1,811,238&lt;/span&gt; shares of our common stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072) at
a weighted-average sales price of $&lt;span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_zrguVuJpBMZ6" title="Shares issued, price per share"&gt;1.95&lt;/span&gt; per share, resulting in net proceeds of approximately $3.4 million under the Sales Agreement
which is net of $&lt;span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock"&gt;112,000&lt;/span&gt; in expenses. During the three and six months ended June 30, 2020, the Company did not sell any shares of our
common stock pursuant to the prior Registration Statement on Form S-3 (File No. 333-220942). As of June 30, 2021, the Company had $&lt;span id="xdx_904_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_z2fhijm6gRxh" title="Proceeds from issuance of common stock, gross"&gt;41.2&lt;/span&gt;
million available for sale under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(b)
Rights Agreement&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 13, 2015, the Company and American Stock Transfer &amp;amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#x201c;Right&#x201d; and collectively, the &#x201c;Rights&#x201d;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $&lt;span id="xdx_90E_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_z76l5ygPZ052" title="Class of warrant or right, redemption price of warrants or rights"&gt;63.96&lt;/span&gt; per one-thousandth share (the &#x201c;Purchase Price&#x201d;). The Rights will generally become
exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or
associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined
by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring
Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of
which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except
in certain situations, a person or group of affiliated or associated persons becomes an &#x201c;Acquiring Person&#x201d; upon acquiring
beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#x2019;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#x2019;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company will be entitled to redeem the Rights at $&lt;span id="xdx_900_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20210630_zQ3O4iENhhM9" title="Class of warrant or right, redemption price of warrants or rights"&gt;0.001&lt;/span&gt; per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#x2019;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021, unless the
rights are earlier redeemed or exchanged by the Company.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(c)
Share-Based Payments&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#x2019;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#x2019;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#x2019;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#x2019;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"/&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#x2019;s common stock price, (ii) the periods of time over
which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected
dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which
is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of
operations amounted to approximately $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630_zW18lo2IIVz9" title="Allocated share-based compensation expense"&gt;147&lt;/span&gt;,000 and $&lt;span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630_zw7mXSh8Vg9b"&gt;465&lt;/span&gt;,000, respectively, for the three months ended June 30, 2021 and 2020, and amounted
to $&lt;span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630_z1f570IcXqD2"&gt;294&lt;/span&gt;,000 and $&lt;span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_zQroveiqLwOh"&gt;787&lt;/span&gt;,000, respectively, for the six months ended June 30, 2021 and 2020, and is allocated as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLmIf86cXnic" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zTBJ1F1cgMLg" style="display: none"&gt;Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 48.95pt; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Six Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zF8Nnry2PyU9" style="width: 10%; text-align: right" title="Allocated Share-based Compensation Expense"&gt;69,483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWDpZeOg2EEc" style="width: 10%; text-align: right"&gt;199,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRKTDCTA07E6" style="width: 10%; text-align: right"&gt;136,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgm0rPZL3m16" style="width: 10%; text-align: right"&gt;334,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTbIMjkqgqc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zABAm4CjHjAi" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;265,281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgqhrLRgq0si" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;157,944&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zonanIsgmPa7" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;452,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Allocated
    Share-based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_zdJtDHK6Qsx6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;146,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_zc5IX2x1QfK5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;465,058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_zD87BeQzAEr1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;294,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_zt6tr7toSVtl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;786,971&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



&lt;p id="xdx_8A3_zeZv2xiL6zX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company issued &lt;span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIOZRETbdzzl" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"&gt;66,000&lt;/span&gt; stock options and &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGY7HOxfEbw3" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"&gt;376,000&lt;/span&gt; stock options, respectively, during the three and six months ended June 30, 2021 and
issued &lt;span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNpwvwMdPyrj" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"&gt;113,000&lt;/span&gt; and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zpxgyen6yLai" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross"&gt;739,000&lt;/span&gt; stock options during the three and six months ended June 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Key
assumptions used in the determination of the fair value of stock options granted are as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Term&lt;/i&gt;: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#x201c;SAB&#x201d;) No. 107, &lt;i&gt;Share-Based Payment,&lt;/i&gt; for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Risk-Free
Interest Rate&lt;/i&gt;: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Dividend&lt;/i&gt;: The expected dividend assumption is based on management&#x2019;s current expectation about the Company&#x2019;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;i&gt;Expected
Volatility&lt;/i&gt;: The volatility factor is based solely on the Company&#x2019;s trading history.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;For
options granted during the six months ended June 30, 2021 and 2020, the Company calculated the fair value of each option grant on the
respective dates of grant using the following weighted average assumptions:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwmpvSuawot1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zgecfC0mfGQd" style="display: none"&gt;Schedule of Key Assumption of Fair Value of Stock Options Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210630_zmDJMKFGsSW8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200101__20200630_zW7zEcE5d5k9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zlLije1vKWVg" title="Expected term"&gt;5.70&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630_zxoJsHRWHrkj" title="Expected term"&gt;5.81&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zcJlPuXYgIZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zvXnDLRRuXS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zgtdnN0Mb3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;FASB
ASC 718, &lt;i&gt;Stock Compensation,&lt;/i&gt; requires the Company to recognize compensation expense for the portion of options that are expected
to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If
the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required
in future periods.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, there was $&lt;span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20210630_z3LIhw34OZU4" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized"&gt;1.1&lt;/span&gt; million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#x2019;s stock option plan. That cost is expected to be recognized over a weighted average period of &lt;span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630_zqNbaQGCgRJd" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition"&gt;2.21&lt;/span&gt; years
and will be adjusted for subsequent changes in estimated forfeitures.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(d)
Stock Option Plan&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#x201c;2014 Plan&#x201d;) subject to shareholder approval
which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation
rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,000,000&lt;/span&gt; shares were authorized for issuance
under the 2014 Plan. Additionally, &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20140430__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;271,906&lt;/span&gt; remaining authorized shares under the 2011 Equity Incentive Plan (&#x201c;2011 Plan&#x201d;)
were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan
was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted
under the 2014 Plan from &lt;span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;1,271,906&lt;/span&gt; to &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;2,471,906&lt;/span&gt;. Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further
amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under
the 2014 Plan from &lt;span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;2,471,906&lt;/span&gt; to &lt;span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;3,221,906&lt;/span&gt;. Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended
and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014
Plan from &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;3,221,906&lt;/span&gt; to &lt;span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;5,721,906&lt;/span&gt;. The board of directors, on an option-by-option basis, determines the number of shares, exercise price,
term, and vesting period for options granted. Options granted generally have a &lt;span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zKndHewrps2l" title="Contractual life::XDX::P10Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1148"&gt;ten&lt;/span&gt;&lt;/span&gt;-year contractual life. The Company issues shares of
common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares
held in treasury. An aggregate of &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zvJRZema1pe7" title="Share-based compensation arrangement by share-based payment award, number of shares authorized"&gt;5,721,906&lt;/span&gt; shares are authorized for issuance under the 2014 Plan, with &lt;span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant"&gt;1,584,874&lt;/span&gt; shares remaining available
for grant as of June 30, 2021.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY50Qz52B1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B5_zponXz4ot0Ui" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Outstanding stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zLwTwd2zLfh7" style="width: 17%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"&gt;3,564,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4uEsg0iVKM9" style="width: 25%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"&gt;3.36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zx2A1aNSMa4c" style="text-align: right" title="Number of shares, Options granted (in shares)"&gt;376,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIuzppetXTx5" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqElCoELOdTa" style="text-align: right" title="Number of shares, Options exercised (in shares)"&gt;(4,584&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zEKKE1j0p4Fi" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKOPcUjH6b71" style="text-align: right" title="Number of shares, Options forfeited (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFy5JTxVWtj" style="text-align: right" title="Number of shares, Options cancelled (in shares)"&gt;(20,084&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zkiISkgOEuv3" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"&gt;6.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zw9KMa1wqCPj" style="text-align: right" title="Number of shares, Balance at end of the period (in shares)"&gt;3,915,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zRy9gaViWFUb" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Options exercisable at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGBFslhK1UUa" style="text-align: right" title="Number of shares, Options exercisable (in shares)"&gt;2,528,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl7VB44qqrA7" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"&gt;4.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zO02laWGFiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zbN5aK9liofg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes information about stock options outstanding and exercisable at June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_z9gHRxkwNHWh" style="display: none"&gt;Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average remaining contractual life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number exerciseable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average remaining contractual life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zYu9Fjg4nOYe" style="text-align: right" title="Number of options outstanding, shares"&gt;3,915,790&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zNNMiMxLBh05" title="Options outstanding, Weighted average remaining contractual life (Years)"&gt;6.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_z1nqIaCWFF4k" style="text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0" style="text-align: right" title="Options outstanding, Aggregate intrinsic value"&gt;636,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20210630_z83YayXslyP7" style="text-align: right" title="Number of options exercisable"&gt;2,528,729&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_z0V2SHtTusWa" title="Options exercisable, Weighted average remaining contractual life (Years)"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_zkC9ca7vZgGc" title="Options exercisable, Weighted average exercise price"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630_pp0p0" title="Options exercisable, Aggregate intrinsic value"&gt;311,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zLFHVuLecOIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. There were &lt;span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zwbS4AjMonLl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;zero
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;and &lt;span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zjv5INWO2DWl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;4,584&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;,
respectively, stock options exercised during the three and six months ended June 30, 2021, and &lt;span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNY6RxuqMC0f" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;&lt;span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zBGMUeeHZWr1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"&gt;no&lt;/span&gt;
&lt;/span&gt;&lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;stock options exercised during the three and
six months ended June 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;(e)
Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company accounts for its common stock warrants under ASC 480, &lt;i&gt;Distinguishing Liabilities from Equity&lt;/i&gt;, which requires any
financial instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#x2019;s
equity shares, or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring
assets, to be classified as a liability. In accordance with ASC 480, the Company&#x2019;s outstanding warrants from the November 2019
Offering are classified as a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair
value recognized as gain (loss) on change in fair value of warrant liability in the Company&#x2019;s consolidated statements of
operations. The warrants issued in the November 2019 Offering allow the warrant holder, if certain change in control events occur,
the option to receive an amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option
pricing model with certain defined assumptions upon a fundamental transaction.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;As
of June 30, 2021, the Company had &lt;span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d" title="Warrants outstanding"&gt;1,094,030&lt;/span&gt; common stock warrants outstanding from the November 2019 Offering to purchase an equal number
of shares of common stock. The fair value of these warrants on June 30, 2021 and on December 31, 2020 was determined using the Black-Scholes
option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zyFENORiDsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zp3NCmSqWXbk" style="display: none"&gt;Schedule of Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z09NG5MkR0Eg" title="Expected life in years"&gt;3.38&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYqGocmKiMe" title="Expected life in years"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf5RGxpsBjDk" style="text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVDPwmuU1Je" style="text-align: right"&gt;0.27&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNZLkp6Is9a" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOwQqz8wAW9j" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcOGy88fz0c" style="text-align: right"&gt;72.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFK1yzVh9NMg" style="text-align: right"&gt;88.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwaZkYUGnL6c" style="text-align: right"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6vyfjDH9hj5" style="text-align: right"&gt;1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zWbRIeQjF1Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and six months ended June 30, 2021, the Company recorded a non-cash gain of $&lt;span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zs6NnteTNPil" title="Fair value adjustment of warrants"&gt;221,000&lt;/span&gt; and $&lt;span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHYhVOSzjJK9" title="Fair value adjustment of warrants"&gt;&lt;span&gt;26,000&lt;/span&gt;&lt;/span&gt;, respectively, from the change
in fair value of the November 2019 Offering warrants. During the three and six months ended June 30, 2020, the Company recorded a non-cash
loss of $&lt;span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWkKNHYUXju9" title="Fair value adjustment of warrants"&gt;2.1&lt;/span&gt; million and $&lt;span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zDVtFQDKo2Re" title="Fair value adjustment of warrants"&gt;3.2&lt;/span&gt; million from the change in fair value of the November 2019 Offering warrants. The following table is a
reconciliation of the warrant liability measured at fair value using level 3 inputs:&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_89F_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zBrfZqVXUHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zbtPMe30hS83" style="display: none"&gt;Schedule of Reconciliation of Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20210630_zAASvD6PZTY4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zRhOtC0TMVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Settlement of liability on warrant exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,365&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Change in fair value of common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A4_z0FpmroS8r9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Additionally,
in the February 2020 Offering, the Company issued &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0d" title="Issued"&gt;5,042,017&lt;/span&gt; common stock warrants, however, because these warrants do not provide the
warrant holder the option to put the warrant back to the Company, the warrants are classified as equity.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SONOWOAWAE-MPE_znLjgJKxw7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span id="xdx_8B8_zWLYDtd7Grbl" style="display: none"&gt;Schedule
of Number of Warrants Outstanding and the Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: center"&gt;Outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmDTWqWwmmah" style="width: 20%; text-align: right" title="Number of shares, Balance at beginning of the period"&gt;1,944,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEGxKHoNM9i" style="width: 25%; text-align: right" title="Weighted average Exercise Price, Beginning of the period"&gt;0.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5j3hk4Nhjj3" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XX0Wv7TZab" style="text-align: right" title="Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sIBrNn3Gu2" style="text-align: right" title="Exercised"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9lDr6uZ8Y3" style="text-align: right" title="Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezwjN9XJ1Hl" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPh0HtUZNjKe" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lJBS67disk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSfdtI9MEUEh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at ending of the period"&gt;1,934,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTPT1VA2txc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average Exercise Price, Ending of the period"&gt;0.51&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8AB_z9WE8xG13hB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;During
the three and six months ended June 30, 2021, &lt;span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_dc_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXVW4WwLGkw9"&gt;zero&lt;/span&gt; and &lt;span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvSbpYrAhALa" title="Common warrants to purchase share of our common stock"&gt;10,000&lt;/span&gt; common stock warrants to purchase one share of our common stock were exercised,
respectively, resulting in proceeds of &lt;span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pp0p0_dc_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxq1tOOwQ8"&gt;zero&lt;/span&gt; and $&lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwxgUEBQx87" title="Proceeds from exercise of warrants"&gt;5,000&lt;/span&gt;. Additionally, during the three and six months ended June 30, 2020, &lt;span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPq1vIEGwFbl" title="Proceeds from exercise of warrants"&gt;13,497,807&lt;/span&gt;
and &lt;span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zgcno4EZRawf" title="Proceeds from exercise of warrants"&gt;13,618,807&lt;/span&gt; common stock warrants to purchase one share of our common stock were exercised, respectively, resulting in proceeds of
approximately $&lt;span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200401__20200630_zRsMVpzsux24"&gt;&lt;span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20200630_z7nwWLCkWVSh"&gt;6.9&lt;/span&gt;&lt;/span&gt; million in each of the three and six-month periods ending June 30, 2020.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_C00_gL3SONOWOAWAE-MPE_zF7xBcdU6fC9"&gt;The
following table summarizes information about common stock warrants outstanding at June 30, 2021:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;div id="xdx_C03_gL3SONOWOAWAE-MPE_zTx5vU2ZE725"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_zeLvIOq7pmD3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt" summary="xdx: Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Number exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Weighted average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 26%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUsDS15dVYd" style="text-align: right" title="Number of warrants exercisable, shares"&gt;&lt;span&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQExU5rxjy3g" title="Weighted average remaining contractual life"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zntgohBvSxsk" style="text-align: right" title="Weighted average exercise price, per share"&gt;&lt;span&gt;&lt;span title="Weighted average Exercise Price, Ending of the period"&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlX259qtjsIg" style="text-align: right" title="Aggregate intrinsic value"&gt;&lt;span&gt;1,715,719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;/div&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_C09_gL3SONOWOAWAE-MPE_z7UxHFC1QoY4"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <LPCN:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="-5"
      unitRef="USD">28700000</LPCN:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="-5"
      unitRef="USD">1900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-262021-01-28_custom_January2021OfferingMember"
      decimals="INF"
      unitRef="Shares">16428571</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <LPCN:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember"
      decimals="-5"
      unitRef="USD">6000000.0</LPCN:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2020-02-262020-02-27_custom_February2020OfferingMember"
      decimals="0"
      unitRef="USD">347000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2020-02-262020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="Shares">10084034</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-02-27_custom_ClassAUnitMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.595</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2020-02-27_us-gaap_CommonStockMember_custom_February2020OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:SharesIssuedPricePerShare>
    <LPCN:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">6000000.0</LPCN:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="From2019-11-172019-11-18_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">404000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-11-172019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="Shares">10450000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2019-11-172019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember"
      decimals="0"
      unitRef="Shares">1550000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_custom_ClassAUnitMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_custom_ClassBUnitsMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.4999</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2019-11-18_custom_PreFundedWarrantsMember_custom_November2019OfferingMember"
      decimals="INF"
      unitRef="USDPShares">0.0001</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2019-11-18"
      decimals="INF"
      unitRef="USDPShares">0.50</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-11-172019-11-18_us-gaap_CommonStockMember_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">768000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="From2019-11-172019-11-18_us-gaap_AdditionalPaidInCapitalMember_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">4800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <LPCN:PercentageOfGrossProceedOnSaleOfShares
      contextRef="From2017-03-052017-03-06_custom_SalesAgreementMember"
      decimals="INF"
      unitRef="Pure">3.0</LPCN:PercentageOfGrossProceedOnSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-06-30_custom_AtMarketOfferingMember"
      decimals="INF"
      unitRef="Shares">15023073</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-06-30_custom_AtMarketOfferingMember"
      decimals="INF"
      unitRef="USDPShares">2.19</us-gaap:SharesIssuedPricePerShare>
    <LPCN:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2021-01-012021-06-30_custom_AtMarketOfferingMember"
      decimals="-5"
      unitRef="USD">32900000</LPCN:ProceedsFromIssuanceOfCommonStockGross>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="From2021-01-012021-06-30_us-gaap_CommonStockMember_custom_AtMarketOfferingMember"
      decimals="INF"
      unitRef="Shares">1811238</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="AsOf2021-06-30_custom_AccreditedInvestorsMember"
      decimals="INF"
      unitRef="USDPShares">1.95</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="From2021-01-012021-06-30_custom_AccreditedInvestorsMember"
      decimals="0"
      unitRef="USD">112000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <LPCN:ProceedsFromIssuanceOfCommonStockGross
      contextRef="From2021-01-012021-06-30_custom_AccreditedInvestorsMember"
      decimals="-5"
      unitRef="USD">41200000</LPCN:ProceedsFromIssuanceOfCommonStockGross>
    <LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="From2015-11-122015-11-13"
      decimals="INF"
      unitRef="USDPShares">63.96</LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights>
    <LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="USDPShares">0.001</LPCN:ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30"
      decimals="-3"
      unitRef="USD">147000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="-3"
      unitRef="USD">465000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="-3"
      unitRef="USD">294000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30"
      decimals="-3"
      unitRef="USD">787000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLmIf86cXnic" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zTBJ1F1cgMLg" style="display: none"&gt;Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span style="display: none"&gt;&#160;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 48.95pt; border-collapse: collapse; width: 80%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Three Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="font-weight: bold; padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Six Months Ended&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;June 30,&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 44%; text-align: left"&gt;Research and development&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zF8Nnry2PyU9" style="width: 10%; text-align: right" title="Allocated Share-based Compensation Expense"&gt;69,483&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWDpZeOg2EEc" style="width: 10%; text-align: right"&gt;199,777&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRKTDCTA07E6" style="width: 10%; text-align: right"&gt;136,369&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgm0rPZL3m16" style="width: 10%; text-align: right"&gt;334,441&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;General and administrative&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTbIMjkqgqc" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;77,264&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zABAm4CjHjAi" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;265,281&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgqhrLRgq0si" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;157,944&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zonanIsgmPa7" style="border-bottom: Black 1.5pt solid; text-align: right"&gt;452,530&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; display: none"&gt;Allocated
    Share-based Compensation Expense&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_zdJtDHK6Qsx6" style="border-bottom: Black 2.5pt double; text-align: right"&gt;146,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_zc5IX2x1QfK5" style="border-bottom: Black 2.5pt double; text-align: right"&gt;465,058&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_zD87BeQzAEr1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;294,313&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_zt6tr7toSVtl" style="border-bottom: Black 2.5pt double; text-align: right"&gt;786,971&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;



</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">69483</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">199777</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">136369</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="0"
      unitRef="USD">334441</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">77264</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">265281</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-012021-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">157944</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30_us-gaap_GeneralAndAdministrativeExpenseMember"
      decimals="0"
      unitRef="USD">452530</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-04-012021-06-30"
      decimals="0"
      unitRef="USD">146747</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-04-012020-06-30"
      decimals="0"
      unitRef="USD">465058</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">294313</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="From2020-01-012020-06-30"
      decimals="0"
      unitRef="USD">786971</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">66000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="0"
      unitRef="Shares">376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484"
      decimals="0"
      unitRef="Shares">739000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwmpvSuawot1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B9_zgecfC0mfGQd" style="display: none"&gt;Schedule of Key Assumption of Fair Value of Stock Options Granted&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210630_zmDJMKFGsSW8" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_495_20200101__20200630_zW7zEcE5d5k9" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected term&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zlLije1vKWVg" title="Expected term"&gt;5.70&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630_zxoJsHRWHrkj" title="Expected term"&gt;5.81&lt;/span&gt; years&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zcJlPuXYgIZh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 52%; text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;0.52&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;1.33&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Expected dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1122"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1123"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zvXnDLRRuXS9" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Expected volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;95.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;99.52&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-06-30">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-06-30">P5Y9M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.0052</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Pure">0.0133</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-01to2021-06-30"
      decimals="INF"
      unitRef="Pure">0.9552</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-06-30"
      decimals="INF"
      unitRef="Pure">0.9952</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2021-06-30" decimals="-5" unitRef="USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2021-01-01to2021-06-30">P2Y2M15D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2014-04-30_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2014-04-30_custom_EquityIncentivePlanMember"
      decimals="0"
      unitRef="Shares">271906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">1271906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2016-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">2471906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2018-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">2471906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2018-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">3221906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-06-30_srt_MinimumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">3221906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2020-06-30_srt_MaximumMember_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">5721906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="AsOf2021-06-30_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">5721906</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="AsOf2021-06-30_custom_StockIncentivePlan2014Member"
      decimals="0"
      unitRef="Shares">1584874</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY50Qz52B1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;A
summary of stock option activity is as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;span id="xdx_8B5_zponXz4ot0Ui" style="display: none"&gt;Schedule of Stock Option Activity&lt;/span&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Outstanding stock options&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number of shares&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 50%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zLwTwd2zLfh7" style="width: 17%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)"&gt;3,564,458&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4uEsg0iVKM9" style="width: 25%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)"&gt;3.36&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options granted&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zx2A1aNSMa4c" style="text-align: right" title="Number of shares, Options granted (in shares)"&gt;376,000&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIuzppetXTx5" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)"&gt;1.44&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqElCoELOdTa" style="text-align: right" title="Number of shares, Options exercised (in shares)"&gt;(4,584&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zEKKE1j0p4Fi" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)"&gt;1.46&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Options forfeited&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKOPcUjH6b71" style="text-align: right" title="Number of shares, Options forfeited (in shares)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1168"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1170"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Options cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFy5JTxVWtj" style="text-align: right" title="Number of shares, Options cancelled (in shares)"&gt;(20,084&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zkiISkgOEuv3" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)"&gt;6.45&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zw9KMa1wqCPj" style="text-align: right" title="Number of shares, Balance at end of the period (in shares)"&gt;3,915,790&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zRy9gaViWFUb" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Options exercisable at June 30, 2021&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGBFslhK1UUa" style="text-align: right" title="Number of shares, Options exercisable (in shares)"&gt;2,528,729&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl7VB44qqrA7" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)"&gt;4.24&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3564458</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="Shares">376000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="USDPShares">1.44</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="USDPShares">1.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="Shares">20084</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="INF"
      unitRef="USDPShares">6.45</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">3915790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="Shares">2528729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="INF"
      unitRef="USDPShares">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zbN5aK9liofg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes information about stock options outstanding and exercisable at June 30, 2021:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BC_z9gHRxkwNHWh" style="display: none"&gt;Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Options exercisable&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number outstanding&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average remaining contractual life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Number exerciseable&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average remaining contractual life (Years)&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Weighted average exercise price&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Aggregate intrinsic value&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 10%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 11%"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 11%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zYu9Fjg4nOYe" style="text-align: right" title="Number of options outstanding, shares"&gt;3,915,790&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zNNMiMxLBh05" title="Options outstanding, Weighted average remaining contractual life (Years)"&gt;6.39&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_z1nqIaCWFF4k" style="text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)"&gt;3.16&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0" style="text-align: right" title="Options outstanding, Aggregate intrinsic value"&gt;636,639&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20210630_z83YayXslyP7" style="text-align: right" title="Number of options exercisable"&gt;2,528,729&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_z0V2SHtTusWa" title="Options exercisable, Weighted average remaining contractual life (Years)"&gt;4.84&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_zkC9ca7vZgGc" title="Options exercisable, Weighted average exercise price"&gt;4.24&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630_pp0p0" title="Options exercisable, Aggregate intrinsic value"&gt;311,190&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">3915790</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-06-30">P6Y4M20D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">3.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">636639</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-06-30" decimals="INF" unitRef="Shares">2528729</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-06-30">P4Y10M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30"
      decimals="INF"
      unitRef="USDPShares">4.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">311190</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_EmployeeStockOptionMember14583468"
      decimals="0"
      unitRef="Shares">4584</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-04-012020-06-30_us-gaap_EmployeeStockOptionMember"
      decimals="0"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="From2020-01-012020-06-30_us-gaap_EmployeeStockOptionMember14583484"
      decimals="0"
      unitRef="Shares">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="AsOf2021-06-30_custom_November2019OfferingMember"
      decimals="0"
      unitRef="Shares">1094030</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <LPCN:ScheduleOfFairValueOfWarrantsTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_891_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zyFENORiDsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8B4_zp3NCmSqWXbk" style="display: none"&gt;Schedule of Fair Value of Warrants&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center"&gt;December 31, 2020&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: left"&gt;Expected life in years&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z09NG5MkR0Eg" title="Expected life in years"&gt;3.38&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;&lt;span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYqGocmKiMe" title="Expected life in years"&gt;3.88&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;Risk-free interest rate&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf5RGxpsBjDk" style="text-align: right"&gt;0.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVDPwmuU1Je" style="text-align: right"&gt;0.27&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;Dividend yield&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNZLkp6Is9a" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1219"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOwQqz8wAW9j" style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1220"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td&gt;Volatility&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcOGy88fz0c" style="text-align: right"&gt;72.62&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFK1yzVh9NMg" style="text-align: right"&gt;88.46&lt;/td&gt;&lt;td style="text-align: left"&gt;%&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td&gt;Stock price&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwaZkYUGnL6c" style="text-align: right"&gt;1.40&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6vyfjDH9hj5" style="text-align: right"&gt;1.36&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</LPCN:ScheduleOfFairValueOfWarrantsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P3Y4M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember">P3Y10M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.0046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.7262</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="From2020-01-012020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Pure">0.8846</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharePrice
      contextRef="AsOf2021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:SharePrice>
    <us-gaap:SharePrice
      contextRef="AsOf2020-12-31_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">1.36</us-gaap:SharePrice>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-04-012021-06-30_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">221000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-012021-06-30_custom_November2019OfferingMember"
      decimals="0"
      unitRef="USD">26000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-04-012020-06-30_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">2100000</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2020-01-012020-06-30_custom_November2019OfferingMember"
      decimals="-5"
      unitRef="USD">3200000</us-gaap:FairValueAdjustmentOfWarrants>
    <LPCN:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_89F_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zBrfZqVXUHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;span id="xdx_8BD_zbtPMe30hS83" style="display: none"&gt;Schedule of Reconciliation of Warrant Liability&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_49C_20210101__20210630_zAASvD6PZTY4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;Warrant Liability&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zRhOtC0TMVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 78%"&gt;Balance at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 18%; text-align: right"&gt;1,170,051&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 10pt; text-align: left"&gt;Settlement of liability on warrant exercise&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;(18,365&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left"&gt;Change in fair value of common stock warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1.5pt solid; text-align: right"&gt;(26,257&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 2.5pt"&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,125,429&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</LPCN:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">1170051</us-gaap:WarrantsAndRightsOutstanding>
    <LPCN:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-18365</LPCN:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="From2021-01-01to2021-06-30"
      decimals="0"
      unitRef="USD">-26257</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:WarrantsAndRightsOutstanding contextRef="AsOf2021-06-30" decimals="0" unitRef="USD">1125429</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="From2021-01-012021-06-30_custom_February2020OfferingMember"
      decimals="0"
      unitRef="Shares">5042017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SONOWOAWAE-MPE_znLjgJKxw7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"&gt;&lt;span id="xdx_8B8_zWLYDtd7Grbl" style="display: none"&gt;Schedule
of Number of Warrants Outstanding and the Weighted Average Exercise Price&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 48.95pt"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;Warrants&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"&gt;&lt;p style="margin-top: 0; margin-bottom: 0"&gt;Weighted Average&lt;/p&gt;
                                                                                &lt;p style="margin-top: 0; margin-bottom: 0"&gt;Exercise Price&lt;/p&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; font-weight: bold"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 47%; text-align: center"&gt;Outstanding at December 31, 2020&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmDTWqWwmmah" style="width: 20%; text-align: right" title="Number of shares, Balance at beginning of the period"&gt;1,944,366&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 2%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEGxKHoNM9i" style="width: 25%; text-align: right" title="Weighted average Exercise Price, Beginning of the period"&gt;0.51&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Issued&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1255"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5j3hk4Nhjj3" style="text-align: right" title="Issued"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1257"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Exercised&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XX0Wv7TZab" style="text-align: right" title="Exercised"&gt;(10,000&lt;/td&gt;&lt;td style="text-align: left"&gt;)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sIBrNn3Gu2" style="text-align: right" title="Exercised"&gt;0.50&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: center"&gt;Expired&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1263"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9lDr6uZ8Y3" style="text-align: right" title="Expired"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1265"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: center"&gt;Cancelled&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezwjN9XJ1Hl" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1267"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPh0HtUZNjKe" style="text-align: right" title="Cancelled"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1269"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;Forfeited&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1271"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lJBS67disk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl1273"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-bottom: 2.5pt; text-align: center"&gt;Balance at June 30, 2021&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSfdtI9MEUEh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at ending of the period"&gt;1,934,366&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTPT1VA2txc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average Exercise Price, Ending of the period"&gt;0.51&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


The
following table summarizes information about common stock warrants outstanding at June 30, 2021:&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" id="xdx_306_134_zeLvIOq7pmD3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt" summary="xdx: Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Warrants outstanding&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Number exercisable&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Weighted average remaining contractual life (Years)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Weighted average exercise price&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"&gt;&lt;span&gt;Aggregate intrinsic value&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 26%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 20%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 22%; text-align: right"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUsDS15dVYd" style="text-align: right" title="Number of warrants exercisable, shares"&gt;&lt;span&gt;1,934,366&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span&gt;&lt;span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQExU5rxjy3g" title="Weighted average remaining contractual life"&gt;3.50&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zntgohBvSxsk" style="text-align: right" title="Weighted average exercise price, per share"&gt;&lt;span&gt;&lt;span title="Weighted average Exercise Price, Ending of the period"&gt;0.51&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&lt;span&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlX259qtjsIg" style="text-align: right" title="Aggregate intrinsic value"&gt;&lt;span&gt;1,715,719&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&#160;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember14584484"
      decimals="INF"
      unitRef="Shares">1944366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2020-12-31_us-gaap_WarrantMember14584484"
      decimals="INF"
      unitRef="USDPShares">0.51</LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      decimals="INF"
      unitRef="USDPShares">0.50</LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515"
      decimals="INF"
      unitRef="USDPShares">0.51</LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-04-012021-06-30_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484"
      decimals="INF"
      unitRef="Shares">10000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-04-012020-06-30_us-gaap_WarrantMember"
      decimals="0"
      unitRef="USD">0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-06-30_us-gaap_WarrantMember14584609"
      decimals="0"
      unitRef="USD">5000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-04-012020-06-30_custom_CommonStockWarrantMember"
      decimals="0"
      unitRef="USD">13497807</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-06-30_custom_CommonStockWarrantMember"
      decimals="0"
      unitRef="USD">13618807</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-04-012020-06-30"
      decimals="-5"
      unitRef="USD">6900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="From2020-01-012020-06-30"
      decimals="-5"
      unitRef="USD">6900000</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515"
      decimals="INF"
      unitRef="Shares">1934366</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms contextRef="From2021-01-012021-06-30_us-gaap_WarrantMember14584484">P3Y6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515"
      decimals="INF"
      unitRef="USDPShares">0.51</LPCN:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="AsOf2021-06-30_us-gaap_WarrantMember14584515"
      decimals="0"
      unitRef="USD">1715719</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ2XWsTWguH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(10)
&lt;span id="xdx_82A_z1vdK7tZE0Y4"&gt;Commitments and Contingencies&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Litigation&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#x2019;s JATENZO&#xae; product infringes six of Lipocine&#x2019;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement for expired
U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus has answered
the complaint and asserted counterclaims of non-infringement, inequitable conduct and invalidity. The Company answered Clarus&#x2019;s
counterclaims on April 29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February
11, 2020 and a Summary Judgement Hearing on January 15, 2021. In May 2021, the Court granted Clarus&#x2019; motion for Summary Judgment,
finding the asserted claims of Lipocine&#x2019;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy
the written description requirement of 35 U.S.C. &#xa7; 112. Clarus still had remaining counterclaims before the Court. On July 13, 2021,
Clarus and the Company entered into a global settlement agreement (&#x201c;Global Agreement&#x2019;) which resolved all outstanding claims
of this litigation as well as the on-going United States Patent and Trademark Office (&#x201c;USPTO&#x201d;) Interference No. 106,128 between
the parties. Under the terms of the Global Agreement, the Company agreed to pay Clarus $&lt;span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_znAXOqCrqB0d" title="Litigation settlement"&gt;4.0&lt;/span&gt; million payable as follows: $&lt;span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_z22uHYa8BcH" title="Litigation settlement"&gt;2.5&lt;/span&gt; million
immediately, $&lt;span id="xdx_902_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zsmNIE49vZs7" title="Litigation settlement"&gt;1.0&lt;/span&gt; million on July 13, 2022 and $&lt;span id="xdx_907_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_pp0p0" title="Litigation settlement"&gt;500,000&lt;/span&gt; on July 13, 2023. No future royalties are owing from either party. On July 15,
2021, the Court dismissed with prejudice the Company&#x2019;s claims and Clarus&#x2019; counterclaims.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,
&lt;i&gt;Solomon Abady v. Lipocine Inc. et al&lt;/i&gt;., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to
the FDA contained deficiencies and as a result the defendants&#x2019; statements about our business and operations were false and misleading
and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#x2019;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this nature. The retention amount
payable by the Company under our policy is $&lt;span id="xdx_900_eus-gaap--RetentionPayable_iI_pn4n6_c20191114_zjL5vveK3R6h" title="Retention payable"&gt;1.25&lt;/span&gt; million. The Company filed a motion to dismiss the class action lawsuit on July 24,
2020. In response, the plaintiffs filed their response to the motion to dismiss the class action lawsuit on September 22, 2020 and the
Company filed its reply to its motion to dismiss on October 22, 2020. The Company intends to vigorously defend itself against these allegations
and has not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate
be made of loss, if any.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (&#x201c;the Lipocine &#x2018;779 Application&#x201d;)
with the USPTO. On October 16 and November 3, 2020, Lipocine filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#x2018;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (&#x201c;the Clarus &#x2018;178 Application&#x201d;). Pursuant to the Company&#x2019;s request, the Patent Trial and Appeal Board (&#x201c;PTAB&#x201d;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and the Company was initially declared Senior Party. A conference
call with the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing
certain motions and setting the schedule for the preliminary motions phase. On July 13, 2021, Clarus and the Company entered into the
Global Agreement to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#x2019;s request
for adverse judgment in interference No. 106,128 in accordance with the Global Agreement.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Guarantees
and Indemnifications&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;&#160;&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnification provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember"
      decimals="-5"
      unitRef="USD">4000000.0</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2019-04-012019-04-02_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember"
      decimals="-5"
      unitRef="USD">2500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2022-07-122022-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember"
      decimals="-5"
      unitRef="USD">1000000.0</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:LitigationSettlementAmountAwardedToOtherParty
      contextRef="From2023-07-122023-07-13_custom_GlobalAgreementMember_custom_ClarusTherapeuticsIncMember_srt_ScenarioForecastMember"
      decimals="0"
      unitRef="USD">500000</us-gaap:LitigationSettlementAmountAwardedToOtherParty>
    <us-gaap:RetentionPayable contextRef="AsOf2019-11-14" decimals="-4" unitRef="USD">1250000</us-gaap:RetentionPayable>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z3CfOZnXV6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(11)
&lt;span id="xdx_824_zJW5cwyEu5ee"&gt;Agreement with Spriaso, LLC&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;On
July 23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned
by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and
transferred to Spriaso all of the Company&#x2019;s rights, title and interest in its intellectual property to develop products for the
cough and cold field. In addition, Spriaso received all rights and obligations under the Company&#x2019;s product development agreement
with a third-party. In exchange, the Company will receive a royalty of &lt;span id="xdx_902_ecustom--PercentageOfRoyalty_pid_dp_uPure_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zPJSXkktasVe" title="Percentage of royalty"&gt;20&lt;/span&gt; percent of the net proceeds received by Spriaso, up to a maximum
of $&lt;span id="xdx_903_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zvEAUNWU2s6h" title="Proceeds from affiliates"&gt;10.0&lt;/span&gt; million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. &lt;span id="xdx_901_ecustom--AgreementDescription_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember" title="Agreement description"&gt;Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain
employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an
amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain
employees to Spriaso at a rate of $&lt;span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zmxMROTlQsc8" title="Employee related liabilities"&gt;230&lt;/span&gt;/hour for a period of six months.&lt;/span&gt; The agreement was further amended on July 23, 2015, on January
23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017, on January 23, 2018, on July 23, 2018 and again on January 23, 2019
to extend the term of the agreement for an additional six months. The agreement was further amended on July 23, 2019 and again on July
23, 2020 to extend the term of the agreement for an additional twelve months. The agreement may be extended upon written agreement of
Spriaso and the Company. The Company did not receive any reimbursements during the three and six months ended June 30, 2021 and 2020,
respectively. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for
a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB
ASC Topic 810-10, &lt;i&gt;Consolidations&lt;/i&gt;, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <LPCN:PercentageOfRoyalty
      contextRef="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember"
      decimals="INF"
      unitRef="Pure">0.20</LPCN:PercentageOfRoyalty>
    <us-gaap:ProceedsFromContributionsFromAffiliates
      contextRef="From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember"
      decimals="-5"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromContributionsFromAffiliates>
    <LPCN:AgreementDescription contextRef="From2013-07-222013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember">Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain
employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an
amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain
employees to Spriaso at a rate of $230/hour for a period of six months.</LPCN:AgreementDescription>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="AsOf2013-07-23_custom_ServiceAgreementMember_custom_SpriasoLLCMember"
      decimals="0"
      unitRef="USD">230</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="From2021-01-01to2021-06-30">&lt;p id="xdx_80C_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zdKyzGwsOKc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;(12)
&lt;span id="xdx_827_zWAE3dhkISEb"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&lt;b&gt;&lt;i&gt;Accounting
Pronouncements Issued Not Yet Adopted&lt;/i&gt;&lt;/b&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif; color: #212529"&gt;In
2016, the FASB issued &lt;/span&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;Accounting Standards Update (&#x201c;ASU&#x201d;)
&lt;span style="color: #212529"&gt;2016-13, &lt;i&gt;Measurement of Credit Losses on Financial Instruments &lt;/i&gt;(&#x201c;ASU 2016-13&#x201d;). This
standard replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on
instruments within its scope, including trade receivables, and requires entities to measure all expected credit losses for financial
assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The original
effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;&#160;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"&gt;&lt;span style="font: 10pt Times New Roman, Times, Serif"&gt;However,
in October 2019, the FASB issued ASU 2019-10, &lt;i&gt;Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates&lt;/i&gt;, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies&lt;i&gt;.&lt;/i&gt; A company&#x2019;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.&lt;/span&gt;&lt;/p&gt;

</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050292072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 04, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-36357<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">LIPOCINE
INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001535955<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">99-0370688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">675
    Arapeen Drive<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 202<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Salt
    Lake City<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">UT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">84108<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">801<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">994-7383<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
    Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">LPCN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88,290,650<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050064552">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 10,967,713<span></span>
</td>
<td class="nump">$ 19,217,382<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Marketable investment securities</a></td>
<td class="nump">35,672,059<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Accrued interest income</a></td>
<td class="nump">232,568<span></span>
</td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid and other current assets</a></td>
<td class="nump">283,180<span></span>
</td>
<td class="nump">661,258<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">47,155,520<span></span>
</td>
<td class="nump">25,329,023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">23,753<span></span>
</td>
<td class="nump">23,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,179,273<span></span>
</td>
<td class="nump">25,352,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">906,476<span></span>
</td>
<td class="nump">1,597,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">1,444,188<span></span>
</td>
<td class="nump">1,653,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Debt - current portion</a></td>
<td class="nump">3,957,627<span></span>
</td>
<td class="nump">3,333,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveCurrent', window );">Litigation settlement liability - current portion</a></td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">8,808,291<span></span>
</td>
<td class="nump">6,583,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Debt - non-current portion</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,257,075<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrant liability</a></td>
<td class="nump">1,125,429<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationReserveNoncurrent', window );">Litigation settlement liability - non-current portion</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">11,433,720<span></span>
</td>
<td class="nump">10,010,857<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (notes 5, 7, 8 and 10)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding</a></td>
<td class="nump">8,830<span></span>
</td>
<td class="nump">7,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">217,986,752<span></span>
</td>
<td class="nump">187,407,634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock at cost, 5,710 shares</a></td>
<td class="num">(40,712)<span></span>
</td>
<td class="num">(40,712)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(182,209,131)<span></span>
</td>
<td class="num">(172,032,008)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">35,745,553<span></span>
</td>
<td class="nump">15,341,919<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 47,179,273<span></span>
</td>
<td class="nump">$ 25,352,776<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 55<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=116646759&amp;loc=d3e15243-108350<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationReserveNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationReserveNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316061101176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">88,296,360<span></span>
</td>
<td class="nump">70,041,967<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">70,036,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">5,710<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050009608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 1,464,687<span></span>
</td>
<td class="nump">$ 2,268,984<span></span>
</td>
<td class="nump">$ 3,045,228<span></span>
</td>
<td class="nump">$ 4,780,739<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">1,525,592<span></span>
</td>
<td class="nump">1,953,535<span></span>
</td>
<td class="nump">3,059,544<span></span>
</td>
<td class="nump">4,038,795<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">2,990,279<span></span>
</td>
<td class="nump">4,222,519<span></span>
</td>
<td class="nump">6,104,772<span></span>
</td>
<td class="nump">8,819,534<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(2,990,279)<span></span>
</td>
<td class="num">(4,222,519)<span></span>
</td>
<td class="num">(6,104,772)<span></span>
</td>
<td class="num">(8,819,534)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest and investment income</a></td>
<td class="nump">17,344<span></span>
</td>
<td class="nump">7,177<span></span>
</td>
<td class="nump">27,993<span></span>
</td>
<td class="nump">67,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(57,428)<span></span>
</td>
<td class="num">(87,847)<span></span>
</td>
<td class="num">(126,401)<span></span>
</td>
<td class="num">(221,192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnDerivatives', window );">Unrealized gain (loss) on warrant liability</a></td>
<td class="nump">221,322<span></span>
</td>
<td class="num">(2,066,445)<span></span>
</td>
<td class="nump">26,257<span></span>
</td>
<td class="num">(3,166,474)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement</a></td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(4,000,000)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Total other expense, net</a></td>
<td class="num">(3,818,762)<span></span>
</td>
<td class="num">(2,147,115)<span></span>
</td>
<td class="num">(4,072,151)<span></span>
</td>
<td class="num">(3,320,551)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss before income tax expense</a></td>
<td class="num">(6,809,041)<span></span>
</td>
<td class="num">(6,369,634)<span></span>
</td>
<td class="num">(10,176,923)<span></span>
</td>
<td class="num">(12,140,085)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,809,041)<span></span>
</td>
<td class="num">$ (6,369,634)<span></span>
</td>
<td class="num">$ (10,177,123)<span></span>
</td>
<td class="num">$ (12,140,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common stock</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding, basic</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">49,769,253<span></span>
</td>
<td class="nump">85,556,110<span></span>
</td>
<td class="nump">45,558,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common stock</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average common shares outstanding, diluted</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">49,769,253<span></span>
</td>
<td class="nump">85,556,110<span></span>
</td>
<td class="nump">45,558,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (6,809,041)<span></span>
</td>
<td class="num">$ (6,369,634)<span></span>
</td>
<td class="num">$ (10,177,123)<span></span>
</td>
<td class="num">$ (12,140,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on available-for-sale securities</a></td>
<td class="nump">22,273<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (6,786,768)<span></span>
</td>
<td class="num">$ (6,369,738)<span></span>
</td>
<td class="num">$ (10,177,309)<span></span>
</td>
<td class="num">$ (12,140,351)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316051023112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>AOCI Attributable to Parent [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2019</a></td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">$ 157,391,969<span></span>
</td>
<td class="num">$ (38)<span></span>
</td>
<td class="num">$ (151,067,189)<span></span>
</td>
<td class="nump">$ 6,287,796<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="nump">37,649,465<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(12,140,285)<span></span>
</td>
<td class="num">(12,140,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(66)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">786,971<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">786,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodValueWarrantsExercises', window );">Common stock issued for warrant exercises</a></td>
<td class="nump">$ 1,362<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,912,796<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,914,158<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Common stock issued for warrant exercises, shares</a></td>
<td class="nump">13,618,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,591,362<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,591,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_CommonStockSoldThroughEquityOffering', window );">Common stock sold through equity offering</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,652,132<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,653,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_CommonStockSoldThroughEquityOfferingShares', window );">Common stock sold through equity offering, shares</a></td>
<td class="nump">10,084,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering', window );">Costs associated with ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2020</a></td>
<td class="nump">$ 6,138<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">176,327,120<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(163,207,474)<span></span>
</td>
<td class="nump">13,084,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">61,377,306<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2020</a></td>
<td class="nump">$ 4,786<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">163,426,502<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(156,837,840)<span></span>
</td>
<td class="nump">6,552,736<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2020</a></td>
<td class="nump">47,854,499<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,369,634)<span></span>
</td>
<td class="num">(6,369,634)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(104)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">465,058<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">465,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units, shares</a></td>
<td class="nump">25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodValueWarrantsExercises', window );">Common stock issued for warrant exercises</a></td>
<td class="nump">$ 1,350<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,852,308<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,853,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Common stock issued for warrant exercises, shares</a></td>
<td class="nump">13,497,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,591,362<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,591,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering', window );">Costs associated with ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2020</a></td>
<td class="nump">$ 6,138<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">176,327,120<span></span>
</td>
<td class="num">(104)<span></span>
</td>
<td class="num">(163,207,474)<span></span>
</td>
<td class="nump">13,084,968<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2020</a></td>
<td class="nump">61,377,306<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Dec. 31, 2020</a></td>
<td class="nump">$ 7,005<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">187,407,634<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(172,032,008)<span></span>
</td>
<td class="nump">15,341,919<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="nump">70,036,257<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(10,177,123)<span></span>
</td>
<td class="num">(10,177,123)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(186)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">294,313<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">294,313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodValueWarrantsExercises', window );">Common stock issued for warrant exercises</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_StockIssuedDuringPeriodSharesWarrantsExercises', window );">Common stock issued for warrant exercises, shares</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,365<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">18,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_CommonStockSoldThroughEquityOffering', window );">Common stock sold through equity offering</a></td>
<td class="nump">$ 1,643<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,838,814<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">26,840,457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_CommonStockSoldThroughEquityOfferingShares', window );">Common stock sold through equity offering, shares</a></td>
<td class="nump">16,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Option exercises</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,693<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,693<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Option exercises, shares</a></td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock sold through ATM offering</a></td>
<td class="nump">$ 181<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,415,934<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">3,416,115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock sold through ATM offering, shares</a></td>
<td class="nump">1,811,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2021</a></td>
<td class="nump">$ 8,830<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">217,986,752<span></span>
</td>
<td class="num">(186)<span></span>
</td>
<td class="num">(182,209,131)<span></span>
</td>
<td class="nump">35,745,553<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Mar. 31, 2021</a></td>
<td class="nump">$ 8,830<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">217,845,280<span></span>
</td>
<td class="num">(22,459)<span></span>
</td>
<td class="num">(175,400,090)<span></span>
</td>
<td class="nump">42,390,849<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Mar. 31, 2021</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(6,809,041)<span></span>
</td>
<td class="num">(6,809,041)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized net loss on marketable investment securities</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,273<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">22,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">146,747<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">146,747<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering', window );">Costs associated with ATM offering</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,275)<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(5,275)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balances at Jun. 30, 2021</a></td>
<td class="nump">$ 8,830<span></span>
</td>
<td class="num">$ (40,712)<span></span>
</td>
<td class="nump">$ 217,986,752<span></span>
</td>
<td class="num">$ (186)<span></span>
</td>
<td class="num">$ (182,209,131)<span></span>
</td>
<td class="nump">$ 35,745,553<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Jun. 30, 2021</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">5,710<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of warrant liability on warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional paid in capital, share-based payment arrangement, costs associated with ATM offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_CommonStockSoldThroughEquityOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock sold through equity offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_CommonStockSoldThroughEquityOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_CommonStockSoldThroughEquityOfferingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock sold through equity offering, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_CommonStockSoldThroughEquityOfferingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_StockIssuedDuringPeriodSharesWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for warrant exercises, shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_StockIssuedDuringPeriodSharesWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_StockIssuedDuringPeriodValueWarrantsExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock issued for warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_StockIssuedDuringPeriodValueWarrantsExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050004120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (10,177,123)<span></span>
</td>
<td class="num">$ (12,140,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">1,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">294,313<span></span>
</td>
<td class="nump">786,971<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Non-cash interest expense</a></td>
<td class="nump">33,886<span></span>
</td>
<td class="nump">63,765<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Non-cash loss (gain) on change in fair value of warrant liability</a></td>
<td class="num">(26,257)<span></span>
</td>
<td class="nump">3,166,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable investment securities</a></td>
<td class="nump">203,958<span></span>
</td>
<td class="num">(9,755)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Accrued interest income</a></td>
<td class="num">(232,177)<span></span>
</td>
<td class="nump">8,603<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid and other current assets</a></td>
<td class="nump">378,078<span></span>
</td>
<td class="nump">398,579<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(690,744)<span></span>
</td>
<td class="num">(275,415)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="num">(208,990)<span></span>
</td>
<td class="nump">543,955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement liability</a></td>
<td class="nump">4,000,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Cash used in operating activities</a></td>
<td class="num">(6,425,056)<span></span>
</td>
<td class="num">(7,455,510)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt', window );">Purchases of marketable investment securities</a></td>
<td class="num">(35,876,211)<span></span>
</td>
<td class="num">(4,466,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities', window );">Maturities of marketable investment securities</a></td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">4,350,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Cash used in investing activities</a></td>
<td class="num">(35,426,211)<span></span>
</td>
<td class="num">(116,811)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Debt repayments</a></td>
<td class="num">(1,666,667)<span></span>
</td>
<td class="num">(1,111,111)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfDebt', window );">Proceeds from debt</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">233,537<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from common stock offering</a></td>
<td class="nump">26,840,457<span></span>
</td>
<td class="nump">5,653,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_NetProceedsFromCostsAssociatedWithAtm', window );">Net proceeds from (costs associated with) ATM</a></td>
<td class="nump">3,416,115<span></span>
</td>
<td class="num">(8,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
<td class="nump">6,693<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Net proceeds from exercise of warrants</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="nump">6,914,158<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Cash provided by financing activities</a></td>
<td class="nump">28,601,598<span></span>
</td>
<td class="nump">11,681,616<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(13,249,669)<span></span>
</td>
<td class="nump">4,109,295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at beginning of period</a></td>
<td class="nump">24,217,382<span></span>
</td>
<td class="nump">14,728,523<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">Cash, cash equivalents, and restricted cash at end of period</a></td>
<td class="nump">10,967,713<span></span>
</td>
<td class="nump">18,837,818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">92,515<span></span>
</td>
<td class="nump">156,979<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_SettlementOfWarrantLiabilityOnWarrantExercises', window );">Settlement of warrant liability on warrant exercises</a></td>
<td class="nump">18,365<span></span>
</td>
<td class="nump">5,591,362<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net unrealized loss on available-for-sale securities</a></td>
<td class="num">(186)<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AccruedFinalPaymentChargeOnDebt', window );">Accrued final payment charge on debt</a></td>
<td class="nump">33,886<span></span>
</td>
<td class="nump">63,765<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseAccruedInterest', window );">Other accrued interest</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 448<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_AccruedFinalPaymentChargeOnDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued final payment charge on debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_AccruedFinalPaymentChargeOnDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_NetProceedsFromCostsAssociatedWithAtm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from (costs associated with) ATM.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_NetProceedsFromCostsAssociatedWithAtm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_SettlementOfWarrantLiabilityOnWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement of warrant liability on warrant exercises.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_SettlementOfWarrantLiabilityOnWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase for accrued, but unpaid interest on the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046419256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p id="xdx_809_eus-gaap--BusinessDescriptionAndBasisOfPresentationTextBlock_zf26RVR5mCV7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(1)
<span id="xdx_82A_z7Dnyaq5GlJ3">Basis of Presentation</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
accompanying unaudited condensed consolidated financial statements included herein have been prepared by Lipocine Inc. (&#8220;Lipocine&#8221;
or the &#8220;Company&#8221;) in accordance with the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;).
The unaudited condensed consolidated financial statements are comprised of the financial statements of Lipocine and its subsidiaries,
collectively referred to as the Company. In management&#8217;s opinion, the interim financial data presented includes all adjustments
(consisting solely of normal recurring items) necessary for fair presentation. All intercompany accounts and transactions have been eliminated.
Certain information required by U.S. generally accepted accounting principles has been condensed or omitted in accordance with rules
and regulations of the SEC. Operating results for the three and six months ended June 30, 2021 are not necessarily indicative of the
results that may be expected for any future period or for the year ending December 31, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">These
unaudited condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial
statements and the notes thereto for the year ended December 31, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
preparation of the unaudited condensed consolidated financial statements requires management to make estimates and assumptions relating
to reporting of the assets and liabilities and the disclosure of contingent assets and liabilities to prepare these condensed consolidated
financial statements and the reported amounts of revenues and expenses during the reporting period in conformity with U.S. generally
accepted accounting principles. Actual results could differ from these estimates.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company believes that its existing capital resources, together with interest thereon, will be sufficient to meet its projected operating
requirements through at least June 30, 2022 which includes an on-going clinical study for LPCN 1144, future clinical studies for LPCN
1148 and LPCN 1154, compliance with regulatory requirements and on-going litigation and settlement activities. The Company has based
this estimate on assumptions that may prove to be wrong, and the Company could utilize its available capital resources sooner than it
currently expects if additional activities are performed by the Company including pre-commercial and commercial activities for TLANDO
and new clinical studies for LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1154. While the Company believes it has sufficient liquidity and
capital resources to fund our projected operating requirements through at least June 30, 2022, the Company will need to raise additional
capital at some point through the equity or debt markets or through out-licensing activities, before or after June 30, 2022, to support
its operations. If the Company is unsuccessful in raising additional capital, its ability to continue as a going concern will become
a risk. Further, the Company&#8217;s operating plan may change, and the Company may need additional funds to meet operational needs and
capital requirements for product development, regulatory compliance and clinical trial activities sooner than planned. In addition, the
Company&#8217;s capital resources may be consumed more rapidly if it pursues additional clinical studies for LPCN 1144, TLANDO XR, LPCN
1148 and LPCN 1154. Conversely, the Company&#8217;s capital resources could last longer if it reduces expenses, reduces the number of
activities currently contemplated under our operating plan or if it terminates, modifies the design or suspends on-going clinical studies..</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045071208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings (Loss) per Share</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--EarningsPerShareTextBlock_z3hFYjXuOHlc" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(2)
<span id="xdx_82C_zPvpJhRmKqgc">Earnings (Loss) per Share</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Basic
earnings (loss) per share is calculated by dividing net income (loss) available to common shareholders by the weighted average number
of common shares outstanding during the period. Diluted earnings (loss) per share is based on the weighted average number of common shares
outstanding plus, where applicable, the additional potential common shares that would have been outstanding related to dilutive options,
warrants and, unvested restricted stock units to the extent such shares are dilutive.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zFklzRIFvkA6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three and six months
ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zEGLUH0xIVKg" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; width: 44%; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(6,809,041</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(6,369,634</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(10,177,123</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(12,140,285</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">88,290,650</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">49,769,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">85,556,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">45,558,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Basic loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.27</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Diluted loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(6,809,041</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(6,369,634</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(10,177,123</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(12,140,285</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">88,290,650</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">49,769,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">85,556,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">45,558,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareDiluted_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareDiluted_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EarningsPerShareDiluted_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.27</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<p id="xdx_8AB_znx1cR5mx2M5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgUzANzH4zb7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
computation of diluted loss per share for the six months ended June 30, 2021 and 2020 does not include the following stock options and
warrants to purchase shares or unvested restricted stock units in the computation of diluted loss per share because these instruments
were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zF1rtWgD3N2" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,915,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,012,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unvested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_zJp5UKSV93Ec" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">605,682</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,934,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,423,210</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AB_zdJO1gF3Lrk8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046438488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Investment Securities</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_zwBgd4irrirh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(3) <span id="xdx_821_zecIPDIXMdJb">Marketable Investment Securities</span> </b></span></p>


<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has classified its marketable investment securities as available-for-sale securities, all of which are debt securities. These
securities are carried at fair value with unrealized holding gains and losses, net of the related tax effect, included in accumulated
other comprehensive income (loss) in stockholders&#8217; equity until realized. Gains and losses on investment security transactions
are reported on the specific-identification method. Dividend income is recognized on the ex-dividend date and interest income is recognized
on an accrual basis. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for available-for-sale
securities by major security type and class of security at June 30, 2021 and December 31, 2020 were as follows:</span></p>

<p id="xdx_899_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zCqDFj7M3vK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zKMnjojBKDl5" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Corporate bonds, notes and commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost">35,672,245</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zst3WqwmDm4i" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses">(186</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zLlkTmW4Idgj" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">35,672,059</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">35,672,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0812">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630_zAi4Bj0aoh87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses">(186</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost">449,992</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zmxd8v90C1W1" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Aggregate fair value">449,992</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231_zPbrHA3pBLta" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0829">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_zqFSCfC6I3vb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 13.5pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Maturities
of debt securities classified as available-for-sale securities at June 30, 2021 are as follows:</span></p>

<p id="xdx_891_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zn0nVmjl1fa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zzdYpf7yemTk" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 60%; text-align: left">Due within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20210630_znVIirmXF7Ei" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year">35,672,245</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year">35,672,059</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20210630_zJ8B4Bhi0one" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost">35,672,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20210630_zasMMEuy9VW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_z6kib6qku1J5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">There
were no sales of marketable investment securities during the three and six months ended June 30, 2021 and 2020 and therefore <span id="xdx_90C_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210401__20210630_zKwGbR2fgt42" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_903_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200401__20200630_zea6w7zv2wJe" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_90D_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20210101__20210630_zR71wdpBYe01" title="Available-for-sale securities, gross realized gain (loss)"><span id="xdx_904_eus-gaap--AvailableForSaleSecuritiesGrossRealizedGainLossNet_pp0p0_do_c20200101__20200630_zeA2Qoe8eJ7f" title="Available-for-sale securities, gross realized gain (loss)">no</span></span></span></span> realized
gains or losses. Additionally, during the three months ended June 30, 2021 and 2020, <span id="xdx_90E_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20210401__20210630_zcWrB1QUvwsg" title="Proceeds from sale and maturity of marketable securities"><span id="xdx_90F_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_do_c20200401__20200630_zqhI4aSg1l18" title="Proceeds from sale and maturity of marketable securities">no</span></span> marketable investment securities matured, and
$<span id="xdx_908_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pp0p0_c20210101__20210630_zVjTQYyspbqf" title="Proceeds from sale and maturity of marketable securities">450,000</span> and $<span id="xdx_901_eus-gaap--ProceedsFromSaleAndMaturityOfMarketableSecurities_pn5n6_c20200101__20200630_zrZHqaVHSr6l" title="Proceeds from sale and maturity of marketable securities">4.3</span> million of marketable investment securities matured during the six months ended June 30, 2021 and 2020, respectively.
The Company determined there were <span title="Other-than-temporary impairments"><span id="xdx_902_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210401__20210630_zMd8HawUJRF6" title="Other-than-temporary impairments"><span id="xdx_90B_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200401__20200630_zYGkwhjna2uj" title="Other-than-temporary impairments"><span id="xdx_905_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20210101__20210630_zsvSuCfsMDZ3" title="Other-than-temporary impairments"><span id="xdx_90A_eus-gaap--OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment_pp0p0_do_c20200101__20200630_z7xRAGNQKJMi" title="Other-than-temporary impairments">no</span></span></span></span></span> other-than-temporary impairments for the three and six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045136536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value</a></td>
<td class="text"><p id="xdx_809_eus-gaap--FairValueDisclosuresTextBlock_zlVS9aypAdT6" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(4)
<span id="xdx_825_zZsThDQdpmO5">Fair Value</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent
possible. The Company determines fair value based on assumptions that market participants would use in pricing an asset or liability
in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following
fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    1 Inputs: Quoted prices for identical instruments in active markets. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    2 Inputs: Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets
    that are not active, and model-derived valuation in which all significant inputs and significant value drivers are observable in
    active markets. </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&#9679;<span style="font: 10pt Times New Roman, Times, Serif">    </span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Level
    3 Inputs: Valuations derived from valuation techniques in which one or more significant inputs or significant value drivers are unobservable.
    </span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">All
of the Company&#8217;s financial instruments are valued using quoted prices in active markets or based on other observable inputs. For
accrued interest income, prepaid and other current assets, accounts payable, and accrued expenses, the carrying amounts approximate fair
value because of the short maturity of these instruments. The following table presents the placement in the fair value hierarchy of assets
and liabilities that are measured at fair value on a recurring basis at June 30, 2021 and December 31, 2020:</span></p>

<p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zsBKdAnZU4a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zrUBVqzHxtQc" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">10,179,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">10,179,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Commercial Paper</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right" title="Assets, fair value">13,987,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Assets, fair value">13,987,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Corporate bonds and notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgtLYI7LEiDl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">21,684,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeJC3drlne3i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbtmpRH0yD3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">21,684,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvXAm5ktI2gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">45,851,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">10,179,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8jtsVdOssfj" style="border-bottom: Black 1.5pt solid; text-align: right">1,125,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzUYEB4ZuPl2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRwp7qyph7Mb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdMb09hfXwQ" style="border-bottom: Black 1.5pt solid; text-align: right">1,125,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630_zDJW2QD4mtOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">46,976,561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z394n7Gf8Kc" style="border-bottom: Black 2.5pt double; text-align: right">10,179,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK2SoRNz2Wd1" style="border-bottom: Black 2.5pt double; text-align: right">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgZ8Bucc3v9j" style="border-bottom: Black 2.5pt double; text-align: right">1,125,429</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">18,399,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">18,399,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">18,849,577</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">18,399,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">1,170,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJHVG9AW6Uu9" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9hoR9TLBpVf" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE6Z3F33HOb8" style="border-bottom: Black 1.5pt solid; text-align: right">1,170,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_z7MtH1P16mO3" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">20,019,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">18,399,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvrtQbFL3ta6" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">1,170,051</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A3_zJkTJfUhi1a2" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following methods and assumptions were used to determine the fair value of each class of assets and liabilities recorded at fair value
in the balance sheets:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Cash
equivalents: Cash equivalents primarily consist of highly-rated money market funds and treasury bills with original maturities to the
Company of three months or less and are purchased daily at par value with specified yield rates. Cash equivalents related to money market
funds and treasury bills are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices
or broker or dealer quotations for similar assets.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Corporate
bonds, notes, and commercial paper: The Company uses a third-party pricing service to value these investments. Corporate bonds, notes
and commercial paper are classified within Level 2 of the fair value hierarchy because they are valued using broker/dealer quotes, bids
and offers, benchmark yields and credit spreads and other observable inputs.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Warrant
liability: <span style="background-color: white">The warrant liability (which relates to warrants to purchase shares of common stock)
is marked-to-market each reporting period with the change in fair value recorded to other income (expense) in the accompanying statements
of operations until the warrants are exercised, expire or other facts and circumstances lead the warrant liability to be reclassified
to stockholders&#8217; equity. The fair value of the warrant liability is estimated using a Black-Scholes option-pricing model. The significant
assumptions used in preparing the option pricing model for valuing the warrant liability as of June 30, 2021, include (i) volatility
of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zDStewBsJte1" title="Expected volatility">72.62</span>%, (ii) risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zQGmDgUTEB0c" title="Risk-free interest rate">0.46</span>%, (iii) strike price of $<span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zs1ivdHxrAna" title="Strike price">0.50</span>, (iv) fair value of common stock of $<span id="xdx_904_eus-gaap--SharePrice_iI_uUSDPShares_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zmZI7KROlM3b" title="Fair value of common stock">1.40</span>, and (v) expected
life of <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zYXJ1wS2EgAl" title="Expected term">3.38</span> years. The significant assumptions used in preparing the option pricing model for valuing the warrant liability as of December
31, 2020, include (i) volatility of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zWNkpRoEqCni" title="Expected volatility">88.46</span>%, (ii) risk free interest rate of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zAlbqTWtL06" title="Risk-free interest rate">0.27</span>%, (iii) strike price of $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zRl268Gaae8a" title="Strike price">0.50</span>, (iv) fair value of common
stock of $<span id="xdx_900_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zKq3vYmuYFbk" title="Fair value of common stock">1.36</span>, and (v) expected life of <span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_zNAsZ0exovC3" title="Expected term">3.9</span> years.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s accounting policy is to recognize transfers between levels of the fair value hierarchy on the date of the event or change
in circumstances that caused the transfer. There were no transfers into or out of Level 1, Level 2, or Level 3 for the three and six
months ended June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046396280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Loan and Security Agreements and Other Liabilities</a></td>
<td class="text"><p id="xdx_801_eus-gaap--DebtDisclosureTextBlock_z7UbT5BzuIja" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(5)
<span id="xdx_82F_zs2chRFIdIbg">Loan and Security Agreements and Other Liabilities</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 22.5pt; text-indent: -22.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Silicon
Valley Bank Loan</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 5, 2018, the Company entered into a Loan and Security Agreement (the &#8220;Loan and Security Agreement&#8221;) with Silicon
Valley Bank (&#8220;SVB&#8221;) pursuant to which SVB agreed to lend the Company $<span id="xdx_904_eus-gaap--DebtInstrumentFaceAmount_iI_pn5n6_c20180105__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zPenQJXHCw5k" title="Aggregate amount">10.0</span> million. <span id="xdx_909_eus-gaap--DebtInstrumentInterestRateBasisForEffectiveRate_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (<span id="xdx_902_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pdd" title="Interest rate">4.25%</span> as of June
30, 2021), which interest is payable monthly</span>. Additionally on April 1, 2020, the Company entered into a Deferral Agreement with SVB.
Under the Deferral Agreement, principal repayments were deferred by six months and the Company was only required to make monthly interest
payments. The loan matures on <span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zEBKDqGbjSFb" title="Debt instrument, maturity date">June 1, 2022</span>. Previously, the Company only made monthly interest payments until December 31, 2018, following
which the Company also made equal monthly payments of principal and interest until the signing of the Deferral Agreement. The Company
will also be required to pay an additional final payment at maturity equal to $<span id="xdx_908_eus-gaap--DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid_iI_pp0p0_c20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z1cyT8gzoNel" title="Debt instrument, balloon payment to be paid">650,000</span> (the &#8220;Final Payment Charge&#8221;). The
Final Payment Charge will be due on the scheduled maturity date and to date approximately $<span id="xdx_903_eus-gaap--DebtInstrumentIncreaseDecreaseForPeriodNet_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, increase in amount">624,000</span> has been recognized as an increase
to the principal balance with a corresponding charge to interest expense with the remaining final payment charge to be recognized over
the term of the facility using the effective interest method. At its option, the Company may prepay all amounts owed under the Loan and
Security Agreement (including all accrued and unpaid interest and the Final Payment Charge).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
connection with the Loan and Security Agreement, the Company granted to SVB a security interest in substantially all of the Company&#8217;s
assets now owned or hereafter acquired, excluding intellectual property and certain other assets. In addition, as TLANDO was not approved
by the United States Food and Drug Administration (&#8220;FDA&#8221;) prior to May 31, 2018, the Company maintained $<span id="xdx_904_eus-gaap--CashCollateralForBorrowedSecurities_iI_pn5n6_c20180531__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zAjDgTLyP5Vh" title="Cash collateral for borrowed securities">5.0</span> million of cash
collateral at SVB as required under the Loan and Security Agreement until such time as TLANDO is approved by the FDA. However on February
16, 2021, the Company amended the Loan and Security Agreement with SVB to, among other things, remove the financial trigger and financial
trigger release event provisions requiring the Company to maintain a minimum cash collateral value and collateral pledge thereof.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_eus-gaap--DebtInstrumentRestrictiveCovenants_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_z4zL5llX0Vn5" title="Debt instrument, restrictive covenants">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus <span id="xdx_907_ecustom--DebtInstrumentBasisSpreadOnInterestRateForDebtDefault_dp_uPure_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_zlbxsicGzdQg" title="Debt instrument, basis spread on interest rate for debt default">5.0</span>% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.</span> These events of default include, among other things,
any failure by the Company to pay principal or interest due under the credit facility, a breach of certain covenants under the credit
facility, the Company&#8217;s insolvency, a material adverse change, and one or more judgments against the Company in an amount greater
than $<span id="xdx_906_ecustom--DebtInstrumentMinimumAmountConsideredForInsolvency_c20210101__20210630__us-gaap--DebtInstrumentAxis__custom--LoanAndSecurityAgreementMember__us-gaap--LineOfCreditFacilityAxis__custom--SiliconValleyBankMember_pp0p0" title="Debt instrument, minimum amount considered for insolvency">100,000</span> individually or in the aggregate.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Future
maturities of principal payments on the Loan and Security Agreement at June 30, 2021 (excluding accrued final payment fee) are as follows:</span></p>

<p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1SZVfVzWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z6RFgppwRNJ1" style="display: none">Schedule of Maturities of Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zPqWdHIQ0u18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">(in thousands)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzdw8_zsgvcvVvWvpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,666</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzdw8_zRO4famUECu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,667</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_iI_pn3n3_maLTDzdw8_zvcuXlIsdiNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzdw8_ztFsB8fyqitf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Long-term
    Debt</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AA_z5Wo6sNsbdtc" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>Other</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">Effective
June 15, 2020 and through December 31, 2020, the Company deferred Federal Insurance Contributions Act (&#8220;FICA&#8221;) taxes under
the CARES Act Section 2302. Payment of these tax deferrals are delayed to December 31, 2021 and December 31, 2022. As of June 30, 2021
the tax deferrals totaled $<span id="xdx_90A_ecustom--DeferredFederalInsuranceContributionsActTaxPayments_c20210630_pp0p0" title="Deferred FICA payroll tax payments">36,000</span> and are included in accrued liabilities.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045136536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p id="xdx_80A_eus-gaap--IncomeTaxDisclosureTextBlock_zlvLaioHuR1k" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(6)
<span id="xdx_82B_zZhI94j6oQQ3">Income Taxes</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
tax provision for interim periods is determined using an estimate of the Company&#8217;s effective tax rate for the full year adjusted
for discrete items, if any, that are taken into account in the relevant period. Each quarter the Company updates its estimate of the
annual effective tax rate, and if the estimated tax rate changes, the Company makes a cumulative adjustment.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">At
June 30, 2021 and December 31, 2020, the Company had a full valuation allowance against its deferred tax assets, net of expected reversals
of existing deferred tax liabilities, as it believes it is more likely than not that these benefits will not be realized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046419256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HealthCareOrganizationsAbstract', window );"><strong>Health Care Organizations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock', window );">Contractual Agreements</a></td>
<td class="text"><p id="xdx_805_eus-gaap--BusinessAndContractualArrangementsDisclosureTextBlock_zqmQ5D9Bnmb2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(7)
<span id="xdx_827_zuTlCzkpXzw1">Contractual Agreements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(a)
Abbott Products, Inc.</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
March 29, 2012, the Company terminated its collaborative agreement with Solvay Pharmaceuticals, Inc. (later acquired by Abbott Products,
Inc.) for TLANDO. As part of the termination, the Company reacquired the rights to the intellectual property from Abbott. All obligations
under the prior license agreement have been completed except that Lipocine will owe Abbott a perpetual <span id="xdx_90C_ecustom--CollaborativeArrangementRoyaltiesPercentageOfNetSales_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zM6Zpn38Nkl7" title="Percentage of net sales">1%</span> royalty on net sales. Such
royalties are limited to $<span><span id="xdx_900_eus-gaap--RoyaltyGuaranteesCommitmentsAmount_iI_pn5n6_c20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zt2tDNeHn1Qa" title="Royalties, commitment amount">1.0</span></span> million in the first two calendar years following product launch, after which period there is not a cap
on royalties and no maximum aggregate amount. If generic versions of any such product are introduced, then royalties are reduced by <span id="xdx_90B_ecustom--PercentageOfRoyaltiesReductionBasedUponProductLaunch_dp_uPure_c20210101__20210630__dei--LegalEntityAxis__custom--AbbottProductsIncMember__us-gaap--TypeOfArrangementAxis__us-gaap--CollaborativeArrangementMember_zRFZ6Ul7fsA1" title="Percentage of royalties reduction based upon product launch">50</span>%.
The Company did not incur any royalties expense during the three and six months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(b)
Contract Research and Development</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has entered into agreements with various contract organizations that conduct preclinical, clinical, analytical and manufacturing
development work on behalf of the Company as well as a number of independent contractors and primarily clinical researchers who serve
as advisors to the Company. The Company incurred expenses of $<span id="xdx_904_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_c20210401__20210630_pp0p0" title="Contract research and development expenses">786,000</span> and $<span id="xdx_903_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200401__20200630_zqTu8K6GJzsf" title="Contract research and development expenses">1.2</span> million, respectively, for the three months ended June
30, 2021 and 2020 and $<span id="xdx_90B_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20210101__20210630_ztlvwdg0UN7a" title="Contract research and development expenses">1.7</span> million and $<span id="xdx_90F_eus-gaap--ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_pn5n6_c20200101__20200630_zJOsrakd2PM7" title="Contract research and development expenses">2.9</span> million, respectively, for the six months ended June 30, 2021 and 2020 under these agreements
and has recorded these expenses in research and development expenses.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 405<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289226<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HealthCareOrganizationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HealthCareOrganizationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045136536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p id="xdx_804_eus-gaap--LesseeOperatingLeasesTextBlock_zBvhC5AE1iv7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(8)
<span id="xdx_822_zdxNOJ0zY7xg">Leases</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
August 6, 2004, the Company assumed a non-cancelable operating lease for office space and laboratory facilities in Salt Lake City, Utah.
On May 6, 2014, the Company modified and extended the lease through February 28, 2018. On February 8, 2018, the Company extended the
lease through February 28, 2019, on January 2, 2019, the Company extended the lease through February 29, 2020, on February 24, 2020,
the Company extended the lease through February 28, 2021 and on March 3, 2021, the Company extended the lease through February 28, 2022.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zUfUMlUBOOp4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Future
minimum lease payments under non-cancelable operating leases as of June 30, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zrEM2MWZVo35" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210630_zFppP7jvIsE3" style="text-align: center; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzsoZ_zB8frL0bvIue" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">165,191</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzsoZ_zUbrtUbBqKTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzsoZ_zERVpyKDdUBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">220,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A7_zVuTwIz5Upsa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company&#8217;s rent expense was $<span id="xdx_90B_eus-gaap--OperatingLeaseExpense_c20210401__20210630_pp0p0" title="Rent expense"><span id="xdx_905_eus-gaap--OperatingLeaseExpense_c20200401__20200630_pp0p0" title="Rent expense">83,000</span></span> for each of the three months ended June 30, 2021 and 2020 and was $<span id="xdx_906_eus-gaap--OperatingLeaseExpense_c20210101__20210630_pp0p0" title="Rent expense"><span id="xdx_900_eus-gaap--OperatingLeaseExpense_c20200101__20200630_pp0p0" title="Rent expense">165,000</span></span> for each of the six
months ended June 30, 2021 and 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046441288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders&#8217; Equity</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zyyQKbNBuRx4" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(9)
<span id="xdx_822_zljeLAwMdnX9">Stockholders&#8217; Equity</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(a)
Issuance of Common Stock</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
January 28, 2021, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;January 2021 Offering&#8221;). The gross proceeds from the January 2021 Offering were
approximately $<span id="xdx_900_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z1ZifzEzVQJg" title="Proceeds from issuance of common stock, gross">28.7</span> million, before deducting underwriter fees and other offering expenses of $<span id="xdx_908_eus-gaap--PaymentsOfStockIssuanceCosts_pn5n6_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_zy8udAiuqHaj" title="Agent fees and other offering expenses">1.9</span> million. In the January 2021 Offering,
the Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210126__20210128__us-gaap--SubsidiarySaleOfStockAxis__custom--January2021OfferingMember_z87TsmWqcuH3" title="Stock issued during period, shares, new issues">16,428,571</span> shares of its common stock.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 22.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">On
February 27, 2020, the Company completed a registered direct offering of securities registered under an effective registration statement
filed pursuant to the Securities Act of 1933, as amended (&#8220;February 2020 Offering&#8221;). The gross proceeds from the February
2020 Offering were approximately $<span id="xdx_901_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_z1hytR5Y1gTi" title="Proceeds from issuance of common stock, gross">6.0</span> million, before deducting placement agent fees and other offering expenses of $<span id="xdx_90F_eus-gaap--PaymentsOfStockIssuanceCosts_c20200226__20200227__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0p0" title="Agent fees and other offering expenses">347,000</span>. In the
February 2020 Offering, the Company sold <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20200226__20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zLOX5oSbAU8d" title="Stock issued during period, shares, new issues">10,084,034</span> Class A Units at an offering price of $<span id="xdx_906_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDAIk3tknmX5" title="Shares issued, price per share">0.595</span> per unit, with each Class A Unit consisting
of one share of its common stock and one-half of a common warrant to purchase one share of common stock at an exercise price of $<span id="xdx_90B_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20200227__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_zDcmCkfOm5Z1" title="Shares issued, price per share">0.53</span>
per share of common stock. Additionally, the common stock warrants were immediately exercisable and expire on February 27, 2025. By their
terms, however, the common stock warrants cannot be exercised at any time that the common stock warrant holder would beneficially own,
after such exercise, more than 4.99% (or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after
giving effect to such exercise.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">On
November 18, 2019, the Company completed a public offering of securities registered under an effective registration statement filed pursuant
to the Securities Act of 1933, as amended (&#8220;November 2019 Offering&#8221;). The gross proceeds from the November 2019 Offering
were approximately $<span id="xdx_90F_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmTg3Iz6obsj">6.0
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million, before deducting placement agent fees
and other offering expenses of $<span id="xdx_907_eus-gaap--PaymentsOfStockIssuanceCosts_c20191117__20191118__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0p0">404,000</span></span><span style="font: 10pt Times New Roman, Times, Serif">.
In the November 2019 Offering, the Company sold (i) <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_z8vFPGNUcZYh">10,450,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Class A Units, with each Class A Unit consisting
of one share of its common stock and a common warrant to purchase one share of its common stock, and (ii) <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20191117__20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d">1,550,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">Class B Units, with each Class B Unit consisting
of one pre-funded warrant to purchase one share of its common stock and a common warrant to purchase one share of its common stock, at
a price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassAUnitMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgyBCUDgVwV2">0.50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per Class A Unit and $<span id="xdx_903_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--ClassBUnitsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zmJObtiULXq3">0.4999
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per Class B Unit. The pre-funded warrants, which
were exercised for common stock in December 2019, were issued in lieu of common stock in order to ensure the purchaser did not exceed
certain beneficial ownership limitations. The pre-funded warrants were immediately exercisable at an exercise price of $<span id="xdx_900_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20191118__us-gaap--StatementClassOfStockAxis__custom--PreFundedWarrantsMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zwdg8vL3Rfm4">.0001
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment. Additionally,
the common stock warrants were immediately exercisable at an exercise price of $<span id="xdx_901_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20191118_zUlwhOJdNCCb">0.50
</span></span><span style="font: 10pt Times New Roman, Times, Serif">per share, subject to adjustment, and expire
on November 17, 2024. By their terms, however, neither the pre-funded warrants nor the common stock warrants can be exercised at any
time that the pre-funded warrant holder or the common stock warrant holder would beneficially own, after such exercise, more than 4.99%
(or, at the election of the holder, 9.99%) of the shares of common stock then outstanding after giving effect to such exercise. On the
date of the November 2019 Offering, the Company allocated approximately $<span id="xdx_901_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pp0p0_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zbDObIxKhwBk">768,000
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and $<span id="xdx_900_eus-gaap--StockIssuedDuringPeriodValueNewIssues_pn5n6_c20191117__20191118__us-gaap--StatementClassOfStockAxis__us-gaap--AdditionalPaidInCapitalMember__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zgjKERfJbjGg">4.8
</span></span><span style="font: 10pt Times New Roman, Times, Serif">million to common stock/additional paid-in capital
and warrant liability, respectively.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
March 6, 2017, the Company entered into the Sales Agreement with Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;) pursuant to which
the Company may issue and sell, from time to time, shares of its common stock having an aggregate offering price of up to the amount
the Company registered on an effective registration statement pursuant to which the offering is being made. The Company currently has
registered up to $50.0 million for sale under the Sales Agreement, pursuant to the Registration Statement on Form S-3 (File No. 333-250072)
through Cantor as the Company&#8217;s sales agent. Cantor may sell the Company&#8217;s common stock by any method permitted by law deemed
to be an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) of the Securities Act, including sales made directly on or
through the Nasdaq Capital Market or any other existing trade market for our common stock, in negotiated transactions at market prices
prevailing at the time of sale or at prices related to prevailing market prices, or any other method permitted by law. Cantor uses its
commercially reasonable efforts consistent with its normal trading and sales practices and applicable law and regulations to sell these
shares. The Company pays Cantor <span id="xdx_905_ecustom--PercentageOfGrossProceedOnSaleOfShares_pid_uPure_c20170305__20170306__us-gaap--FinancialInstrumentAxis__custom--SalesAgreementMember_zzzbtHM5gGMk" title="Percentage of gross proceeds on sale of shares">3.0</span>% of the aggregate gross proceeds from each sale of shares under the Sales Agreement. In addition,
the Company has also provided Cantor with customary indemnification rights.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
shares of the Company&#8217;s common stock sold under the Sales Agreement are sold and issued pursuant to the Registration Statement
on Form S-3 (File No. 333-250072) (the &#8220;Form S-3&#8221;), which was previously declared effective by the Securities and Exchange
Commission, and the related prospectus and one or more prospectus supplements.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is not obligated to make any sales of its common stock under the Sales Agreement. The offering of common stock pursuant to the
Sales Agreement will terminate upon the termination of the Sales Agreement as permitted therein. The Company and Cantor may each terminate
the Sales Agreement at any time upon ten days&#8217; prior notice.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, we had sold an aggregate of <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zFLwBGDdEs4e" title="Stock issued during period, shares, new issues">15,023,073</span> shares at a weighted-average sales price of $<span id="xdx_908_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zF5HJzr6DXX2" title="Shares issued, price per share">2.19</span> per share under the Sales
Agreement for aggregate gross proceeds of $<span id="xdx_907_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_z6ipZYcjzE86" title="Proceeds from issuance of common stock, gross">32.9</span> million and net proceeds of $31.7 million, after deducting sales agent commission and
discounts and our other offering costs. During the three months ended June 30, 2021, the Company did not sell any shares of our common
stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072). During the six months ended June 30, 2021, the
Company sold <span id="xdx_905_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__us-gaap--SubsidiarySaleOfStockAxis__custom--AtMarketOfferingMember_zie1VQsNJ05e" title="Stock issued during period, shares, new issues">1,811,238</span> shares of our common stock pursuant to the current Registration Statement on Form S-3 (File No. 333-250072) at
a weighted-average sales price of $<span id="xdx_909_eus-gaap--SharesIssuedPricePerShare_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_zrguVuJpBMZ6" title="Shares issued, price per share">1.95</span> per share, resulting in net proceeds of approximately $3.4 million under the Sales Agreement
which is net of $<span id="xdx_904_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_pp0p0" title="Proceeds from issuance of common stock">112,000</span> in expenses. During the three and six months ended June 30, 2020, the Company did not sell any shares of our
common stock pursuant to the prior Registration Statement on Form S-3 (File No. 333-220942). As of June 30, 2021, the Company had $<span id="xdx_904_ecustom--ProceedsFromIssuanceOfCommonStockGross_pn5n6_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--AccreditedInvestorsMember_z2fhijm6gRxh" title="Proceeds from issuance of common stock, gross">41.2</span>
million available for sale under the Sales Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(b)
Rights Agreement</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">On
November 13, 2015, the Company and American Stock Transfer &amp; Trust Company, LLC, as Rights Agent, entered into a Rights Agreement.
Also on November 12, 2015, the board of directors of the Company authorized and the Company declared a dividend of one preferred stock
purchase right (each a &#8220;Right&#8221; and collectively, the &#8220;Rights&#8221;) for each outstanding share of common stock of
the Company. The dividend was payable to stockholders of record as of the close of business on November 30, 2015 and entitles the registered
holder to purchase from the Company one one-thousandth of a fully paid non-assessable share of Series A Junior Participating Preferred
Stock of the Company at a price of $<span id="xdx_90E_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20151112__20151113_z76l5ygPZ052" title="Class of warrant or right, redemption price of warrants or rights">63.96</span> per one-thousandth share (the &#8220;Purchase Price&#8221;). The Rights will generally become
exercisable upon the earlier to occur of (i) 10 business days following a public announcement that a person or group of affiliated or
associated persons has become an Acquiring Person (as defined below) or (ii) 10 business days (or such later date as may be determined
by action of the board of directors prior to such time as any person or group of affiliated or associated persons becomes an Acquiring
Person) following the commencement of, or announcement of an intention to make, a tender offer or exchange offer the consummation of
which would result in the beneficial ownership by a person or group of 15% or more of the outstanding common stock of the Company. Except
in certain situations, a person or group of affiliated or associated persons becomes an &#8220;Acquiring Person&#8221; upon acquiring
beneficial ownership of 15% or more of the outstanding shares of common stock of the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">In
general, in the event a person becomes an Acquiring Person, then each Right not owned by such Acquiring Person will entitle its holder
to purchase from the Company, at the Right&#8217;s then current exercise price, in lieu of shares of Series A Junior Participating Preferred
Stock, common stock of the Company with a market value of twice the Purchase Price. In addition, if after any person has become an Acquiring
Person, (a) the Company is acquired in a merger or other business combination, or (b) 50% or more of the Company&#8217;s assets, or assets
accounting for 50% or more of its earning power, are sold, leased, exchanged or otherwise transferred (in one or more transactions),
proper provision shall be made so that each holder of a Right (other than the Acquiring Person, its affiliates and associates and certain
transferees thereof, whose Rights became void) shall thereafter have the right to purchase from the acquiring corporation, for the Purchase
Price, that number of shares of common stock of the acquiring corporation which at the time of such transaction would have a market value
of twice the Purchase Price.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.7pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company will be entitled to redeem the Rights at $<span id="xdx_900_ecustom--ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights_pid_uUSDPShares_c20210101__20210630_zQ3O4iENhhM9" title="Class of warrant or right, redemption price of warrants or rights">0.001</span> per Right at any time prior to the time an Acquiring Person becomes such. The
terms of the Rights are set forth in the Rights Agreement, which is summarized in the Company&#8217;s Current Report on Form 8-K dated
November 13, 2015. The rights plan was originally set to expire on November 12, 2018; however, on November 5, 2018 our Board of Directors
approved an Amended and Restated Rights Agreement pursuant to which the expiration date was extended to November 5, 2021, unless the
rights are earlier redeemed or exchanged by the Company.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(c)
Share-Based Payments</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company recognizes stock-based compensation expense for grants of stock option awards, restricted stock units and restricted stock under
the Company&#8217;s Incentive Plan to employees, nonemployees and nonemployee members of the Company&#8217;s board of directors based
on the grant-date fair value of those awards. The grant-date fair value of an award is generally recognized as compensation expense over
the award&#8217;s requisite service period. In addition, the Company has granted performance-based stock option awards and restricted
stock units, which vest based upon the Company satisfying certain performance conditions. Potential compensation cost, measured on the
grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options or units
will vest, which is based on whether the Company considers the performance conditions to be probable of attainment. The Company&#8217;s
estimates of the number of performance-based options or units that will vest will be revised, if necessary, in subsequent periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"/>&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company uses the Black-Scholes model to compute the estimated fair value of stock option awards. Using this model, fair value is calculated
based on assumptions with respect to (i) expected volatility of the Company&#8217;s common stock price, (ii) the periods of time over
which employees and members of the board of directors are expected to hold their options prior to exercise (expected term), (iii) expected
dividend yield on the Common Stock, and (iv) risk-free interest rates. Stock-based compensation expense also includes an estimate, which
is made at the time of grant, of the number of awards that are expected to be forfeited. This estimate is revised, if necessary, in subsequent
periods if actual forfeitures differ from those estimates. Stock-based compensation cost that has been expensed in the statements of
operations amounted to approximately $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210401__20210630_zW18lo2IIVz9" title="Allocated share-based compensation expense">147</span>,000 and $<span id="xdx_909_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200401__20200630_zw7mXSh8Vg9b">465</span>,000, respectively, for the three months ended June 30, 2021 and 2020, and amounted
to $<span id="xdx_906_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20210101__20210630_z1f570IcXqD2">294</span>,000 and $<span id="xdx_902_eus-gaap--AllocatedShareBasedCompensationExpense_pn3n3_c20200101__20200630_zQroveiqLwOh">787</span>,000, respectively, for the six months ended June 30, 2021 and 2020, and is allocated as follows:</span></p>

<p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLmIf86cXnic" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zTBJ1F1cgMLg" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 48.95pt; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zF8Nnry2PyU9" style="width: 10%; text-align: right" title="Allocated Share-based Compensation Expense">69,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWDpZeOg2EEc" style="width: 10%; text-align: right">199,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRKTDCTA07E6" style="width: 10%; text-align: right">136,369</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgm0rPZL3m16" style="width: 10%; text-align: right">334,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTbIMjkqgqc" style="border-bottom: Black 1.5pt solid; text-align: right">77,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zABAm4CjHjAi" style="border-bottom: Black 1.5pt solid; text-align: right">265,281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgqhrLRgq0si" style="border-bottom: Black 1.5pt solid; text-align: right">157,944</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zonanIsgmPa7" style="border-bottom: Black 1.5pt solid; text-align: right">452,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Allocated
    Share-based Compensation Expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_zdJtDHK6Qsx6" style="border-bottom: Black 2.5pt double; text-align: right">146,747</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_zc5IX2x1QfK5" style="border-bottom: Black 2.5pt double; text-align: right">465,058</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_zD87BeQzAEr1" style="border-bottom: Black 2.5pt double; text-align: right">294,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_zt6tr7toSVtl" style="border-bottom: Black 2.5pt double; text-align: right">786,971</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<p id="xdx_8A3_zeZv2xiL6zX2" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company issued <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIOZRETbdzzl" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">66,000</span> stock options and <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGY7HOxfEbw3" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">376,000</span> stock options, respectively, during the three and six months ended June 30, 2021 and
issued <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNpwvwMdPyrj" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">113,000</span> and <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pp0d_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zpxgyen6yLai" title="Share-based compensation arrangement by share-based payment award, options, grants in period, gross">739,000</span> stock options during the three and six months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">Key
assumptions used in the determination of the fair value of stock options granted are as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Term</i>: The expected term represents the period that the stock-based awards are expected to be outstanding. Due to limited historical
experience of similar awards, the expected term was estimated using the simplified method in accordance with the provisions of Staff
Accounting Bulletin (&#8220;SAB&#8221;) No. 107, <i>Share-Based Payment,</i> for awards with stated or implied service periods. The simplified
method defines the expected term as the average of the contractual term and the vesting period of the stock option. For awards with performance
conditions, and that have the contractual term to satisfy the performance condition, the contractual term was used.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Risk-Free
Interest Rate</i>: The risk-free interest rate used was based on the implied yield currently available on U.S. Treasury issues with an
equivalent remaining term.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Dividend</i>: The expected dividend assumption is based on management&#8217;s current expectation about the Company&#8217;s anticipated
dividend policy. The Company does not anticipate declaring dividends in the foreseeable future.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>&#160;</i></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><i>Expected
Volatility</i>: The volatility factor is based solely on the Company&#8217;s trading history.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">For
options granted during the six months ended June 30, 2021 and 2020, the Company calculated the fair value of each option grant on the
respective dates of grant using the following weighted average assumptions:</span></p>

<p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwmpvSuawot1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zgecfC0mfGQd" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210630_zmDJMKFGsSW8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20200630_zW7zEcE5d5k9" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zlLije1vKWVg" title="Expected term">5.70</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630_zxoJsHRWHrkj" title="Expected term">5.81</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zcJlPuXYgIZh" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">0.52</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">1.33</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zvXnDLRRuXS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95.52</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99.52</td><td style="text-align: left">%</td></tr>
  </table>

<p id="xdx_8A2_zgtdnN0Mb3S1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">FASB
ASC 718, <i>Stock Compensation,</i> requires the Company to recognize compensation expense for the portion of options that are expected
to vest. Therefore, the Company applied estimated forfeiture rates that were derived from historical employee termination behavior. If
the actual number of forfeitures differs from those estimated by management, additional adjustments to compensation expense may be required
in future periods.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, there was $<span id="xdx_906_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20210630_z3LIhw34OZU4" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized">1.1</span> million of total unrecognized compensation cost related to unvested share-based compensation arrangements
granted under the Company&#8217;s stock option plan. That cost is expected to be recognized over a weighted average period of <span id="xdx_903_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20210101__20210630_zqNbaQGCgRJd" title="Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition">2.21</span> years
and will be adjusted for subsequent changes in estimated forfeitures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(d)
Stock Option Plan</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
April 2014, the board of directors adopted the 2014 Stock and Incentive Plan (&#8220;2014 Plan&#8221;) subject to shareholder approval
which was received in June 2014. The 2014 Plan provides for the granting of nonqualified and incentive stock options, stock appreciation
rights, restricted stock units, restricted stock and dividend equivalents. An aggregate of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20140430__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,000,000</span> shares were authorized for issuance
under the 2014 Plan. Additionally, <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20140430__us-gaap--AwardTypeAxis__custom--EquityIncentivePlanMember_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">271,906</span> remaining authorized shares under the 2011 Equity Incentive Plan (&#8220;2011 Plan&#8221;)
were issuable under the 2014 Plan at the time of the 2014 Plan adoption. Upon receiving shareholder approval in June 2016, the 2014 Plan
was amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted
under the 2014 Plan from <span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">1,271,906</span> to <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20160630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">2,471,906</span>. Additionally, upon receiving shareholder approval in June 2018, the 2014 Plan was further
amended and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under
the 2014 Plan from <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">2,471,906</span> to <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20180630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">3,221,906</span>. Finally, upon receiving shareholder approval in June 2020, the 2014 Plan was further amended
and restated to increase the authorized number of shares of common stock of the Company issuable under all awards granted under the 2014
Plan from <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MinimumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">3,221,906</span> to <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_c20200630__srt--RangeAxis__srt--MaximumMember__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">5,721,906</span>. The board of directors, on an option-by-option basis, determines the number of shares, exercise price,
term, and vesting period for options granted. Options granted generally have a <span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dxL_c20210101__20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zKndHewrps2l" title="Contractual life::XDX::P10Y"><span style="-sec-ix-hidden: xdx2ixbrl1148">ten</span></span>-year contractual life. The Company issues shares of
common stock upon the exercise of options with the source of those shares of common stock being either newly issued shares or shares
held in treasury. An aggregate of <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_iI_pp0d_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_zvJRZema1pe7" title="Share-based compensation arrangement by share-based payment award, number of shares authorized">5,721,906</span> shares are authorized for issuance under the 2014 Plan, with <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_c20210630__us-gaap--AwardTypeAxis__custom--StockIncentivePlan2014Member_pp0d" title="Share-based compensation arrangement by share-based payment award, number of shares available for grant">1,584,874</span> shares remaining available
for grant as of June 30, 2021.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY50Qz52B1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zponXz4ot0Ui" style="display: none">Schedule of Stock Option Activity</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding stock options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zLwTwd2zLfh7" style="width: 17%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)">3,564,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4uEsg0iVKM9" style="width: 25%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)">3.36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zx2A1aNSMa4c" style="text-align: right" title="Number of shares, Options granted (in shares)">376,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIuzppetXTx5" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)">1.44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqElCoELOdTa" style="text-align: right" title="Number of shares, Options exercised (in shares)">(4,584</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zEKKE1j0p4Fi" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKOPcUjH6b71" style="text-align: right" title="Number of shares, Options forfeited (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFy5JTxVWtj" style="text-align: right" title="Number of shares, Options cancelled (in shares)">(20,084</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zkiISkgOEuv3" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)">6.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zw9KMa1wqCPj" style="text-align: right" title="Number of shares, Balance at end of the period (in shares)">3,915,790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zRy9gaViWFUb" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)">3.16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGBFslhK1UUa" style="text-align: right" title="Number of shares, Options exercisable (in shares)">2,528,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl7VB44qqrA7" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)">4.24</td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AD_zO02laWGFiP8" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zbN5aK9liofg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z9gHRxkwNHWh" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number exerciseable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 10%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zYu9Fjg4nOYe" style="text-align: right" title="Number of options outstanding, shares">3,915,790</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zNNMiMxLBh05" title="Options outstanding, Weighted average remaining contractual life (Years)">6.39</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_z1nqIaCWFF4k" style="text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)">3.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0" style="text-align: right" title="Options outstanding, Aggregate intrinsic value">636,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20210630_z83YayXslyP7" style="text-align: right" title="Number of options exercisable">2,528,729</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_z0V2SHtTusWa" title="Options exercisable, Weighted average remaining contractual life (Years)">4.84</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_zkC9ca7vZgGc" title="Options exercisable, Weighted average exercise price">4.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630_pp0p0" title="Options exercisable, Aggregate intrinsic value">311,190</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8AF_zLFHVuLecOIg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
intrinsic value for stock options is defined as the difference between the current market value and the exercise price. There were <span id="xdx_90C_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210401__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zwbS4AjMonLl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">zero
</span></span><span style="font: 10pt Times New Roman, Times, Serif">and <span id="xdx_908_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zjv5INWO2DWl" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">4,584</span></span><span style="font: 10pt Times New Roman, Times, Serif">,
respectively, stock options exercised during the three and six months ended June 30, 2021, and <span id="xdx_903_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200401__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zNY6RxuqMC0f" title="Share-based compensation arrangement by share-based payment award, options, exercises in period"><span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pp0d_do_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zBGMUeeHZWr1" title="Share-based compensation arrangement by share-based payment award, options, exercises in period">no</span>
</span></span><span style="font: 10pt Times New Roman, Times, Serif">stock options exercised during the three and
six months ended June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>(e)
Common Stock Warrants</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
Company accounts for its common stock warrants under ASC 480, <i>Distinguishing Liabilities from Equity</i>, which requires any
financial instrument, other than an outstanding share, that, at inception, embodies an obligation to repurchase the issuer&#8217;s
equity shares, or is indexed to such an obligation, and requires or may require the issuer to settle the obligation by transferring
assets, to be classified as a liability. In accordance with ASC 480, the Company&#8217;s outstanding warrants from the November 2019
Offering are classified as a liability. The liability is adjusted to fair value at each reporting period, with the changes in fair
value recognized as gain (loss) on change in fair value of warrant liability in the Company&#8217;s consolidated statements of
operations. The warrants issued in the November 2019 Offering allow the warrant holder, if certain change in control events occur,
the option to receive an amount of cash equal to the value of the warrants as determined in accordance with the Black-Scholes option
pricing model with certain defined assumptions upon a fundamental transaction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
of June 30, 2021, the Company had <span id="xdx_90D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_pp0d" title="Warrants outstanding">1,094,030</span> common stock warrants outstanding from the November 2019 Offering to purchase an equal number
of shares of common stock. The fair value of these warrants on June 30, 2021 and on December 31, 2020 was determined using the Black-Scholes
option pricing model with the following Level 3 inputs (as defined in the November 2019 Offering):</span></p>

<p id="xdx_891_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zyFENORiDsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zp3NCmSqWXbk" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Expected life in years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z09NG5MkR0Eg" title="Expected life in years">3.38</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYqGocmKiMe" title="Expected life in years">3.88</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf5RGxpsBjDk" style="text-align: right">0.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVDPwmuU1Je" style="text-align: right">0.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNZLkp6Is9a" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOwQqz8wAW9j" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcOGy88fz0c" style="text-align: right">72.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFK1yzVh9NMg" style="text-align: right">88.46</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwaZkYUGnL6c" style="text-align: right">1.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6vyfjDH9hj5" style="text-align: right">1.36</td><td style="text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8A9_zWbRIeQjF1Jg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and six months ended June 30, 2021, the Company recorded a non-cash gain of $<span id="xdx_90E_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210401__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zs6NnteTNPil" title="Fair value adjustment of warrants">221,000</span> and $<span id="xdx_900_eus-gaap--FairValueAdjustmentOfWarrants_pp0p0_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zHYhVOSzjJK9" title="Fair value adjustment of warrants"><span>26,000</span></span>, respectively, from the change
in fair value of the November 2019 Offering warrants. During the three and six months ended June 30, 2020, the Company recorded a non-cash
loss of $<span id="xdx_901_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200401__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zWkKNHYUXju9" title="Fair value adjustment of warrants">2.1</span> million and $<span id="xdx_90C_eus-gaap--FairValueAdjustmentOfWarrants_pn5n6_c20200101__20200630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember_zDVtFQDKo2Re" title="Fair value adjustment of warrants">3.2</span> million from the change in fair value of the November 2019 Offering warrants. The following table is a
reconciliation of the warrant liability measured at fair value using level 3 inputs:</span></p>

<p id="xdx_89F_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zBrfZqVXUHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zbtPMe30hS83" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zAASvD6PZTY4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zRhOtC0TMVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,170,051</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Settlement of liability on warrant exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,365</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Change in fair value of common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,257</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,125,429</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p id="xdx_8A4_z0FpmroS8r9i" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">Additionally,
in the February 2020 Offering, the Company issued <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--February2020OfferingMember_pp0d" title="Issued">5,042,017</span> common stock warrants, however, because these warrants do not provide the
warrant holder the option to put the warrant back to the Company, the warrants are classified as equity.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SONOWOAWAE-MPE_znLjgJKxw7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span id="xdx_8B8_zWLYDtd7Grbl" style="display: none">Schedule
of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">Outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmDTWqWwmmah" style="width: 20%; text-align: right" title="Number of shares, Balance at beginning of the period">1,944,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEGxKHoNM9i" style="width: 25%; text-align: right" title="Weighted average Exercise Price, Beginning of the period">0.51</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5j3hk4Nhjj3" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XX0Wv7TZab" style="text-align: right" title="Exercised">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sIBrNn3Gu2" style="text-align: right" title="Exercised">0.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9lDr6uZ8Y3" style="text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezwjN9XJ1Hl" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPh0HtUZNjKe" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lJBS67disk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: center">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSfdtI9MEUEh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at ending of the period">1,934,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTPT1VA2txc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average Exercise Price, Ending of the period">0.51</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


<p id="xdx_8AB_z9WE8xG13hB7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">During
the three and six months ended June 30, 2021, <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_dc_uShares_c20210401__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zXVW4WwLGkw9">zero</span> and <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_pid_uShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvSbpYrAhALa" title="Common warrants to purchase share of our common stock">10,000</span> common stock warrants to purchase one share of our common stock were exercised,
respectively, resulting in proceeds of <span id="xdx_902_eus-gaap--ProceedsFromWarrantExercises_pp0p0_dc_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zRxq1tOOwQ8">zero</span> and $<span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zIwxgUEBQx87" title="Proceeds from exercise of warrants">5,000</span>. Additionally, during the three and six months ended June 30, 2020, <span id="xdx_904_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200401__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zPq1vIEGwFbl" title="Proceeds from exercise of warrants">13,497,807</span>
and <span id="xdx_901_eus-gaap--ProceedsFromWarrantExercises_pp0p0_c20200101__20200630__us-gaap--StatementEquityComponentsAxis__custom--CommonStockWarrantMember_zgcno4EZRawf" title="Proceeds from exercise of warrants">13,618,807</span> common stock warrants to purchase one share of our common stock were exercised, respectively, resulting in proceeds of
approximately $<span id="xdx_90F_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200401__20200630_zRsMVpzsux24"><span id="xdx_90D_eus-gaap--ProceedsFromWarrantExercises_pn5n6_c20200101__20200630_z7nwWLCkWVSh">6.9</span></span> million in each of the three and six-month periods ending June 30, 2020.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C00_gL3SONOWOAWAE-MPE_zF7xBcdU6fC9">The
following table summarizes information about common stock warrants outstanding at June 30, 2021:</span></span></p>

<div id="xdx_C03_gL3SONOWOAWAE-MPE_zTx5vU2ZE725"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zeLvIOq7pmD3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt" summary="xdx: Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Warrants outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Number exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average remaining contractual life (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average exercise price</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Aggregate intrinsic value</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 26%"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 22%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUsDS15dVYd" style="text-align: right" title="Number of warrants exercisable, shares"><span>1,934,366</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>&#160;</span></td><td style="text-align: right"><span><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQExU5rxjy3g" title="Weighted average remaining contractual life">3.50</span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zntgohBvSxsk" style="text-align: right" title="Weighted average exercise price, per share"><span><span title="Weighted average Exercise Price, Ending of the period">0.51</span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlX259qtjsIg" style="text-align: right" title="Aggregate intrinsic value"><span>1,715,719</span></td><td style="text-align: left"><span>&#160;</span></td></tr>
  </table>

</div><p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_C09_gL3SONOWOAWAE-MPE_z7UxHFC1QoY4">&#160;</span></span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046867816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p id="xdx_80E_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zJ2XWsTWguH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(10)
<span id="xdx_82A_z1vdK7tZE0Y4">Commitments and Contingencies</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Litigation</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">The
Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting
business. The Company records a liability when a particular contingency is probable and estimable.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
April 2, 2019, the Company filed a lawsuit against Clarus in the United States District Court for the District of Delaware alleging that
Clarus&#8217;s JATENZO&#174; product infringes six of Lipocine&#8217;s issued U.S. patents: 9,034,858; 9,205,057; 9,480,690; 9,757,390;
6,569,463; and 6,923,988. However on February 11, 2020, the Company voluntarily dismissed allegations of patent infringement for expired
U.S. Patent Nos. 6,569,463 and 6,923,988 in an effort to streamline the issues and associated costs for dispute. Clarus has answered
the complaint and asserted counterclaims of non-infringement, inequitable conduct and invalidity. The Company answered Clarus&#8217;s
counterclaims on April 29, 2019. The Court held a scheduling conference on August 15, 2019, a claim construction hearing on February
11, 2020 and a Summary Judgement Hearing on January 15, 2021. In May 2021, the Court granted Clarus&#8217; motion for Summary Judgment,
finding the asserted claims of Lipocine&#8217;s U.S. patents 9,034,858; 9,205,057; 9,480,690; and 9,757,390 invalid for failure to satisfy
the written description requirement of 35 U.S.C. &#167; 112. Clarus still had remaining counterclaims before the Court. On July 13, 2021,
Clarus and the Company entered into a global settlement agreement (&#8220;Global Agreement&#8217;) which resolved all outstanding claims
of this litigation as well as the on-going United States Patent and Trademark Office (&#8220;USPTO&#8221;) Interference No. 106,128 between
the parties. Under the terms of the Global Agreement, the Company agreed to pay Clarus $<span id="xdx_900_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember_znAXOqCrqB0d" title="Litigation settlement">4.0</span> million payable as follows: $<span id="xdx_90A_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20190401__20190402__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember_z22uHYa8BcH" title="Litigation settlement">2.5</span> million
immediately, $<span id="xdx_902_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_pn5n6_c20220712__20220713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_zsmNIE49vZs7" title="Litigation settlement">1.0</span> million on July 13, 2022 and $<span id="xdx_907_eus-gaap--LitigationSettlementAmountAwardedToOtherParty_c20230712__20230713__us-gaap--TypeOfArrangementAxis__custom--GlobalAgreementMember__dei--LegalEntityAxis__custom--ClarusTherapeuticsIncMember__srt--StatementScenarioAxis__srt--ScenarioForecastMember_pp0p0" title="Litigation settlement">500,000</span> on July 13, 2023. No future royalties are owing from either party. On July 15,
2021, the Court dismissed with prejudice the Company&#8217;s claims and Clarus&#8217; counterclaims.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
November 14, 2019, the Company and certain of its officers were named as defendants in a purported shareholder class action lawsuit,
<i>Solomon Abady v. Lipocine Inc. et al</i>., 2:19-cv-00906-PMW, filed in the United District Court for the District of Utah. The complaint
alleges that the defendants made false and/or misleading statements and/or failed to disclose that our filing of the NDA for TLANDO to
the FDA contained deficiencies and as a result the defendants&#8217; statements about our business and operations were false and misleading
and/or lacked a reasonable basis in violation of federal securities laws. The lawsuit seeks certification as a class action (for a purported
class of purchasers of the Company&#8217;s securities from March 27, 2019 through November 8, 2019), compensatory damages in an unspecified
amount, and unspecified equitable or injunctive relief. The Company has insurance that covers claims of this nature. The retention amount
payable by the Company under our policy is $<span id="xdx_900_eus-gaap--RetentionPayable_iI_pn4n6_c20191114_zjL5vveK3R6h" title="Retention payable">1.25</span> million. The Company filed a motion to dismiss the class action lawsuit on July 24,
2020. In response, the plaintiffs filed their response to the motion to dismiss the class action lawsuit on September 22, 2020 and the
Company filed its reply to its motion to dismiss on October 22, 2020. The Company intends to vigorously defend itself against these allegations
and has not recorded a liability related to this shareholder class action lawsuit as the outcome is not probable nor can an estimate
be made of loss, if any.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
March 13, 2020, the Company filed U.S. patent application serial number 16/818,779 (&#8220;the Lipocine &#8216;779 Application&#8221;)
with the USPTO. On October 16 and November 3, 2020, Lipocine filed suggestions for interference with the USPTO requesting that a patent
interference be declared between the Lipocine &#8216;779 Application and US patent application serial number 16/656,178 to Clarus Therapeutics,
Inc. (&#8220;the Clarus &#8216;178 Application&#8221;). Pursuant to the Company&#8217;s request, the Patent Trial and Appeal Board (&#8220;PTAB&#8221;)
at the USPTO declared the interference on January 4, 2021 to ultimately determine, as between the Company and Clarus, who is entitled
to the claimed subject matter. The interference number is 106,128, and the Company was initially declared Senior Party. A conference
call with the PTAB was held on January 25, 2021 to discuss proposed motions. On February 1, 2021, the PTAB issued an order authorizing
certain motions and setting the schedule for the preliminary motions phase. On July 13, 2021, Clarus and the Company entered into the
Global Agreement to resolve interference No. 106,128 among other items. On July 26, 2021, the PTAB granted the Company&#8217;s request
for adverse judgment in interference No. 106,128 in accordance with the Global Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>




<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Guarantees
and Indemnifications</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>&#160;</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">In
the ordinary course of business, the Company enters into agreements, such as lease agreements, licensing agreements, clinical trial agreements,
and certain services agreements, containing standard guarantee and / or indemnification provisions. Additionally, the Company has indemnified
its directors and officers to the maximum extent permitted under the laws of the State of Delaware.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046963816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Agreement with Spriaso, LLC<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Agreement with Spriaso, LLC</a></td>
<td class="text"><p id="xdx_808_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_z3CfOZnXV6F3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(11)
<span id="xdx_824_zJW5cwyEu5ee">Agreement with Spriaso, LLC</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">On
July 23, 2013, the Company entered into an assignment/license and a services agreement with Spriaso, a related-party that is majority-owned
by certain current and former directors of Lipocine Inc. and their affiliates. Under the license agreement, the Company assigned and
transferred to Spriaso all of the Company&#8217;s rights, title and interest in its intellectual property to develop products for the
cough and cold field. In addition, Spriaso received all rights and obligations under the Company&#8217;s product development agreement
with a third-party. In exchange, the Company will receive a royalty of <span id="xdx_902_ecustom--PercentageOfRoyalty_pid_dp_uPure_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zPJSXkktasVe" title="Percentage of royalty">20</span> percent of the net proceeds received by Spriaso, up to a maximum
of $<span id="xdx_903_eus-gaap--ProceedsFromContributionsFromAffiliates_pn5n6_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--LicenseAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zvEAUNWU2s6h" title="Proceeds from affiliates">10.0</span> million. Spriaso also granted back to the Company an exclusive license to such intellectual property to develop products outside
of the cough and cold field. <span id="xdx_901_ecustom--AgreementDescription_c20130722__20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember" title="Agreement description">Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain
employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an
amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain
employees to Spriaso at a rate of $<span id="xdx_903_eus-gaap--EmployeeRelatedLiabilitiesCurrentAndNoncurrent_iI_pp0p0_c20130723__us-gaap--TypeOfArrangementAxis__custom--ServiceAgreementMember__dei--LegalEntityAxis__custom--SpriasoLLCMember_zmxMROTlQsc8" title="Employee related liabilities">230</span>/hour for a period of six months.</span> The agreement was further amended on July 23, 2015, on January
23, 2016, on July 23, 2016, on January 23, 2017, on July 23, 2017, on January 23, 2018, on July 23, 2018 and again on January 23, 2019
to extend the term of the agreement for an additional six months. The agreement was further amended on July 23, 2019 and again on July
23, 2020 to extend the term of the agreement for an additional twelve months. The agreement may be extended upon written agreement of
Spriaso and the Company. The Company did not receive any reimbursements during the three and six months ended June 30, 2021 and 2020,
respectively. Spriaso filed its first NDA and as an affiliated entity of the Company, it used up the one-time waiver for user fees for
a small business submitting its first human drug application to the FDA. Spriaso is considered a variable interest entity under the FASB
ASC Topic 810-10, <i>Consolidations</i>, however the Company is not the primary beneficiary and has therefore not consolidated Spriaso.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050848968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Recent Accounting Pronouncements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p id="xdx_80C_eus-gaap--NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_zdKyzGwsOKc7" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>(12)
<span id="xdx_827_zWAE3dhkISEb">Recent Accounting Pronouncements</span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.45pt; text-indent: -24.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><b><i>Accounting
Pronouncements Issued Not Yet Adopted</i></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif; color: #212529">In
2016, the FASB issued </span><span style="font: 10pt Times New Roman, Times, Serif">Accounting Standards Update (&#8220;ASU&#8221;)
<span style="color: #212529">2016-13, <i>Measurement of Credit Losses on Financial Instruments </i>(&#8220;ASU 2016-13&#8221;). This
standard replaces the incurred loss impairment methodology in current GAAP with a methodology that reflects expected credit losses on
instruments within its scope, including trade receivables, and requires entities to measure all expected credit losses for financial
assets held at the reporting date based on historical experience, current conditions and reasonable and supportable forecasts. The original
effective date for ASU 2016-13 was for annual and interim periods beginning after December 15, 2019.</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-align: justify; color: #212529"><span style="font: 10pt Times New Roman, Times, Serif">However,
in October 2019, the FASB issued ASU 2019-10, <i>Financial Instruments - Credit Losses, Derivatives and Hedging, and Leases: Effective
Dates</i>, which deferred the effective date of ASU 2016-13 for certain entities, including those that are eligible to be smaller reporting
companies<i>.</i> A company&#8217;s determination about whether it is eligible for the deferral is a one-time assessment as of November
15, 2019 based on its most recent determination of its small reporting company eligibility as of the last business day of the most recently
completed second quarter. Based on this determination, the Company qualifies as a smaller reporting entity and is therefore eligible
for the deferral of adoption of ASU 2016-13, resulting in a new effective date of January 1, 2023. The Company has historically not had
credit losses on financial instruments and is currently evaluating the impact the adoption of ASU 2016-13 will have on its consolidated
financial statements.</span></p>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -URI http://asc.fasb.org/topic&amp;trid=2122394<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=SL108384541-122693<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (i)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124402435&amp;loc=SL124402458-218513<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=123338486&amp;loc=SL49131195-203048<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038215&amp;loc=d3e31137-122693<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120154821&amp;loc=SL120154904-197079<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123597120&amp;loc=SL121967933-165497<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122150657&amp;loc=SL122150809-237846<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (c)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045009512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings (Loss) per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</a></td>
<td class="text"><p id="xdx_898_eus-gaap--ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_zFklzRIFvkA6" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table sets forth the computation of basic and diluted earnings (loss) per share of common stock for the three and six months
ended June 30, 2021 and 2020:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BB_zEGLUH0xIVKg" style="display: none">Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; white-space: nowrap; text-align: center; font-weight: bold">Three Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Six Months Ended June 30,</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font-weight: bold; text-align: left">Basic loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; width: 44%; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(6,809,041</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(6,369,634</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(10,177,123</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 2.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--NetIncomeLossAvailableToCommonStockholdersBasic_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; width: 10%; text-align: right" title="Net loss">(12,140,285</td><td style="padding-bottom: 2.5pt; width: 1%; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_987_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">88,290,650</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">49,769,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_984_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">85,556,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_982_eus-gaap--WeightedAverageNumberOfSharesOutstandingBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">45,558,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Basic loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareBasic_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--EarningsPerShareBasic_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--EarningsPerShareBasic_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--EarningsPerShareBasic_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Basic loss per share attributable to common stock">(0.27</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="font-weight: bold; text-align: left">Diluted loss per share attributable to common stock:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Numerator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left">Net loss</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210401__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(6,809,041</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200401__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(6,369,634</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20210101__20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(10,177,123</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--NetIncomeLossAvailableToCommonStockholdersDiluted_c20200101__20200630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Net loss">(12,140,285</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt">Denominator</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt">Weighted avg. common shares outstanding</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">88,290,650</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">49,769,253</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98D_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">85,556,110</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--WeightedAverageNumberOfDilutedSharesOutstanding_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted avg. common shares outstanding">45,558,442</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left">Diluted loss per share attributable to common stock</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--EarningsPerShareDiluted_c20210401__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.08</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_988_eus-gaap--EarningsPerShareDiluted_c20200401__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.13</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--EarningsPerShareDiluted_c20210101__20210630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.12</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--EarningsPerShareDiluted_c20200101__20200630_pdd" style="border-bottom: Black 2.5pt double; text-align: right" title="Diluted loss per share attributable to common stock">(0.27</td><td style="padding-bottom: 2.5pt; text-align: left">)</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><p id="xdx_892_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zgUzANzH4zb7" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
computation of diluted loss per share for the six months ended June 30, 2021 and 2020 does not include the following stock options and
warrants to purchase shares or unvested restricted stock units in the computation of diluted loss per share because these instruments
were antidilutive:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zF1rtWgD3N2" style="display: none">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 85%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30,</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 64%; text-align: left">Stock options</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,915,790</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--OptionIndexedToIssuersEquityEquityAxis__us-gaap--EmployeeStockOptionMember_pdd" style="width: 14%; text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,012,041</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Unvested restricted stock units</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_zJp5UKSV93Ec" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"><span style="-sec-ix-hidden: xdx2ixbrl0791">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--AwardTypeAxis__custom--UnvestedRestrictedStockUnitsMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">605,682</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Warrants</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20210101__20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">1,934,366</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_c20200101__20200630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount">3,423,210</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045026744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Securities</a></td>
<td class="text"><p id="xdx_899_eus-gaap--DebtSecuritiesAvailableForSaleTableTextBlock_zCqDFj7M3vK3" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8BB_zKMnjojBKDl5" style="display: none">Schedule of Available-for-Sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="text-align: center; margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="text-align: center; margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Corporate bonds, notes and commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98A_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost">35,672,245</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0805">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zst3WqwmDm4i" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses">(186</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">)</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__custom--CorporateBondsNotesAndCommercialPaperMember_zLlkTmW4Idgj" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right">35,672,059</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">35,672,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0812">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20210630_zAi4Bj0aoh87" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding losses">(186</td><td style="padding-bottom: 2.5pt; text-align: left">)</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">gains</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Gross</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">unrealized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">holding</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">losses</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 44%; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Amortized Cost">449,992</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0820">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_zmxd8v90C1W1" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Gross unrealized holding losses"><span style="-sec-ix-hidden: xdx2ixbrl0822">-</span></td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; width: 10%; text-align: right" title="Aggregate fair value">449,992</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AvailableForSaleDebtSecuritiesAmortizedCostBasis_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Amortized Cost">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross unrealized holding gains"><span style="-sec-ix-hidden: xdx2ixbrl0828">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_iNI_pp0p0_di_c20201231_zPbrHA3pBLta" style="border-bottom: Black 2.5pt double; text-align: right">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;<span style="-sec-ix-hidden: xdx2ixbrl0829">&#160;</span>-</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtSecurities_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Aggregate fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</a></td>
<td class="text"><p id="xdx_891_eus-gaap--InvestmentsClassifiedByContractualMaturityDateTableTextBlock_zn0nVmjl1fa9" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 13.5pt; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B8_zzdYpf7yemTk" style="display: none">Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Amortized</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Cost</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><p style="margin-top: 0; margin-bottom: 0">Aggregate</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">fair value</p></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; width: 60%; text-align: left">Due within one year</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_iI_pp0p0_c20210630_znVIirmXF7Ei" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year">35,672,245</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_c20210630_pp0p0" style="border-bottom: Black 1.5pt solid; width: 16%; text-align: right" title="Due within one year">35,672,059</td><td style="padding-bottom: 1.5pt; width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_iI_pp0p0_c20210630_zJ8B4Bhi0one" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, amortized cost">35,672,245</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_eus-gaap--AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_iI_pp0p0_c20210630_zasMMEuy9VW3" style="border-bottom: Black 2.5pt double; text-align: right" title="Total maturities of debt securities classified as available-for-sale securities, fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045068984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Fair Value, Assets Measured on Recurring Basis</a></td>
<td class="text"><p id="xdx_89D_eus-gaap--FairValueAssetsMeasuredOnRecurringBasisTextBlock_zsBKdAnZU4a9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 60pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BA_zrUBVqzHxtQc" style="display: none">Schedule of Fair Value, Assets Measured on Recurring Basis</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">10,179,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">10,179,073</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0875">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0877">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; text-align: left">Commercial Paper</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="text-align: right" title="Assets, fair value">13,987,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0881">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="text-align: right" title="Assets, fair value">13,987,623</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0885">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Corporate bonds and notes</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember_zgtLYI7LEiDl" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">21,684,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zeJC3drlne3i" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0889">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zbtmpRH0yD3a" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">21,684,436</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--CorporateDebtSecuritiesMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvXAm5ktI2gf" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0893">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20210630_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">45,851,132</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">10,179,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_989_eus-gaap--AssetsFairValueDisclosure_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0901">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_z8jtsVdOssfj" style="border-bottom: Black 1.5pt solid; text-align: right">1,125,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zzUYEB4ZuPl2" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0903">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_989_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zRwp7qyph7Mb" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0904">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zdMb09hfXwQ" style="border-bottom: Black 1.5pt solid; text-align: right">1,125,429</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630_zDJW2QD4mtOb" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">46,976,561</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_z394n7Gf8Kc" style="border-bottom: Black 2.5pt double; text-align: right">10,179,073</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_zK2SoRNz2Wd1" style="border-bottom: Black 2.5pt double; text-align: right">35,672,059</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20210630__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zgZ8Bucc3v9j" style="border-bottom: Black 2.5pt double; text-align: right">1,125,429</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="10" style="border-bottom: Black 1.5pt solid; font-weight: bold">Fair value measurements at reporting date using</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; white-space: nowrap; font-weight: bold">December 31, 2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 1 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 2 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold">Level 3 inputs</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Assets:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 36%; text-align: left">Cash equivalents - money market funds</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">18,399,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value">18,399,585</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0916">-</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_986_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--MoneyMarketFundsMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="width: 12%; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0918">-</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Commercial paper</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0922">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--CashAndCashEquivalentsAxis__us-gaap--CommercialPaperMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0926">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_981_eus-gaap--AssetsFairValueDisclosure_c20201231_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">18,849,577</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">18,399,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_984_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--AssetsFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Assets, fair value"><span style="-sec-ix-hidden: xdx2ixbrl0934">-</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Liabilities:</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Warrant liability</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember_pp0p0" style="border-bottom: Black 1.5pt solid; text-align: right">1,170,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_986_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_zJHVG9AW6Uu9" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0936">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_z9hoR9TLBpVf" style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FinancialInstrumentAxis__us-gaap--WarrantMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zE6Z3F33HOb8" style="border-bottom: Black 1.5pt solid; text-align: right">1,170,051</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_985_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231_z7MtH1P16mO3" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">20,019,628</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel1Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">18,399,585</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98E_eus-gaap--LiabilitiesFairValueDisclosure_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel2Member_pp0p0" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">449,992</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_987_eus-gaap--LiabilitiesFairValueDisclosure_iI_pp0p0_c20201231__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member_zvrtQbFL3ta6" style="border-bottom: Black 2.5pt double; text-align: right" title="Liabilities, fair value">1,170,051</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046867816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Debt</a></td>
<td class="text"><p id="xdx_895_eus-gaap--ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_z1SZVfVzWFbi" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BE_z6RFgppwRNJ1" style="display: none">Schedule of Maturities of Debt</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_495_20210630_zPqWdHIQ0u18" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold">Years Ending December 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Amount</p>
                                                                  <p style="margin-top: 0; margin-bottom: 0">(in thousands)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_40E_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_iI_pn3n3_maLTDzdw8_zsgvcvVvWvpi" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">1,666</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40D_eus-gaap--LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_iI_pn3n3_maLTDzdw8_zRO4famUECu" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">2022</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">1,667</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40B_ecustom--LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths_iI_pn3n3_maLTDzdw8_zvcuXlIsdiNb" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Thereafter</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0995">&#8212;</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr id="xdx_400_eus-gaap--LongTermDebt_iTI_pn3n3_mtLTDzdw8_ztFsB8fyqitf" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Long-term
    Debt</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,333</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316045091080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><p id="xdx_89C_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_zUfUMlUBOOp4" style="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">Future
minimum lease payments under non-cancelable operating leases as of June 30, 2021 are:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zrEM2MWZVo35" style="display: none">Schedule of Future Minimum Rental Payments for Operating Leases</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 65%; margin-left: 0.75in">
  <tr style="display: none; vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" id="xdx_49E_20210630_zFppP7jvIsE3" style="text-align: center; font-weight: bold">&#160;</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="text-align: left">&#160;</td><td>&#160;</td>
    <td colspan="2" style="text-align: center; font-weight: bold">Operating</td><td style="font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">leases</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Year ending December 31:</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr id="xdx_401_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_pp0p0_maLOLLPzsoZ_zB8frL0bvIue" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; width: 80%; text-align: left">2021</td><td style="width: 2%; text-align: left">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 16%; text-align: right">165,191</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_pp0p0_maLOLLPzsoZ_zUbrtUbBqKTf" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 1.5pt; padding-left: 10pt; text-align: left">2022</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">55,064</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">&#160;</td><td style="text-align: left">&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_407_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_pp0p0_mtLOLLPzsoZ_zERVpyKDdUBk" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; padding-left: 20pt; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif">Total minimum lease payments</span></td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">220,255</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046167992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_zLmIf86cXnic" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zTBJ1F1cgMLg" style="display: none">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span style="display: none">&#160;</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: 48.95pt; border-collapse: collapse; width: 80%">
  <tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Three Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="font-weight: bold; padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Six Months Ended</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">June 30,</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2020</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td><td>&#160;</td>
    <td colspan="2">&#160;</td><td>&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 44%; text-align: left">Research and development</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zF8Nnry2PyU9" style="width: 10%; text-align: right" title="Allocated Share-based Compensation Expense">69,483</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98E_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zWDpZeOg2EEc" style="width: 10%; text-align: right">199,777</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zRKTDCTA07E6" style="width: 10%; text-align: right">136,369</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zgm0rPZL3m16" style="width: 10%; text-align: right">334,441</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: left">General and administrative</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zoTbIMjkqgqc" style="border-bottom: Black 1.5pt solid; text-align: right">77,264</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_988_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zABAm4CjHjAi" style="border-bottom: Black 1.5pt solid; text-align: right">265,281</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgqhrLRgq0si" style="border-bottom: Black 1.5pt solid; text-align: right">157,944</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630__us-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zonanIsgmPa7" style="border-bottom: Black 1.5pt solid; text-align: right">452,530</td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font: 10pt Times New Roman, Times, Serif; display: none">Allocated
    Share-based Compensation Expense</span></td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210401__20210630_zdJtDHK6Qsx6" style="border-bottom: Black 2.5pt double; text-align: right">146,747</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_980_eus-gaap--AllocatedShareBasedCompensationExpense_c20200401__20200630_zc5IX2x1QfK5" style="border-bottom: Black 2.5pt double; text-align: right">465,058</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_986_eus-gaap--AllocatedShareBasedCompensationExpense_c20210101__20210630_zD87BeQzAEr1" style="border-bottom: Black 2.5pt double; text-align: right">294,313</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98D_eus-gaap--AllocatedShareBasedCompensationExpense_c20200101__20200630_zt6tr7toSVtl" style="border-bottom: Black 2.5pt double; text-align: right">786,971</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>



<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Key Assumption of Fair Value of Stock Options Granted</a></td>
<td class="text"><p id="xdx_89E_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zwmpvSuawot1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B9_zgecfC0mfGQd" style="display: none">Schedule of Key Assumption of Fair Value of Stock Options Granted</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_494_20210101__20210630_zmDJMKFGsSW8" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" id="xdx_495_20200101__20200630_zW7zEcE5d5k9" style="border-bottom: Black 1.5pt solid; text-align: center">2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected term</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630_zlLije1vKWVg" title="Expected term">5.70</span> years</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20200630_zxoJsHRWHrkj" title="Expected term">5.81</span> years</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_zcJlPuXYgIZh" style="vertical-align: bottom; background-color: White">
    <td style="width: 52%; text-align: left">Risk-free interest rate</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">0.52</td><td style="width: 1%; text-align: left">%</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 20%; text-align: right">1.33</td><td style="width: 1%; text-align: left">%</td></tr>
  <tr id="xdx_402_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_i_pdd" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Expected dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1122">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1123">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_zvXnDLRRuXS9" style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Expected volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">95.52</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">99.52</td><td style="text-align: left">%</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zY50Qz52B1dd" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">A
summary of stock option activity is as follows:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_8B5_zponXz4ot0Ui" style="display: none">Schedule of Stock Option Activity</span>&#160;</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 60%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Outstanding stock options</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number of shares</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 50%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zLwTwd2zLfh7" style="width: 17%; text-align: right" title="Number of shares, Balance at beginning of the period (in shares)">3,564,458</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_z4uEsg0iVKM9" style="width: 25%; text-align: right" title="Weighted average exercise price, Balance at beginning of the period (in dollars per share)">3.36</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options granted</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zx2A1aNSMa4c" style="text-align: right" title="Number of shares, Options granted (in shares)">376,000</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zIuzppetXTx5" style="text-align: right" title="Weighted average exercise price, Options granted (in dollars per share)">1.44</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqElCoELOdTa" style="text-align: right" title="Number of shares, Options exercised (in shares)">(4,584</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zEKKE1j0p4Fi" style="text-align: right" title="Weighted average exercise price, Options exercised (in dollars per share)">1.46</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Options forfeited</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zKOPcUjH6b71" style="text-align: right" title="Number of shares, Options forfeited (in shares)"><span style="-sec-ix-hidden: xdx2ixbrl1168">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_pdd" style="text-align: right" title="Weighted average exercise price, Options forfeited (in dollars per share)"><span style="-sec-ix-hidden: xdx2ixbrl1170">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Options cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_iN_pid_di_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zqFy5JTxVWtj" style="text-align: right" title="Number of shares, Options cancelled (in shares)">(20,084</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zkiISkgOEuv3" style="text-align: right" title="Weighted average exercise price, Options cancelled (in dollars per share)">6.45</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Balance at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zw9KMa1wqCPj" style="text-align: right" title="Number of shares, Balance at end of the period (in shares)">3,915,790</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zRy9gaViWFUb" style="text-align: right" title="Weighted average exercise price, Balance at end of the period (in dollars per share)">3.16</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">&#160;</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Options exercisable at June 30, 2021</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zGBFslhK1UUa" style="text-align: right" title="Number of shares, Options exercisable (in shares)">2,528,729</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20210101__20210630__us-gaap--OptionIndexedToIssuersEquityTypeAxis__us-gaap--EmployeeStockOptionMember_zl7VB44qqrA7" style="text-align: right" title="Weighted average exercise price, Options exercisable (in dollars per share)">4.24</td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock', window );">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</a></td>
<td class="text"><p id="xdx_89F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock_zbN5aK9liofg" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes information about stock options outstanding and exercisable at June 30, 2021:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BC_z9gHRxkwNHWh" style="display: none">Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Options exercisable</td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number outstanding</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Number exerciseable</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average remaining contractual life (Years)</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Weighted average exercise price</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Aggregate intrinsic value</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 10%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 11%">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 11%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 10%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 9%; text-align: right">&#160;</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iI_c20210630_zYu9Fjg4nOYe" style="text-align: right" title="Number of options outstanding, shares">3,915,790</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20210101__20210630_zNNMiMxLBh05" title="Options outstanding, Weighted average remaining contractual life (Years)">6.39</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_z1nqIaCWFF4k" style="text-align: right" title="Options outstanding, Weighted average exercise price (in dollars per share)">3.16</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_c20210630_pp0p0" style="text-align: right" title="Options outstanding, Aggregate intrinsic value">636,639</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iI_pid_uShares_c20210630_z83YayXslyP7" style="text-align: right" title="Number of options exercisable">2,528,729</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20210101__20210630_z0V2SHtTusWa" title="Options exercisable, Weighted average remaining contractual life (Years)">4.84</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_pid_uUSDPShares_c20210630_zkC9ca7vZgGc" title="Options exercisable, Weighted average exercise price">4.24</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td style="text-align: right"><span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c20210630_pp0p0" title="Options exercisable, Aggregate intrinsic value">311,190</span></td><td style="text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock', window );">Schedule of Fair Value of Warrants</a></td>
<td class="text"><p id="xdx_891_ecustom--ScheduleOfFairValueOfWarrantsTableTextBlock_zyFENORiDsXf" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8B4_zp3NCmSqWXbk" style="display: none">Schedule of Fair Value of Warrants</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">June 30, 2021</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">December 31, 2020</td><td style="padding-bottom: 1.5pt; text-align: center">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 56%; text-align: left">Expected life in years</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z09NG5MkR0Eg" title="Expected life in years">3.38</span></td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td style="width: 18%; text-align: right"><span id="xdx_908_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_znYqGocmKiMe" title="Expected life in years">3.88</span></td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: left">Risk-free interest rate</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zf5RGxpsBjDk" style="text-align: right">0.46</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zeVDPwmuU1Je" style="text-align: right">0.27</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: left">Dividend yield</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zvNZLkp6Is9a" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1219">&#8212;</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOwQqz8wAW9j" style="text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl1220">&#8212;</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td>Volatility</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20210101__20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zMcOGy88fz0c" style="text-align: right">72.62</td><td style="text-align: left">%</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20200101__20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zFK1yzVh9NMg" style="text-align: right">88.46</td><td style="text-align: left">%</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td>Stock price</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_985_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20210630__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zwaZkYUGnL6c" style="text-align: right">1.40</td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">$</td><td id="xdx_98E_eus-gaap--SharePrice_iI_pid_uUSDPShares_c20201231__us-gaap--SubsidiarySaleOfStockAxis__custom--November2019OfferingMember__us-gaap--FairValueByFairValueHierarchyLevelAxis__us-gaap--FairValueInputsLevel3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6vyfjDH9hj5" style="text-align: right">1.36</td><td style="text-align: left">&#160;</td></tr>
  </table>


<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock', window );">Schedule of Reconciliation of Warrant Liability</a></td>
<td class="text"><p id="xdx_89F_ecustom--ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock_zBrfZqVXUHf1" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;<span id="xdx_8BD_zbtPMe30hS83" style="display: none">Schedule of Reconciliation of Warrant Liability</span></span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td>
    <td colspan="2" id="xdx_49C_20210101__20210630_zAASvD6PZTY4" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold">Warrant Liability</td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold">&#160;</td></tr>
  <tr id="xdx_404_eus-gaap--WarrantsAndRightsOutstanding_iS_pp0p0_zRhOtC0TMVEc" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 78%">Balance at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">1,170,051</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr id="xdx_40C_ecustom--AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise_i_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-left: 10pt; text-align: left">Settlement of liability on warrant exercise</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td style="text-align: right">(18,365</td><td style="text-align: left">)</td></tr>
  <tr id="xdx_405_eus-gaap--FairValueAdjustmentOfWarrants_i_pp0p0" style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-left: 10pt; padding-bottom: 1.5pt; text-align: left">Change in fair value of common stock warrants</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(26,257</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr>
  <tr id="xdx_408_eus-gaap--WarrantsAndRightsOutstanding_iE_pp0p0" style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 2.5pt">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,125,429</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>

<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price</a></td>
<td class="text"><p id="xdx_891_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_gL3SONOWOAWAE-MPE_znLjgJKxw7Va" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.7pt; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
following table summarizes the number of common stock warrants outstanding and the weighted average exercise price:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; background-color: white"><span id="xdx_8B8_zWLYDtd7Grbl" style="display: none">Schedule
of Number of Warrants Outstanding and the Weighted Average Exercise Price</span></p>

<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 75%; margin-left: 48.95pt">
  <tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Warrants</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">Weighted Average</p>
                                                                                <p style="margin-top: 0; margin-bottom: 0">Exercise Price</p></td><td style="padding-bottom: 1.5pt; font-weight: bold">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="width: 47%; text-align: center">Outstanding at December 31, 2020</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">&#160;</td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zmDTWqWwmmah" style="width: 20%; text-align: right" title="Number of shares, Balance at beginning of the period">1,944,366</td><td style="width: 1%; text-align: left">&#160;</td><td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: left">$</td><td id="xdx_98D_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zUEGxKHoNM9i" style="width: 25%; text-align: right" title="Weighted average Exercise Price, Beginning of the period">0.51</td><td style="width: 1%; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Issued</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl1255">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z5j3hk4Nhjj3" style="text-align: right" title="Issued"><span style="-sec-ix-hidden: xdx2ixbrl1257">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Exercised</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_iN_di_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z0XX0Wv7TZab" style="text-align: right" title="Exercised">(10,000</td><td style="text-align: left">)</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z6sIBrNn3Gu2" style="text-align: right" title="Exercised">0.50</td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="text-align: center">Expired</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1263">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zH9lDr6uZ8Y3" style="text-align: right" title="Expired"><span style="-sec-ix-hidden: xdx2ixbrl1265">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="text-align: center">Cancelled</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zezwjN9XJ1Hl" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1267">-</span></td><td style="text-align: left">&#160;</td><td>&#160;</td>
    <td style="text-align: left">&#160;</td><td id="xdx_989_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zPh0HtUZNjKe" style="text-align: right" title="Cancelled"><span style="-sec-ix-hidden: xdx2ixbrl1269">-</span></td><td style="text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="padding-bottom: 1.5pt; text-align: center">Forfeited</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_pdd" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1271">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td><td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: Black 1.5pt solid; text-align: left">&#160;</td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_z8lJBS67disk" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited"><span style="-sec-ix-hidden: xdx2ixbrl1273">-</span></td><td style="padding-bottom: 1.5pt; text-align: left">&#160;</td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td style="padding-bottom: 2.5pt; text-align: center">Balance at June 30, 2021</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">&#160;</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSfdtI9MEUEh" style="border-bottom: Black 2.5pt double; text-align: right" title="Number of shares, Balance at ending of the period">1,934,366</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td><td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td id="xdx_98C_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iE_uUSDPShares_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSTPT1VA2txc" style="border-bottom: Black 2.5pt double; text-align: right" title="Weighted average Exercise Price, Ending of the period">0.51</td><td style="padding-bottom: 2.5pt; text-align: left">&#160;</td></tr>
  </table>


The
following table summarizes information about common stock warrants outstanding at June 30, 2021:<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 76.5pt; text-indent: -27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellpadding="0" cellspacing="0" id="xdx_306_134_zeLvIOq7pmD3" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 70%; margin-left: 48.95pt" summary="xdx: Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)">
  <tr style="vertical-align: bottom">
    <td colspan="13" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Warrants outstanding</span></td></tr>
  <tr style="vertical-align: bottom">
    <td style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Number exercisable</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average remaining contractual life (Years)</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Weighted average exercise price</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td>
    <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center; font-weight: bold"><span>Aggregate intrinsic value</span></td><td style="padding-bottom: 1.5pt; text-align: center; font-weight: bold"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: White">
    <td style="width: 26%"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 20%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 2%"><span>&#160;</span></td>
    <td style="width: 1%; text-align: left"><span>&#160;</span></td><td style="width: 22%; text-align: right"><span>&#160;</span></td><td style="width: 1%; text-align: left"><span>&#160;</span></td></tr>
  <tr style="vertical-align: bottom; background-color: rgb(204,238,255)">
    <td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zoUsDS15dVYd" style="text-align: right" title="Number of warrants exercisable, shares"><span>1,934,366</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>&#160;</span></td><td style="text-align: right"><span><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20210101__20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zQExU5rxjy3g" title="Weighted average remaining contractual life">3.50</span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_985_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice_iI_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zntgohBvSxsk" style="text-align: right" title="Weighted average exercise price, per share"><span><span title="Weighted average Exercise Price, Ending of the period">0.51</span></span></td><td style="text-align: left"><span>&#160;</span></td><td><span>&#160;</span></td>
    <td style="text-align: left"><span>$</span></td><td id="xdx_987_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_iI_pp0p0_c20210630__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zlX259qtjsIg" style="text-align: right" title="Aggregate intrinsic value"><span>1,715,719</span></td><td style="text-align: left"><span>&#160;</span></td></tr>
  </table>

&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Reconciliation of Warrant Liability [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316061032888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td>
<td class="num">$ (6,809,041)<span></span>
</td>
<td class="num">$ (6,369,634)<span></span>
</td>
<td class="num">$ (10,177,123)<span></span>
</td>
<td class="num">$ (12,140,285)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted avg. common shares outstanding</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">49,769,253<span></span>
</td>
<td class="nump">85,556,110<span></span>
</td>
<td class="nump">45,558,442<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic loss per share attributable to common stock</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss</a></td>
<td class="num">$ (6,809,041)<span></span>
</td>
<td class="num">$ (6,369,634)<span></span>
</td>
<td class="num">$ (10,177,123)<span></span>
</td>
<td class="num">$ (12,140,285)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted avg. common shares outstanding</a></td>
<td class="nump">88,290,650<span></span>
</td>
<td class="nump">49,769,253<span></span>
</td>
<td class="nump">85,556,110<span></span>
</td>
<td class="nump">45,558,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted loss per share attributable to common stock</a></td>
<td class="num">$ (0.08)<span></span>
</td>
<td class="num">$ (0.13)<span></span>
</td>
<td class="num">$ (0.12)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 40<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1930-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050833368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">1,934,366<span></span>
</td>
<td class="nump">3,423,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LPCN_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">605,682<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">3,915,790<span></span>
</td>
<td class="nump">3,012,041<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LPCN_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LPCN_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050457144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Available-for-Sale Securities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 35,672,245<span></span>
</td>
<td class="nump">$ 449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="nump">35,672,059<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LPCN_CorporateBondsNotesAndCommercialPaperMember', window );">Corporate Bonds Notes And Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">35,672,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="num">(186)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="nump">$ 35,672,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross unrealized holding gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross unrealized holding losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Aggregate fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 449,992<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LPCN_CorporateBondsNotesAndCommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LPCN_CorporateBondsNotesAndCommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050813432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 35,672,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">35,672,059<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total maturities of debt securities classified as available-for-sale securities, amortized cost</a></td>
<td class="nump">35,672,245<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total maturities of debt securities classified as available-for-sale securities, fair value</a></td>
<td class="nump">$ 35,672,059<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316044834424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Investment Securities (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet', window );">Available-for-sale securities, gross realized gain (loss)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from sale and maturity of marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">450,000<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment', window );">Other-than-temporary impairments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which no such other than temporary impairment (OTTI) was previously recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=SL6284393-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316061269336">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Fair Value, Assets Measured on Recurring Basis (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 45,851,132<span></span>
</td>
<td class="nump">$ 18,849,577<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">46,976,561<span></span>
</td>
<td class="nump">20,019,628<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">21,684,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,125,429<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">10,179,073<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">10,179,073<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">35,672,059<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">35,672,059<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">21,684,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,125,429<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">1,125,429<span></span>
</td>
<td class="nump">1,170,051<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">10,179,073<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">10,179,073<span></span>
</td>
<td class="nump">18,399,585<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">13,987,623<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">13,987,623<span></span>
</td>
<td class="nump">449,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316047266584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value (Details Narrative) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.52%<span></span>
</td>
<td class="nump">99.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems', window );"><strong>Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">72.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.27%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Strike price</a></td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of common stock</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">3 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 24 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046980952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Maturities of Debt (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 1,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2022</a></td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths', window );">Thereafter</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt</a></td>
<td class="nump">$ 3,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050565848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Loan and Security Agreements and Other Liabilities (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>May 31, 2018</div></th>
<th class="th"><div>Jan. 05, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_DeferredFederalInsuranceContributionsActTaxPayments', window );">Deferred FICA payroll tax payments</a></td>
<td class="nump">$ 36,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=LPCN_LoanAndSecurityAgreementMember', window );">Loan And Security Agreement [Member] | Silicon Valley Bank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Aggregate amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate', window );">Debt Instrument, Interest Rate, Basis for Effective Rate</a></td>
<td class="text">The principal borrowed under the Loan
and Security Agreement bears interest at a rate equal to the Prime Rate, as reported in the money rates section of The Wall Street Journal
or any successor publication representing the rate of interest per annum then in effect, plus one percent per annum (4.25% as of June
30, 2021), which interest is payable monthly<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Interest rate</a></td>
<td class="nump">4.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt instrument, maturity date</a></td>
<td class="text">Jun.  01,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid', window );">Debt instrument, balloon payment to be paid</a></td>
<td class="nump">$ 650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet', window );">Debt instrument, increase in amount</a></td>
<td class="nump">$ 624,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCollateralForBorrowedSecurities', window );">Cash collateral for borrowed securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRestrictiveCovenants', window );">Debt instrument, restrictive covenants</a></td>
<td class="text">While
any amounts are outstanding under the Loan and Security Agreement, the Company is subject to a number of affirmative and negative covenants,
including covenants regarding dispositions of property, business combinations or acquisitions, incurrence of additional indebtedness
and transactions with affiliates, among other customary covenants. The credit facility also includes events of default, the occurrence
and continuation of which could cause interest to be charged at the rate that is otherwise applicable plus 5.0% and would provide SVB,
as collateral agent, with the right to exercise remedies against the Company and the collateral securing the credit facility, including
foreclosure against the property securing the credit facilities, including its cash.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault', window );">Debt instrument, basis spread on interest rate for debt default</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency', window );">Debt instrument, minimum amount considered for insolvency</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt instrument, basis spread on interest rate for debt default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of debt instrument minimum amount considered for insolvency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_DeferredFederalInsuranceContributionsActTaxPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This information is pertaining to the amount of deferral of FICA tax payments totaled and are included in accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_DeferredFederalInsuranceContributionsActTaxPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCollateralForBorrowedSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCollateralForBorrowedSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net increase or decrease in the carrying amount of the debt instrument for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of any adjustments made to the stated rate to determine the effective rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRestrictiveCovenants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of covenants that limit or prohibit certain actions or activities without the lender's prior consent within a specified period of time or until certain specified targets are achieved for example, reduction of the debt or an increase in net worth to a specified amount).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRestrictiveCovenants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=LPCN_LoanAndSecurityAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=LPCN_LoanAndSecurityAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityAxis=LPCN_SiliconValleyBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityAxis=LPCN_SiliconValleyBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316061582056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contractual Agreements (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Contract research and development expenses</a></td>
<td class="nump">$ 786,000<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">$ 2,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=LPCN_AbbottProductsIncMember', window );">Abbott Products Inc [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales', window );">Percentage of net sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount', window );">Royalties, commitment amount</a></td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch', window );">Percentage of royalties reduction based upon product launch</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties reduction based upon product launch.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyGuaranteesCommitmentsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount the entity has committed to make for future royalty guarantees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473578&amp;loc=d3e63223-108013<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyGuaranteesCommitmentsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LPCN_AbbottProductsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LPCN_AbbottProductsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316044967704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Schedule of Future Minimum Rental Payments for Operating Leases (Details)<br></strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021</a></td>
<td class="nump">$ 165,191<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">55,064<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total minimum lease payments</a></td>
<td class="nump">$ 220,255<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316041458712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeDisclosureAbstract', window );"><strong>Lessee Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Rent expense</a></td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 83,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
<td class="nump">$ 165,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316046650696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 146,747<span></span>
</td>
<td class="nump">$ 465,058<span></span>
</td>
<td class="nump">$ 294,313<span></span>
</td>
<td class="nump">$ 786,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">69,483<span></span>
</td>
<td class="nump">199,777<span></span>
</td>
<td class="nump">136,369<span></span>
</td>
<td class="nump">334,441<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated Share-based Compensation Expense</a></td>
<td class="nump">$ 77,264<span></span>
</td>
<td class="nump">$ 265,281<span></span>
</td>
<td class="nump">$ 157,944<span></span>
</td>
<td class="nump">$ 452,530<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316044873704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">95.52%<span></span>
</td>
<td class="nump">99.52%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050372920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Stock Option Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at end of the period (in shares)</a></td>
<td class="nump">3,915,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at end of the period (in dollars per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable (in shares)</a></td>
<td class="nump">2,528,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,528,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityLineItems', window );"><strong>Option Indexed to Issuer's Equity [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at beginning of the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,564,458<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at beginning of the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of shares, Options granted (in shares)</a></td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="nump">376,000<span></span>
</td>
<td class="nump">739,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of shares, Options exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,584)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of shares, Options forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of shares, Options cancelled (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,084)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price, Options cancelled (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of shares, Balance at end of the period (in shares)</a></td>
<td class="nump">3,915,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,915,790<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted average exercise price, Balance at end of the period (in dollars per share)</a></td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of shares, Options exercisable (in shares)</a></td>
<td class="nump">2,528,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,528,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted average exercise price, Options exercisable (in dollars per share)</a></td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316044880664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of options outstanding, shares | shares</a></td>
<td class="nump">3,915,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, Weighted average remaining contractual life (Years)</a></td>
<td class="text">6 years 4 months 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate intrinsic value | $</a></td>
<td class="nump">$ 636,639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of options exercisable | shares</a></td>
<td class="nump">2,528,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable, Weighted average remaining contractual life (Years)</a></td>
<td class="text">4 years 10 months 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable, Weighted average exercise price | $ / shares</a></td>
<td class="nump">$ 4.24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate intrinsic value | $</a></td>
<td class="nump">$ 311,190<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050618648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Fair Value of Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 9 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.52%<span></span>
</td>
<td class="nump">1.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">95.52%<span></span>
</td>
<td class="nump">99.52%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Fair Value, Inputs, Level 3 [Member] | Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life in years</a></td>
<td class="text">3 years 4 months 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 10 months 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</a></td>
<td class="nump">0.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</a></td>
<td class="nump">72.62%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="nump">$ 1.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316041284040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Reconciliation of Warrant Liability (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 1,170,051<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise', window );">Settlement of liability on warrant exercise</a></td>
<td class="num">(18,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of common stock warrants</a></td>
<td class="num">(26,257)<span></span>
</td>
<td class="nump">$ 3,166,474<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Balance at June 30, 2021</a></td>
<td class="nump">$ 1,125,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment for settlement of liability on warrant exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050763352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details) - Warrant [Member]<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Balance at beginning of the period | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,944,366<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted average Exercise Price, Beginning of the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised | shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice', window );">Exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations', window );">Expired | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice', window );">Expired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures', window );">Forfeited | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice', window );">Cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of shares, Balance at ending of the period | shares</a></td>
<td class="nump">1,934,366<span></span>
</td>
<td class="nump">1,934,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted average Exercise Price, Ending of the period</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Number of warrants exercisable, shares | shares</a></td>
<td class="nump">1,934,366<span></span>
</td>
<td class="nump">1,934,366<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Weighted average remaining contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice', window );">Weighted average exercise price, per share</a></td>
<td class="nump">$ 0.51<span></span>
</td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Aggregate intrinsic value | $</a></td>
<td class="nump">$ 1,715,719<span></span>
</td>
<td class="nump">$ 1,715,719<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average Exercise Price, period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average Exercise Price, issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140315969504584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders&#8217; Equity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2021</div></th>
<th class="th"><div>Feb. 27, 2020</div></th>
<th class="th"><div>Nov. 18, 2019</div></th>
<th class="th"><div>Mar. 06, 2017</div></th>
<th class="th"><div>Nov. 13, 2015</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Apr. 30, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,416,115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,840,457<span></span>
</td>
<td class="nump">$ 5,653,140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights', window );">Class of warrant or right, redemption price of warrants or rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 63.96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Allocated share-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 146,747<span></span>
</td>
<td class="nump">$ 465,058<span></span>
</td>
<td class="nump">$ 294,313<span></span>
</td>
<td class="nump">786,971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee service share-based compensation, nonvested awards, compensation cost not yet recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 2 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (26,257)<span></span>
</td>
<td class="nump">3,166,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,900,000<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 6,914,158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LPCN_StockIncentivePlan2014Member', window );">Stock Incentive Plan2014 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,584,874<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LPCN_StockIncentivePlan2014Member', window );">Stock Incentive Plan2014 [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,221,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,221,906<span></span>
</td>
<td class="nump">2,471,906<span></span>
</td>
<td class="nump">1,271,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LPCN_StockIncentivePlan2014Member', window );">Stock Incentive Plan2014 [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based compensation arrangement by share-based payment award, number of shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,721,906<span></span>
</td>
<td class="nump">3,221,906<span></span>
</td>
<td class="nump">2,471,906<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=LPCN_EquityIncentivePlanMember', window );">Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based compensation arrangement by share-based payment award, number of shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,906<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based compensation arrangement by share-based payment award, options, grants in period, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,000<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="nump">376,000<span></span>
</td>
<td class="nump">739,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based compensation arrangement by share-based payment award, options, exercises in period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,584<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Common warrants to purchase share of our common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=LPCN_CommonStockWarrantMember', window );">Common Stock Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,497,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,618,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=LPCN_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_PercentageOfGrossProceedOnSaleOfShares', window );">Percentage of gross proceeds on sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_January2021OfferingMember', window );">January2021 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="nump">$ 28,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Agent fees and other offering expenses</a></td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="nump">16,428,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_February2020OfferingMember', window );">February2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Agent fees and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,042,017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_February2020OfferingMember', window );">February2020 Offering [Member] | Class A Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,084,034<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_February2020OfferingMember', window );">February2020 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Agent fees and other offering expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 404,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Warrants outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,094,030<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value adjustment of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 221,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 26,000<span></span>
</td>
<td class="nump">$ 3,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Class A Unit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,450,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 768,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Class B Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.4999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Pre Funded Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember', window );">November 2019 Offering [Member] | Additional Paid-in Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_AtMarketOfferingMember', window );">At Market Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,023,073<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_AtMarketOfferingMember', window );">At Market Offering [Member] | Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock issued during period, shares, new issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,811,238<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_AccreditedInvestorsMember', window );">Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockLineItems', window );"><strong>Subsidiary, Sale of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_ProceedsFromIssuanceOfCommonStockGross', window );">Proceeds from issuance of common stock, gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares issued, price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 112,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Redemption Price of Warrants or Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_PercentageOfGrossProceedOnSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of gross proceeds on sale of shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_PercentageOfGrossProceedOnSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_ProceedsFromIssuanceOfCommonStockGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_ProceedsFromIssuanceOfCommonStockGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LPCN_StockIncentivePlan2014Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LPCN_StockIncentivePlan2014Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=LPCN_EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=LPCN_EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=LPCN_CommonStockWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=LPCN_CommonStockWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=LPCN_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=LPCN_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_January2021OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_January2021OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_February2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_February2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LPCN_ClassAUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LPCN_ClassAUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_November2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LPCN_ClassBUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LPCN_ClassBUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=LPCN_PreFundedWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=LPCN_PreFundedWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_AtMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_AtMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=LPCN_AccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=LPCN_AccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316050486872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th"><div>Jul. 13, 2023</div></th>
<th class="th"><div>Jul. 13, 2022</div></th>
<th class="th"><div>Apr. 02, 2019</div></th>
<th class="th"><div>Nov. 14, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetentionPayable', window );">Retention payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LPCN_GlobalAgreementMember', window );">Global Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LPCN_GlobalAgreementMember', window );">Global Agreement [Member] | Clarus Therapeutics Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LPCN_GlobalAgreementMember', window );">Global Agreement [Member] | Clarus Therapeutics Inc [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityListingsLineItems', window );"><strong>Entity Listings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty', window );">Litigation settlement</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityListingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityListingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementAmountAwardedToOtherParty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount awarded to other party in judgment or settlement of litigation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementAmountAwardedToOtherParty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetentionPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetentionPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LPCN_GlobalAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LPCN_GlobalAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LPCN_ClarusTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LPCN_ClarusTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140316041392280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Agreement with Spriaso, LLC (Details Narrative) - Spriaso L L C [Member]<br></strong></div></th>
<th class="th">
<div>Jul. 23, 2013 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LPCN_LicenseAgreementMember', window );">License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_PercentageOfRoyalty', window );">Percentage of royalty</a></td>
<td class="nump">20.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromContributionsFromAffiliates', window );">Proceeds from affiliates</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=LPCN_ServiceAgreementMember', window );">Service Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_LPCN_AgreementDescription', window );">Agreement description</a></td>
<td class="text">Under the service agreement, the Company provided facilities and up to 10 percent of the services of certain
employees to Spriaso for a period of 18 months which expired January 23, 2015. Effective January 23, 2015, the Company entered into an
amended services agreement with Spriaso in which the Company agreed to continue providing up to 10 percent of the services of certain
employees to Spriaso at a rate of $230/hour for a period of six months.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Employee related liabilities</a></td>
<td class="nump">$ 230<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_AgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_AgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_LPCN_PercentageOfRoyalty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalty.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">LPCN_PercentageOfRoyalty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>LPCN_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributionsFromAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromContributionsFromAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LPCN_LicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LPCN_LicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=LPCN_SpriasoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=LPCN_SpriasoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=LPCN_ServiceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=LPCN_ServiceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>58
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M:\EPQ0:RJ@K0LZJ GF)"F0=O70M9/Q9PG9E(VLSW.<B 2+ 7Q-;Z505PSZH
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M?2#1X&V*K#K^ZSRWMN[,V1RJNMBW@U4$^S0__9]\:R?B8@"E P-H.X#J _C
M -8.8-H Y@T,X.T K@_P!P:(=H#00QH:X+4#/&T 80,#_': ?R3K-+M':E9)
MG=S=E,6S4S;6"JWYX<CO<;1B),V;5/Q4E^JOJ1I7WRV+?*L22VX=]5-59.DV
MJ=6+3[7Z3V5<73G%@[/<)?FCK)PT5W\H-E]V1;:59?5W9_W7(:V_.S]]SI/#
M-E4#?W;FSN=/*^>GO_U\LZA5?(V7Q::-Y==3+'0PEOV^:%TX_WDO]_>R_"\
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MWL4P!-V.J>W"JMJ/ADME:=#T8DF3/6JG0.<K19_"[<(YZ/XKS/X"4$L#!!0
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MYV W^>_.:8:'PMGD@ZHJO:9S93^1P+RUR6ME6[0N'7#JQZ^&!&NZ<'6C[)J
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ME*V>G_\^.J6%#PV-@GAHO=NJ5 ]2CJ!L(*\,M/+K*@;%\AYE29X)5="QLAM
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M93JX2I:S3S*@:B)%;%+-%M(B@1@7C:RX=U2',\4,G'8[X'U>C8R 'L$OJL0
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M8MI_Y_$W5C7NV\I:6:LJ=XEY&L;3 KS?*&6[&]J@_]AV_A]02P,$%     @
M(T %4T!%@1S, P  LP@  !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL
MK5;?;]LV$'[W7W%0AV$#4NN'DS;(; -)UJ(-4C1(UNYAV ,MG22N%*F25!3_
M][NC9,W9:N]A>[%%ZGY\WW=WI):]L5]<C>CAJ5':K:+:^_8BCEU>8R/<W+2H
MZ4UI;",\+6T5N]:B*()3H^(L25[%C9 Z6B_#WIU=+TWGE=1X9\%U32/L]@J5
MZ5=1&NTV[F55>]Z(U\M65/B _E-[9VD53U$*V:!VTFBP6*ZBR_3BZI3M@\%G
MB;W;>P9FLC'F"R_>%ZLH84"H,/<<0=#?(UZC4AR(8'P=8T932G;<?]Y%?QNX
M$Y>-<'AMU*^R\/4J.H^@P%)TRM^;_AV.?,XX7FZ4"[_0#[8+,LX[YTTS.A."
M1NKA7SR-.NPYG"<''++1(0NXAT0!Y<_"B_72FAXL6U,T?@A4@S>!DYJ+\N M
MO97DY]>7E44DD3WE]34\M%8*9T[@]O9Z&7M*P&9Q/@:[&H)E!X*]@@]&^]K!
M&UU@\=P_)F 3NFR'[BH[&O"FTW-8)">0)5EZ)-YB8KL(\18'XMVC$AX+N!/6
M;^$7*[03H3L<_':Y<=[2ZO<C>4ZG/*<AS^G_H^K18#R6%ZX5.:XBFCN']A&C
M]0]I^N/L2!KXJ&<WG=I"MF#U4OKU-<*U:5JAMT ^:$D(J;T!0</AG*PTAXJ5
MS&GFD'8+$,#I:,.!.)!+T&@&45^V051?"P_248_^8:STVY>FUUC,-EO(T7HZ
M):BKK>4XG(!/%;102$M3:JP#4\*M;$U.&L![G<^#%2&7%D192B4IE9O#)VHP
M&QA-<'?XGA,=B!%3BC/S7/ 2+3,GWB,'$$IQWCVW[U^<9^GKGQQ8'FI'(:57
M@R0R*.>(HP;I75@K/F,ZH:"U=%H&%0P=#8]TY+6\5W0Y61)7SC'+35?5(18-
M+TD@415S(@NB*"0WX\F$C%1!.K2* '' $AS-1LE*#(W;35+\'?R8>8<D%&^2
M:1;**,A1VK%V 00^Y;70%3Z7L9<,8$##)3=;H8@FJ98ED";S9*\B8\L<J@BA
M>I1T/$ I<JJGESAPZEI6+4V %,P9ZEB2J0-I/;;0#)M6F2W2YEX965_!WM(4
M;)R>0S,<1WTM\YJ8M9(K?R-T1_?/;C+.YO"F+#'<#O]X=W1J9H+8,9-_&1)N
ME0'"L\YDV]"'.:&4NL-1&JFK_RX&#2&5B8:%+;\C/@DEULXH68Q]\ZUC+MZ[
M2&@NJW!=.@+8:3_<*=/N="-?#A?17^;#=?Y!V$I2&H4EN2;SUV?1T,&[A3=M
MN)8VQM,E%QYK^JI RP;TOC3&[Q:<8/I.6?\)4$L#!!0    ( "- !5-"*@A)
MK (  .<%   9    >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;*U4WT_;0 Q^
M[U]A9=($4FE^M# &;:6V@&""K:+JIFG:PS5QFA/)7;B[4/;?SW=ILS!!][*7
MG'VV/W]VSAYNI'K0&:*!YR(7>N1EQI1GOJ_C# NF>[)$0994JH(94M7:UZ5"
MEKB@(O>C(#CQ"\:%-QZZN[D:#V5E<BYPKD!71<'4KRGF<C/R0F]W<<_7F;$7
M_GA8LC4NT"S+N2+-;U 27J#07 I0F(Z\27@V'5A_Y_"5XT:W9+"5K*1\L,I-
M,O("2PASC(U%8'0\X0SSW (1C<<MIM>DM(%M>8=^Y6JG6E9,XTSFWWABLI%W
MZD&"*:MR<R\WU[BMY]CBQ3+7[@N;VO<X\B"NM)'%-I@8%%S4)WO>]J$5<!J\
M$1!M R+'NT[D6%XPP\9#)3>@K#>A6<&5ZJ*)'!?VIRR,(BNG.#.^QQB%@4D<
MRTH8+M8P5U*0'".UWNBA;RB+]?7C+>*T1HS>0#R!.RE,IN%2))B\C/>)74,Q
MVE&<1GL!/U6B!_V@"U$0A7OP^DW)?8?7?P.O5>LL8V*-&IA(X%(IJ6 FE:H?
MC(8?DY4VBM[-SSU9!TW6@<LZ^(^-WH]X$$:'G7_!MBR=ORPW6E>8P&=IX#M-
M_R21I2']1G2B(#SI@LD0KB:+*?#:L95C8:AC3"4:EF7"#,+!^W>G412<3Q9+
M)X7GAP[E*.QWX0Z9KI3+"C*%F<*$&[B56E/K:3*ON& BYBRGW-3PJJ9W+3?X
MA*K;X0*^Q$:N4-$+"#^^0FRQ=):CD![)ZV!'+[-VX0(5?V)V(]1__QJ3-576
M=<HM$49]!I=IBFYK=&BVR+'WVCOP6\-7H%J[%:/!]:J>P^:VV6*3>GC_N-<K
M\(XI(J$AQY1"@]Z'8P]4O59JQ<C2C?)*&EH,3LQH$Z.R#F1/I30[Q29H=OOX
M-U!+ P04    "  C0 53C1;!<O8#   P"P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q.2YX;6S=5DMOXS80ONM7#(0>$D!KO?T(; -Y%6W1703K;',H>J"E
ML25$(E62BM-_OT/*EIVLXTV+]M*+/2-Q/G[SU$PW0CZJ E'#<UUQ-7,+K9L+
MWU=9@353 ]$@IS<K(6NF295K7S4266Z-ZLJ/@F#HUZSD[GQJG]W)^52TNBHY
MWDE0;5TS^=<55F(S<T-W]^!SN2ZT>>#/IPU;XP+UE^9.DN;W*'E9(U>EX"!Q
M-7,OPXNKU)RW!WXK<:,.9#">+(5X-,K/^<P-#"&L,-,&@='?$UYC51D@HO'G
M%M/MKS2&A_(._4?K._FR9 JO1?50YKJ8N6,7<ERQMM*?Q>8GW/IC"6:B4O87
M-MNS@0M9J[2HM\;$H"YY]\^>MW%XCT&T-8@L[^XBR_*&:3:?2K$!:4X3FA&L
MJ]::R)7<)&6A);TMR4[/;YGD)5\K./M5*'4.#4I8%$PBG-VS987J?.IKNL><
M]K,MYE6'&;V!.82/@NM"P2W/,7]I[Q._GF2T(WD5G03\I>4#B ,/HB *3^#%
MO=.QQ8N_Y_1=[^WOETNE)=7('R?PDQX_L?C)&_@+:IV\K1#$"JY%W;2:V1(D
M]8JI,@/&<[@IJU9C#OL,5#8#>TZ==4V&"RVRQV.).,WCOD!G)2IJ/+H M,DG
M*-0*J)EU ;I R%[26_;T\BT]?$7/%(C:T<LZ>LK0,Z 64A<2T6*H\AEJ6PH.
MFE( 2B3VB;1'2 @NX+\)F'-OF1P6XY[!@K@=?>-8;H87])+3L3#W'02 :2W+
M9=O%58L7T;AP/K4U2J:%=#[1;+6F/\#9T!L'$R](0CCOU'@X\89QTJEAX(6C
MD1=&\5:/O# )O&B<PKES@US0!+"0#W;:$&OVM![T%QM6"FCT*DT!,SD?C[UH
M$GC#-(!DXHWHKBB-89QZ:3KTPI">&G'L)4GT]WTT#(-!,.ZX!H,P[J5H)T4C
MPWR;N?]W_/Z!E^^-X(F9E/8S*7WW3+KDNK3]31]$6&#6RE*7Y/GM<U:UIA=6
M4M2O&_';H7EL()TD83:,"]6P#&<NK1 *Y1.Z=DJ]&D/Y\5#N)LQ^KL"IN0*Y
M(*>XT%!RZY@UW@_$+@6B,;<J8^5LF)2,TX"D/#6MS KZWO=E(:'E3Z@,+](I
MJ9D1.Y"6EV15\F,S]0UGEIBQ5EE.]%MR0J2*I\N=#9JR.<C1RP'Y+V7/^7;@
M.8L7$8F]29AZHTE 4D"M1%WG?/E."#[ ,$B]X3AR'G:Q#+U)G%"?#@DFB6(O
MHK8Y5M#^P19#K;^VNYJB:+9<=PM-_[1?!R^[+6A_O-LE/S*YIHA"A2LR#08C
M*DO9[6>=HD5C=Z*ET+1A6;&@E1:E.4#O5T+HG6(NZ)?D^5=02P,$%     @
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M?^^6"$_N7BIIXU\8 Z7JI.VOX6%T>,2N^[O[&-Z_@'=<;X0T4..:H-'E) ]
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MB<8GT/I::[<//$'_]A9_ %!+ P04    "  C0 53H7;"23(&  " $P  &0
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M_SO)^KJG?M%B9JY8[H36HC3#*6<9E[0 Y\="Z-4+&6@OW<[^ 5!+ P04
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M$>;I$N$B09,T*P5)T!2S(BW6'%UEE/-K-",,S3>8[=DY$.>"+I_1U80(G&:
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M!B$WTX &CQ-W/%\9.Q'.)A7+80[F8W6K<!2V+!DOH-1<ED3!<AI<T<N$CBS
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MU+4^"C-!O\\Y5_N.^4#S[V'R+U!+ P04    "  C0 53S;5R!C4"   [!0
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MG-M('1%>]O9R(MG:-*\%DZH5FF&JGD/ -4#]OV1,[B<Z0/W &OP&4$L#!!0
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MF'+D77FD@"6MN7F0VV_0QI-8OEQR[;YDV_BFZ)S7VLBJ!:."BHGF3W=M'@X
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M6AL.>(V-K0_>U076R[8M%MB!RIF&/E4->7*@ZB*\BM.D7U3:B4I/BIJ65*R
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M:+ZN'A7=^8V5E&>8:RYS4#@?>3?A]30*K$(I\1?'C=Y9@PUE)N4/>W.?CKS
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MRO[M:::;KK9F;[=F[W^[YA.PSM$&S#/_+[[.Z'61;1;5EB,SD0 ;2'A(EPF
M&/CL.3% .;14C689![]F@0"/&1X"YO]'EH6R<TJKX:M-ZE;#*&]L8C> J*2K
M^JL#"4$NTAL/5DI+> "*\FW:,<M]4PY:E9MX.J?3$.(&U:UV.(A@);KKRU.I
M'-I]DI=,#%%6'(/[D$59F0!^N^.K!RY,:1RJ/ Z=82L&J)(Q[,C&;0B;6VO!
M<Z][>*Y%X9H]YU_G42?#<).M/),Q)TH VZ3+6+3A2RE0U?>P:T//VL\M?0GO
M-(0%$K5 $50E 337!(-HYU$V6.Q!6C4#H$46$UHUX>:B,$6T$J*EFKH)ZZM7
M907LJ"LDJ@DV2S<L!&$PUV7;:<<0T"HPTN2KJBR YKJ@,_C G^ NB(+59M4K
M'E4:AG3@>%39#YISRE\>CS>E0+5<8&O"[+8OX4<-H8W<)N$G#2&TZX3UCDME
M3]N</7NY"OO>UU5LE?]L.*RKV)6VLB,7_>6N4@K4B<BW?0D_:@BU/O5)0[CO
M4W4UJF1KF[OF<N>K[BN]G$(E61L-[!0J8]G_KQGKSFXF(F,PJSQDFY-(=4WW
MI:R7:CDGX*>BP^UC,Y5L;'=@FZGT8IO;O%>P69QK0'9 BZ*U#Z*RR\F^B1-=
MT?VAE*IJ+T(:Q?2-A@Q"IUF::^@<MSG>K8;.=;S68LU6J=,>/'7NU+AM7"J:
MU*JPF< :ZNLDF6I(D*S@]O5F&JB^7ZC2I&-.DU?%SE;IU]WAXZ@\Z R<!QV5
M!YT^/5E0;"CZQ8;BUOD+!).8QI\*"FW;[#23"Z00VDY+O^A4=F3-R>7HS<YR
M?%(7K44LE9"<P;N^ T-EZC2;M)J3UU>B\IUCSG?;K>X^SJL2CD,&=EZ59AQS
M3U.XAE9A1L;L</]MLF8S?CY:2Q?GXI&/+H!))I6/'',^*E%AMT^<QF"]$;.E
M=(/"(S)]Q!O1M3'^P6E"_3[V:4A@>^?NJ&3@F)/!R_:ARD%)N\"W&A+<*B]2
M2(P.0.(#G!HI1$8#(S)2B(S,B/PRY2,-"CO(<ZFUOWVII2205BGKHBO 1AV
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ (T %4YOFH#E#!   WAX
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M=HUK539'?];]U)M_ E!+ 0(4 Q0    ( "- !5,'04UB@0   +$    0
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M965T,RYX;6Q02P$"% ,4    "  C0 53Q5$PH#(&  !*&@  &
M    @($)%P  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @
M(T %4Q\<C#5?"@  @DP  !@              ("!<1T  'AL+W=O<FMS:&5E
M=',O<VAE970U+GAM;%!+ 0(4 Q0    ( "- !5/82*U6? <  %<>   8
M          " @08H  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M    "  C0 53OZZ]ZY$'  #8$@  &               @(&X+P  >&PO=V]R
M:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @ (T %4YDP(\B0!   -PP
M !@              ("!?S<  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+
M 0(4 Q0    ( "- !5-;"NV,< 0  &P+   8              " @44\  !X
M;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4    "  C0 53/$:'9V8(
M  "^%0  &0              @('K0   >&PO=V]R:W-H965T<R]S:&5E=#$P
M+GAM;%!+ 0(4 Q0    ( "- !5-=&/V#\ 4  !L-   9              "
M@8A)  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ (T %
M4[.E:<Q" P  Y 8  !D              ("!KT\  'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6Q02P$"% ,4    "  C0 53RFHI_:4#  "N!P  &0
M        @($H4P  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0
M   ( "- !5/\.1,C4@,  *4'   9              " @017  !X;"]W;W)K
M<VAE971S+W-H965T,30N>&UL4$L! A0#%     @ (T %4QH;:VA1$P  WC<
M !D              ("!C5H  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q0
M2P$"% ,4    "  C0 53C_I?CE$(  !X$P  &0              @($5;@
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( "- !5- 18$<
MS ,  +,(   9              " @9UV  !X;"]W;W)K<VAE971S+W-H965T
M,3<N>&UL4$L! A0#%     @ (T %4T(J"$FL @  YP4  !D
M ("!H'H  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  C
M0 53C1;!<O8#   P"P  &0              @(&#?0  >&PO=V]R:W-H965T
M<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( "- !5,I"9DW_@(  !4(   9
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M970R-"YX;6Q02P$"% ,4    "  C0 53T8)09F #  #K"P  &0
M    @($GE   >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    (
M "- !5.N']UA# ,  (<)   9              " @;Z7  !X;"]W;W)K<VAE
M971S+W-H965T,C8N>&UL4$L! A0#%     @ (T %4^=<\W-- P    T  !D
M             ("! 9L  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"
M% ,4    "  C0 53@H=SXFP"   H!@  &0              @(&%G@  >&PO
M=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( "- !5.327TPZ@(
M +D(   9              " @2BA  !X;"]W;W)K<VAE971S+W-H965T,CDN
M>&UL4$L! A0#%     @ (T %4RY845%[!0  7"H  !D              ("!
M2:0  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    "  C0 53
M/FO V6 #  !)#   &0              @('[J0  >&PO=V]R:W-H965T<R]S
M:&5E=#,Q+GAM;%!+ 0(4 Q0    ( "- !5/-M7(&-0(  #L%   9
M      " @9*M  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%
M  @ (T %4Y 4)$/Q!0  OA   !D              ("!_J\  'AL+W=O<FMS
M:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    "  C0 53TW-)720#  "!"0
M&0              @($FM@  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+
M 0(4 Q0    ( "- !5-*QJ7K* (  ,T$   9              " @8&Y  !X
M;"]W;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ (T %4R;BIP=3
M @  =08  !D              ("!X+L  'AL+W=O<FMS:&5E=',O<VAE970S
M-BYX;6Q02P$"% ,4    "  C0 53.Y <60\#  !L"0  &0
M@(%JO@  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( "-
M!5.Y8H+IL0(  ,P'   9              " @;#!  !X;"]W;W)K<VAE971S
M+W-H965T,S@N>&UL4$L! A0#%     @ (T %4Y?VH?Q_!   #14  !D
M         ("!F,0  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
M    "  C0 53W9JXW#0#  "+"0  &0              @(%.R0  >&PO=V]R
M:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    ( "- !5-9$=JKUP,  ,L/
M   9              " @;G,  !X;"]W;W)K<VAE971S+W-H965T-#$N>&UL
M4$L! A0#%     @ (T %4[3,VM>T @  Q@8  !D              ("!Q]
M 'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  C0 53=MG
MWR0$   5$   &0              @(&RTP  >&PO=V]R:W-H965T<R]S:&5E
M=#0S+GAM;%!+ 0(4 Q0    ( "- !5-K((B*J0H  *5    9
M  " @0W8  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @
M(T %4Y9?(7'' @  7@D  !D              ("![>(  'AL+W=O<FMS:&5E
M=',O<VAE970T-2YX;6Q02P$"% ,4    "  C0 53H3 SLT$#  #,"   &0
M            @('KY0  >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4
M Q0    ( "- !5/Q\1))& ,  ) 1   -              "  6/I  !X;"]S
M='EL97,N>&UL4$L! A0#%     @ (T %4Y>*NQS     $P(   L
M     ( !INP  %]R96QS+RYR96QS4$L! A0#%     @ (T %4YOFH#E#!
MWAX   \              ( !C^T  'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0
M   ( "- !5/]+-6EK@$  ,$;   :              "  ?_Q  !X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( "- !5,F^H>GM0$  -P;
M   3              "  >7S  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@
0   V #8 L0X  ,OU      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>181</ContextCount>
  <ElementCount>310</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>46</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/BalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfChangesInStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Disclosure - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/BasisOfPresentation</Role>
      <ShortName>Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Earnings (Loss) per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/EarningsLossPerShare</Role>
      <ShortName>Earnings (Loss) per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Marketable Investment Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecurities</Role>
      <ShortName>Marketable Investment Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Fair Value</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/FairValue</Role>
      <ShortName>Fair Value</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - Loan and Security Agreements and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities</Role>
      <ShortName>Loan and Security Agreements and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Contractual Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ContractualAgreements</Role>
      <ShortName>Contractual Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Stockholders??? Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquity</Role>
      <ShortName>Stockholders??? Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Agreement with Spriaso, LLC</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/AgreementWithSpriasoLlc</Role>
      <ShortName>Agreement with Spriaso, LLC</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Recent Accounting Pronouncements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/RecentAccountingPronouncements</Role>
      <ShortName>Recent Accounting Pronouncements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Earnings (Loss) per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/EarningsLossPerShareTables</Role>
      <ShortName>Earnings (Loss) per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/EarningsLossPerShare</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Marketable Investment Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecuritiesTables</Role>
      <ShortName>Marketable Investment Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/MarketableInvestmentSecurities</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Fair Value (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/FairValueTables</Role>
      <ShortName>Fair Value (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/FairValue</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables</Role>
      <ShortName>Loan and Security Agreements and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/Leases</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Stockholders??? Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquityTables</Role>
      <ShortName>Stockholders??? Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://lipocine.com/role/StockholdersEquity</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails</Role>
      <ShortName>Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails</Role>
      <ShortName>Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails</Role>
      <ShortName>Schedule of Available-for-Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails</Role>
      <ShortName>Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Marketable Investment Securities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative</Role>
      <ShortName>Marketable Investment Securities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/MarketableInvestmentSecuritiesTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Schedule of Fair Value, Assets Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Fair Value (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/FairValueDetailsNarrative</Role>
      <ShortName>Fair Value (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/FairValueTables</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Schedule of Maturities of Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails</Role>
      <ShortName>Schedule of Maturities of Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative</Role>
      <ShortName>Loan and Security Agreements and Other Liabilities (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Contractual Agreements (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ContractualAgreementsDetailsNarrative</Role>
      <ShortName>Contractual Agreements (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/ContractualAgreements</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails</Role>
      <ShortName>Schedule of Future Minimum Rental Payments for Operating Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Leases (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/LeasesDetailsNarrative</Role>
      <ShortName>Leases (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/LeasesTables</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails</Role>
      <ShortName>Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfStockOptionActivityDetails</Role>
      <ShortName>Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails</Role>
      <ShortName>Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails</Role>
      <ShortName>Schedule of Fair Value of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails</Role>
      <ShortName>Schedule of Reconciliation of Warrant Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails</Role>
      <ShortName>Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Stockholders??? Equity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/StockholdersEquityDetailsNarrative</Role>
      <ShortName>Stockholders??? Equity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/StockholdersEquityTables</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="form10-q.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative</Role>
      <ShortName>Agreement with Spriaso, LLC (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://lipocine.com/role/AgreementWithSpriasoLlc</ParentRole>
      <Position>46</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="form10-q.htm">form10-q.htm</File>
    <File>ex31-1.htm</File>
    <File>ex31-2.htm</File>
    <File>ex32-1.htm</File>
    <File>ex32-2.htm</File>
    <File>lpcn-20210630.xsd</File>
    <File>lpcn-20210630_cal.xml</File>
    <File>lpcn-20210630_def.xml</File>
    <File>lpcn-20210630_lab.xml</File>
    <File>lpcn-20210630_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>64
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form10-q.htm": {
   "axisCustom": 0,
   "axisStandard": 16,
   "contextCount": 181,
   "dts": {
    "calculationLink": {
     "local": [
      "lpcn-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "lpcn-20210630_def.xml"
     ]
    },
    "inline": {
     "local": [
      "form10-q.htm"
     ]
    },
    "labelLink": {
     "local": [
      "lpcn-20210630_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "lpcn-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "lpcn-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 119,
    "http://lipocine.com/20210630": 43,
    "http://xbrl.sec.gov/dei/2021": 4,
    "total": 166
   },
   "keyCustom": 28,
   "keyStandard": 282,
   "memberCustom": 22,
   "memberStandard": 19,
   "nsprefix": "LPCN",
   "nsuri": "http://lipocine.com/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://lipocine.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000010 - Disclosure - Fair Value",
     "role": "http://lipocine.com/role/FairValue",
     "shortName": "Fair Value",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000011 - Disclosure - Loan and Security Agreements and Other Liabilities",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities",
     "shortName": "Loan and Security Agreements and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000012 - Disclosure - Income Taxes",
     "role": "http://lipocine.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000013 - Disclosure - Contractual Agreements",
     "role": "http://lipocine.com/role/ContractualAgreements",
     "shortName": "Contractual Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000014 - Disclosure - Leases",
     "role": "http://lipocine.com/role/Leases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000015 - Disclosure - Stockholders\u2019 Equity",
     "role": "http://lipocine.com/role/StockholdersEquity",
     "shortName": "Stockholders\u2019 Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000016 - Disclosure - Commitments and Contingencies",
     "role": "http://lipocine.com/role/CommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000017 - Disclosure - Agreement with Spriaso, LLC",
     "role": "http://lipocine.com/role/AgreementWithSpriasoLlc",
     "shortName": "Agreement with Spriaso, LLC",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000018 - Disclosure - Recent Accounting Pronouncements",
     "role": "http://lipocine.com/role/RecentAccountingPronouncements",
     "shortName": "Recent Accounting Pronouncements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000019 - Disclosure - Earnings (Loss) per Share (Tables)",
     "role": "http://lipocine.com/role/EarningsLossPerShareTables",
     "shortName": "Earnings (Loss) per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://lipocine.com/role/BalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000020 - Disclosure - Marketable Investment Securities (Tables)",
     "role": "http://lipocine.com/role/MarketableInvestmentSecuritiesTables",
     "shortName": "Marketable Investment Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000021 - Disclosure - Fair Value (Tables)",
     "role": "http://lipocine.com/role/FairValueTables",
     "shortName": "Fair Value (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000022 - Disclosure - Loan and Security Agreements and Other Liabilities (Tables)",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables",
     "shortName": "Loan and Security Agreements and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000023 - Disclosure - Leases (Tables)",
     "role": "http://lipocine.com/role/LeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000024 - Disclosure - Stockholders\u2019 Equity (Tables)",
     "role": "http://lipocine.com/role/StockholdersEquityTables",
     "shortName": "Stockholders\u2019 Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000025 - Disclosure - Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)",
     "role": "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
     "shortName": "Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000026 - Disclosure - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "role": "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
     "shortName": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000027 - Disclosure - Schedule of Available-for-Sale Securities (Details)",
     "role": "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
     "shortName": "Schedule of Available-for-Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000028 - Disclosure - Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)",
     "role": "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails",
     "shortName": "Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000029 - Disclosure - Marketable Investment Securities (Details Narrative)",
     "role": "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative",
     "shortName": "Marketable Investment Securities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "span",
       "span",
       "p",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesGrossRealizedGainLossNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://lipocine.com/role/BalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000030 - Disclosure - Schedule of Fair Value, Assets Measured on Recurring Basis (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
     "shortName": "Schedule of Fair Value, Assets Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000031 - Disclosure - Fair Value (Details Narrative)",
     "role": "http://lipocine.com/role/FairValueDetailsNarrative",
     "shortName": "Fair Value (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_us-gaap_WarrantMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000032 - Disclosure - Schedule of Maturities of Debt (Details)",
     "role": "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails",
     "shortName": "Schedule of Maturities of Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LPCN:DeferredFederalInsuranceContributionsActTaxPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000033 - Disclosure - Loan and Security Agreements and Other Liabilities (Details Narrative)",
     "role": "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative",
     "shortName": "Loan and Security Agreements and Other Liabilities (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "LPCN:DeferredFederalInsuranceContributionsActTaxPayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000034 - Disclosure - Contractual Agreements (Details Narrative)",
     "role": "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
     "shortName": "Contractual Agreements (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:BusinessAndContractualArrangementsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000035 - Disclosure - Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails",
     "shortName": "Schedule of Future Minimum Rental Payments for Operating Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000036 - Disclosure - Leases (Details Narrative)",
     "role": "http://lipocine.com/role/LeasesDetailsNarrative",
     "shortName": "Leases (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "span",
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000037 - Disclosure - Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)",
     "role": "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
     "shortName": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30_us-gaap_ResearchAndDevelopmentExpenseMember",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000038 - Disclosure - Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)",
     "role": "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails",
     "shortName": "Schedule of Key Assumption of Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000039 - Disclosure - Schedule of Stock Option Activity (Details)",
     "role": "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
     "shortName": "Schedule of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_EmployeeStockOptionMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "role": "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-04-012021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2021-06-30",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000040 - Disclosure - Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)",
     "role": "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
     "shortName": "Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000041 - Disclosure - Schedule of Fair Value of Warrants (Details)",
     "role": "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
     "shortName": "Schedule of Fair Value of Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "LPCN:ScheduleOfFairValueOfWarrantsTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-012021-06-30_custom_November2019OfferingMember_us-gaap_FairValueInputsLevel3Member_us-gaap_WarrantMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:WarrantsAndRightsOutstanding",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000042 - Disclosure - Schedule of Reconciliation of Warrant Liability (Details)",
     "role": "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails",
     "shortName": "Schedule of Reconciliation of Warrant Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "LPCN:ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "lang": null,
      "name": "LPCN:AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember14584484",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000043 - Disclosure - Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)",
     "role": "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
     "shortName": "Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2020-12-31_us-gaap_WarrantMember14584484",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Shares",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-11-18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000044 - Disclosure - Stockholders\u2019 Equity (Details Narrative)",
     "role": "http://lipocine.com/role/StockholdersEquityDetailsNarrative",
     "shortName": "Stockholders\u2019 Equity (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-11-18",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPShares",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-11-14",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetentionPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000045 - Disclosure - Commitments and Contingencies (Details Narrative)",
     "role": "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
     "shortName": "Commitments and Contingencies (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-11-14",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:RetentionPayable",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "LPCN:PercentageOfRoyalty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000046 - Disclosure - Agreement with Spriaso, LLC (Details Narrative)",
     "role": "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
     "shortName": "Agreement with Spriaso, LLC (Details Narrative)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2013-07-222013-07-23_custom_LicenseAgreementMember_custom_SpriasoLLCMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "LPCN:PercentageOfRoyalty",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000005 - Statement - Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "role": "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "AsOf2019-12-31_us-gaap_CommonStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://lipocine.com/role/StatementsOfCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2020-01-012020-06-30",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000007 - Disclosure - Basis of Presentation",
     "role": "http://lipocine.com/role/BasisOfPresentation",
     "shortName": "Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000008 - Disclosure - Earnings (Loss) per Share",
     "role": "http://lipocine.com/role/EarningsLossPerShare",
     "shortName": "Earnings (Loss) per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "00000009 - Disclosure - Marketable Investment Securities",
     "role": "http://lipocine.com/role/MarketableInvestmentSecurities",
     "shortName": "Marketable Investment Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "form10-q.htm",
      "contextRef": "From2021-01-01to2021-06-30",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 46,
   "tag": {
    "LPCN_AbbottProductsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abbott Products Inc Member.",
        "label": "Abbott Products Inc [Member]"
       }
      }
     },
     "localname": "AbbottProductsIncMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_AccreditedInvestorsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredited Investors Member.",
        "label": "Accredited Investors [Member]"
       }
      }
     },
     "localname": "AccreditedInvestorsMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_AccruedFinalPaymentChargeOnDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued final payment charge on debt.",
        "label": "Accrued final payment charge on debt"
       }
      }
     },
     "localname": "AccruedFinalPaymentChargeOnDebt",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for settlement of liability on warrant exercised.",
        "label": "Settlement of liability on warrant exercise"
       }
      }
     },
     "localname": "AdjustmentOfWarrantsForSettlementOfLiabilityOnWarrantExercise",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of warrant liability on warrant exercises.",
        "label": "Settlement of warrant liability on warrant exercises"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSettlementOfWarrantLiabilityOnWarrantExercises",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional paid in capital, share-based payment arrangement, costs associated with ATM offering.",
        "label": "Costs associated with ATM offering"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationCostsAssociatedWithAtmOffering",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_AgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement description.",
        "label": "Agreement description"
       }
      }
     },
     "localname": "AgreementDescription",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "LPCN_AtMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At Market Offering Member.",
        "label": "At Market Offering [Member]"
       }
      }
     },
     "localname": "AtMarketOfferingMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ClarusTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clarus Therapeutics, Inc [Member]",
        "label": "Clarus Therapeutics Inc [Member]"
       }
      }
     },
     "localname": "ClarusTherapeuticsIncMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ClassAUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class A Unit [Member]",
        "label": "Class A Unit [Member]"
       }
      }
     },
     "localname": "ClassAUnitMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ClassBUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to class B units.",
        "label": "Class B Units [Member]"
       }
      }
     },
     "localname": "ClassBUnitsMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of Warrant or Right, Redemption Price of Warrants or Rights",
        "label": "Class of warrant or right, redemption price of warrants or rights"
       }
      }
     },
     "localname": "ClassOfWarrantsOrRightRedemptionPriceOfWarrantsOrRights",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_CollaborativeArrangementRoyaltiesPercentageOfNetSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Percentage of net sales"
       }
      }
     },
     "localname": "CollaborativeArrangementRoyaltiesPercentageOfNetSales",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LPCN_CommonStockSoldThroughEquityOffering": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sold through equity offering.",
        "label": "Common stock sold through equity offering"
       }
      }
     },
     "localname": "CommonStockSoldThroughEquityOffering",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_CommonStockSoldThroughEquityOfferingShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock sold through equity offering, shares.",
        "label": "Common stock sold through equity offering, shares"
       }
      }
     },
     "localname": "CommonStockSoldThroughEquityOfferingShares",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "LPCN_CommonStockWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock Warrant [Member]"
       }
      }
     },
     "localname": "CommonStockWarrantMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_CorporateBondsNotesAndCommercialPaperMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate Bonds Notes And Commercial Paper Member.",
        "label": "Corporate Bonds Notes And Commercial Paper [Member]"
       }
      }
     },
     "localname": "CorporateBondsNotesAndCommercialPaperMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_DebtInstrumentBasisSpreadOnInterestRateForDebtDefault": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument, basis spread on interest rate for debt default.",
        "label": "Debt instrument, basis spread on interest rate for debt default"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnInterestRateForDebtDefault",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LPCN_DebtInstrumentMinimumAmountConsideredForInsolvency": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of debt instrument minimum amount considered for insolvency.",
        "label": "Debt instrument, minimum amount considered for insolvency"
       }
      }
     },
     "localname": "DebtInstrumentMinimumAmountConsideredForInsolvency",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_DeferredFederalInsuranceContributionsActTaxPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This information is pertaining to the amount of deferral of FICA tax payments totaled and are included in accrued liabilities.",
        "label": "Deferred FICA payroll tax payments"
       }
      }
     },
     "localname": "DeferredFederalInsuranceContributionsActTaxPayments",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Incentive Plan Member.",
        "label": "Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlanMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_February2020OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to February 2020 Offering.",
        "label": "February2020 Offering [Member]"
       }
      }
     },
     "localname": "February2020OfferingMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_GlobalAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Global Agreement [Member]",
        "label": "Global Agreement [Member]"
       }
      }
     },
     "localname": "GlobalAgreementMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_January2021OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "January 2021 Offering [Member].",
        "label": "January2021 Offering [Member]"
       }
      }
     },
     "localname": "January2021OfferingMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_LicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License Agreement [Member]",
        "label": "License Agreement [Member]"
       }
      }
     },
     "localname": "LicenseAgreementMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_LoanAndSecurityAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan and Security Agreement",
        "label": "Loan And Security Agreement [Member]"
       }
      }
     },
     "localname": "LoanAndSecurityAgreementMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Thereafter"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterEighteenMonths",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_NetProceedsFromCostsAssociatedWithAtm": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from (costs associated with) ATM.",
        "label": "Net proceeds from (costs associated with) ATM"
       }
      }
     },
     "localname": "NetProceedsFromCostsAssociatedWithAtm",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_November2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "November 2019 Offering Member.",
        "label": "November 2019 Offering [Member]"
       }
      }
     },
     "localname": "November2019OfferingMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_PercentageOfGrossProceedOnSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of gross proceeds on sale of shares",
        "label": "Percentage of gross proceeds on sale of shares"
       }
      }
     },
     "localname": "PercentageOfGrossProceedOnSaleOfShares",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LPCN_PercentageOfRoyaltiesReductionBasedUponProductLaunch": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties reduction based upon product launch.",
        "label": "Percentage of royalties reduction based upon product launch"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesReductionBasedUponProductLaunch",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LPCN_PercentageOfRoyalty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalty.",
        "label": "Percentage of royalty"
       }
      }
     },
     "localname": "PercentageOfRoyalty",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "LPCN_PreFundedWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to prefunded warrants.",
        "label": "Pre Funded Warrants [Member]"
       }
      }
     },
     "localname": "PreFundedWarrantsMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ProceedsFromIssuanceOfCommonStockGross": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from issuance of common stock, gross"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStockGross",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement [Member].",
        "label": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_ScheduleOfFairValueOfWarrantsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Fair Value of Warrants"
       }
      }
     },
     "localname": "ScheduleOfFairValueOfWarrantsTableTextBlock",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LPCN_ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Reconciliation of Warrant Liability [Table Text Block]",
        "label": "Schedule of Reconciliation of Warrant Liability"
       }
      }
     },
     "localname": "ScheduleOfReconciliationOfWarrantLiabilityTableTextBlock",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "LPCN_ServiceAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Service Agreement [Member]",
        "label": "Service Agreement [Member]"
       }
      }
     },
     "localname": "ServiceAgreementMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_SettlementOfWarrantLiabilityOnWarrantExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of warrant liability on warrant exercises.",
        "label": "Settlement of warrant liability on warrant exercises [Default Label]",
        "verboseLabel": "Settlement of warrant liability on warrant exercises"
       }
      }
     },
     "localname": "SettlementOfWarrantLiabilityOnWarrantExercises",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Cancelled Weighted Average Exercise Price",
        "label": "Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionCancelledWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Exercised Weighted Average Exercise Price",
        "label": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExercisedWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Option Expired Weighted Average Exercise Price",
        "label": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice",
        "verboseLabel": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionExpiredWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average Exercise Price, period",
        "label": "Weighted average exercise price, per share",
        "periodEndLabel": "Weighted average Exercise Price, Ending of the period",
        "periodStartLabel": "Weighted average Exercise Price, Beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average Exercise Price, issued.",
        "label": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice",
        "verboseLabel": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardEquityInstrumentsOtherthanoptionsGrantInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "LPCN_SiliconValleyBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Silicon Valley Bank",
        "label": "Silicon Valley Bank [Member]"
       }
      }
     },
     "localname": "SiliconValleyBankMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_SpriasoLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Spriaso LLC[Member]",
        "label": "Spriaso L L C [Member]"
       }
      }
     },
     "localname": "SpriasoLLCMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_StockIncentivePlan2014Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock Incentive Plan 2014 Member.",
        "label": "Stock Incentive Plan2014 [Member]"
       }
      }
     },
     "localname": "StockIncentivePlan2014Member",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "LPCN_StockIssuedDuringPeriodSharesWarrantsExercises": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for warrant exercises, shares.",
        "label": "Common stock issued for warrant exercises, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesWarrantsExercises",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "LPCN_StockIssuedDuringPeriodValueWarrantsExercises": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock issued for warrant exercises.",
        "label": "Common stock issued for warrant exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueWarrantsExercises",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "LPCN_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested Restricted Stock Units Member.",
        "label": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://lipocine.com/20210630",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r487",
      "r489",
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r490"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r492"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Series [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r483"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r481"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://lipocine.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r245",
      "r278",
      "r280",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r421",
      "r461",
      "r462",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r209",
      "r245",
      "r278",
      "r280",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r421",
      "r461",
      "r462",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r209",
      "r245",
      "r269",
      "r278",
      "r280",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r421",
      "r461",
      "r462",
      "r475",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r209",
      "r245",
      "r269",
      "r278",
      "r280",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r421",
      "r461",
      "r462",
      "r475",
      "r476"
     ],
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r101",
      "r279"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r101",
      "r106",
      "r279"
     ],
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r101",
      "r106",
      "r190",
      "r279",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premium (discount) on marketable investment securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionExpense": {
     "auth_ref": [
      "r182",
      "r183",
      "r184"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.",
        "label": "Non-cash interest expense"
       }
      }
     },
     "localname": "AccretionExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued expenses"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r16",
      "r42",
      "r43",
      "r44",
      "r451",
      "r467",
      "r470"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r50",
      "r51",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r41",
      "r44",
      "r50",
      "r51",
      "r52",
      "r89",
      "r90",
      "r91",
      "r343",
      "r463",
      "r464",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r14",
      "r318",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r314",
      "r315",
      "r316",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r281",
      "r283",
      "r321",
      "r322"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r283",
      "r310",
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "verboseLabel": "Allocated share-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r83",
      "r138",
      "r140",
      "r144",
      "r166",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r341",
      "r344",
      "r362",
      "r387",
      "r389",
      "r430",
      "r448"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets [Default Label]",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r5",
      "r6",
      "r38",
      "r83",
      "r166",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r341",
      "r344",
      "r362",
      "r387",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r154"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross unrealized holding gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r155"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross unrealized holding losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r152",
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r156",
      "r158",
      "r444"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Total maturities of debt securities classified as available-for-sale securities, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r156",
      "r158",
      "r442"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Total maturities of debt securities classified as available-for-sale securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r157"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r156",
      "r157",
      "r443"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "verboseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtSecuritiesClassifiedAsAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r149",
      "r153",
      "r175",
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Aggregate fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r151",
      "r175"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Marketable investment securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesGrossRealizedGainLossNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents the difference between the gross realized gains and losses realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.",
        "label": "Available-for-sale securities, gross realized gain (loss)"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesGrossRealizedGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r284",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAndContractualArrangementsDisclosureTextBlock": {
     "auth_ref": [
      "r473"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for prepaid health care service provider's significant business and contractual arrangements with hospitals, physicians, or other associated entities.",
        "label": "Contractual Agreements"
       }
      }
     },
     "localname": "BusinessAndContractualArrangementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "auth_ref": [
      "r3",
      "r88",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Presentation"
       }
      }
     },
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r22",
      "r76"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r70",
      "r76",
      "r78"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations",
        "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of period",
        "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r70",
      "r366"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash, cash equivalents, and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCollateralForBorrowedSecurities": {
     "auth_ref": [
      "r435",
      "r455"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of cash collateral held for borrowed securities, for which the cash is restricted as to withdrawal or usage.",
        "label": "Cash collateral for borrowed securities"
       }
      }
     },
     "localname": "CashCollateralForBorrowedSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activity:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r80",
      "r83",
      "r112",
      "r113",
      "r118",
      "r121",
      "r123",
      "r131",
      "r132",
      "r133",
      "r166",
      "r195",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r243",
      "r244",
      "r247",
      "r251",
      "r362",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r34",
      "r189",
      "r437",
      "r454"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and contingencies (notes 5, 7, 8 and 10)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r186",
      "r187",
      "r188",
      "r192",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r89",
      "r90",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r13",
      "r258"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r13",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, par value $0.0001 per share, 100,000,000 shares authorized; 88,296,360 and 70,041,967 issued and 88,290,650 and 70,036,257 outstanding"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r46",
      "r48",
      "r49",
      "r55",
      "r439",
      "r458"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Comprehensive loss:"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r270",
      "r277",
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r27"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt - current portion"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r79",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r223",
      "r230",
      "r231",
      "r233",
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Loan and Security Agreements and Other Liabilities"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r8",
      "r9",
      "r10",
      "r82",
      "r87",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r376",
      "r431",
      "r432",
      "r447"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r206",
      "r236",
      "r237",
      "r374",
      "r376",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Aggregate amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseAccruedInterest": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period.",
        "label": "Other accrued interest"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentIncreaseDecreaseForPeriodNet": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net increase or decrease in the carrying amount of the debt instrument for the period.",
        "label": "Debt instrument, increase in amount"
       }
      }
     },
     "localname": "DebtInstrumentIncreaseDecreaseForPeriodNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateBasisForEffectiveRate": {
     "auth_ref": [
      "r31",
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of any adjustments made to the stated rate to determine the effective rate.",
        "label": "Debt Instrument, Interest Rate, Basis for Effective Rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasisForEffectiveRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r31",
      "r235",
      "r374",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentMaturityDate": {
     "auth_ref": [
      "r32",
      "r209",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format.",
        "label": "Debt instrument, maturity date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r33",
      "r82",
      "r87",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r213",
      "r219",
      "r220",
      "r221",
      "r222",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r236",
      "r237",
      "r238",
      "r239",
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment greater than the preceding installment payments to be paid at final maturity date of debt.",
        "label": "Debt instrument, balloon payment to be paid"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentTermsBalloonPaymentToBePaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRestrictiveCovenants": {
     "auth_ref": [
      "r86",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of covenants that limit or prohibit certain actions or activities without the lender's prior consent within a specified period of time or until certain specified targets are achieved for example, reduction of the debt or an increase in net worth to a specified amount).",
        "label": "Debt instrument, restrictive covenants"
       }
      }
     },
     "localname": "DebtInstrumentRestrictiveCovenants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r162"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Schedule of Available-for-Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r74",
      "r180"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation expense"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r56",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r109",
      "r112",
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r352",
      "r353",
      "r440",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Basic loss per share attributable to common stock"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r56",
      "r98",
      "r99",
      "r100",
      "r101",
      "r102",
      "r112",
      "r121",
      "r122",
      "r123",
      "r127",
      "r128",
      "r352",
      "r353",
      "r440",
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Diluted loss per share attributable to common stock"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings (Loss) per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/EarningsLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r436",
      "r456"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Employee related liabilities"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee service share-based compensation, nonvested awards, compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee service share-based compensation, nonvested awards, compensation cost not yet recognized, period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r308"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r50",
      "r51",
      "r52",
      "r89",
      "r90",
      "r91",
      "r95",
      "r103",
      "r105",
      "r130",
      "r167",
      "r258",
      "r260",
      "r314",
      "r315",
      "r316",
      "r328",
      "r329",
      "r351",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r463",
      "r464",
      "r465",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r74",
      "r241"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Non-cash loss (gain) on change in fair value of warrant liability",
        "terseLabel": "Fair value adjustment of warrants",
        "verboseLabel": "Change in fair value of common stock warrants"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails",
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r354",
      "r355",
      "r356",
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r354",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets Measured on Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r355",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValue"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r221",
      "r270",
      "r271",
      "r276",
      "r277",
      "r355",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r270",
      "r271",
      "r276",
      "r277",
      "r355",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r355",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r221",
      "r236",
      "r237",
      "r270",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r394",
      "r395",
      "r396"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOffBalanceSheetRisksDisclosureInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Off-balance Sheet Risks, Disclosure Information [Line Items]"
       }
      }
     },
     "localname": "FairValueOffBalanceSheetRisksDisclosureInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r176",
      "r177",
      "r178",
      "r179",
      "r232",
      "r256",
      "r348",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r57"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HealthCareOrganizationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Health Care Organizations [Abstract]"
       }
      }
     },
     "localname": "HealthCareOrganizationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r138",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax expense"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r181",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement."
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r84",
      "r325",
      "r326",
      "r327",
      "r333",
      "r335",
      "r337",
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r85",
      "r104",
      "r105",
      "r137",
      "r324",
      "r334",
      "r336",
      "r460"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "negatedLabel": "Income tax expense"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes paid"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.",
        "label": "Increase (Decrease) in Accrued Interest Receivable, Net",
        "negatedLabel": "Accrued interest income"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedInterestReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "verboseLabel": "Accrued expenses"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid and other current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r53",
      "r136",
      "r373",
      "r375",
      "r441"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r69",
      "r71",
      "r77"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest paid"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Accrued interest income"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r59",
      "r135"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Interest and investment income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Schedule of Maturities of Debt Securities Classified as Available-for-sale Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r162",
      "r428",
      "r445",
      "r472",
      "r500"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Marketable Investment Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee Disclosure [Abstract]"
       }
      }
     },
     "localname": "LesseeDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r379"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r380"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/Leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r28",
      "r83",
      "r141",
      "r166",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r342",
      "r344",
      "r345",
      "r362",
      "r387",
      "r388"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r19",
      "r83",
      "r166",
      "r362",
      "r389",
      "r433",
      "r453"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r30",
      "r83",
      "r166",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r342",
      "r344",
      "r345",
      "r362",
      "r387",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r354"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityAxis": {
     "auth_ref": [
      "r25",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of lender, which may be a single entity (for example, but not limited to, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit.",
        "label": "Lender Name [Axis]"
       }
      }
     },
     "localname": "LineOfCreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityLenderDomain": {
     "auth_ref": [
      "r25",
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the lender, which may be a single entity (for example, a bank, pension fund, venture capital firm) or a group of entities that participate in the line of credit, including a letter of credit facility."
       }
      }
     },
     "localname": "LineOfCreditFacilityLenderDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationReserveCurrent": {
     "auth_ref": [
      "r34",
      "r189",
      "r191"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.",
        "label": "Litigation settlement liability - current portion"
       }
      }
     },
     "localname": "LitigationReserveCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationReserveNoncurrent": {
     "auth_ref": [
      "r34",
      "r189"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of estimated litigation liability for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid after one year or beyond the normal operating cycle, if longer.",
        "label": "Litigation settlement liability - non-current portion"
       }
      }
     },
     "localname": "LitigationReserveNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementAmountAwardedToOtherParty": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount awarded to other party in judgment or settlement of litigation.",
        "label": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementAmountAwardedToOtherParty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation settlement liability",
        "negatedLabel": "Litigation settlement"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r10",
      "r220",
      "r234",
      "r236",
      "r237",
      "r432",
      "r449"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "totalLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r87",
      "r194",
      "r225"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in remainder of current fiscal year.",
        "label": "2021"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfMaturitiesOfDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r33"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Debt - non-current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Cash used in investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r70",
      "r72",
      "r75"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r45",
      "r47",
      "r52",
      "r54",
      "r75",
      "r83",
      "r94",
      "r98",
      "r99",
      "r100",
      "r101",
      "r104",
      "r105",
      "r119",
      "r138",
      "r139",
      "r142",
      "r143",
      "r145",
      "r166",
      "r195",
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r202",
      "r203",
      "r204",
      "r205",
      "r353",
      "r362",
      "r438",
      "r457"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r98",
      "r99",
      "r100",
      "r101",
      "r109",
      "r110",
      "r120",
      "r123",
      "r138",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r111",
      "r114",
      "r115",
      "r116",
      "r117",
      "r120",
      "r123"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "verboseLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r1",
      "r92",
      "r93",
      "r96",
      "r97",
      "r106",
      "r107",
      "r108",
      "r147",
      "r148",
      "r168",
      "r169",
      "r265",
      "r266",
      "r267",
      "r268",
      "r317",
      "r330",
      "r331",
      "r332",
      "r350",
      "r363",
      "r364",
      "r365",
      "r381",
      "r424",
      "r425",
      "r426",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.",
        "label": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/RecentAccountingPronouncements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r138",
      "r139",
      "r142",
      "r143",
      "r145"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Operating loss"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Rent expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LeasesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "auth_ref": [
      "r242",
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of options indexed to an issuer's equity.",
        "label": "Option Indexed to Issuer's Equity [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityTable": {
     "auth_ref": [
      "r242",
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different types of options indexed to an issuer's equity along with the different attributes of those options.",
        "label": "Option Indexed to Issuer's Equity, Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Option Indexed to Issuer's Equity [Line Items]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTable": {
     "auth_ref": [
      "r242",
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Freestanding contracts issued by an Entity that are indexed to, and potentially settled in, an Entity's own stock by the different attributes of these freestanding contracts, including the strike price, number of shares, and settlement dates.",
        "label": "Option Indexed to Issuer's Equity [Table]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeAxis": {
     "auth_ref": [
      "r242",
      "r346",
      "r347",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of freestanding contracts issued by an entity that are indexed to, and potentially settled in, an entity's own stock.",
        "label": "Option Indexed to Issuer's Equity, Type [Axis]"
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r39",
      "r40",
      "r42"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Net unrealized loss on available-for-sale securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r39",
      "r42"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Net unrealized gain (loss) on available-for-sale securities",
        "verboseLabel": "Unrealized net loss on marketable investment securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r60"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "totalLabel": "Total other expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment": {
     "auth_ref": [
      "r161"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This item represents an increase to the cumulative amount of credit losses recognized in earnings for an other than temporary impairment (OTTI) of a debt security held for which no such other than temporary impairment (OTTI) was previously recognized.",
        "label": "Other-than-temporary impairments"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsAdditionsNoPreviousImpairment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Agent fees and other offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r61",
      "r63",
      "r150"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Payments to Acquire Debt Securities, Available-for-sale",
        "negatedLabel": "Purchases of marketable investment securities"
       }
      }
     },
     "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r12",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r12",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r12",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred stock, par value $0.0001 per share, 10,000,000 shares authorized; zero issued and outstanding"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r5",
      "r20",
      "r21"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromContributionsFromAffiliates": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.",
        "label": "Proceeds from affiliates"
       }
      }
     },
     "localname": "ProceedsFromContributionsFromAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from common stock offering",
        "verboseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfDebt": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow during the period from additional borrowings in aggregate debt. Includes proceeds from short-term and long-term debt.",
        "label": "Proceeds from debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities": {
     "auth_ref": [
      "r61",
      "r62",
      "r150"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale, maturity, prepayment and call of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Maturities of marketable investment securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from sale and maturity of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/MarketableInvestmentSecuritiesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r64",
      "r313"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from stock option exercises"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "Net proceeds from exercise of warrants",
        "verboseLabel": "Proceeds from exercise of warrants"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r382",
      "r383",
      "r384",
      "r385",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Agreement with Spriaso, LLC"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlc"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Debt repayments"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r323",
      "r422",
      "r477"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r323"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Contract research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalents": {
     "auth_ref": [
      "r7",
      "r76",
      "r78",
      "r429",
      "r450"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r15",
      "r260",
      "r318",
      "r389",
      "r452",
      "r466",
      "r470"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r89",
      "r90",
      "r91",
      "r95",
      "r103",
      "r105",
      "r167",
      "r314",
      "r315",
      "r316",
      "r328",
      "r329",
      "r351",
      "r463",
      "r465"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetentionPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts owed to vendors and subcontractors that have been withheld because of retainage provisions in a contract.",
        "label": "Retention payable"
       }
      }
     },
     "localname": "RetentionPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyGuaranteesCommitmentsAmount": {
     "auth_ref": [
      "r427"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount the entity has committed to make for future royalty guarantees.",
        "label": "Royalties, commitment amount"
       }
      }
     },
     "localname": "RoyaltyGuaranteesCommitmentsAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Computation of Basic and Diluted Earnings (loss) Per Share of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/EarningsLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r283",
      "r309",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueOffBalanceSheetRisksTable": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing the information required and determined to be disclosed regarding the fair value of financial assets and financial liabilities, which are not recognized in the financial statements (off-balance sheet) because they fail to meet some other criterion for recognition.",
        "label": "Schedule of Fair Value, Off-balance Sheet Risks [Table]"
       }
      }
     },
     "localname": "ScheduleOfFairValueOffBalanceSheetRisksTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Debt"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r288",
      "r299",
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Key Assumption of Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r263",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Number of Warrants Outstanding and the Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Warrants outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted average remaining contractual life"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.",
        "label": "Strike price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend yield",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate",
        "verboseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Common warrants to purchase share of our common stock",
        "negatedLabel": "Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements for which rights to exercise lapsed.",
        "label": "Expired"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpirations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event.",
        "label": "Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r289",
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Number of warrants exercisable, shares",
        "periodEndLabel": "Number of shares, Balance at ending of the period",
        "periodStartLabel": "Number of shares, Balance at beginning of the period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based compensation arrangement by share-based payment award, number of shares available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Number of options exercisable",
        "periodEndLabel": "Number of shares, Options exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Options exercisable, Weighted average exercise price",
        "periodEndLabel": "Weighted average exercise price, Options exercisable (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of shares, Options cancelled (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Number of shares, Options forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Number of shares, Options granted (in shares)",
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, grants in period, gross"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r290",
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of options outstanding, shares",
        "periodEndLabel": "Number of shares, Balance at end of the period (in shares)",
        "periodStartLabel": "Number of shares, Balance at beginning of the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options outstanding, Weighted average exercise price (in dollars per share)",
        "periodEndLabel": "Weighted average exercise price, Balance at end of the period (in dollars per share)",
        "periodStartLabel": "Weighted average exercise price, Balance at beginning of the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails",
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock": {
     "auth_ref": [
      "r302"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for exercisable or convertible options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Schedule of Share-based Compensation of Stock Options Outstanding and Exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r282",
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Weighted average exercise price, Options exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Weighted average exercise price, Options cancelled (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Weighted average exercise price, Options forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Weighted average exercise price, Options granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Fair value of common stock",
        "verboseLabel": "Share Price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Contractual life"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r304",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term",
        "verboseLabel": "Expected life in years"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfKeyAssumptionOfFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Options exercisable, Aggregate intrinsic value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r312"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options exercisable, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Options outstanding, Weighted average remaining contractual life (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfShare-basedCompensationOfStockOptionsOutstandingAndExercisableDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares issued, price per share"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/LoanAndSecurityAgreementsAndOtherLiabilitiesDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r11",
      "r12",
      "r13",
      "r80",
      "r83",
      "r112",
      "r113",
      "r118",
      "r121",
      "r123",
      "r131",
      "r132",
      "r133",
      "r166",
      "r195",
      "r199",
      "r200",
      "r201",
      "r204",
      "r205",
      "r243",
      "r244",
      "r247",
      "r251",
      "r258",
      "r362",
      "r493"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r36",
      "r50",
      "r51",
      "r52",
      "r89",
      "r90",
      "r91",
      "r95",
      "r103",
      "r105",
      "r130",
      "r167",
      "r258",
      "r260",
      "r314",
      "r315",
      "r316",
      "r328",
      "r329",
      "r351",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r372",
      "r463",
      "r464",
      "r465",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r89",
      "r90",
      "r91",
      "r130",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfEmployeeServiceShare-basedCompensationAllocationOfRecognizedPeriodCostsDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Common stock sold through ATM offering, shares",
        "verboseLabel": "Stock issued during period, shares, new issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r258",
      "r260"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Vesting of restricted stock units, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r12",
      "r13",
      "r258",
      "r260",
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Option exercises, shares",
        "negatedLabel": "Number of shares, Options exercised (in shares)",
        "verboseLabel": "Share-based compensation arrangement by share-based payment award, options, exercises in period"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfStockOptionActivityDetails",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r12",
      "r13",
      "r258",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Common stock sold through ATM offering",
        "verboseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r12",
      "r13",
      "r258",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r258",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Option exercises"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r13",
      "r17",
      "r18",
      "r83",
      "r146",
      "r166",
      "r362",
      "r389"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balances",
        "periodStartLabel": "Balances",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets",
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r81",
      "r244",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r257",
      "r260",
      "r264"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders\u2019 Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Different names of stock transactions and the different attributes of each transaction.",
        "label": "Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table]"
       }
      }
     },
     "localname": "SubsidiaryOrEquityMethodInvesteeSaleOfStockBySubsidiaryOrEquityInvesteeTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Subsidiary, Sale of Stock [Line Items]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r159",
      "r160",
      "r163",
      "r164",
      "r165",
      "r232",
      "r256",
      "r348",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfAvailable-for-saleSecuritiesDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r35",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfChangesInStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r35",
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r35",
      "r261",
      "r262"
     ],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock at cost, 5,710 shares"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/AgreementWithSpriasoLlcDetailsNarrative",
      "http://lipocine.com/role/CommitmentsAndContingenciesDetailsNarrative",
      "http://lipocine.com/role/ContractualAgreementsDetailsNarrative"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnrealizedGainLossOnDerivatives": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of derivative instruments, including options, swaps, futures, and forward contracts, held at each balance sheet date, that was included in earnings for the period.",
        "label": "Unrealized gain (loss) on warrant liability"
       }
      }
     },
     "localname": "UnrealizedGainLossOnDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/FairValueDetailsNarrative",
      "http://lipocine.com/role/ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareDetails",
      "http://lipocine.com/role/ScheduleOfFairValueAssetsMeasuredOnRecurringBasisDetails",
      "http://lipocine.com/role/ScheduleOfFairValueOfWarrantsDetails",
      "http://lipocine.com/role/ScheduleOfNumberOfWarrantsOutstandingAndWeightedAverageExercisePriceDetails",
      "http://lipocine.com/role/StockholdersEquityDetailsNarrative"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "calculation": {
      "http://lipocine.com/role/BalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "Warrant liability",
        "periodEndLabel": "Balance at June 30, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/BalanceSheets",
      "http://lipocine.com/role/ScheduleOfReconciliationOfWarrantLiabilityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r111",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted average common shares outstanding, diluted",
        "verboseLabel": "Weighted avg. common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted average common shares outstanding, basic",
        "verboseLabel": "Weighted avg. common shares outstanding"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://lipocine.com/role/ScheduleOfComputationOfBasicAndDilutedEarningsLossPerShareOfCommonStockDetails",
      "http://lipocine.com/role/StatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 4
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=SL108384541-122693"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "250",
   "URI": "http://asc.fasb.org/topic&trid=2122394"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1930-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(d)(2)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL6284393-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "410",
   "URI": "http://asc.fasb.org/extlink&oid=6392676&loc=d3e7480-110848"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394232&loc=d3e17558-110866"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=116646759&loc=d3e15243-108350"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "63",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=117411753&loc=d3e23176-110880"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90193-114008"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90198-114008"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(1)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(2)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(f)(3)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473578&loc=d3e63223-108013"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.1)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62586-112803"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Subparagraph": "(g)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "405",
   "Topic": "954",
   "URI": "http://asc.fasb.org/subtopic&trid=2289226"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r478": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r479": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r480": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r481": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r482": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r483": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r484": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r485": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r486": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r487": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r488": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r489": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r490": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r491": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r492": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r493": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r494": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r495": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r496": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r497": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r498": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r499": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r500": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r501": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r502": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r503": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r504": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "848"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>65
<FILENAME>0001493152-21-018675-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-018675-xbrl.zip
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M;^V[2XXE%NDQ"@<A2%DJT.51!!5:>[1XOSI0# .AL<M85NJ#.5U[]<ION7K
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M&)&P72:MCPL0N7@*]'SGPG5PC7KKNEM66ZIK6)/(P*949(Y5(UBR.&:AY5.
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MM^VTV%OSG)<EJ5!S!DUF$^4Y+ET*#(#AC^3PZ^/]P7/RQQT1?&C1?<,ARQ5
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M3ELQT\4\=ULP%\6T5":SA;/I9\S-<PM_>\3_& G^9LE_4$L#!!0    ( "-
M!5-,9:H,)@0  )\2   *    97@S,BTQ+FAT;=58;6_:2!#^CL1_F$-J%"3>
M#*&Z@HO$6RX^T4#!5UT_+O8:]KK>=>QUD]ROOUDO!N>ENDM+3@5%.-Z7V6>>
MF7G&V+YR/\P&Y9)]-1U.\ KZ8[N..YL.[*:YXFQS-VV/YI//L'(_SZ;O*X$4
MJ@=6*U+@LI F<$UO82E#(FIFH 8K&K.@HC<N7KJK#R&)-TSTH-4'1>]4G7"V
MP=N_TD2QX+XRL"_GUV[1;#T@(>/WO7\SG*U-V-_4X*@,SL0ZB?IV4QM$MQ<(
M^*B08[;9JF,"MD>#Z9]7SLAQRZ5.NV'9S='@M.#GE+\F;H\*1>,C Q]/EZYS
MZ8R'KC._/D'\_P?QNQ+=#3+A4VVP?='H1D?-(T>42YX4@GJ*20&W3&U!;2E\
M3$F,S/%[6-)(Q@IP\E+&(6ZK?P09P(Q%TF."@B.\!ISK/6?<OTEE?RQCW$&T
MO;,X&ZGBN7%F]L:8!8H.^?![BOL[K1JT6VVK7"()!(SC^![%BGIIS!1#EXCP
M87KG;8G84!C+,&1)HA'CGU[I$T5A2V.*T(I@#/H<1RU;F^+A<8(T4[\&'\B6
M)EOXU( %FN"U<FD1TX1IOK,SQUM& SP9D2CVE<(\")B''N YVE;!V5IV_OH>
MDR[&V#%->Y3&24K0E)*P3#D%JT/JUL7YN@K(B!GI^KL1?9SU*_S16#7&C7)I
MM8N)U>DB14@.\66DD)ZBT7S1N];;'-**Q&LB:%*?WW%Z#T-/Z9EVJ]76[I-L
MVY8E\$7(6V1[0WNGG\:OW7Y>H6.>6]5RR<5X[0HL2#E6FR?#B.M\W]= 3&]2
M%M,0F4MT( ]I<4ZR++*ZYWYU'_Q#Q>RK99<!UKO.A<FC,"N_FDZXDZ+L%*/<
MWD69"=3 ,!,*#+)0!+73Q]$L:GD*$*85-T(!TM&NZ6G".<)%S62$8RXD$88_
M,3H6,$&$I\?1H,\RTUI#<%7*3;+(B!IQ2LJEIXK5."DJGX^^.QS-IC">SF:K
MQ7#L7/_VOM*J9/>+X622W[_8K5OFJZU>VGK3A[6,L6/4/<DYB1($E/]7R9[W
M;7?Y/0_TYG?"Y.78ONK^XA&><ZUDM ?<;;TY)N<3S#R_9[ .TPT&%;JF7<,^
M$.[DJ3,[QM92*1GV8,2)]P4LK?J02,Y\<]3WN6N,?J//O X-MC-H)DWCY:,'
M!KOI#(I4X-?R9\F*5ZR^YX+^HR%%N#^U )G(&[?WSXOPGQX7'ZA61MN/>'K4
M!K6(&3:1B' #[ GT:@%[,</QHJ7W4>,H8,PS9B?4O]3K<,DH]WO(W(;V$=%-
M2H6GD?1A'F5=J@<S@AI3K^<T39Q/#TWO->5MI/;*_$V=0:8.#:+8$!XWC(>Z
M]53I'W6$IPIQJ/9GY;F8FIP&V8Y]X11,'VC+F<YYMIO(14Y+@<RF9M,PEO'<
MU"^8S!LG_6+J'U!+ P04    "  C0 53K4KW<4($  "\%   "@   &5X,S(M
M,BYH=&W56.]OVD@0_8[$_S"'U"B1  ,)U15<)'ZE\8D&"K[J^G&QU[!7>]=9
MKYOD_OJ;]6)#(;U3>N04HBC$Z]WQF_=FWRRV;]R/DUZY9-^,^R/\!/UCNXX[
M&?=LRWSB76MSVQY,1U]@X7Z9C-]7 L%5!YJ-6('+(IK +;V'N8@(KYJ!*BRH
M9$%%+YP]=U47(B)7C'>@T05%'U2-A&R%EW^FB6+!8Z5G7T]OW=VPM8!$+'SL
M_%O@;&["_J(&1Z5WQI=)W+4M'1#3GB'@HT*6;+56QP1L#WKC/VZ<@>.62Y>M
M>LNV!KW3@I]3_I*X/<H5E4<&/AS/7>?:&?9=9WI[@OC_#^(W6W0SR+A/=<#6
M5;T='[6.'%XN>8)SZBDF.-PSM0:UIO I)1*9"Q]A3F,A%>#-:R$C7%;[!"*
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M2V/_>&3IMX_F=:1^:_DW4$L#!!0    ( "- !5.[L'P.O\<! #T;%@ ,
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M*1:A@<" G!O9[I/3?;9F90IU:4$JX\\+US,T%7#V[*9NX=\3>6-%)R8-86N
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MZHQ8-&AF3GG3*I)XS"B)^P?.9KBYQ[CQF4-X@?8/F,6R8JH!$P@9TF%&.3N
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MEU0WS+%AXJ=<&+IBM0P;635=(:L!R"2<OI7PTXX</:Z7VH 1!UP<.U0IU>F
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M$?H@VR"<B+OC]"Q54?'8.I*&<>&>/AB 9.3 #V_@A-+&!HZ(-!T#-\MB"AZ
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MC%YN61XT%T#O8R8-V@C:>)3:>* T!:@5J-6)J%6JZ9[(S4$PTZ=FII_5_4
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M:,#AXWFS@,.'?JJ*)DX5301% T7+O**)VRB:F*:B^;U_O'/L#[<&MNOZP&0
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M-/PEV3A@X;]_.RJ)(W'XV$/^!?B>F^TB>/TJL(V 41QR=IQ[[=A$,G*GA+S
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M6<H 1.<&XO'MVJV>R:;DLT1K\BB]0[:DZDB9-#&:0%+76VWY4^]C8XPR ,F
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M^SPX>,RR;32"XY"BP);%K&:8DJ_(BW.4[DDN^VVOW'1% HEYM^3).31S "P
M%@ +@ 7  F !L%###P +@ 7  F !L !8J)'.<8,EM,29"Y8SMY#MG<U!MM%W
MU>YXS(VYK%0P)\4YS 2/"&U=+P'0ML-I6YYB13MIG,1=H:WR2_0#M !:8((
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M^D_1ZYRAV=_F]A9V%H&]30E:L&,$H)42M,H K<VA!:67)Z1*E$7%U*\? 5@
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MW+$QAC\X !AH)C .& >, \8!XX!QP+@L,PXRKR<K>F <, X8!XP#Q@'C@''
M.(HBT5GFM=Y%@4[FT8V6W._:8U+H,&VVI&0Q#^N-(;A#"E %Z@B, \8!XX!Q
MP#A@'# NNXR#=.O)BAX8!XP#Q@'C@'' .& <,(ZB2'26;N5BIEOQ0]UO=NAX
M16.I:^W^!NI<03&!<< X8!PP#A@'C /&'07CX)"AO3T;NHND3LZAF0-@ ;
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M&>QS6O;Y=*PMU J""8 %#P +@ 7  F"AESD %@ +@ 7  F !L !8J.$'@ 7
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M>ITS-/O;V-[RL*L([&U*T(+=(@"ME* E K0VAQ:479Z0*E$6%5._=@1@ ;
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MSPO0 L^=5K--XI-%EB]D:I,NU'V"-L/B%8 %P )@ ;#0RQP "X %P )@ ;
M6  LU/ #P )@ ;#$KON\FM7<K>IU\DTR34FWK<83,F750E;W1;"_%?7>8^G+
MISX4@*HNVTB:DGGT6,6@":M 95?KR*P ]&(M&+U*OV4T[J/)YEPMYRJ!TUW+
MN1EG#UO/*;(EOL)6N'*6$OB@XO1XY<WU(-S=':ZP4RQ!10F '];PCPDGL<M#
MRE > M#*L@DZD/]-I<*SQ%9Y@2U72^"/,Z(,L>TLM#$&:*4#+1&*AP%:X,)C
MN_!=G'.!Y8N9V@4)I9Z@UK!>!6 !L !8 "ST,@?  F !L !8 "P %@ +-?P
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M">=ABD<MS"QL8!9K4"HLSR7?ARIE??T+5'5_?B?FYB0:M1O\#H!Y'LPQM[D
MF ',$$1E/XB"\ @*=F'5$58= 2P %@#+P?D!8 &P %@ +  6  LUT@&P %@
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M0E>F,?+*A IYCO=>[>.XSQ);X:HL5^ 3KRNBI&@.T)XAM)\<G*$L#M07<OL
M%@ +@ 7 0B]S "P %@ +@ 7  F !L%###P +@ 7 $KLLKAXHBXMJ4_!%-Q&F
MZ04I'PV-](DBY^*0#%Y;[R#9,55;15;-5"W\U25^JP]N,16&TD)VNW\O/75?
M;EZJ]J?BIP?K:^_4*NQFS/-HT9'-#,BY0H9.SLO[A6RIIR%&U1^099.&9(PU
MY2DH.Z7*#HM_E.(D]KIR!=:5 5I@@BCARS'A)+8)JH() FBE JT*!] ":&79
MNZTN(TEKHKIA_54*'?Z6&OL)99':NA70H2W-,Y3B [3 /*=DGD_'V$*E(%@
M6.X L !8 "P %GJ9 V !L !8 "P %@ +@(4:?@!8 "P EMB5@HU I6!-^>EX
MU6K6O1%Q^I=[OF-/LI!"4H%(MR1RT1WZ[:B6:B/\^ =51EZ&[P[)QD!W[_)5
MTAS4?9&+H_8/].-[HZ&<6L6@>WQ(WN6<1XP<X!]H-:5:#4LGE.(D]JI<$5;E
M %I@@BCARS'A)+8)*H$) FAEV02M+@Q(>]JP:?U6&L<6\X426RZ4LU1'<-(*
M%-LVPXX1@%9*T(*=   M</LIN_T3<NA0& BF %8W "P %@ +@(5>Y@!8 "P
M%@ +@ 7  F"AAA\ %@ +@"5V86"YBV3'LHW1!G6!%XN9OKIAV5;-L@Q9)?T4
MOJGVL&:/VOT^(ON NR]/EMS29.?^JBIEI1YP+"EDDW/>>]H9P[\ICNWDY.-R
MS*-.FO*-><2,8VKW-XSALVY7.(6.(D4CT#-,!9G3QUUH6$;>0QG+T%3E'4.#
M)J1.[V&7;5*&;C*&#I 9>X6Q&K/C"( 9P QF%I )R-S.S,8\"!? #& &,QN7
MX(@S):]OZZWXI24;3C@/4TD:<8)ED17*Q<3K3U+6UQW/: 55W<3OQ-RZ1*-V
M@]\!,,^#.>8F&  S@!F"J.P'41 >0<$NK#K"JB. !< "8#DX/P L !8 "X %
MP )@H48Z !8 "X %P )@V8R:T()=D>O*)/W&%3B^VW5?E?!GL^Z>;@/*H:$I
MR+0:OQW5?NZJC>[+4^_K1>W#YQ\?[5)62W"%73+5%Y(FZ3*:U-S:S"='1XS(
ML0SA8=+YQIU(W3:I[CZ440RGIR%JLNH3X%8K5T&0DH2TU79LRY9TPCF"T3!<
M=P.XEFQ$TMP>J$DBV]!)UKOVI%J!Z_ 7(T-WM<!;P>^^#,71R)1O!-D9Y!A;
MM<FP?#RPC.62DDN;LREVZ%ABYGSJOF:U^R%5#TM\BIG*;[:N CE\[]FY\PI6
M]RK'EHI<ZKE\(0NK:J=H /Z[R8H:Y2JUY$13U:FEMC45MB*")IVL)JUSI;7]
MN-)[$TF68S[/.=.7CYIYXS3XYJ!T>DXSA",[N<TB6^9!ST]6SS/E,2.*4'9T
MF=MK5'1-28'#:B5D3:T2K[D%C:)<HU)1J%3Z(@M\F:U62FRYF#FU F]UDKJ5
MCK>JR;(S<C12+AEU3GI"/HROE+*F:># 0,F24+([9$NJCI2&9.H8#E9B&B6P
M E=E>9$'S0+-HENSDE2L;8,^L<B6"T6V6!2SIB^K%E/?VA*6*7[]^M7[\?R=
M>6X]Y2/)'*B8/"Z4MO5W6")N[)'B4L7(2--\WK@"(>_Q=?+D_:9\]K$M&YHF
MC2UTQDQ>O6,>5<4>$HJY/W();U](N>^2C##2S13G SVL6932.F,LEB3Y^._<
MFC1LR-:EN.-+;B#>PHA'O&N\LLK_+-&:4:Q,,H* ED.C1<A12OTLQY55;F>)
MUDPA8Y:@\<AVTS19Y7Q& J@8 *&3\(SP-TN0S9*QN#?L#'N0Y+>=P[SM,&JQ
MEUA\O+%(O51'WC;&9PPW?3NA,CP!$H,Y+8>D<SV&Q/UC].?R)9O\-,X?>ICC
M%08%!ILYI&>)UL-KY79![LAP=#NK3,\2K7L%R"/I\)(GZ5YTQNC&HRF-P9:#
M+0=5I4]5P99GC]:, H14\>6;_MJ)7\R751%DB=:,PF6N(LT;PP=)U9D_KPW+
M6EU'0K$PLD1K1H&SE#F_1'U55L$U 60B ]Q &=+__E,1^/*[]SV3>>M6M) 1
M>;5)694*51G68VM"LOU*T7%P J1  R= "C1P J1  R= "C1P J1  R= "C1P
M J1  R<B^M 5_28C_ 9]Z#K=%[OSW>G)1;GZK&2E#YV_4T(H_9%8\[E+)+N;
MVAB1=QO0<;M6I4UV<VQ-8I(-(Z?$[*\C#K^Z(TXG%*R)-)>K:R/C1NE\^VJ4
MUS:7VY2#I04.'KP?#I?GA;S(I]1$[O^S]ZW-:2O+VM]=Y?^@D[W7KJ1*]I*X
MDZPW5?B6.'%LQY=D)5]<0AJ,8B$176S#KW^[9W0#! B00#AS]EE[>]D@S?0\
M?>_IKDNB5*X!O]8SOW"V-DARQAU=WK1;ET5FA72W*[/BA8E[EW51DK(?B<0Y
MH%!42MW,+2O5E=C,[9/ZZ8?A25\'YJ_,E5>UZ,IK.YJY<;[=<LV5*1]DTW$C
M.TY8>Q.V' YZY>X:G!/2K:E>>!LNE^9I<J,N5J2Z6"M7MH$=N';87IZ(?VOZ
ME.:J7(I/.^8(Y @LMGV25T>P>DF4RO"/U-@&P<SME,UR!-N]3X.-VRQ+6R-5
ML5R1Q:;<W ;,ITY'-9=+1TFM^ZI^^]/\H<B+!SHTW>D;R@ O:YED,]FI53-2
M14DR%G4Z612F.]Q8ANG3S8_FK]KY-_VIE%V0KM"1N:U)*Q7)XGU)S+BR)B]V
MF*'@J2*.ZLVHF,H&,T%?/QZH#4F_J-[+?XB2V8[T#^?%EZYA_OB43D'B(QS=
M6V,_;5V:ADOQ%X_SE*F74CF[U M'U4M'%4^G<!MAFU#.4R2;$]DL+Y)=KX*D
MQ,5W;%''FQALFG6S*9#(3$MEOYQ-$X>#A8.%@X6#A8.%@X6#I3#TX&#A8.%@
MX6#A8.%@*<SIO&RP)%;;2B>Q2I5SXK+)]]AA^&XH/YZT[HV&>G'VL"T-7K(B
M'U""+<( 2G"6*RC+[168V_YHG*1-H9;EB?5S:'%H<1'$<;(V$53B(HA#*Q]H
ME3FT.+3R@5:%0XM#:YL-ISGU<".AB-'*H!/;ZN&=F3T)_Y_]5-LK2[D7Q4FB
M7*^+<JE<V%HB7A/WTN'N6A'@_SQ$9S_&AY?&<0Y^(?%]#A8.%@X6#I8"$(>#
MA8.%@X6#A8.%@X6#I3#TX&#A8.%@25T:5XN5QEVX76)C'R:;=(GIZ(^$Q>MN
M39O FH9$^V@9V+#H@Z*;&,2[,*^)ZMFZJQ.G9>L._.D(_M6\OX156-HY<2\Z
M-\KSW;!^>M2S![](36_\:55V$?'86DSBTH([P3*%GF(_$%=I&T30S4?BN-@.
M2W!"FG)F+RBS\P1@07&2.K?<X+EE#BTN@@I"EY>$D]0BJ,E%$(=6+M"J2!Q:
M'%K;K-WFE)+DY:DN6(354E6OYQF*2[1I*\JJ+JM1VY+RE3^:BU(+:%Z0SP4T
M%]#9"NALRP:W1N#R>D$N!7C2@X.%@X6#A8.EN,3A8.%@X6#A8.%@X6#A8"D,
M/3A8.%@X6%+7"S9B]8(M[9?':M:<&VO*D"LZ;K"M.$3#:" Q'04_=$5^>[JC
MNP1>_ZBKA 7YKHAJW9OT*=\4PR-WP]K/IO.)7/_^VJO^:76#=';('J4<6XP:
MHQ_GZH)R-4^?%!0GJ3-S59Z9X]#B(J@@='E).$DM@FI<!'%H;;,(FET;D+?;
ML&@15Q[3>4O-BEB6B]MRB#/0DK*9WQOAT,H)6OP^ (<65_NYJ/WE2@.W7J7S
MTD N#'A^@X.%@X6#A8.EN,3A8.%@X6#A8.%@X6#A8"D,/3A8.%@X6)8J#:35
M:Z>.XQ$M?HV7!NKHWR[Z&#QSCI^)K>H.T>Z&AY]_=ESIH5H^(7]:K1\C!EL'
M\2G"F__-X8< >,U&93[P:&#924:>?EE> ;<J1I8E^,_='?VI5I;N[F+/4UR"
M,>_CWY[N#C"J;9D8 F\]ZT[L<_"'GF72-[#$\]W0?')NG7\[MC+HOA)<W462
ML;='&!$%AVYL<8994]!_\>-8,'L_0;B4X?W3\Y-8@)^MY]7[BEAM5+8IPO]'
MRX6TF=4J[[;"H;5I$XSCY"7B)+4(XF-R.;2V6@0M9>=-MYN+4*19$VO-K:KG
M^*/Y(;6HY3=X.+1R@A:_F<&AQ;5X.BV>1<WEUFEH7G')>9NGC3A8.%@X6#A8
MBDL<#A8.%@X6#A8.%@X6#I;"T(.#A8.%@R5UQ67SCJB>XUJ]D0*R:\O0;KJV
MY=UW6=791:=#,)IW-_0NY))F7YK5X_L_K<:2$8BMPT$R"0[027 9H01"*258
M/JDXI\YFC:CXLK$8!EFE76Y5DWU-"XLEV5]3''9AJRC/+@_/WZ:GZD9+)^6:
M6"DUQ&I=WJ9X/6?MXBCA%7E@3>B?R%')8JVR53DJCOGB8)[G[0N*D[0E(35>
M6\ZAM=4B:+UJ-Y]NFS6Q :YF0^9W=[:%"5++UPJ7KQQ:^4"+%PIS:''5G6/'
M3%#+%4FL5.O;I)9Y"2=G:)Z'XF#A8.%@X6 I+G$X6#A8.%@X6#A8.%@X6 I#
M#PX6#A8.EM0EG.6H?&[6[>OOBFTKIAO>O';NAO;5P&E]N_IP\E'AM9PZ)1O&
M*84G1BK>2#,MCT2UG-6Y8&35?I-H7'L]YZP#+W8]YV*4W6Q-IR1*DK1-P7O.
MWL71R(OS0+*JVUAA)P<^!SY/W[\@G*2M#*G+O#*$0VN;1="&=&\NU9T5L=EL
M<EV\)8R06L;RCL@<6CE!B]<,<VAQ]3U'?6=1X5G=MO@0+^[D3,TS5!PL'"P<
M+!PLQ24.!PL'"P<+!PL'"P<+!TMAZ,'!PL'"P9*ZN+,>U=.UM%_P$]; .3?6
ME#39-7%=@];)773\4-Z9KK1U ^]LF_YO8A6@SV?2;>]4*5V4_[ANGA&IV%JL
M3E@&: 0D$RR3%X-N#8OSU$A!<9(ZZ];D63<.+2Z""D*7EX23M"*H(7$1Q*&U
MS2)H1N(_>P^B",5]<D,LUZK;5$+P1[-+:DG,V^)R:.4$+5XXRJ'%E7P62CZ+
M$L#M4^"\!I"S/D]D<+!PL'"P<+ 4ES@<+!PL'"P<+!PL'"P<+(6A!P<+!PL'
M2^H:P,,[$NN#-_WN+KR)_L6Y&WZR+SODT\_J4[.R+75]?4738#][[&UO!7F_
MVG?S;/@X,L^Y=?,EH\G=4W:2(UNW+5LC=OBZ P/.B;T4]ZAK[X0B8-N-MXD\
MF ]IUD$PPK1^65Z0"_+J*#FLV%^>*L??&ZV'4HI1X7%H3?25S.GL<D@N^ 29
MW7PR)/YFFTZ*#5E&H91Y3B%G(96-@N+R9S8A7PS/C<J[C36Y;&3?YI+S&>>S
M7/ALY0(+CLSM0&;J6J!ZNEH@#F8.9BYFBVO.Y%):7!8K<E5LEK,?"L\Y;SLX
M+[4:27EUK8C,RM4(!_,(F)LI+T%Q,',P<YNH(#91%I78:._41%G.OAA[_5S%
M:[1YHIDGFCE8.%@X6#A8BDL<#A8.%@X6#A8.%@X6#I;"T(.#A8.%@R5MC7:Y
MF5AM.E;DVK4,C=@.*SB]TX_OAD;UJ7(Q^/WQNM?>UCKMTBJAYP/%4$R5.&PY
MBBM\\DPBE"510!IF'71<::G+1LGI2P7-\MH&*4R8?$HE-JV?O?!<QU5,I!QB
M-+<JZM]GM^IS[;/UX]]&6$7MXR%=F70&E,TSH#].S-'@?<NYZ.1>"-T =F]*
M8JV:_82U1-XJFE;B N#5^_\NDB(K.$M-*-%<>6HB/=80&V7.27\L)\U3I>7U
MJ-(;FRB.9P]&E*E=)Y<_B?QDW-QS91HP?@*E5E*G5;$N<_[_8_E_JS3IZUQ4
MZ?(<!<K4@5W]OU=[XUJU(@%;E;:-K=YPCOK#."H7ALJE;+TDU\5FHR;6JUO'
M5EQ;_9&\E8^V:JFJU_,,,*NU"[=+;#2I;=(EIJ,_DE-3M7HD(QTF-VK;QFE<
M@7$FRX+)KHBKZ";1CA7;!#@XF7%422Q)35$NYW^[G',6YZS"F(9+U^Y7Q7JE
M*E:KY6WCE]1)UO)R2=;>Z;G]='8P^&S6%T^R:KK3-Y3!6P$(2EY4SI5+J?Q#
MPI6-95>[A];O1ZW<^G[6Y0%AGEWE7C8W4WAVE7-2<3EIGBJM;3"[^NNB_N7'
M9;]]W>]P9<JSJYS__W1-RK.K/(3&.:KPMBG/KG)MQ7F+9U>Y N-,MIU,QK.K
MG+/^=,[BV=5<LJOP/PJ<*/P$/_='GRM+\]?=4^Q['18G):YL_A,FEM9??2DI
MR99F<=>$[.XH*I@Q\/4!')!@6BY\P;4 &HH'C@71$&@:&#SL)]I9$,TAH:.;
MBJGJB@&O]<..3G[;5.'QH!,R/058X/_M[0DG.C&TM\*E<@^<?TU^>\14R5NA
M^DZ@C0D!K,+>7B#R-/UQIAP9Z;_(]A)^HD9%, 4D[,<P?*:@G(C_#HM3@W\?
M?8=J&8;2=V MP4_OA"==<[NX>^DO)K#V''U(&#GP-6%'P/%TOFOU$R$4L?4D
MX4=>!Y^-T2V@V#OA9M"'][=LI:VK[X1SD&",JN<6$K :_]+?P;?P+\'A!&P;
M,.T_?P.UDPAO$^5AKTU RL$;^O3<?%+#WK:(SB,T346%. F1M R9RW%:TBG'
MR2A- +@ 4G"=B_ZG_?[L]/+B\/3\>'?G]/QP7VB='PG7MP?7IT>GK:O3X^M_
M_FZ_W[)-'0;2?'?G,"[.P]R1(U@=X5!QNL*)83UE(=+7N;W7MX'>>K-E*T]F
MD712+,@@EB7Y3I9+=\,?'S[U;SH_S2=2!1GG]6"5 _J1M]%!"WM"" 8A%1:$
M&'5?+4[-=$+VU7A'VU35:0F59RG:\09615SV+O$ 7R\\$?0 <$6&-O+,:&FP
M8SS?__>J%!U:I5F]2TCK#G^UOGZ^_6 TU9_R J/T4JZ.M1[):;^;H.$14DX*
M:2@Q&O[\;KB-Q^9%[4S-A892?C1,Z.W\,J!?R_XDKO5GX0O\NNL(QR#1M+#%
M#C^>9;B*"YMUD:5@\F.,KG-),N/SJWX]>4ST4:Q ZIRX:)I<VM:C#CQ_,+@%
M0^;4O.@36W&!ABW5U1]U5R=.J^VX&,FZTP]>S:;%DD7NDUX>-9HZU&CJV%9/
ML()5"4JXK+>S"37UV<G@3PA%SO]@T@.+M)K4($XSMZ# ^RS6:I)YKS7*>RS[
M>68YSIT.1E>_+_6ENYYR?GAY<#ML?"1W0T^Z^M?SS.Z_][_R8;M 6.(.F L2
M>A*URE])P1=8MV# DL?IX7^K]-<4-3 6L$E\]G^G/%0>7XI_,G.2:2,DSGXH
MB@.'0&:FSR11KM=%N924#4C>:")9WKP(6DOA4#XI>TJ71+DBB:5&TDB:Q2G-
M969Q9&:\759+^^4Y+@VKW%A7!$"FZ@89@=Z-M;!%(\EKLVEB&\ ,D1UL03!]
MJ8J_5='P\3"DI)O<ZN%6SW92/>+@>._8(]('T.L*BN:6J;5Z%AS*D/XK,&(I
MR09J/ROUVM>;J\M#LCX;:'*?\94+Y+F/0=\ESR#E@,5:J3:G%C/AV/:*@I_9
MYL(,'.1G/(S9#&*UV9AK+BP#^-+X':0#!:0Y%CX":&9BW=1_F)7;QZY;70+J
MTX;,I<,W+9#9:RNL2B%:ZHI8SP@OR63,TZ8?J^9N5L2R/-^.+R:W+4"]'!BM
MWJB)S7I2!>'JK!;OZ]!259O@DX\98J<Q6>^;)!\UJO]:1]HF%<JY9>Y14T_'
M8"1QW&)PVC@5U\=CY;+82"SAW@862T6V')BK5A;KM?E>[S*\58_QUHFBV[26
M*_)@+CK?%=M6P)69QFC-QU:_^^&Z]Z%?6;LZ"[F+>E6O[Q7=?"/ J:E=Q;PG
MZ%EU8$O"(^X)4_1/;"^"H2MMW=#=0=YPFA-/F4GP#<2R2C60=O4E</9FLWRY
M.!US8-*R*-=J8J5>R85/6TDZ,&Y17W2.=$<%WG(=L+4O;=+3O9YS:CX2/Q:!
M#'SN<["FW_6<&!/_V_]L_#ZZ[=Y\5#>I+>/[07[MLUT(KS5_:Y2[>XK]0%C!
MCQYN3P /R[-IY*0@.F*AP]D$LTMEL5E=U3G:F.S,D,XY"(.F6*\NH[!Y;+K0
MD:U34\5[^>2(L/^-!9W]^\1KB#BGDZ6'U 9RQL++CD-<1U!,+;2!>*@Y&\=T
M$AHHH3Q,3##/[XJH1']$M75.W%G*^.3'+[OW0+JGO5)N%G5IF@9F:X[<59TF
M738LZQ>C[1H#1N42)G^WSV#.@*!Y9GH;8DU:-0R7S+&5F1P+!D-?T;4CTB&V
M333?RP=+@EYJ;U'A.8MSS[]5FD_]DZO>H+T.T3^-B?UM4#%OX<H%,(UM-)*9
M_"\:]M*0?0,&<KG>$*5Z<0WDM9$Y3U8O-QMBM=[,A=F/YJEGZBA<*@.4<]/B
M6\<WGWY_U+]^^-AK;D(;TR4*?;;&(JKA. TWP*2UIB36*\O$7')7P;E0,T]>
M+-6K8D7.R&U-+NZ9:GB<1>[(-$[LMDL?W8/!V;]?EXDT9Z9= Q/93^3DKDV7
MM8UC%-U(=*DA-IM)/1PWSI<YT3.'*%*U@B&Z?!(_S1A7GL&N[FD [9JXKL%Z
MH\[.KTK?GK7S]F?C<T_/02V.7>M(QYC1+@0GW,9DKF?FNV;7VBYVI646+!=[
M4BK@SCC$]7G$%5&2)/QG+F93W."91< UG5[:*JYJ?4X5UU('/E'GM1315@HF
MSU";!0[7%6LU\P5P^CM:&%>^"02R&PGDGG)X>'QU.'0_/MX-'YP/TO>G\U]?
MO^<AG)D4+DMQR3P7D(?SZIVW7SS/OSR1\HPWX4:)E5)5E*KS*W-2G_C$A19^
MHNMSY>IBI5H5JXE-U%<[3ZY-"JE-CN=K$Y8&S_#&[S1%,47ZQZ[YZL%2^(67
M98^>\UYA>"]>FW6I#/RK:RWUMZ?;I/6HZ :&\TXL^QJD]G58IW1$VK1,("&;
M-+ [=\/[?Z\/?YTVR=<OG;575EYZMMI5'$([&VVZX&J.&EZ0Y&NL=:Z*C7I-
M+,G+E,5O.CR=!55S"(E5Q$JM)C96(6DR$\=G"H'F5 G1'-P&;K5E:E\4%W<[
MN.A,IT/"!7_*R/6F1TCE^- M=?,-7,\,FTUC=7]G^F*\OKU&_1S8+W?T:XRP
M55]2?&TKSS47L5;.\UQY/6EQK,7:4IY:4MP/E<M(W*]Q,AR0D\_],R_G^J.9
MBJ8\K2(U'@),\@"W7P8M%S!*..Y-E#M5Q4HIG;7*8X!9'6FN_7+D=(;R6B.
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MX?+L!R2)<KTNRDN,N7@AF"NM+.3DERCD<FN)))=$N2*)I<;\7BTK("Y3=ZG
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M;7O$[5KPIB/]$?^B!<O5'7B$:MV;E%+^0\CSGA9\3H,=TY7IJ+)A18G?!)(
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MCSXO9 /TFRZQB3_.VK0$!#SEDKG=Q#7XP;RG?:K=KDU8&^>T8[_Q!^S=3=-
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M3MQB:X/1GJX3"-;]C:$UNHSS.(LP*>N'"X+:4F4F:KL*1M*)&878\9(LBM*
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MQ;.85?.1-OM0#BW7\F1;[UHMZ<IT,@7F$7H*-H^6P^:I>0XONWDBX!%\H?6
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M_19>2@96TXQ,7;DV,U$7#"#R4^;TLG"0^(G-L<H^7[<B#R47_.7?-.:43O&
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M1N-?9Z,[7NL)J)ZHU9F/ZFR0?$"IDS&4021J&X/PR(XR%)J3"!:KZP#PP30
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M8.\H>8[@?$D>]\K?O\@6&U^_-Q+*])2CHEDU*5&\-[&B_KG\+JG\+L+=T]_
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MATO(E8;((--68W@;.[J!/@VTSRP0EYR^0M-PY!K0;*RCCC,C4B.^GZ>A=F9
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MZ]<KX71KL0V57>V$&YDDGV<C06(F?\$;MF@!7"X_4C3_TZ:BG-CU" <T[(Q
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M2AV3UDIMIWUJJ:G9;J]M@@2L$T +>>,"+<>M!\+ P6LR( L/#L3%] Q5VC7
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MG(K]>I2_!5D#=Q4>A.95B$6)(^.\AI1!!%HID3<5M! 5;VM8EI2-QO6@;]9
MJ,JNV1'E.7HE33C$0]0:*;A+2IJC(&I9CAL@-P*3 FDLSR5X)^RA^N6X=P0>
MV1[TW);KF(AC1^V;U%U%&>&AW:5D73(N1 0IB=/%TC%!W27HT4YHL%">O3\
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ME8/_&CQ6DH;A48@O7&_3;O;1G<''\@LBCX6'8%-%3^V)PNO</1)6!5$A1@A
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MC8#60%N98XR3L:HI3BODDJ?(V6>>=6N[@0^\[4X8+I,"'B,.ZUA8Y6(:67&
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M;&_5K/_/WILVMXTE::/?&<'_@%OMGK C(#9)[>6>BI"W:E=7V1[+U35QO]P
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MWLY.0LV9K<;G]8<NLVH&I@-Q@/CM0A0\:"0M N]1BHW 8C;AR3.B!,BK+%]
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M"J9T^GM!%P 4 %DZ9L(H].B3M*3_XL>DBZ0T]-C\?A)/283A+WHFGLU(3:D
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M()H5&'!BB- ,:T<C@G ;**G ^D()_PJ>\"Q5FZ7Y$'K=SF^Q) OP"T=Q;4$
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M3IQ\B5?;&B4U%Z>>J%V=OS193[<#- :KI%Z>J.1[TMY?)-G,^C.G\80[^GA
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MC_"Y,"DM6"":FQ> (3JK$'($HU_NG.#>;,96SJ7EJ:WKK[;.Y<"5NB\ R9M
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M4;"#Z.IX\;2J'4NZ8P;J76Y]Y:( G # !^!S0?A<0A#QXGPX!QH .,"0 'P
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MW!SQ_1OJ^*KN04A%)Y1&OFN<NGCW1./0@P-FI6/U_5@UC-*X?WP#OSG\OPJ
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M7Z&/K_>"\F/+'C6!C_\'4$L#!!0    ( "- !5.#!T\'-A$  (S"   5
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M])JRI?/$^+?@M<OF>@CO0B>,@@S;P?-!\B\&_\4G]-L'\=^#$V $ZJ+!A^>
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MH8((144Z?W<6+/@9Q>1*^S[];'I5G[<HB?IN(U$!)Y)(;=G(@JXHF+KA;$E
M3Y]67T"$"YH%X<G%8,IS"R8X_A]N;A![&%KH9;JX4PS3JQM? R:V>>:,A^1/
MI_B82]W),@70T(YF:\MIJ,0^.\I+]SZMW[G7;,*F]D.G2;>VGEH1]AE.G#[%
M@L76]&BUY= YT:V-U22\?6;*;[[V_AO%.8#\3L%FF[6 #5V:NK4!M=1BGS6S
M?E><W"?34Q+$)_9AVK_A>$ZB>:"5K-X4W]"%K-T-X(T4:6%V!F(V456/3W'\
M\X(FUP-4;SL"Y2F3:D9X]'K"C_;VA,T4]R)Z0')?TFER;*SVWB23GJ"'3Z]'
M_/22>H2)(E]$SUB[X<5P.BB#ZMG[_4NR=X-Z[(L'&B<OK1LD]* U,QH'+\S
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MH2EJRYKE2B)0\9^8R.&;_P%02P,$%     @ (T %4U$ZJ27<)   \E4" !4
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M;?7=E#*QUNP5,:W,"P;#>#C7\$\OIS: /4^M:1:'&,V5<J9JVXO8PJ4XE$&
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M\.GHP*V/)EP\DX\<BU:N_T"8W (G%EN'^OS%M/">)\H>]&1YBF0#4<TG&Y;
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M$%,=$GR1D7NJ?WEY)<;Y&7XLFG^IU^8F2W$ZV$XSL3,,CQ,!!JK3].XC]W-
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M&MW%3ZO"<,_"CL4EIFR4;R/+1 \&7Q9*2N_V")9FN ,"+FD,'_94)@ZOL=2
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MP08&C?:Z6F[1P4.A96!GY/"$.IN0SD .$666P5P775 C.<DN8QBGI?:*+GT
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MQDJ3-G%F* M,MYG90%7_VVHWR(/G($Y8L'F\S,AQ'M"H,Z\+ ])E#4Y^_+
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M4PXB[-;K;0R[58$);-Q>Q&F0AGL(NXV" .#8PE +/!ND@''2DU4?"KN7E02
M8?<=WI0QV<W2$%?+9"ZAJ5.R#;P^#;305Z.??/+XL4"DI@6"DG;\PNZ\LZN&
M1KR8&'S%H&K%=6%FEQJ,DQI44=X[% S"%464$#2F6JG%1M5 A\\_PA1F# .M
MQ00<;[*FJH<:-QWHM1__GCN]("V]K;@ZJ4#/XC&,SO)1C#*D3BYAQ>4=8J-5
M'<;8NU"5">)KE@H"H-<;DVO-@L_;VHYM)K5!)N^0'*NI>; M71W,+(!M$P?2
M7]NQ^(*?*3&U#3U(T%FFC)8]8 6SULT-*(BSGU_O/$&'NG*RVXK)0:P ZO56
M+I-L2G;T^*I<)P&"7:8K^Q]+?/0<)&QJWCPGPSXLTJC[0XM2)(V3#SJ%R9;E
M]#E_$5>O[FC <D[C8NT*HFLEG+XM[J6".\^5.]4 5E_V8KMJ,(M+*>A=5,KY
MFNT/L/N*1R+] VX*/N('HEMO,S&"M^ PZKH[B_--E@?)#R3;;B@'O]N6%G&Z
MQ5%YPHE&I7,TZF@5#L993*S<O;F*D>5#?#79@_VJX,'2(Z"@0(_X*4[3\C4W
M8:6GT\*_*^P"3*GHQ?X=T8O9O1\;W+K,0[/=;,0)[R"I,@E>ILN,K$6>G8$L
MC[;<3C/5C#.ID[K&CA7,6L,X?:7D-BUNQ"[()UF^)7S-(:SVOFG85HN#LME=
MW2]E>8A-5X=[5&ZO_BA5[-[RZ9" P91:KSYV*BK$;C2"P06[.OP0O.!\"!HR
MH>.+81I%>]? >E2 ,*)1388)(T0%HX0$E<I97M/&HG]MSKNED6+EZZSVC0/C
MX>YB7<^_]E$)_;AT%YE@(+XG0T:,N6F3.ZP^1DDC1FDY]77G<5CW-O#.CZN"
M?3AUQT=1 3]X:KB;.UUU"&^:[LG3\[0,+-,CP2N<YO$S;K+>ZH_L-XG8Z-AV
MLZ0CG<9-[$^\2\^_[TIICP#[D@UF)-BS0:KU\FU*<)#$?\>12.='^U-023ZF
M\Z_CG,K>XV40W2M#XB8^&]^2\H[7Z2H@3_@F51P2M6-Q]^:/G?+-TSUF>N_P
M&Z&D+J,""QT25!Y"9IDA*2/#%J#CH\R*RY2&3%NF8[7[U$LDI>F8EKQNTVZ/
M,*>;@-N"T3LFIV@K/4+),Q\%O;Q?0.!8IL5A3\1E21Q:/+%@8'"<571 \5[F
M4 TU&(@-JJC):,0F2A4'O+=M3K9YG.(\/\-Y2.)-F<K^),CC_&9Y2^N030S9
MKP_XI3A)],?GIPARB<?IAK9Q.EX*&/Q.5EU^$HRRL&E7FPD(G,\#PG9CV=D1
MGE9_P%GJR5U"<TCI-@!UM&!@-J!@'TP5.:+TB#/ \Y%]DX9<H8'>)ZR,CDU+
M#!980VZJ1M8[-B_^FNUR"X !054K=SB+7JDO%J]?MF;L0\FT[06XW4P::UAW
MD\F6&PPR1ZLL;TK5 HX0OZG+UMF%$-1(@><96XI?IJ7MG^N\(5(MI-$I)D40
MIP\D8*==1'+:9JMBR+'.5YRG_C%+I6EZTU[+@MCWYC!03I%3)\5I2FYU42#]
MLGZ_I;%L:#0QLWAY4\>@O/))'04]&)Q:*-G'&F-!G >UF. - BK3ACSY (]O
MN!E]JI$!-."&O%N#."#08@[=^JR+CMCU<KO=N10U)1CX&-53)I=IJ.&YJ*XU
M0\Y)2^T/24:'I"$%BJ4A)W25!2F?_Y11U2M:/!&,Q1.^['>Q7]-*XPX$9/49
M1&N/9>3P<O[3SG<9R,& ;EA'S=%0R@+:ERD,&YXWFU@\ VU@_JJGAPRU(2?7
M8 V,^_HW'"3%ZC0@^(8\!6GY9N'0M'&0RR6Z+$UH VR !0S&[/3LPTQP(<:&
M.GSPW%JU/<F6:+*4J[8-*% (N^,MUE:M_=U$63ZVHR>9J]J1'B4(#*QWT5ZZ
M_-@(:(6,0.!]18W$V#HRU).[!.F0TIWGAS2T8* VH* T#>'DH"-!H6+](LT5
M._(VN/(VQ.0>7T,&R"C3<0##VH":,N(".+<4Q,[)T/&9'I'3TPU*!3M'&CH4
M8+"A5$LZO"#V?L&Y')ZT<)4E$2:YT/$Z*[!]9#:"W^D-_;%F=>[HVS*#@>!8
MC:7;5RW^__9/?_[XX4]_*4\K ($IRR,<BUWA,K*D7ABGX:BKL^-D.+TG.\6\
MSJ78,0+ P':*UO(DH9;!%Y,[4D!'>U;6#_G?L4+ H=KHB<=)."Q<#\]^#< &
M N$[G+#DV;<!*5X?Z!0_9Q?(A]<8A]G</AIB9T3W$1$S#Q@H6BK:!U_)AC@?
M:C/"\Z,Z$^V=Z"@)$*!IZ3Y'L(,'K+WCK)<*>4Y_=+\A<9!G1^CJZA0(8IN+
M9*<\XRD;)<X)R<AI1@BV<J'C1/BY)VAOG/KFX# _&-1.4-IPN["4(0Z-,RFH
M)0:> [[&7UIW*4F6TK^&N Y_A#&7:9LFIE',)AE>W-R/:+<YWO=7&=WL[[O+
M!=-=]FB,'+F$S/6W[^IVY /I,_?A"D?;!-\L^]>@V&W,D&<*3;9T('Q@9],'
M5^&F2G.Z)K>;R9T5NFFBP.!_-_VEU;M2&KO"R[+(;,4-7O9/+HZ/(Z5 U-RB
M2_@MNN::IN!F3V_QY4!P'65!NW/$K(B?6UEPSE]8IET<B4>A:N/EFK7O0_LK
MR$_WVG=%J7O>ODH!V"GW;)JIO[:+:M\,K H3C_7T>K5\QQI(9V4'@UN7LWJI
MJZR&LG$B7!_@'FM<_U2W+3^83C%!:2/<.SG'F AX=^U:-Q!/DR#/XV7,7BUJ
MG4;Z'!3\(/M94-B!>C>1GNZR3C9><U]UM#PPG6 /1I@Z1<G,W#[]%[][TQH)
MFA)1D/<Z4 ZR ]4WU<1EW,\X8,MVT4UZQS1EK[GRC#/65PJMQ7BY93C22.7%
M0TL98#K$1,5-G:"YJGB$A%14B64)!6O!?$H#!>E-R-CTX9OE598^/6"R9CUY
MY/3=5HR?B<4X(]73!CL98) ^4?%Q[AX(FE6''.M,SM4(9P7H29)\'U2U-'7H
M].J &##(GJZ[T8UO"W;8YG.<QNOMFKIMGH:^3"R;(QJTH+I(!.J ;&M-;KU)
MLE=,I_[D.0YQM2Z'(S8-QVDN7KY)N#)\ 8 .3ME3RI(KBR<.^>/D(]9L]UV>
MIU7=>:I-L^Z[W\+ ],JY+33UW:I$5!8IEI:.'UFAJ%TJC=#J<AEC4S(212->
M-KB.W=1AZ9 67P(2M=]M9P&HJ-@\WZ[%;R-#N/T4XJ<+[[."U/UV'R4 [*Q[
M-,O40_\#OZ*&OSMM8O_B!:*R1/0#>RX#0WD02559;:?2KJSRV1N[8',?@GUW
MMVD5,=3%QDD%W:TFF6+J2NVN@BHI4+J*>JQO+M&>O*H=3N5K<$[[/3N"]++!
M[('0AXS]5+[!PVO*JF,Y5\-I-_14R9U.ZU@'.%W<C^%&AZ )=N5Q]69;Y$60
M1M7[::U2YWHWK?:(]<IK_=:6.3X=S^[NQ;3Q1C7/I=GS>L?\1(7M%LO9ORHQ
MLX./S?/2,$[B<L;9?^UM#!+'RO( RVGF*C Z3A TP$[2WH3>KL 6@NL<<& "
ML2825=ZPK7K>#;F+GU9CUOQ&R_,T0YEFMF9B,DZ8]WZP+PM,?>%ZNW[$I.W%
MI?"B6&'T,V:2:62R>,8D>,)5S('1+8E#*,>_KG&A>+CP(1/'2MN5Q\^E:@^'
MCY3B]GC_)!.[)_E'B8#RUNMNZJO>I&0'D$W(G;$9J_Y4=B?1"\OUAKS5 ;6-
M.$K KQ^A->(T]?N-6'NEX/GI&Q2*P^,YEX&R1LC!>:?RK/S.':"6 ]-#]<R<
MYJ-*(=  /M6 P_!3I<Y2=QWAJ70B#L97#1IPV-Y*+#9=IA%^8:M;EWF^K8-.
M\2>?=VGJS)K;Z9O@XTSJ//EMQPIFRC!.7^D!6[$K4;*C(D-"P#_G95:FH^HM
MJ5^X&"@7@4U67\4IOBSP.I]08RU>*'B5S+%%:\UX$%CM:SL:J>@7)@)Q&5!@
MNN/UKL6:W2S65.:>9#M-V+#/ZNAD<MB'8##=9)_62+D?]G,+\ B)4H#TL^9M
MM<8D4]!BH'?9'P;5;F-<2PP&MT,:&E[$:[]4"2K04-DT%& ,\/A&F#&@,#*
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M]*X2]#7;G*Y>O:OG48TT[I/!M#=%(WNMNGI"HQS<*?CY1$._<35-$NCV'V6
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M O+E$I$Y-6H?"?Z2+<J[G3*P!1UT00?,;)6R"@/^R_8>>7'_38I\3VOMZ@2
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M>+9'+9#/0OC] 9CO] (PV\]X>.9M/^11??4:G_+8MURI.50<8&R(5P=AA!U
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M&T%'_4][HZ]P;R2(99UCLL+$S] 'G(0INRM0%)Y?+ME-+#^^\U>(2(-:1B-
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M'8O]&,7.-Z'3P/9M^P2@.U79I%9B\%?^$J2\_OMW;Z5O.#6J"%;CG8*G@PU
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M7.*$M>LV@[Z&*E:,NOT2L>>(V3K'RR5.. ^J"C,]3:'ODZE%(*;=ZKK-"?O
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M3J:_^?]02P$"% ,4    "  C0 536BNOF@0(  "]1   "@
M@ $     97@S,2TQ+FAT;5!+ 0(4 Q0    ( "- !5/!9CL )@@  +I$   *
M              "  2P(  !E>#,Q+3(N:'1M4$L! A0#%     @ (T %4TQE
MJ@PF!   GQ(   H              ( !>A   &5X,S(M,2YH=&U02P$"% ,4
M    "  C0 53K4KW<4($  "\%   "@              @ '(%   97@S,BTR
M+FAT;5!+ 0(4 Q0    ( "- !5.[L'P.O\<! #T;%@ ,              "
M 3(9  !F;W)M,3 M<2YH=&U02P$"% ,4    "  C0 53>KUZ%7D.  #/B@
M$0              @ $;X0$ ;'!C;BTR,#(Q,#8S,"YX<V102P$"% ,4
M"  C0 53@P=/!S81  ",P@  %0              @ '#[P$ ;'!C;BTR,#(Q
M,#8S,%]C86PN>&UL4$L! A0#%     @ (T %4U$ZJ27<)   \E4" !4
M         ( !+ $" &QP8VXM,C R,3 V,S!?9&5F+GAM;%!+ 0(4 Q0    (
M "- !5-]:ETV<E8  *CX!  5              "  3LF @!L<&-N+3(P,C$P
M-C,P7VQA8BYX;6Q02P$"% ,4    "  C0 53U38'/^L[   W\@, %0
M        @ '@? ( ;'!C;BTR,#(Q,#8S,%]P<F4N>&UL4$L%!@     *  H
*90(  /ZX @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
